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Decision-analytic models have an important role in healthcare funding decisions in the UK 
and internationally. However, errors have been reported in published models, which may 
indicate poor modelling practices, potentially leading to sub-optimal recommendations on 
cost-effectiveness. Little in-depth research has been undertaken to investigate the processes 
used by modellers in model development. The objective of this research was to explore the 
modelling methods used by modellers, with particular focus on problems encountered. 
This work involved two qualitative phases of research. In the first phase, twenty-four in-depth 
interviews with modellers were undertaken. Constant comparative analysis was used to 
compare informant practices, and identify common issues in model development. The second 
phase involved two separate model-building case studies with teams of modellers and 
clinicians. Methods of non-participant observation, qualitative interviews, and think-aloud 
were used to investigate model development. The findings of the case studies were compared 
using framework analysis. 
Important themes emerging from both phases of the research concerned the diversity of 
practices in structural development, problems with clinician involvement in modelling, and a 
lack of time and resources to carry out good practice methods. This work offers important 
recommendations for modelling practice, and suggestions for future research to improve 
modelling methods.  
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This thesis has used qualitative research to explore the process of decision-analytic modelling 
from the perspective of those involved. The research was undertaken on the basis of literature 
that highlighted methodological errors in models, and the findings of a systematic review 
suggesting that there was limited detailed guidance available to support modellers in model 
development. Exploratory qualitative methods were chosen, specifically in-depth interviews 
with modellers, and case studies with modellers and clinicians, which used non-participant 
observation, think-aloud and qualitative interviews. The aim of the research contained within 
this thesis was to understand where problems were occurring in modelling processes, and 
provide recommendations around good practice in decision-analytic model development.  
The first chapter sets the context for this thesis in the use of decision-analytic models for 
economic evaluation, and in healthcare funding decisions. The chapter provides a summary of 
the theoretical and practical basis for decision-analytic models, and outlines their use by 
decision-making organisations such as the National Institute for Health and Care Excellence 
(NICE) in the UK and the Canadian Agency for Drugs and Technologies in Health (CADTH) 
in Canada. Decision-analytic models are used within these agencies to compare the costs and 
health consequences of competing healthcare interventions to determine their relative cost-
effectiveness.  
The second chapter presents a review of the modelling literature, demonstrating 
methodological errors present in both industry submission and published decision-analytic 
models. The latter part of the chapter presents a systematic review of model-building 
guidance, which aimed to determine what guidance was currently available to assist modellers 
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in the modelling process, and where further guidance and research on modelling methods 
might be required. 
The third chapter explores how qualitative research has been used in health services research 
and health economics to understand methodological issues in healthcare processes. The 
chapter begins by outlining the methodological basis for qualitative research, including its 
theoretical underpinnings, the nature of the methods applied, and how qualitative methods 
have generally been used in health research. A review was then undertaken of the use of 
qualitative methods to understand and improve processes in two other areas, to ascertain 
whether qualitative research could also be used to understand problems in the development of 
decision-analytic models. The areas chosen were individual’s completion of valuation tasks, 
and issues with recruitment to randomised controlled trials. The latter part of the chapter 
presents a systematic review of the small number of existing studies that have used qualitative 
methods to explore decision-analytic model development. 
The fourth chapter concerns the design of the empirical research reported within this thesis. 
The first part of this chapter outlines the research design for the first phase of the research, 
detailing the sampling, recruitment, data collection and analysis undertaken for the in-depth 
interviews with modellers. The latter part of the chapter details the research design chosen for 
the two model-building case studies undertaken within this thesis. Case study selection, 
recruitment of informants, data collection, analysis and the qualitative methods used within 
each of the case studies are discussed.  
The fifth and sixth chapters present the results of the empirical work undertaken within this 
thesis. The fifth chapter focuses on the findings of the in-depth interviews with modellers, and 
is organised under the themes that emerged from the qualitative analysis, including the 
modelling process, clinician involvement, model reflection, modelling guidance and future 
research. The findings of the two case studies with modellers and clinicians are presented 
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individually in chapter six, with the first case study focusing on the processes and methods 
used to develop an academic model, and the second the development of a model within a 
healthcare policy context.    
The final chapter discusses the findings of the thesis, as presented in the previous two 
chapters. The results of the first phase of the research are summarised, and the findings of the 
two case studies are compared for similarities and differences. Findings across both phases of 
the research are then considered and synthesised into common themes. Later in the chapter, 
the findings of this research are compared to existing relevant literature, and reflections are 
given on the appropriateness of the methods used. The final part of the chapter discusses the 
implications of research conclusions for model building practice, and offers recommendations 
for improvements to modelling practice and suggestions for future research.  
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CHAPTER 1: BACKGROUND TO THE USE 
OF DECISION-ANALYTIC MODELS 
1.1 Introduction 
According to the World Health Organization (2015), ‘the ultimate goal of primary health care 
is better health for all’, of which a key element is ‘organizing health services around people’s 
need and expectations’. The organisation of healthcare typically falls to those who determine 
and manage healthcare systems, and requires decisions to be made about how healthcare 
resources are allocated (Wonderling et al. 2005). However, the resources used to produce 
healthcare services, in a similar sense to other economic goods, are finite, and scarce in 
relation to the demand for them (McPake and Normand, 2008; Morris et al., 2007). Because 
of this scarcity, and because healthcare is seen as fundamental to people’s lives, choices 
around how to allocate healthcare resources are difficult. Economics, and the undertaking of 
economic analyses can potentially assist in making these difficult choices. 
This chapter describes the theoretical and practical background to the use of decision-analytic 
models in healthcare decision-making. The chapter begins by setting the context of decision-
analytic modelling in normative economics and economic evaluation, and outlines the 
different theoretical approaches that can underpin economic analysis. Next the different 
practical applications of economic evaluation are presented, and it is ascertained that 
economic evaluation and decision-analytic modelling is typically undertaken within an extra-
welfarist framework, using cost-effectiveness analysis. Finally, a decision-analytic model is 
defined, and key aspects of model development are described.  
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1.2 Positive and normative economics 
Within health economics, and the economics field generally, distinctions are made between 
positive and normative approaches to economic study (Zweifel and Breyer, 1997). Positive 
economics is concerned with ‘investigating the relationship between economic variables’,  
and providing empirical insight into societal behaviour, such as the factors that determine the 
demand for healthcare (Morris et al. 2007, p.15). Normative economics on the other hand 
involves addressing decisions about how economic systems should work (Black et al., 2009), 
such as how the demand for healthcare should be addressed. The difference in the approach of 
these two branches of economics, then, is the distinction between looking at how things are 
done (positive economics) and how things ought to be done (normative economics).  
Normative economics requires value judgements to be made about the outcomes that are most 
desirable within a particular context, and how these can best be achieved. Morris et al. (2007, 
p.16) define a value judgement as ‘a weighing up of evidence based on the ethical and 
ideological values held by an individual or society’. In the context of health, normative 
economics is needed to make choices about how scarce healthcare resources should be 
produced and distributed, with these judgements being informed by efficiency and equity 
considerations (Black et al., 2009). Economic evaluation provides a normative approach to 
resource allocation within the health sector, allowing alternative health technologies, 
treatments and interventions to be compared according to both their costs and consequences 
(Drummond et al., 2005). The normative elements underpinning the analytical approaches 
used within economic evaluation are thus the decisions around how these costs and 
consequences are defined and measured. Although definitions of costs are fairly consistent 
across the different approaches to economic evaluation, definitions of consequences in terms 
of the outcomes of value, and the way in which benefit is measured, vary. The next sections 
of this chapter outline the theoretical frameworks that traditionally form the basis of the 
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different approaches to economic evaluation in healthcare. These are known as welfarism and 
extra-welfarism.  
1.3. Welfarism  
Welfarism or neo-classical welfare economics is the traditional theoretical basis for economic 
evaluation (McGuire, 2001). ‘Welfarism is generally defined as the systematic analysis of the 
social desirability of any set of arrangements, for example a state of the world or allocation of 
resources, solely in terms of the utility obtained by individuals’ (Morris et al. 2007, p.120). 
This is utility defined as the representation of an individual’s preference for a particular good, 
in terms of the satisfaction and/or happiness that they gain from it (Brouwer et al., 2008). 
Indeed, the only outcome of interest in resource allocation decisions undertaken within the 
welfare economics framework is the utility gained by individuals. This is reiterated in the four 
central tenets that form the basis of the welfarist approach (Hurley 1998, pp.376-77): 
1. Utility maximisation – individuals are rational and consistent in their choices, and will 
seek to maximise their own utility. 
2. Consumer sovereignty – individuals are considered to be the best judges of their own 
welfare, and thus individual assessments of well-being are what matter in decision-
making. The opinions of any third party are irrelevant.  
3. Consequentialism – based on consumer theory, welfare economics only considers the 
outcomes and resulting utilities for individuals in relation to their consumption of 
particular goods or services. The process involved in the individual ‘choosing or 
receiving those goods’ is not accounted for (Morris et al. 2007, p.211).  
4. Welfarism – the desirability of any situation, for example, a resource allocation 
decision, can be judged solely on the basis of the subsequent utilities achieved by the 
individuals affected. 
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Within Paretian welfare economics, to allow particular states of the world to be compared and 
ranked, and thus decisions to be made around how healthcare resources should be allocated, 
trade-offs in terms of the utility attained by individuals need to be made. These trade-offs 
were originally undertaken on the basis of the criterion of Pareto optimality; for practical 
reasons, this was later replaced by the notion of the potential Pareto improvement (Hurley, 
1998). Both concepts are outlined below. 
1.3.1 Pareto optimality criterion 
McGuire (2001) asserts that Pareto optimality encompasses two concepts: Pareto 
improvement and Pareto efficiency. The former concept is considered to be a weak value 
judgement, thus uncontroversial, as it suggests that all individuals should benefit from the 
reallocation of resources (Boadway and Bruce, 1984). Pareto efficiency however, is defined 
as a strong value judgement, in asserting that ‘a reallocation of resources is efficient if at least 
one individual in the economy is made better off and no other individual is made worse off’ 
(McGuire 2001, p.3). With both approaches, ‘a resource allocation is judged to be Pareto 
optimal if and only if it is impossible to increase one person’s utility without simultaneously 
decreasing another’s’ (Hurley 1998, p.377). Both concepts can theoretically be applied within 
welfare economics, and to policy decisions; however, there are problems with the practical 
application of these value judgements. First, Pareto optimality is not concerned with the 
distribution of utilities across individuals, and thus could result in a highly inequitable 
allocation of resources (Tsuchiya and Williams, 2001). Second, Pareto optimality cannot rank 
all states of the world, specifically those that are considered Pareto optimal, as to order these 
states would require some individuals to lose whilst others gain (Tsuchiya and Williams, 
2001). As McPake and Normand (2008) note, there are very few policy decisions that would 
satisfy every individual and/or guarantee no losers. Therefore, use of the Pareto optimality 
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criterion eventually leads to ‘policy paralysis’, as a ‘single, best allocation’ of resources 
cannot be generated (Hurley 1998, p.377).  
The practical drawbacks associated with the Pareto optimality criterion led to the adoption of 
the potential Pareto improvement concept. This concept is based on the independent works of 
Kaldor (1939) and Hicks (1939), and is also often referred to as the Kaldor-Hicks criterion, or 
the compensation principle. The notion behind the potential Pareto improvement is that if 
those who gain from a particular resource allocation decision can theoretically compensate 
those who lose and still be better off, in essence there are no losers, and thus a Pareto 
improvement is possible (McPake and Normand, 2008). Using the compensation principle, 
further trade-offs can be made between states, provided that the gains to those who gain from 
a particular reallocation of resources exceed the losses to those who lose (McPake and 
Normand, 2008). Although in reality compensation is rarely exchanged, the fact that the 
losers can potentially be compensated is considered an overall improvement to societal 
welfare.  
The practical application of the potential Pareto improvement in economic evaluation is 
through cost-benefit analysis. The cost-benefit approach uses monetary weights as a proxy for 
utility, and asks consumers to value the benefits of competing resource allocations through 
their willingness-to-pay (Tsuchiya and Williams, 2001). A change in policy, for example, the 
introduction of a new healthcare service and/or intervention, is deemed to be justifiable if the 
monetary benefits outweigh the costs of implementation i.e. there is an overall net gain to 
society (Robinson, 1993a). 
1.3.2 Criticisms of welfarism 
Despite the theoretical basis that welfarism apparently offers to economic evaluation, related 
to its grounding in microeconomic theory, there are criticisms around the ability of welfare 
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economics to address concerns that are important to the allocation of healthcare resources 
(Morris et al., 2007). In terms of its theoretical groundings, Sen (1985) questioned the focus 
of welfare economics on utility, and the appropriateness of utility as a measure of individual 
well-being. Sen (1985) argues that individuals differ in terms of their capacity to derive utility 
and thus well-being from commodities, as people adapt their desires and levels of happiness 
to their expectations and real life situations. Individual assessments of well-being and utility 
are thus affected by personal characteristics (Morris et al., 2007); however, personal 
characteristics are ignored in resource allocation decisions based within the welfarist 
framework. Further, it has been argued that measuring social welfare only in terms of the 
utility that individuals gain from consumption is too restrictive, as health can only be valued 
insofar as it results in utility (Coast, 2009; Mooney and Russell, 2003). Arguably, additional 
factors, such as changes to an individual’s health, may be important in decisions around the 
reallocation of healthcare resources. Such criticisms of utility raise issues around the 
suitability of using welfare economics in a healthcare decision-making context, given the 
reliance of the framework on consumer choice theory as a predictor of consumer behaviour 
(Morris et al., 2007). Indeed, Arrow (1963) highlights how the nature of people’s demand for, 
and consumption of healthcare is irregular and unpredictable when compared to that for other 
economic goods, and how elements of traditional economic theory are largely not applicable 
within the healthcare market.  
On a practical level, welfare economics is criticised because of its indifference to the 
distribution of resources, on the basis of the use of the potential Pareto improvement criterion. 
Monetary value is used as a proxy for utility within cost-benefit analysis, and thus benefit is 
measured on the basis of income gains or losses (McGuire, 2001). The problem with the 
criterion is that it assumes that individuals place the same amount of value on one unit of 
currency, when in reality this value is likely to be influenced by initial level of income 
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(Tsuchiya and Williams, 2001). The implication of this, as outlined by Coast et al. (2008), is 
that measures of willingness-to-pay are likely to be affected by an individuals’ ability to pay, 
and thus the allocation of healthcare resources could be ‘skewed’ towards the wealthy. Given 
that interpersonal comparisons are not permitted using the welfarist approach (i.e. everyone 
starts from the same point), and compensation under the potential Pareto improvement 
criterion is unlikely to be paid, decisions could result in the very inequitable distribution of 
healthcare resources (McGuire, 2001). In response to these criticisms, the extra-welfarist 
approach was developed. 
1.4 Extra-welfarism 
Brouwer et al. (2008) imply that the introduction and use of extra-welfarism has grown in part 
from ‘seeds’ of criticism sown by Sen (1970; 1980). In summary, this refers to the focus of 
welfare economics on utility as being too narrow a measure of well-being, and the argument 
that a broader perspective is needed to measure the wider capabilities that a person can 
acquire from a particular healthcare good. Further, welfarism was criticised for not explicitly 
taking into account equity concerns under the strict application of the Pareto principle. The 
work of Sen and also Culyer (1989) is largely credited for the development of the extra-
welfarist approach as an alternative framework for economic evaluation. In terms of the 
contribution of Culyer (1989), this particularly relates to the maximisation and distribution of 
health, as opposed to utility, as the outcome of focus in resource allocation decisions. Culyer 
(1989) asserts that healthcare resources should be allocated on the basis of need, as the need 
for healthcare implies a deprivation in health, and thus healthcare can reduce this deprivation. 
The extra-welfarist approach therefore takes account of personal characteristics within its 
decision-making, given that these characteristics describe and provide a comparison of 
people’s ill-health, incorporating factors into evaluations such as whether or not people are 
happy, free of pain, and/or physically mobile (Brouwer et al., 2008; Culyer, 1989). Equity 
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issues can then be addressed through adding distributional weights to particular characteristics 
of people, on the basis of societal values outlining who needs to benefit from health 
production (Culyer, 1989; Hurley, 1998). The very definition of extra-welfarism implies that 
the approach adds something ‘extra’ to welfarism, and indeed, Brouwer et al. (2008) suggest 
that extra-welfarism transcends welfarism in four general ways. These are that ‘it permits the 
use of outcomes other than utility, it permits the use of sources of valuation other than the 
affected individuals, it permits the weighting of outcomes (whether utility or not) according to 
principles that need not be preference-based, and it permits interpersonal comparisons of well-
being in a variety of dimensions’ (Brouwer et al. 2008, p.330).  
Culyer (1989) also advocates the use of the quality adjusted life year (QALY) as an approach 
to health measurement. ‘The QALY is a measure of health outcome which assigns to each 
period of time a weight, ranging from 0 to 1, corresponding to the quality of life during that 
period, where a weight of 1 corresponds to perfect health and a weight of 0 corresponds to a 
health state judged equivalent to death’ (Garber et al. 1996, p.29). The benefit of a health 
intervention is thus measured as ‘the difference over a period of time between expected 
QALYs with a particular procedure and without it (or with an alternative)’ (Culyer 1989, 
p.52).  
However, extra-welfarism has been met with some criticism, particularly in terms of its 
practical application, as it has been argued that the focus on health as the single outcome of 
importance within economic evaluation is too narrow and restrictive (Coast, 2004; Hurley, 
1998). Hurley (1998) asserts that extra-welfarism and welfarism share the same limitation, in 
the fact that they are both consequentialist in nature, and thus the benefits of an intervention 
within the extra-welfarist framework can only be valued in terms of the intervention’s ability 
to produce health. It is possible that other, non-health related, benefits could be generated as a 
result of a particular healthcare programme (Coast et al., 2008); however, these cannot be 
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captured using health focussed measures, such as the QALY. A further criticism relates to the 
consideration of equity within the extra-welfarist framework, and the implicit assumption 
underlying the calculation of health effectiveness, that QALYs are of equal value to society 
no matter who gains them (Birch and Donaldson, 2003). Russell et al. (1996) argue that, as a 
society, we are likely to place different values on different people’s need for healthcare, and 
although the extra-welfarist approach theoretically allows us to do this, in practice there is 
uncertainty in applying these distributional weights. 
Despite such problems, extra-welfarism, including the focus on the QALY as a measure of 
health, is typically the basis on which economic evaluation is undertaken within the UK and 
internationally (Coast et al., 2008; Torrance et al., 1996; Tsuchiya and Williams, 2001). In the 
UK and Canada (the settings for empirical work undertaken within this thesis), the National 
Institute for Health and Care Excellence (NICE) and the Canadian Agency for Drugs and 
Technologies in Health (CADTH) respectively, are responsible, among other things, for 
advising via technology appraisal or health technology assessment (HTA), whether new 
health technologies should be adopted (CADTH, 2015; NICE, 2015a). For NICE this is in the 
form of recommendations made to the National Health Service (NHS), and for CADTH, 
advice to decision and policy makers responsible for funding decisions in the various Federal, 
Provincial and Territorial Ministries of Health across Canada. In the case of NICE, the NHS, 
at least in England, is legally obliged to fund and resource treatments and medicines that are 
recommended within their technology appraisals (NICE, 2015b). Both NICE and CADTH 
rely on information submitted from external sources (for example, academic groups and 
manufacturers and sponsors), and base their recommendations on economic and clinical 
evidence, specifically the economic evaluation of competing health interventions in terms of 
their relative cost-effectiveness (CADTH 2006; NICE 2013).  
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The purpose of economic evaluation, and the practical applications of the welfarist and extra-
welfarist approaches to economic evaluation, are outlined next. An introduction to decision-
analytic modelling is given in section 1.6. 
1.5 Economic evaluation in healthcare 
In economic evaluation, choices around the allocation of scarce healthcare resources are based 
on comparative evidence of the costs and health benefits associated with competing 
interventions (Drummond et al., 2005). Gray et al. (2011) suggest that economic evaluation 
has developed from the recognition that cost and effectiveness information, particularly 
related to the benefits forgone by choosing a particular course of action, is necessary for 
decision-making. Thus, underlying the choices made in the allocation of healthcare resources, 
is the notion of opportunity cost, that committing resources to the production of one good or 
service ‘is the benefits forgone from those resources not being used in their next best 
alternative’ (Morris et al. 2007, p.3). A criterion used to help decision-makers to decide across 
alternative options, is efficiency (Shiell et al., 2002). There are two key types of efficiency 
with which economics is concerned: technical efficiency and allocative efficiency. Technical 
efficiency relates to how best to allocate resources, either in terms of maximising a particular 
output relative to its input, or minimising costs to achieve a desired level of output (Shiell et 
al., 2002). Allocative efficiency is concerned with questions around whether to allocate 
resource to an intervention, and is said to have been met when no further benefit can be 
generated from reallocating resources between interventions within a healthcare system 
(Shiell et al., 2002). The different approaches to economic evaluation addresses these 
efficiency concerns to various degrees, in addition to using different methods to value and 
measure outcomes for decision-making. The next sections briefly describe the different types 
of economic evaluation undertaken, specifically cost-benefit analysis, cost-effectiveness 
analysis and cost-utility analysis. 
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1.5.1 Cost-benefit analysis 
Cost-benefit analysis is theoretically grounded in welfarism, and is a method of economic 
evaluation where both the costs and benefits of a healthcare intervention are valued in 
monetary units (Wonderling et al., 2005). Monetary equivalents are assigned to prolongations 
of life and change of health status, derived from the use of a particular treatment (Zweifel and 
Breyer, 1997). Using units of money as a measure of (positive and negative) benefit allows 
the cost-benefit of interventions and services to be compared within the health sector and 
across different areas of health, but also between different areas of expenditure within society 
(Gray et al., 2011). To generate the results of a cost-benefit analysis, the cost of an 
intervention is compared with the monetary value of the outcomes achieved, producing a 
calculation of net benefit (Wonderling et al., 2005). Net benefit involves subtracting the 
resource cost of an intervention from its monetary benefit, asserting that if the benefit from an 
intervention is greater than the cost i.e. the net benefit is greater than zero, an intervention is 
cost-beneficial and should be implemented (Wonderling et al., 2005). Competing 
interventions can thus be compared according to the level of net benefit offered. Cost-benefit 
analysis enables both technical and allocative efficiency concerns to be addressed, given that 
the results can indicate which health intervention(s), if funded, maximise societal welfare, and 
how resources can optimally be allocated within a healthcare system, and across broader 
sectors of the economy. 
However, the cost-benefit approach has had limited use in economic evaluation and policy 
decision-making, due to equity (see section 1.3.2) and ethical concerns around whether it is 
appropriate to value health benefit, and thus human life, in monetary units (Ryan et al., 2003; 
Zweifel and Breyer, 1997).  
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1.5.2 Cost-effectiveness analysis and cost-utility analysis 
Both cost-effectiveness analysis and cost-utility analysis have their theoretical underpinnings 
in extra-welfarism, and thus both focus on the comparison of healthcare interventions in terms 
of the health outcomes generated. Cost-effectiveness analysis involves comparing the cost of 
the resources spent on an intervention, with the quantity of health gained as a result 
(Wonderling et al., 2005). Health outcomes are measured in natural units on a unidimensional 
scale i.e. the unit of outcome is the same between interventions, for example, different 
diagnostic tests might be compared according to the cost per case detected (Gray et al., 2011; 
Zweifel and Breyer, 1997). The results of a cost-effectiveness analysis can therefore address 
questions around technical efficiency, in indicating whether an intervention compares 
favourably to an alternative, specifically whether it can minimise the costs associated with 
achieving a certain level of health benefit (Donaldson, 1998). However, information on 
allocative efficiency from a cost-effectiveness analysis is limited, as interventions cannot 
directly be compared across different areas of health, or across different sectors of the 
economy.  
When using cost-effectiveness analysis, the costs and effects of an intervention and its 
alternatives are established, and the differences in costs and the differences in effects between 
the interventions are calculated and presented in the form of a ratio (Gray et al., 2011). This is 
referred to as an incremental cost-effectiveness ratio (ICER), and is the difference in costs 
divided by the difference in effects between competing options. An ICER can thus be 
interpreted as the incremental price of obtaining an additional unit of health effect from a 
particular health intervention, when compared to an alternative (Garber et al., 1996). When an 
intervention is both less expensive and more effective than its alternative, it is considered to 
be dominant, and thus the most cost-effective option (Robinson, 1993b). However, an 
intervention may be more costly but also more effective than its alternative, and in this case 
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the ICER must be compared to a given cost-effectiveness threshold, which represents 
society’s willingness-to-pay for a unit of health benefit (Morris et al., 2007). Although there is 
uncertainty around how the cost-effectiveness threshold should be determined (McCabe et al., 
2008), current cost-effectiveness thresholds are valued in cost-per-QALY (Morris et al., 
2007), thus requiring a cost-utility analysis to be undertaken.  
Considered to be a subset of the cost-effectiveness analysis approach, cost-utility analysis 
typically involves comparing the benefits of interventions in terms of QALYs. The QALY 
combines into one measure the effectiveness of an intervention in relation to survival in terms 
of life-years and health-related quality of life (Gray et al., 2011). Methods to derive quality of 
life weights draw on utility theory, and involve asking people to value or indicate their 
preference for spending time in a particular diminished health state, or, in the case of those 
affected, asking them to assess their quality of life directly (McPake and Normand, 2008). 
Like cost-effectiveness analysis, the most cost-effective intervention, from those compared, is 
considered to be that which produces the most QALYs for the least cost, subject to a budget 
constraint (Tsuchiya and Williams, 2001). A cost-utility analysis allows both technical and 
allocative efficiency questions to be addressed, as the results can give an indication as to 
which interventions offer the most health gain for the least financial investment, and 
interventions can be compared across different clinical areas. Both NICE and CADTH 
advocate the use of cost-utility analysis as the appropriate method for economic evaluation 
(NICE 2013; CADTH 2006). 
 ‘For the reference case, cost-effectiveness (specifically cost–utility) analysis is the 
preferred form of economic evaluation. This seeks to establish whether differences in 
expected costs between options can be justified in terms of changes in expected health 
effects. Health effects should be expressed in terms of QALYs’ (NICE 2013, p.37) 
‘Use a cost-utility analysis (CUA) as the Reference Case where meaningful 
differences in health-related quality of life (HRQL) between the intervention and 
comparators have been demonstrated’ (CADTH 2006, p.4) 
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1.6 Decision-analytic modelling for economic evaluation 
To inform economic evaluation and cost-effectiveness analyses, data on the costs and 
effectiveness of interventions are needed. To gather these data, a primary research design can 
be used, in which economic and additional health outcomes are ‘piggybacked’ onto an 
existing randomised controlled trial (RCT) (Torrance et al., 1996). However, reliance on a 
single RCT to inform economic evaluation has been criticised because of the inability of a 
clinical trial to compare all relevant interventions for the treatment of a disease, to incorporate 
all (alternative) evidence that is important to a resource allocation decision, and to compare 
the long-term costs and outcomes associated with competing interventions (Mandelblatt et al., 
1996; Sculpher et al., 2006). Decision-analytic models are thus recommended as a vehicle for 
economic evaluation, due to their ability to provide a platform for the comparison of all 
relevant treatment options, and to synthesise all relevant data over an extended time horizon 
(Buxton et al., 1997; Sculpher et al., 2006). NICE and CADTH advocate the use of decision-
analytic models in economic evaluation and decision-making, with NICE describing 
modelling as ‘an important framework for synthesising available evidence and generating 
estimates of clinical and cost effectiveness’, and both organisations including guidance on 
model building in their respective reference case of methods (NICE 2013, p.49; CADTH 
2006). 
A decision-analytic model is essentially a mathematical structure that can represent the health 
and economic outcomes for patient populations receiving particular medical interventions 
(Kuntz and Weinstein, 2001). A model uses mathematical relationships to express the 
likelihood of particular health consequences occurring within each of the interventions 
compared. The nature of these consequences informs the structure of a model. Each 
consequence has a related cost and outcome, which, when weighted with the probability of its 
occurrence, enables a calculation of the expected costs and expected outcomes associated with 
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each intervention under evaluation (Briggs et al., 2006; Drummond et al., 2005). Although 
guidance on how to develop decision-analytic models varies (this will be explored further in 
chapter 2), there are broadly considered to be three key aspects to model construction. After a 
decision problem has been defined (for example, the setting, perspective and disease area of 
focus), these are: structuring the model, populating the model (identifying and collecting 
appropriate data), and assessing uncertainty within the model and its results. 
1.6.1 Structure 
In terms of structural development, there are a number of different types of model that can be 
used to address a decision problem. Those most commonly referred to are the decision tree, 
the Markov model and individual sampling models. Of these, the decision tree model is 
considered the simplest.  
In a decision tree, an initial decision node represents the strategies being compared, and 
downstream from this are a series of branches with accompanying chance nodes, which 
denote the probability of a patient following one particular clinical pathway as opposed to 
another. At the end of a decision tree structure are a number of outcome nodes, which indicate 
both the costs and health effects associated with each pathway (Kuntz and Weinstein, 2001). 
The cost-effectiveness of each intervention is then determined by rollback calculation of the 
sum of the values in each pathway, weighted by the pathway probabilities (Briggs et al., 
2006).  
A Markov model structure is represented as a set of mutually exclusive and exhaustive health 
states that patients remain in for a fixed period of time (cycle length), and to which transition 
probabilities are assigned to indicate patients’ movement from one health state to another. 
Each health state is assigned a utility (effectiveness) value, and the overall utility gained from 
each intervention being compared is dependent on the total length of time that patients spend 
    
19 
 
in each state, over the time horizon of the model (Sonnenberg and Beck, 1993). Costs are then 
similarly calculated according to the proportion of patients in a given health state during each 
cycle (Barton et al., 2004).  
Individual sampling models require patients to be tracked individually through a model, 
following different sequences of health states, and allowing total expected costs and outcomes 
to be calculated for each patient (Barton et al., 2004). This type of model is aimed at 
representing the variability between the costs and outcomes of patients, for a more appropriate 
estimate of cost-effectiveness (Briggs et al., 2006).  
Despite the mathematical nature of the relationships underlying a model structure, decisions 
around the structural inputs are rather more subjective in comparison. This includes decisions 
on the appropriate approach or type of model to use, how a particular structure represents the 
disease or condition in question (for example, the pathways or health states involved), and 
how the boundaries of a model are defined. These decisions are largely made in response to 
the context of the decision problem and the nature of the condition being modelled (Briggs et 
al., 2006; Drummond et al., 2005), but are also influenced by the choices and preferences of 
the modeller. 
1.6.2 Data  
After a model structure has been developed, data are required to populate the input parameters 
of a model. These include clinical data, specifically the probabilities associated with the 
transition of patients from one health state or pathway to another, and clinical effectiveness 
data, where the outcome of interventions are measured in natural units. Economic data are 
then needed for the costs and, in the case of cost-utility analysis, utility values (utilities) 
associated with patients’ experiences of a particular pathway or health state within a model. 
Utilities generally refer to the quality of life weights used to value particular health outcomes, 
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and therefore inform the overall measure of the effectiveness of an intervention. Both clinical 
and economic data can be collected through a variety of methods, including the use of 
primary and secondary sources. Again, the choices around which data to use and how to 
identify them are somewhat subjective, as modellers have a number of different evidence 
sources to select from. 
1.6.2.1 Discounting 
Discounting is based on the principle that all future costs and health consequences within a 
cost-effectiveness analysis (and thus in a model) should be stated in terms of their “present 
value” to the decision-maker (Lipscomb et al., 1996). The process of discounting involves 
identifying the year in which costs and benefits occur, and adjusting these to represent their 
worth today. Discounting enables a comparison between interventions that incur costs and 
generate benefits over a number of years. The rationale for discounting encompasses the 
argument that individuals have a positive time preference for earlier consumption over later 
consumption, and thus favour having money and benefits now (hence why future costs and 
consequences are discounted) (Cairns, 2001). Despite widespread acceptance that discounting 
should be undertaken, there remains controversy over how discount rates should be 
determined, and what these discount rates should be (for example, whether rates should be the 
same for costs and benefits) (McPake and Normand, 2008). Currently, for both costs and 
outcomes, NICE promote a discount rate of 3.5% per year, and CADTH recommend a 
discount rate of 5% (CADTH 2006; NICE 2013). 
1.6.3 Assessment of uncertainty 
A requirement of modelling for economic evaluation is to acknowledge the potential 
uncertainty inherent in a particular cost-effectiveness result (Briggs et al., 2006). Andronis et 
al. (2009) distinguish between three types of uncertainty: methodological uncertainty, 
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parameter uncertainty and structural uncertainty. Methodological  uncertainty is concerned 
with the analytical methods used to develop a model, such as how costs and outcomes are 
discounted, what outcome measures are used, and how costs are calculated and health 
outcomes valued (Briggs, 2000). Parameter uncertainty relates to the data that inform the 
input parameters to a model, and whether the estimates used are accurate and appropriate. 
Structural uncertainty asks whether an appropriate approach has been taken to develop a 
structure, in terms of pathways and health states used to combine the input parameters 
(Andronis et al., 2009). 
Andronis et al. (2009) assert that all of these types of uncertainty can be addressed by using 
sensitivity analysis to determine the impact on the model results. Sensitivity analyses on the 
parameters in a model can be univariate or multivariate, with single or multiple data estimates 
being varied to note the effect on the results (Manning et al., 1996). With the latter, best/worst 
case scenario analysis can also be carried out, to check whether the results are robust to the 
most optimistic or pessimistic combination of input values. As an alternative to deterministic 
sensitivity analysis (in which uncertain parameters are assigned a point estimate value), 
probabilistic sensitivity analysis involves each parameter being assigned a distribution, 
allowing where appropriate for correlation between the uncertainty in different parameters. 
Values from these distributions are drawn randomly over the large number of times that a 
model is run, to produce a joint distribution of the differences in cost and effectiveness 
between the interventions modelled (Andronis et al., 2009; Doubilet et al., 1985). Similarly, 
methodological and structural uncertainty can be addressed by varying the analytic methods 
and structural assumptions used, and reporting the effect on the model results (Briggs, 2001; 
Manning et al., 1996). Model validation and other model checking activities focus on 
evaluating the base case model. This can involve checks to the inputs and internal workings of 
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the model, and the validation of the structure, data and results against external sources, such 
as other studies and expert opinion (Mandelblatt et al., 1996). 
1.6.4 The submission of decision-analytic models to decision-making bodies 
Although decision-analytic models are developed for different purposes, for example, to 
generate clinical knowledge in an academic context, NICE and CADTH are concerned with 
reviewing models that will potentially contribute to policy decision-making, and how 
healthcare technologies are funded. NICE have a well-established process for the submission 
of models for technology appraisal, following either the single technology appraisal process 
(STA) or multiple technology appraisal (MTA) process. Where the former refers to the 
appraisal of a single technology, through review of cost-effectiveness evidence submitted by a 
manufacturer/pharmaceutical company, the latter involves the appraisal of multiple 
technologies, with evidence submitted through a variety of sources and consultee 
organisations, including manufacturers (NICE, 2014). In the STA process, models are 
appraised by an independent evidence review group, who subsequently produce a report on 
the cost-effectiveness of a technology. The MTA appraisal process is similar, but it is an 
independent academic assessment group who prepare a review and report of the comparative 
cost-effectiveness of technologies, based on the evidence available. Submissions via both of 
these processes inform funding recommendations and clinical guidance within the NHS. 
CADTH uses a similar process to NICE, whereby manufacturers submit cost-effectiveness 
evidence (including a model) on a particular drug to the common drug review (CDR), where 
the Canadian Drug Expert Committee (CDEC) evaluate the evidence, and provide 
recommendations for the funding of a drug on its basis (CADTH, 2014). 
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1.7 Conclusion  
This chapter has given an overview of the background to the use of decision-analytic models, 
including their theoretical and practical underpinnings in economic theory and economic 
evaluation. The importance given to use of decision-analytical models in economic evaluation 
has been outlined, particularly in relation to their ability to compare the cost-effectiveness of 
numerous healthcare interventions over an extended time horizon. The chapter has also 
demonstrated the reliance of organisations such as NICE and CADTH on the cost-
effectiveness results generated by models, to inform healthcare funding and adoption 
decisions. However, there have been various reports of errors present in published and 
industry submission models (Chilcott et al., 2010), with the latter referring to those that are 
submitted by pharmaceutical companies to NICE, for recommended use within the NHS. The 
implication of the development of poor quality or ‘erroneous’ models is the potential for these 
to generate less than optimum cost-effectiveness recommendations and resource allocation 
decisions. The next chapter explores examples of models in which methodological errors have 
been identified.  
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CHAPTER 2: METHODOLOGICAL ERRORS 
IN MODELS AND A REVIEW OF THE 
MODEL-BUILDING GUIDANCE 
2.1 Introduction 
Chapter 1 has introduced the role of decision-analytic models in cost-effectiveness decisions 
within the UK and internationally. Clearly, and particularly in the context of NICE 
policymaking, these models play an important part in deciding how scarce healthcare 
resources are distributed. However, there is some suggestion that economic models are using 
inappropriate information and methods in their development (Chilcott et al., 2010; Karnon et 
al., 2007; Roberts et al., 2006). The first section of this chapter discusses the definition of an 
error, and focuses the thesis on the exploration of methodological ‘errors’ in modelling 
processes. The second section examines examples of literature that highlight these errors in 
industry submission and published models. Finally, the chapter finishes with a systematic 
review of modelling guidance, aimed at identifying the guidance that is currently available to 
modellers.  
2.2 The definition of modelling error 
Chilcott et al. (2010) distinguish between two types of model error: (1) those that are related 
to software implementation and the ‘technical’ aspects of model development, and (2) those 
that are methodological and concern the choice of approach used by modellers. Whilst 
Chilcott et al. (2010) argue that the former type of error is well-researched, but unavoidable 
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within models, the authors suggest that there is less known about methodological errors, and 
thus greater clarification required in terms of what constitutes poor practice in modelling 
methods. Decisions around model structure are inevitably subjective, dependent on both the 
context of the model and the choices of the modeller. However, these subjective decisions are 
likely to impact on model cost-effectiveness results and recommendations, and thus it seems 
right to argue that there should be basic standards of good practice in place for modellers to 
follow. Going forward, this thesis is focused on the context of methodological errors, with the 
next section exploring examples of existing models in which this type of problem has been 
identified. 
2.3 Methodological errors in economic models  
A number of papers have highlighted problems with existing economic models. These include 
industry submission models, and those that have been published for academic purposes, 
which can also inform decision-making. The majority of the papers cited refer to industry 
submission models, and were collected via a search of STAs published on the NICE website. 
This search generated a number of examples of models that had been deemed to be poor 
quality by NICE evidence review groups (ERGs).  
A commonly highlighted problem in submitted economic models was the validity of clinical 
pathways or states in the structure. For example, concerning the submission for ranibizumab 
for the treatment of diabetic macular oedema, the NICE summary of the ERG’s comments 
suggested that the manufacturer’s model did not accurately represent clinical practice, as all 
patients were receiving treatment on only one eye, when in reality a significant proportion 
receive treatment on two (NICE, 2011). When the cost of this additional treatment was 
incorporated into the ICER calculations by the ERG, the ICER increased by 50%. Similarly, 
in the submissions for erubulin and fludarabine monotherapy for the treatment of breast 
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cancer and chronic lymphocytic leukaemia respectively (NICE, 2007, 2012), the ERG 
commented that manufacturers had not included important adverse events associated with the 
drugs, which if incorporated would increase the ICER due to associated disutility. In a 
submission for Eltrombopag, for the treatment of chronic immune (idiopathic) 
thrombocytopenic purpura, the ERG considered the model structure to be based on an 
inappropriate clinical assumption, specifically that patients received treatment solely 
according to bleeding events experienced, rather than additional outcomes, such as adverse 
events (NICE, 2010). The ERGs also continually cited problems with the data used to 
populate models, including the lack of a systematic review for clinical parameters, and 
highlighted instances of manufacturers using outdated and inappropriate costs, and utility 
values that were not representative of the patient population. 
The above findings are supported by a more rigorous analysis of ERG’s critiques of 
manufacturers’ submissions to NICE (Kaltenthaler et al. 2012). Kaltenthaler et al. (2012) 
found that the majority of ERG reports expressed uncertainty about the quality of submitted 
models, implying that manufacturers were exaggerating the effect of their technologies, and 
were not fully representing risk to patients. This relates to the findings of the technology 
appraisals cited earlier, as manufacturers were criticised for the clinical representativeness of 
their models, and excluding important adverse events, generating more favourable model 
outcomes for their interventions.  
The review of manufacturer’s submissions and related ERG comments did not indicate why 
these ‘errors’ were present within the models, although there are a few possible explanations. 
It may be that manufacturers are intentionally submitting models that provide an optimistic 
representation of the cost-effectiveness of their interventions. Miners et al. (2004), for 
example, demonstrated in the case of MTAs, that ICERs submitted by manufacturers for their 
own interventions were significantly lower than those calculated by independent academic 
    
27 
 
groups. However, it is also possible that modellers are using inappropriate methods, for 
example, in not referring to clinical literature or seeking clinician opinion to determine the 
clinical aspects of a structure. Either way, the suggestion is that modellers could improve their 
approaches to model development. Although poor practice in these model submissions has 
been detected (and thus revised, or the particular technology has not been recommended), it is 
possible that despite thorough consideration from an ERG, some errors go unnoticed. More 
certain is that the submission of poor quality models to NICE for appraisal is an inefficient 
use of NICE resources.  
There have been a number of studies that have identified errors in published models. 
Arguably, errors at this level have greater consequence, as the results produced by these 
models are widely available and could potentially be referred to by the clinical community in 
decision-making. The studies highlighting errors in published models were either systematic 
reviews, or case studies of economic evaluations within a specific disease area (Chen et al., 
2006; Karnon et al., 2007; Roberts et al., 2006). In their systematic review of economic 
evaluations of screening for chlamydia trachomatis, Roberts et al. (2006) found that the 
majority of models published were using inappropriate structures, based on static rather than 
dynamic approaches (decision trees and Markov models). Only three of forty-two models 
reviewed were considered to be using a suitable structure, specifically a transmission dynamic 
model, which could account for interaction between individuals, and represent factors such as 
the risk of reinfection to a cured individual, as is possible within some infectious diseases. 
Roberts et al. (2006) concluded that the majority of models were methodologically flawed, 
which would impact on the validity of their results. Indeed, a study undertaken in the 
Netherlands that compared the results of a static and dynamic model for chlamydia screening, 
found that the static structure was likely to underestimate the cost-effectiveness of chlamydia 
screening, as it could not account for the ‘indirect protection effects’ associated with an 
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individual being screened and cured (Welte et al. 2005, p.478).  This was in terms of the 
negative health outcomes and costs avoided in curing the individual and their current partner, 
and preventing future partners from contracting chlamydia.  
A similar issue was identified in a systematic review of cancer screening models undertaken 
by Karnon et al. (2007). The authors noted that the use of simple decision tree structures 
within a number of the studies did not reflect the natural history of the disease, and thus did 
not represent the true costs and consequences associated with the cancer being detected at 
various stages of its progression i.e. in terms of the aggression of treatment required, and 
treatment effectiveness in eradicating cancerous cells. Chen et al. (2006) found in reviewing 
economic evaluations for the treatment of rheumatoid arthritis that published models had used 
inappropriate structural assumptions, for example, in assuming that patients could not swap 
between treatments, and had used irrelevant treatment comparators, and inappropriate cycle 
lengths within Markov models. The industry submission on which two of the published 
papers were based was deemed particularly problematic, as model health states, costs and 
utility data were not representative of a recent UK population, but instead were from a 
decade-old North American database. The authors noted that the two models published that 
had used these data had reported ICERs within NICE’s ‘acceptable range’ (Chen et al., 2006). 
The review of this modelling literature has highlighted methodological errors in industry 
submission and published models. Problems were identified at various stages of structural 
development, particularly the use of inappropriate information to inform model structures. 
These errors were seemingly related to modellers’ decisions around model structure, which 
were demonstrated to have an influential impact on the quality of models, but also on cost-
effectiveness results. Arguably more needs to be done to encourage modellers to use 
appropriate methods; however, it was unclear from the studies why methodological errors 
were occurring. A possibility is that modellers were not aware of what constitutes good 
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practice in model development, particularly in terms of structure. The next section looks at the 
modelling guidance currently available for the model-building process.  
2.4 A systematic review of current model-building guidance 
A systematic literature review was undertaken to explore current model-building guidance. The 
aim was to identify guidance available to modellers about modelling methods and processes. 
The review was motivated by the presence of methodological errors in models, and the question 
of whether modelling guidance could, if referred to, help to prevent these. This review was 
originally undertaken in September 2012 as part of an MSc dissertation, but was updated and 
extended in September 2015 to take into account any recent and relevant studies that had been 
published. The methods used within the systematic review are described next.  
2.4.1 Review question  
What guidance currently exists for the process of decision-analytic model building?  
The review question was broken down into a number of different aims: 
1. To search for guidance on the entire process of model building 
2. To search for guidance that offers advice on particular stages of model development 
3. To look at what guidance is currently available, for example, who is it aimed at? How 
detailed is it? 
4. To establish which aspect(s) of model development are least focused on within 
modelling guidance (and potentially require improvement). 
2.4.2 The search strategy  
In preparation for a full review of the literature and in line with guidance from the Centre for 
Reviews and Dissemination (CRD 2008), the first stage of the search involved a check for 
similar reviews. This check was undertaken through a search of the Cochrane Database of 
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Systematic Reviews. Given that the objective of this phase was to justify the need for a new 
review in the proposed research area (CRD 2008), the search was designed to be as broad as 
possible, so as to demonstrate with confidence that there were no current reviews that 
specifically addressed the research question. The original search undertaken in August 2012 
generated 1443 articles, none of which were deemed to be directly relevant to the systematic 
review proposed. One review was identified on model-building guidance, but its aim was to 
synthesise existing guidelines to provide advice on good practice, rather than comment on the 
type of guidance available (Philips et al., 2006). This paper was therefore later captured in the 
results of this systematic review. However, on updating this review, a recent study was 
identified that directly addressed the research question, and similarly aimed to explore the focus 
and quality of existing modelling guidance (Penaloza Ramos et al., 2015). However, the 
objective of this work was different to that of the current review, as the authors ultimately aimed 
to compare the advice available in current guidelines for various stages of model development 
(Penaloza Ramos et al. 2015), as opposed to highlighting stages for which guidance was less 
detailed, or missing completely. Additionally, the final search date for the current review was 
24th September 2015, meaning that the search undertaken here extended beyond that of 
Penaloza Ramos et al. (2015), which was completed in March 2014. The findings of the 
Penaloza Ramos et al., (2015) review are compared to the results of the current review in section 
2.4.6.4.  
Following this stage, a full systematic review was undertaken. This review aimed to be both 
thorough and exhaustive in identifying papers that offered model-building guidance, to ensure 
that research conclusions were as informed and unbiased as possible (Petticrew and Roberts, 
2006). The search strategy involved a number of stages: 
 The searching of major electronic bibliographic databases for potentially relevant 
articles 
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 Forward citation searching on key papers within electronic databases  
 The systematic scanning of reference lists of relevant key papers 
 The searching of published textbooks  
 The searching of relevant online sources.  
2.4.2.1 Pilot search  
Pilot searches were undertaken to test the effectiveness of different search strategies within 
electronic databases. Perhaps not surprisingly, it was established that searches that included 
further variations on a particular search term retrieved a larger number of relevant papers. This 
related particularly to the use of terms that broadened searches to include guidance on individual 
stages of model development, in addition to papers focused on the entire model-building 
process. The pilot searches also demonstrated the sensitivity of the databases to the use of 
particular search terms. For example, using MEDLINE®, additional papers were retrieved 
through including the term ‘Economics, Medical’ as an alternative to ‘health economics’. 
2.4.2.2 Electronic database searching 
As recommended within the CRD guidance (CRD, 2008), the search terms used in the 
electronic databases were determined by the research question. Given that the focus was on 
finding methodological rather than effectiveness papers, the widely used ‘PICO’ strategy was 
not considered appropriate. The research question was therefore broken down into three 
components: context (health economics), subject (modelling process) and area of interest 
(guidance). The first component related to the context of the search, i.e. the circumstances in 
which decision-analytic models are used, whilst the second referred to the phenomenon being 
studied, and the third, the particular aspect of the subject with which the research was 
concerned. To increase the scope of review findings, a full set of search terms were generated 
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as expressions, synonyms or spelling variants of the three original search components. The 
search strategy was implemented in the following major bibliographic databases: Ovid 
MEDLINE®, EMBASE, and Health Management Information Consortium (HMIC). Search 
terms were modified and expanded as searching progressed, relative to the contents of each 
individual electronic database. The searches were not restricted by date. 
The ‘find citing articles’ feature of the electronic databases was used to retrieve papers that had 
referenced the articles found through database searching. A number of ‘key papers’ were 
selected for this, based on their perceived relevance to the research question. This particular 
element of the search was considered important, given that authors may have cited previous 
guidance in the development of their own guidelines. Details of the full search strategies 
undertaken within each database are given in Appendix 1. 
2.4.2.3 Reference list searching  
Reference list searching was used to identify additional papers relevant to the research 
question (Lefebvre et al., 2008). The process of reference list searching began with two key 
papers, whose reference lists were scanned for additional articles that met the inclusion 
criteria. Next, the reference lists of the papers identified via the key papers were reviewed, 
and this continued until the reference list of every article at each stage was searched, and no 
further relevant papers were retrieved. The key papers were recognised as such because they 
provided in-depth guidance on structural development (Chilcott et al., 2010; Roberts et al., 
2012). 
2.4.2.4 Searches in textbooks 
The University of Birmingham’s library search engine was used to search for textbooks that 
contained guidance on decision-analytic modelling. This involved searching specifically for 
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modelling textbooks, but also for health economics textbooks that contained sections on 
modelling.  
2.4.2.5 Online sources 
Given the role of models in healthcare funding decisions within the UK and Canada, and the 
focus on these settings as the context for this research, both the NICE and CADTH websites 
were reviewed for their guidelines on the model-building process. 
2.4.3 The selection of literature  
The papers returned through the various methods of literature searching were all screened using 
predefined inclusion and exclusion criteria. The aim was to separate papers relevant to the 
research question from those that were not. The selection of literature for inclusion in the review 
was iterative, in the sense that the inclusion criteria were applied to the final list of papers a 
number of times. Initially, at the stage at which the papers were identified, their titles and 
abstracts were checked against the inclusion criteria with the aim of avoiding the exclusion of 
any literature that could potentially be relevant to the research question. However, the papers 
whose titles and abstracts were clearly not relevant were discarded at this point. The papers that 
made it through this stage were then downloaded or considered in their full-text format, for a 
more in-depth check against the criteria. Those included at this stage informed the results of the 
review.  
2.4.3.1 Inclusion and exclusion criteria 
The inclusion criteria were intentionally broad, accepting any article or form of literature that 
focused on offering some level of advice, for example, guidance, guidelines, methods, critical 
appraisal, or a checklist, on at least one aspect or stage of the model-building process. The 
exclusion criteria applied to papers that simply compared different methods for model building 
(without direction as to which were optimal) and those that focused only on the mathematical 
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construction of a decision-analytic model. For practical reasons, the exclusion criteria also 
extended to articles that were published in languages other than English. 
2.4.3.2 Quality of the papers  
Due to the economic context of the papers retrieved, it was difficult to assess their quality 
against the (mostly) clinical criteria outlined in the CRD (2008) guidance. However, the quality 
principles outlined in the CRD publication, and those recommended by GRADE (Balshem et 
al., 2011) were used broadly to make inferences about the standard of the studies collected, and 
the guidance offered within.  
2.4.4 Data extraction  
To facilitate data synthesis, a data extraction form was designed to retrieve and organise 
relevant information from each paper. The development of this form was iterative, in that the 
content of the papers informed the ‘themes’ that the data were extracted under. These themes 
referred to the subject and type of guidance represented within a particular paper which, when 
all of the completed forms were combined, gave an overall indication of the level and focus of 
the modelling guidance available. The data extraction form is available in Appendix 2.   
2.4.5 Narrative synthesis  
A narrative approach to the synthesis of the data was undertaken. This involved comparing and 
analysing text within and between papers to develop a general theory about the phenomena 
under study (CRD 2008). All papers retrieved were examined fully to generate an impression 
of the content and level of modelling guidance being offered, and then were compared to one 
another in terms of their similarities and differences. An iterative and qualitative approach was 
undertaken for the process of synthesis, as comprehensive themes of guidance were drawn and 
developed from the retrieved papers. The themes generated referred to five perceived stages of 
the model-building process. These are explored within the results section. 
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A research protocol detailing the methods used throughout the systematic review is available 
in Appendix 3.  
2.4.6 Results of the review 
The updated search of the modelling literature returned a total of 1968 papers for potential 
inclusion in the review. After paper titles and abstracts were compared against the inclusion 
criteria, 1923 papers were excluded. A further eleven papers were excluded on review of the 
full-text versions, leaving a final total of thirty-four articles for review. Of these, seventeen 
were recovered through searching in electronic databases, eight were retrieved through 
reference list searching, three were textbook excerpts identified through searches in the library 
database, and six were found through internet searches. Of the papers identified through 
online searches, four of these were specific searches for the remaining papers belonging to the 
ISPOR-SMDM Taskforce series, which were not identified through the electronic databases. 
The search process is documented in Figure 1. The figures in the QUOROM flow diagram 
represent the papers retrieved through electronic database searching, plus (+) those that were 
found via other strategies i.e. reference list searching, searches in textbooks, and online 
searches. 
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Figure 1: QUOROM flow diagram of study selection (updated review). Numbers represent 
the papers retrieved via database searching + those retrieved using other search strategies 
(Moher et al., 1999) 
 
2.4.6.1 Characteristics of the papers 
The papers collected in the review varied in terms of the date that the guidance was published, 
the setting in which the guidance was developed, the type of publication, and importantly, the 
aspect of the modelling process focused on. The earliest guidance captured was published in 
1996, and the latest in 2013, with papers being produced at various times between these dates, 
suggesting that modelling guidance has been released and updated in line with the progression 
of modelling techniques. The majority of the papers were from the UK, although some were 
developed in international settings, and the ISPOR-SMDM taskforce guidelines combined the 
input of modellers from numerous countries. In terms of publication type, the majority of 
papers were journal articles, although one was a HTA report, three were textbook excerpts, 
and two were guidelines from NICE and CADTH. Two of the papers were based on 
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qualitative studies, and offered guidance and/or good practice recommendations based on the 
findings of primary research with modellers (Chilcott et al., 2010; Kaltenthaler et al., 2013). 
Of the thirty-four papers retrieved, most provided guidance on more than one stage of model 
development, and ten of the articles were focused on the entire modelling process (Briggs et 
al., 2006; Caro et al., 2012; Chilcott et al., 2010; Drummond et al., 2005; Halpern et al., 1998; 
Petrou and Gray, 2011; Philips et al., 2006; Sculpher et al., 2000; Soto, 2002; Sun and 
Faunce, 2008), theoretically allowing a modeller to use the resource as an accompaniment to 
each stage of model building. This number increased when the ISPOR-SMDM guidance was 
considered as a whole, as each individual paper corresponded to a stage within the modelling 
process. However, the depth of the guidance provided in these papers and the others collected 
varied greatly, with some giving in-depth, methodological advice, but most providing less 
detailed recommendations. 
The themes generated from the synthesis of all papers related to five perceived stages of the 
model-building process. These were: understanding the modelling context, structuring the 
model, populating the model (data), model implementation, and assessing uncertainty/model 
checking activities. The type of guidance offered in the papers in relation to each of these 
themes is examined next. Table 1 demonstrates the characteristics of the papers retrieved. 
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Table 1: Summary of paper characteristics 
  











Stage(s) of the modelling process referred to  
Barton et al. 2004 UK Journal 
article 
Good  Individual 
stages 





2006 UK Journal 
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Good  Individual 
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Briggs et al. 
 
  
2006 UK Textbook 
excerpt 
 
Good Process Specifying the decision problem (context), 
structuring a decision model, identifying and 
synthesising evidence, dealing with uncertainty and 
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Data and populating the model, dealing with 
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Cooper et al.  
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2005 UK Textbook 
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1998 France Journal 
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Good Process The need for modelling (context), understanding the 
study question (context), model structure, handling 
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Model structure, populating the model, handling 
uncertainty 
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2011 UK Journal 
article 
Good Process Defining the question, structure of the model, 
populating the model, handing 
variability/uncertainty, model evaluation, model 
reporting 
 









Process Scoping the decision problem, structuring a decision 
model, data and populating the model, handling 
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2000 UK Journal 
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Good Process The purpose of decision models, structuring a decision 




Sendi et al.  
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structure, data and populating the model, sensitivity 
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2006 Canada Journal 
article 
Good Process The purpose of decision models (context), 
understanding the decision problem (context), data 













Scoping the decision problem (context), developing a 



















Model evaluation/validation, structure of the model, 
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Understanding the modelling context 
For ten of the thirty-four papers, the initial requirement for model building was to understand 
whether modelling was actually needed to answer a particular research question. For example, 
Buxton et al. (1997, p225) argued that modelling should be used only as a ‘last resort when 
there is no more reliable way to provide appropriate information for decision makers’. The 
authors recommended the use of models only in the absence of suitable RCTs, and 
specifically for:  
 ‘Extrapolating beyond the data observed in a trial…  
 ...Linking intermediate clinical endpoints to final outcomes… 
 …Generalizing [findings] to other [clinical] settings… 
 …Synthesizing head-to-head comparisons where relevant trials do not exist… 
 …Informing decisions in the absence of hard data…’  (Buxton et al. 1997, pp. 218-
222) 
The guidance offered by Buxton et al., (1997) was similar to the perspective held by Gold et 
al., (1996) and Halpern et al. (1998, p.132), who gave the impression that ‘modelling is most 
appropriate for certain specified, select purposes’. A further seven papers cited one or more of 
the above circumstances as a reason to model; however, these were instead presented as 
situations in which modelling is required and valuable. The date of publications linked to their 
content demonstrates an apparent shift in the opinion of the literature towards the acceptance 
of models, with earlier papers tending to debate the use of modelling as a fundamental aspect 
of their content. More recent papers have tended to either advocate the advantages of 
modelling (Soto 2002; Garrison 2003; CADTH 2006; NICE 2013), or perceived it 
unnecessary to justify a model’s role in decision-making. 
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Very few papers offered advice on how a modeller could initially gain an understanding of the 
clinical and economic issues informing a model. Six of the papers gave advice similar to that 
of  Sculpher et al. (2000, p.466), who argued that there should be ‘a clear statement of the 
decision problem prompting the analysis’ within a model write-up. On similar lines, both Soto 
(2002) and Sun and Faunce (2008) specified that an initial requirement was to define model 
objectives, and make clear the reasons for model development. Despite the emphasis within 
these papers on the importance of reporting the context for model development, none offered 
methods for gaining this contextual knowledge.  
However, two papers did represent the modellers’ understanding of a decision problem as a 
distinct stage within the modelling process. Chilcott et al. (2010) and Roberts et al. (2012) 
emphasised a step prior to model development, which involved the modelling team learning 
about the clinical condition being modelled, and specifically why a cost-effectiveness analysis 
was needed. The papers suggested that modellers should talk to stakeholders and clinical 
experts, and review relevant clinical literature, and existing economic models. 
 ‘Existing models addressing related problems should be reviewed. The clinical and 
policy literature describing the problem should be understood by the modeling team.’ 
(Roberts et al., 2012) 
‘…this phase of model development may draw on evidence, including published 
research and clinical judgement…’ (Chilcott et al., 2010) 
Structuring the model 
Advice on model structure was an important focus of the guidance, with twenty-six of the 
thirty-four papers commenting on structure in some respect. The guidance was divided as to 
whether it offered methodological support or less detailed advice. A number of the papers 
came under the latter category and were seemingly aimed at ensuring the quality of structures 
and apparent robustness of structural development. Examples of advice were to make sure 
that models are ‘structured so that its inputs and outputs are relative to the decision-making 
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perspective of the economic evaluation’ (Weinstein et al. 2003, p.11), ‘possible pathways 
described by the model are feasible and sensible’ (Chris McCabe and Dixon, 2000, p.508), 
and that model assumptions are ‘clear, transparent and justified’ (Philips et al. 2006, p.359). 
This type of guidance seems to be aimed at a model reviewer, or alternatively a modeller at 
the end of their model development, looking at what information to include in the model 
write-up.  
In terms of content, nine papers referred to defining the boundaries of a model as an initial 
requirement of model building, involving ‘making clear’ a number of issues, (not limited to) 
‘the disease(s) or condition(s) being modelled, interventions in question, specific study 
populations, and study perspective’ (Halpern et al. 1998, p.132). Five of the nine papers 
offered guidance on identifying boundaries; however, most guidance was fairly minimal, with 
three of the articles stating simply that the decision problem and boundaries of the model 
should be determined by the decision-maker/commissioner’s requirements and/or the focus of 
the research question (CADTH, 2006; Petrou and Gray, 2011; Tappenden et al., 2006). 
Drummond et al. (2005, p.290) expanded on this advice slightly by suggesting that ‘decisions 
about the boundaries in decision models…should mainly be driven by the extent to which 
extending the boundaries is considered likely to impact on the cost-effectiveness of the options 
being compared’. Both sets of statements left it unclear as to how making these decisions 
worked in practice. Roberts et al. (2012) was the only paper to offer methods for determining 
model boundaries, based on a process of model conceptualisation, in which all factors 
potentially relevant to a decision problem are first considered, before these are reduced to the 
elements most appropriate to the research question being asked. The authors suggested that 
this simplification involved consultation with experts, and diagrams to facilitate problem 
conceptualisation. However, the paper gave little detail on how communication should work 
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between the various parties, in terms of deciding on key elements of importance to inform 
model structure. 
‘An explicit process (expert consultations, influence diagrams, concept mapping, or 
similar method) should be used to convert the problem conceptualization into an 
appropriate model structure…’ (Roberts et al., 2012). 
There was also a lack of any detailed guidance on how to translate clinical and economic 
information into model pathways or states. Of the thirteen papers that commented on the 
required complexity of model structure, eleven gave guidance no more elaborate or 
explanatory than that offered by Soto (2002):  
‘To know the level of complexity, the analyst must consider whether the model is able 
to capture the key issues necessary to fully describe the efficiency of all options under 
evaluation’ (Soto 2002, p.100) 
Similarly, of the nine papers that offered advice on deciding what information should inform 
the basis of a structure, seven gave a similar level of guidance to that of CADTH (2006) and 
Sun and Faunce (2008). This guidance was vague both in terms of how modellers could learn 
about (the aspects important to) a clinical condition, and the practical steps involved in 
transferring clinical knowledge into model structure:  
‘The model should incorporate all facets of the condition of interest that are 
important, and the potential impact of the interventions considered’ (CADTH, 2006, 
p.24) 
‘The structure of the model is developed on the basis of an understanding of the 
nature of the disease progression’ (Sun and Faunce, 2008, p.314) 
Only two papers discussed methods for identifying and/or selecting pathways or states for a 
model structure, with Roberts et al. (2012) implying that clinical experts should be consulted 
for their knowledge on disease progression, and Chilcott et al. (2010) suggesting that 
decisions around the pathways and states to include was an iterative process between 
modellers and clinicians. Again however, there was a lack of detail on how to involve 
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clinicians in structural development, for example, how many should be asked, and how to get 
the required information from them.  
Fifteen of the papers, and most of the guidance on structure, focused on the appropriate type 
of model to use for a decision problem. The majority of papers commented on three main 
types of model, with the guidance being repetitive across papers, and authors agreeing that ‘if 
the timeframe is short…a simple decision tree is appropriate’ (Barton et al. 2004, p.111), 
Markov models ‘are particularly effective in clinical situations which involve continuous risk 
over an extended time horizon’ (Karnon and Brown, 1998, p.137), and discrete event 
simulation (DES) models should be used ‘if the problem requires examining behaviour at an 
individual level’ (Brennan et al. 2006, p.1306). This guidance varied in terms of the level of 
detail given, although most provided a descriptive summary of the situations in which 
particular structures were most suitable.  Some of the papers were more methodological, with 
seven offering process style guidance, either on the use of specific types of structures (Karnon 
et al., 2012; Pitman et al., 2012; Siebert et al., 2012), or again on how to decide on a suitable 
structure for a particular decision scenario (Barton et al., 2004; Brennan et al., 2006; Cooper 
et al., 2007; Stahl, 2008). The latter group of papers all provided schematic methods for 
modellers to follow in selecting an appropriate structure, with a series of questions typically 
being posed to the reader regarding the clinical nature of their decision problem, to determine 
the most suitable model type.  
Although collectively the guidance on choosing an appropriate model type was quite 
thorough, the use of the schematic tools and interpretation of the descriptive advice given 
relied somewhat on the modeller having a knowledge of the clinical condition and the 
intervention being modelled. Unfortunately, guidance on how to seek information on the 
clinical context of the decision problem has been demonstrated to be fairly limited.  
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Populating the model (data) 
Twenty-one papers included guidance related to the use of data in models, specifically the 
data used to populate model parameters. For fifteen of these papers the main focus was on 
ensuring that the data sources that modellers used were transparent and of good quality. 
Statements included seven similar to the one given by NICE (2013, p.50), that ‘data inputs 
should be clearly documented and justified in the context of a valid review of alternatives’, 
and eleven related to the assertion by Halpern et al. (1998, p.137), that parameter values 
‘should be based on the highest quality data available’. Guidance mostly focused on clinical 
data sources, with only four of the papers commenting on the use of economic data (NICE 
2013; Halpern et al. 1998; Kaltenthaler et al. 2013; Soto 2002). Indeed, Petrou and Gray 
(2011, p.2) only discussed economic resources insofar as mentioning that there is not 
currently a clear strategy to ‘identify and synthesise evidence on other [non-clinical] 
variables, such as costs and health utilities’. Methodological guidance therefore applied 
mostly to data for clinical parameters, although some of the papers referred to principles for 
identifying evidence generally. For those papers that offered any methods for data collection, 
most were very brief, with the emphasis being on the importance of conducting systematic 
reviews to inform data parameters. More detailed guidance offered suggestions of data 
sources to use, and methods on how specific data could be retrieved (Halpern et al. 1998; 
Siebert et al. 2012; Soto 2002; Kaltenthaler et al. 2013; NICE 2013). Most of these papers 
were quite directive in their advice, with NICE (2013) specifying the data sources that they 
expected modellers who were submitting models for technology appraisal to include. Soto 
(2002) and Siebert et al. (2012) similarly made it clear that data for clinical parameters should 
be informed by epidemiological studies and/or data from RCTs. The study by Halpern et al. 
(1998) was alone in providing detailed methods for identifying appropriate economic data, 
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suggesting a range of sources for costs depending on the country of origin, and the standard 
gamble technique for deriving utility values during primary data collection. 
Kaltenthaler et al. (2013) was the only paper focused solely on identifying evidence to 
populate models, and as such it gave the most detailed guidance on this topic. The authors 
gave an overview of the factors considered most important when using evidence to populate 
models, including an outline of review methods suitable for modelling, suggestions for 
minimising bias in data collection, and how to select the most appropriate data to populate 
parameters. However, although the guidance was methodological in content, some aspects 
were lacking in detail in terms of the level of advice given. For example, the authors 
emphasised that it was ‘important to prioritise parameters and focus reviewing resources on 
those most likely to have an impact on model outputs’ (Kaltenthaler et al. 2013, p.832). 
However, there was no clear indication within the paper as to how these important parameters 
could be recognised.  
An additional focus of the guidance on populating a model was on the use of expert opinion 
to inform data parameters. Of the twenty-one papers collected, eight mentioned using 
clinicians to retrieve data values where evidence was lacking. Again this advice varied in 
terms of the level of detail given, as five of the articles offered fairly brief guidance on the 
involvement of experts in this context. Typically these papers implied that expert opinion 
should be used as a last resort (Buxton et al., 1997; CADTH, 2006; Petrou and Gray, 2011), 
or emphasised the importance of testing values from clinicians using sensitivity analysis 
(Philips et al., 2006; Weinstein et al., 2003). Of the three papers offering more in-depth 
guidance, Karnon et al. (2012) gave suggestions for how expert opinion used in DES models 
could be validated, and the remaining two articles offered relatively thorough and detailed 
methods for eliciting expert opinion (Soto 2002; Halpern et al. 1998), with both advising on 
possible ways to conduct meetings, synthesise values, and recruit appropriate clinicians. The 
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papers similarly recommended using a DELPHI style approach for gaining clinician estimates 
(allowing experts to modify values after they have been commented on by additional relevant 
experts), and involving experts from a range of clinical backgrounds and geographical 
locations (Halpern et al., 1998; Soto, 2002). Further, Halpern et al. (1998) commented on the 
optimum number of clinicians to consult, stating that the dynamic of involving five to eight 
experts would avoid discussions being dominated by a single clinician, but make it possible 
for all individuals to fully express their views. Interestingly, this was the type of guidance 
largely missing from the literature on model structure.  
Implementation 
Few papers recognised model implementation as a distinct stage within the modelling 
process. For the majority of papers offering guidance on structural development, the 
programming of a structure into a software platform was implied. Most focused their advice 
on the design of a structure, particularly on identifying an appropriate model type, without 
mentioning when and how the pathways or states of a model should be transferred into a 
computer program. One paper also discussed structural development only in the context of 
implementation, outlining how particular model types work and are represented within 
modelling software (Brennan et al., 2006). This leaves it unclear as to whether it is considered 
good practice to draft the structure prior to implementation (on paper for example) and then 
program it, or whether the structure should be drafted immediately within the software.  
Only three of the twenty-six papers on structure mention (and separate) a design and 
implementation phase. Sun and Faunce (2008, p.314), for example, discussed ‘developing the 
model structure’ as a separate stage to ‘the calculation of…incremental analyses’, with the 
latter section containing advice such as how total costs and health outcomes are calculated 
within a decision tree. Similarly, Karnon et al. (2012, p.824) distinguished between guidance 
on designing a DES structure, particularly deciding on the downstream decisions/clinical 
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events to represent, and more technical advice specific to implementation, referred to as 
‘transferring a defined structure into a computer program’. Chilcott et al. (2010, p.13) defined 
implementation as involving ‘the transposition of the pre-specified set conceptual model 
framework into a ‘hard’ quantitative model’, implying also that some level of design was 
recommended prior to implementation. However, given that this guidance was based on a 
qualitative study, Chilcott et al. (2010) reported that the modeller informants varied in terms 
of how far they drafted a structure before programming.  
Arguably, the guidance as a whole would benefit from a clearer message regarding good 
practice in terms of the relationship between the design and implementation of a model 
structure. This clearly also relates to the lack of methodological advice currently available on 
the planning/conceptual stages of structural development, highlighted in previous sections. 
Assessing uncertainty/model checking activities 
Assessing uncertainty in models and/or undertaking model checking activities was the most 
discussed aspect of model development within the guidance, referred to in twenty-eight of the 
thirty-four papers. For five papers, model checking was the sole focus. Guidance was 
concentrated both on assessing uncertainty in model results (i.e. sensitivity analysis), and on 
validating the base case model.  
The majority of papers, seventeen in total, focused on uncertainty in data/parameter values, 
and testing the effect that changes to these had on model results. These papers varied in terms 
of the level of detail provided, with most outlining definitions of deterministic and 
probabilistic sensitivity analysis. The primary message of ten of these papers was similar to 
Philips et al. (2006, p.361), that ‘probabilistic sensitivity analysis is the most appropriate 
method for handling parameter uncertainty because it facilitates the assessment of the joint 
effect of uncertainty over all parameters’.  
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Six of the papers provided more in-depth and methodological guidance on sensitivity 
analysis, with four of these articles being dedicated entirely to dealing with uncertainty. This 
guidance varied in terms of its specific focus and the level of technicality offered, with Briggs 
et al. (2012) for example, concentrating on how to choose parameter values for sensitivity 
analysis, Cooper et al. (2004) discussing how sensitivity analysis is undertaken within a 
Bayesian framework, and Jain et al. (2011) offering fairly technical guidance on the use of 
sensitivity analysis in the development of different types of models.  
Only four of the papers mentioned undertaking structural sensitivity analysis, or accounting 
for structural uncertainty, which largely encompassed changing the structural assumptions 
within a model to gauge the impact on the results. For two of the articles the guidance given 
was rather brief, with the apparent focus being on highlighting the importance of testing for 
uncertainty in a structure (NICE, 2013; Petrou and Gray, 2011). The guidance offered by 
Pitman et al. (2012) was a little more detailed, and suggested carrying out uncertainty 
analyses on the structural assumptions likely to impact on the cost-effectiveness result; 
however, no methods for undertaking this were proposed. The paper by Briggs et al. (2012) 
was the only paper to provide methodological guidance on structural uncertainty, suggesting 
approaches that modellers could undertake.  
Another lesser focus of the guidance was on model validation, and checking the base case 
model. Nine papers discussed the validation of a structure, data and/or the model results to 
some extent. Most of the guidance covered the same types of validation, although different 
terminology was sometimes used. The papers referred to internal validity (or technical 
validity), external validity, cross-validation, predictive validity, and face validity (or structural 
and content validity (Halpern et al., 1998)). For most articles, definitions of internal validation 
were similar, focused on ‘debugging’ models within computer software and checking for 
programming errors. The same was to be said for external validation, although the extent of 
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the model checking activities discussed varied between the papers. While some simply 
recommended that modellers compare the results of their models to those of similar models 
and/or clinical studies (Buxton et al., 1997; Halpern et al., 1998; Petrou and Gray, 2011; Soto, 
2002; Weinstein et al., 2003), Eddy et al. (2012) provided methods on how to simulate 
external data sources to produce outcomes that could be used to verify those generated by a 
model.  
In the same way as the guidance on sensitivity analysis, the validation papers varied in terms 
of the level of detail provided. For most who mentioned it (Chilcott et al., 2010; Eddy et al., 
2012; Petrou and Gray, 2011), face validity involved the verification of the model, 
particularly structure, according to the feedback of those with relevant clinical expertise. Two 
papers suggested methods for undertaking these checks with clinicians, including emphasis on 
the importance of the clinical experts being external to the project (Eddy et al., 2012), and the 
use of modelling simulation software to allow a clinical advisor to understand how a model 
works, and facilitate feedback (Chilcott et al., 2010). However, there was no discussion 
regarding the number of clinical experts that should be consulted to ensure face validity. On 
the whole, and similar to the papers on sensitivity analysis, there was less guidance available 
on assessing uncertainty around structure, than on data inputs and results.  
2.4.6.2 Principal findings of the review 
This systematic review of the modelling literature has demonstrated that there is currently a 
lack of detailed and methodological guidance on particular stages of the model-building 
process. This lack of guidance relates particularly to steps involved in developing model 
structure, specifically, how modellers should define model boundaries and plan a structure, 
involve and communicate with clinicians regarding structural development, and decide on the 
information to inform model pathways or states. Other areas where guidance was relatively 
minimal included advice on how a modeller could understand and gain knowledge on the 
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clinical and economic context of a model, how to identify data to populate economic 
parameters, and how model structures should be checked/validated.  
Despite the fairly large number of papers that contained guidance on the process of model 
building, papers were generally lacking a procedural element. Guidance tended to focus on 
distinct stages within the model-building process, rather than offering continuous and 
methodological advice. Many of the papers on structure, for example, were concentrated 
around recommendations on how to choose an appropriate model type, with choices being 
based on the modeller’s knowledge of the clinical condition being modelled. However, no 
methods were offered within these papers as to how modellers could seek information on the 
clinical context of the decision problem.  
The modelling guidance also generally lacked depth and detail, and was not reflective of all of 
the elements involved in the development of a model. Only one of the ten papers (Chilcott et 
al., 2010) offering guidance on the modelling process included iterations between modelling 
stages, which should be an inevitable part of model development, particularly if the structure 
is being checked at various intervals by clinical experts, and/or the structure is being updated 
in light of available data. Other perhaps more implicit features of the modelling process were 
also missing from the guidance, such as how communication between modellers and 
clinicians should be managed during structural development. 
2.4.6.3 Quality of the papers 
Although there were no relevant quality criteria available to directly assess the standard of the 
papers collected within this review, the guidance contained was broadly compared to the quality 
principles outlined in the CRD (2008) and GRADE (Balshem et al., 2011). These resources are 
aimed at assessing the quality of clinical research collected within a systematic review; 
however, general quality recommendations cited within these papers are potentially applicable. 
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Both favoured studies that incorporated evidence that had the least risk of bias, specifically 
findings based on robust primary investigation, as opposed to inferences and expert opinion. In 
the context of the development of model-building guidance, it may therefore be legitimate to 
argue that guidance based on first-hand research into the modelling process, if formulated as a 
result of the expertise of credible and experienced modellers, may be more valid and robust 
than that developed on the opinion of one or even a few authors. Indeed, the guidance by 
Chilcott et al. (2010) offered a more ‘truthful’ portrayal of model development, with the 
inclusion of iterations between stages in the modelling process. Adhering to this particular 
quality consideration suggests that the qualitative papers by Chilcott et al. (2010) and 
Kaltenthaler et al. (2013), and the guidance by Weinstein et al. (2003) and the seven ISPOR-
SMDM papers, which were developed using working groups comprised of academic and 
industry modelling experts, should be considered of higher quality than others. Additionally, 
and based on frameworks for assessing hierarchies of evidence (Evans, 2003), one could also 
argue that systematic reviews of guidelines (McCabe and Dixon, 2000; Philips et al., 2006) are 
more robust than those created by only one set of authors.  
The drawback of using this quality criteria is that it does not necessarily account for the 
usefulness of guidance (i.e. the level of depth and detail provided). One also cannot be sure of 
the methods used to develop guidance within the remaining papers. However, given that 
judgement around the quality of research relies somewhat on the quality of reporting (CRD 
2008), perhaps authors of modelling papers should be encouraged to be more explicit about the 
methods that they are using to make suggestions around good practice in model development.  
2.4.6.4 Other systematic reviews in the research area 
In updating the original review undertaken in 2012, a further relevant and recent systematic 
review was identified (Penaloza Ramos et al., 2015). This review had similar objectives to 
those outlined within this research, although the focus of this alternative study was largely on 
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comparing the content and recommendations of the guidance for similarities and differences. 
The authors focused on highlighting any conflicting advice that was given across the 
guidance, implying that these aspects would require further clarification. The areas in which 
the guidance was apparently inconsistent referred to the methods used to check for structural 
uncertainty, the methods for performing predictive validity checks, and whether model 
structure should be affected by the availability of data. Although Penaloza Ramos et al. 
(2015) have a valid point in arguing that discrepancy within guidance can lead to uncertainty 
around what constitutes good practice, the review undertaken within this chapter has largely 
concentrated on identifying aspects of model development where there was little or no 
guidance available for modellers. Arguably, errors and poor practice are more likely to occur 
within stages of the modelling process for which there is no guidance available, providing that 
modellers are using modelling guidance. Developing recommendations in underrepresented 
areas may thus be a priority. However, both studies identified similar areas of the guidance to 
be ‘problematic’, specifically uncertainty (lack of guidance) around the information that 
should be used to inform model structure, and how model structure should be checked. 
2.4.7 Conclusion  
This chapter has highlighted the nature of errors present in industry submission and published 
models, and has presented a systematic review of the model-building guidance available. The 
first half of the chapter found that methodological errors identified across the models explored 
were similar, based around structure and the decisions made by modellers on what to include. 
Interestingly, and potentially relevant, were the findings of the systematic review, which 
revealed that very little in-depth and detailed guidance existed for particular aspects of 
structural development. This included guidance on planning model structure, the involvement 
of clinical experts in structural development, and the translation of economic and clinical 
information into model health states and pathways. The guidance was also lacking in advice 
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on how modellers could understand the context of a model, how to identify economic 
parameter data, and how to check model structure. This suggests that future research and 
guidance might be required in these areas.  
However, one cannot be sure from the findings of the systematic review that modellers are 
experiencing problems with these aspects of model development, although the methodological 
errors highlighted within the reviewed models might be a good indication. Perhaps more 
importantly, it was not possible to identify whether there are any other aspects of model 
building that modellers are having difficulty undertaking, or where less robust practices are 
being used. Also, it is unclear why methodological errors are present within models, and 
whether all modellers are paying attention to the guidance available. Further research is 
needed to explore these issues. 
The systematic review captured a small number of papers that had used qualitative research to 
develop model-building guidance. This guidance was deemed to be of greater quality than 
that offered in other papers, as advice was generated on the basis of first-hand research into 
the methods used by multiple modellers, rather than on the opinions of a few individuals. It is 
possible therefore, that qualitative research could be used to investigate the current practices 
and opinions of modellers, and to understand where and why problems are occurring, and 
potentially how these could be addressed. The next chapter looks at other examples of how 
qualitative methods have been used to understand and potentially suggest improvements to 
methodological issues present within health research processes, to see whether qualitative 
research might be a good option to undertake further exploration of model building.  
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CHAPTER 3: THE USE OF QUALITATIVE 
METHODS TO UNDERSTAND 
METHODOLOGICAL ISSUES IN HEALTH 
RESEARCH 
3.1 Introduction 
The previous chapter reported on methodological errors identified in industry submission and 
published models. In addition, the systematic review undertaken within the chapter found a 
lack of in-depth guidance on various aspects of the modelling process, particularly model 
structure. These findings suggest that modellers are encountering problems in their model 
building that could, without awareness and appropriate guidance for the modeller, potentially 
lead to sub-optimal recommendations on cost-effectiveness. Arguably, therefore, more in-
depth research is required to explore the processes used by modellers, to identify good 
practice and to understand where and why problems are occurring. Qualitative research could 
potentially be used to explore these issues, and generate recommendations for model 
development. The current chapter therefore seeks to establish whether qualitative methods can 
provide a suitable and fruitful basis on which to investigate methodological problems in the 
modelling process. 
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The first part of this chapter focuses on exploring the methodological basis for qualitative 
research, including how qualitative research is used, the theoretical assumptions associated, 
and how the natures of qualitative and quantitative inquiry differ. Next, the chapter explores 
how qualitative research has been undertaken to understand, and potentially provide solutions 
to, methodological issues in other areas of health research, in order to learn from the 
approaches used. Finally, the chapter concludes with a systematic review of the papers that 
use qualitative methods to explore decision-analytic model development. 
3.2 Qualitative research  
Owing to its use across multiple disciplines and traditions, fields and subject matter, there is 
no single definition of qualitative research (Denzin and Lincoln, 1998; Snape and Spencer, 
2003). Denzin and Lincoln (1998, p.2) argue that ‘qualitative research is a field of inquiry in 
its own right’, and thus encompasses a wide range of approaches to data collection and 
analysis. However, most qualitative inquiry appears to have a common interest, in seeking to 
understand and interpret phenomena in their natural context, particularly in terms of the 
meanings that people assign to them (Denzin and Lincoln, 1998; Malterud, 2001; Miller and 
Crabtree, 1999). Flick et al. (2004, p.3) suggest that qualitative research is concerned with 
gaining a deeper ‘understanding of social realities’ from the perspective of those ‘who 
participate…to draw attention to processes, meaning patterns and structural features’. 
Therefore the emphasis of qualitative methods is often on ‘capturing the individual’s point of 
view’ and ‘seeking rich descriptions of [their] social world’ (Denzin and Lincoln, 2000, pp.9-
10). Furthermore, qualitative analysis, whilst aiming to provide explanations for phenomena, 
also seeks to preserve the context and detail of the social world being explored (Bryman, 
2008). 
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Qualitative inquiry typically takes place within a particular interpretive paradigm (Crotty, 
1998; Denzin and Lincoln, 2000; Guba, 1990; Silverman, 2000). Guba (1990, p.17) defines a 
paradigm as a ‘basic set of beliefs that guide action’ and indeed Crotty (1998) argues that a 
researcher’s theoretical perspective directs their approach to research, and the methods that 
they use. Each paradigm has its own ontological, epistemological and methodological 
position, which in turn dictates how ‘reality’ is defined, the relationship that the researcher 
has with informants, and the strategy used to collect and analyse data. Denzin and Lincoln 
(2000) cite the four major interpretive paradigms underlying qualitative research as positivist 
and postpositivist, constructionist-interpretive, critical, and feminist-poststructural. Regardless 
of the belief systems and methods typically adopted within these paradigms however, Denzin 
and Lincoln (2000, p.8) argue that all qualitative research ‘implies an emphasis on the 
qualities of entities…that are not…measured in terms of quantity, amount, intensity, or 
frequency’.  
Qualitative research is often understood and discussed in relation to the objectives and 
methods associated with quantitative approaches. Green and Thorogood (2009, p.5) argue that 
‘qualitative studies seek answers to questions about the ‘what’, ‘how’ or ‘why’ of a 
phenomenon, rather than questions about ‘how many’ or ‘how much’’. Therefore, methods 
such as detailed interviewing and observation, rather than surveys, structured observation and 
experiments, are used within qualitative research to capture naturally occurring data, and the 
depth and nuances associated with social ‘reality’ (Silverman, 2000).  
The benefits and drawbacks of quantitative and qualitative research are also frequently 
considered in relation to one another. For example, the reductionist and deductive nature of 
quantitative research is often seen as advantageous, as conclusions are drawn from general 
theories occurring in data, and findings are thought of as broad and generalizable (Patton, 
2002). This is in relation to the inductive nature of qualitative research, which involves ‘the 
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formation of theories, concepts and types’ from what is ‘observed’ in the field (Flick et al., 
2004). Polit and Beck (2010, p.1452) state that qualitative findings are often critiqued for 
seemingly being specific to only one particular ‘human experience’, and biased towards the 
pre-existing views and experiences of the researcher (Dancy, 2001). However, qualitative 
researchers dispute the above claims, and Guba and Lincoln (1998, p.197) argue that rather 
than being objective and generalisable, quantitative research is ‘context stripping’ and 
‘exclusionary’, as research questions typically focus on identifying patterns between pre-
selected ‘subsets of variables’, not exploring ‘other variables…that might…greatly alter 
findings’. Not only do qualitative researchers consider detailed investigation and rich 
description to be valuable, it is suggested that qualitative research should not be concerned 
with achieving statistical generalisability (Mays and Pope, 2000).  
Polit and Beck (2010, p.1454) recommend that researchers implement strategies to enhance 
the generalisability and transferability of qualitative research conclusions. Such strategies 
might include techniques such as purposive sampling, which allows a researcher to capture a 
variety of perspectives on a phenomenon, and explore whether conclusions are replicated 
across informants. Transparency, in relation to the researcher providing sufficient detail on 
informants and phenomenon, can also allow the reader to make judgements about how valid 
research conclusions appear in relation to the data, as well as how transferable findings are to 
similar settings (BMJ, 2015; Mays and Pope, 2000). Other quality considerations involve 
triangulation, the use of multiple methods to strengthen research conclusions (Mays and Pope, 
2000), and the importance of reflexivity during the qualitative process (Saukko, 2003), in 
terms of researchers recognising and acknowledging how their ‘cultural baggage’, such as 
their personal and intellectual background, might influence findings. Denzin and Lincoln 
(1998) argue that ‘value-free’ qualitative inquiry is not possible, meaning that researchers 
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must be open and reflective about their contributions to research conclusions, to ensure 
credible practice (Malterud, 2001).  
3.3 The use of qualitative methods in health research 
Qualitative methods are increasingly being used to explore phenomena within a health 
research, or health services research context (Mays and Pope, 2000). Health services research 
is a multidisciplinary field concerned with access to, and delivery of, healthcare (Phillips, 
2006), via the study of ‘the organisation and culture of those who provide [it]’ (Pope and 
Mays, 1995, p.1). Gagliardi and Dobrow (2011, p.1) suggest that the ability of qualitative 
research to ‘produce rich data on perceptions, beliefs, experiences and behaviour to create a 
thorough understanding of a problem, and how it could be resolved’ has led to its application 
to ‘improve health service delivery [in] a variety of clinical…settings’. The emphasis of 
qualitative research on process (Bryman 2008) seems to fit well with the objective of health 
services research, which is to identify where healthcare processes can be improved, to make 
them more ‘effective, equitable, and efficient’ (Phillips, 2006, p.2).   
Qualitative research has the potential to be as useful in the field of health economics. 
Regarded as a component of health services research, health economics aims to improve 
healthcare processes, in terms of analysing ‘decision making by individuals, health care 
providers and governments with respect to [the allocation of] health and health care’ (Morris 
et al. 2007, p.2). Qualitative research has, for example, been used to explore the role of 
economic analysis in NICE’s technology appraisal process (Williams et al., 2007). However, 
some authors have reported on the dearth of qualitative research being undertaken within this 
field (Coast, 1999; Coast et al., 2004; Obermann et al., 2013), with Coast (1999) suggesting 
that this is due to tension between the philosophical positions of the discipline of economics, 
and the qualitative approach. Whilst mainstream economics is situated within a positivist 
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paradigm and advocates a single reality that can be studied objectively for universal truths, 
qualitative research typically adopts a constructivist position, which assumes multiple 
context-bound realities that can only be explored through interaction between ‘the investigator 
and investigated’ (Coast, 1999, p.347). A number of authors however, have noted the 
increasing use of qualitative research in health economics, albeit typically alongside the use of 
a quantitative approach (Coast et al., 2004; Obermann et al., 2013). 
The next sections of this chapter explore how qualitative methods have been used in different 
areas of health research to understand methodological issues. This is in line with the objective 
of this research, which is to explore modelling processes and identify how and why problems 
and errors are occurring. The two areas of research selected for investigation were studies 
using qualitative research to understand how people complete valuation tasks to inform 
economic evaluation, and studies using qualitative methods alongside randomised controlled 
trials (RCTs) to identify problems with recruitment. These bodies of literature were chosen 
because of their similarity to the research proposed within this thesis, in that both areas of 
research are based on pre-existing concerns regarding the appropriateness of current methods, 
and aim to explore processes that contribute to decision-making within healthcare.   
The searches of the literature undertaken for these papers were not systematic, but were 
broad, and aimed to identify a range of papers within each research area that had used 
different qualitative methods to address similar aims. The objective of the review of these 
papers in relation to the research proposed within this thesis was twofold: (1) to establish 
whether qualitative research would be useful and suitable for the exploration of model-
building processes, and (2) whether any particular qualitative methods or approaches 
appeared optimum compared to others. 
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3.3.1 The use of qualitative research to understand how people complete preference-
based valuation tasks 
Although qualitative methods have been used more extensively in the development of 
attributes for preference-based measures (see Coast and Horrocks, 2007; Fegert et al., 2011; 
Ke et al., 2013; Miners et al., 2012), the focus of this review is on the smaller number of 
studies using qualitative methods to explore how people complete preference-based valuation 
exercises. Briefly, these exercises are designed to elicit people’s preferences for particular 
healthcare goods or states, to use in economic evaluations to assist resource allocation 
decisions. These exercises or techniques include the visual analogue scale (VAS) standard 
gamble (SG), person trade-off (PTO), time trade-off (TTO), willingness to pay (WTP) and 
discrete choice experiments (DCEs). A total of eight papers were reviewed.  
The studies captured had different aims but similar overall objectives, which concerned 
establishing whether current methods for eliciting preferences were appropriate, and whether 
the ways in which people value healthcare were in line with the economic theory underlying 
the measures. These studies were mostly undertaken out of concern that people’s valuations 
of healthcare were not based upon their true and underlying preferences. Inevitably, the 
qualitative research was undertaken alongside quantitative research, as preference-based 
measures typically use quantitative techniques to calculate the values that individuals assign 
to healthcare goods (Morris et al., 2007). However, in line with the comments of Coast et al. 
(2004) and Obermann et al. (2013), almost half of these studies used qualitative research only 
to explore or explain quantitative findings. Studies also ranged from those undertaking 
deductive qualitative analysis, examining existing or pre-specified issues, to those exploring 
valuation processes inductively. Despite this, all of the papers collected had the same 
objective, namely to gain an understanding of how people value health states and/or goods. 
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Given the focus on learning about the type of findings that different qualitative methods can 
generate, the papers are compared according to the methods used.  
The qualitative methods undertaken across the studies comprised ‘open-ended’ survey 
questions, semi-structured interviews, think-aloud, and the triangulation of these approaches. 
The qualitative survey was only used in one study, which aimed to investigate whether 
informants gave rational and valid responses within valuation exercises (Miguel et al., 2005). 
Qualitative analysis was undertaken alongside quantitative rationality tests of informants’ 
answers to a DCE questionnaire. Where informants failed the quantitative rationality tests 
they were asked to explain their answers on paper. The qualitative findings indicated that the 
informants often had rational reasons for their ‘irrational’ preferences, with the implication of 
the research being that those who would typically be ‘dropped’ from stated preference studies 
were actually offering meaningful answers. In terms of methods, however, the limited space 
that the authors allowed informants to explain their answers in the survey meant that around 
half could not be analysed and/or understood due to the lack of depth provided. This raised 
the question of how valid the authors’ interpretations of the informants’ reasoning was, given 
the lack of detail in their responses. 
Semi-structured interviews were undertaken in two of the studies (Geneau et al., 2008; 
Robinson and Bryan, 2013). These studies aimed to ascertain whether informants’ preferences 
satisfied the axioms of expected utility theory on which WTP and PTO measures are based 
i.e. that people always act to maximise utility for themselves and thus have rational and 
complete preferences for particular goods. In both studies the authors reflected on their use of 
semi-structured interviews, and concluded that the data gathered were lacking in terms of 
what was required to answer the research question. Geneau et al. (2008) found that the limited 
length of interviews affected an informant’s ability to give a nuanced answer about the factors 
contributing to their WTP values. The authors implied that being unable to engage with and 
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allow informants time to consider how they valued a healthcare good, led informants to value 
goods according to their ability to pay.  
Robinson and Bryan (2013) aimed to look at whether deliberation during the valuation 
process using PTO elicited more ‘considered’ preferences from informants. The authors stated 
that deliberation could help informants to fully reflect on and construct their preferences 
during the valuation task, but could also possibly lead to their valuations being influenced by 
the opinions of others, meaning that the PTO exercise was not capturing valid choices. The 
authors recorded examples of informants changing their valuations after deliberation, but their 
comments in interviews suggested that individuals considered discussion with others useful, 
but not influential, in realising their own preferences. However, because no observational 
analysis was undertaken on the deliberation process, the authors could not definitively 
conclude that informants’ valuations were not influenced by other members of the group, 
despite informants suggesting otherwise. This highlights the importance of using 
observational methods where communication is an important aspect of study, given that 
informants might not be aware of, or articulate, the effect that particular phenomena have on 
their behaviour. Both of these papers generated theoretical conclusions, in finding that 
preferences did not satisfy utility theory, however, each also had practical implications, with 
Robinson and Bryan (2013) stating that future research was needed into how researchers can 
use deliberation more optimally in the elicitation of people’s preferences.  
Think-aloud was the most commonly used method among the studies (Ryan et al., 2009; 
Smith, 2007; Van Osch and Stiggelbout, 2008), with a further two papers using think-aloud 
alongside interviews (Baker and Robinson, 2004; Robinson et al., 1997). Within these studies 
informants were asked to verbalise their thought processes as they valued healthcare goods, 
generating rich and explanatory findings about how people make decisions during valuation 
tasks. Van Osch and Stiggelbout (2008) reflected on their use of think-aloud, stating that the 
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method had enabled them to explore bias in informants’ responses to SG exercises, generating 
an in-depth understanding of informants’ thought processes as they valued health states, and 
allowing the authors to identify the reference point from which people focused their SG 
valuations, and thus control for the impact of bias in SG results. 
Despite the benefits associated with think-aloud, two studies reported that the use of this 
method may have biased study results, by encouraging informants to think more thoroughly 
about their preferences than they would have done otherwise. Smith (2007) found that 
responses at higher levels of WTP had higher rates of reliability, suggesting that informants 
gave more considered and valid responses where decisions impacted significantly on their 
income. However, the authors could not be sure whether more reliable responses were 
recorded because informants had been asked to verbalise their thought processes during the 
WTP exercise, facilitating their recall of previous answers during tests of reliability. 
Similarly, Ryan et al. (2009, p.333) suggested that results indicating that informants held 
complete and well-defined preferences, may have been as a result of informants being ‘more 
careful about, and conscious of, their thinking’ and decisions whilst ‘thinking aloud’.  
The remaining two studies used a triangulation of think-aloud and interview methods (Baker 
and Robinson, 2004; Robinson et al., 1997). The authors used these in combination to 
different ends, as Robinson et al. (1997) investigated pre-specified differences between 
people’s valuations using VAS and TTO techniques, and Baker and Robinson (2004) used an 
inductive approach, aimed at understanding more broadly how individuals completed SG 
valuation tasks. Both Robinson et al. (1997) and Baker and Robinson (2004) were able to 
fulfil the aims of their research via the approaches selected, as the former authors asked 
specific questions of informants in relation to differences in their TTO and VAS valuations, 
and the latter authors generated numerous themes around the factors that people considered 
when making their valuations.  
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Reflecting on their methods, Baker and Robinson (2004) reported that their use of semi-
structured interviews as a follow-up to think-aloud was essential in collecting in-depth data, 
as informants sometimes found it difficult to verbalise all of their thoughts while completing 
valuation tasks. In this sense the shortcomings of one method were supported by the use of 
another. Robinson et al. (1997) commented that using structured interviews alongside think-
aloud enabled them to generate data on issues of interest more efficiently. However, the 
impression was that think-aloud and questioning were undertaken simultaneously, with 
informants being asked specific questions about their responses at certain points in the 
exercise, potentially disrupting the flow of their verbalisations. Further, although informants 
were asked open questions about their responses to the valuation exercise, informants’ 
answers were not then probed for detail. This deductive style approach may provide an 
explanation for why the authors struggled to explain certain findings, such as why older 
informants gave lower TTO valuations than younger informants. It is possible that the reasons 
underlying people’s valuation of health states were complex and personal, suggesting that 
data collection may have benefited from further time and engagement between the researcher 
and informant. 
The review of this literature has demonstrated how qualitative methods have been used to 
understand and explore preference-based valuation processes. Qualitative analysis was largely 
undertaken to identify issues related to the way in which people constructed and delivered 
their preferences, such as whether preferences adhered to the axioms of utility theory. This 
has emphasised the potential for qualitative research to be used in a similar capacity to 
investigate model-building processes. The underlying context of the papers reviewed is 
similar to that of the modelling research proposed, as qualitative methods would be used to 
understand and explore the processes that modellers are using to develop decision-analytic 
models, particularly any issues with the methods undertaken. Collectively, the preference-
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based valuation studies generated a range of theoretical but also practical findings, including 
suggestions for enhancing valuation processes. These practical implications are indicative of 
those that this modelling research is aiming to generate. 
Although all studies addressed the objectives of their research using different approaches, 
lessons were learnt about the strengths and limitations of the methods used. The authors of 
studies using surveys and semi-structured interviews were unable to capture enough detail on 
relevant issues because of the less exploratory nature of these methods. Robinson and Bryan 
(2013) noted that interviews were less useful where communication between informants was 
important, suggesting that the observation of informants’ discussions and deliberations would 
have allowed for a deeper understanding of their research conclusions. Think-aloud was 
reflected on as a useful method for gaining a detailed understanding of informant thought 
processes, and thus the way in which informants carried out tasks. However, it was also 
suggested that informants’ verbalisations of their thought processes may have directly 
influenced research conclusions, by encouraging informants to think more deeply about the 
exercises that they were undertaking. This emphasised the importance of choosing an 
appropriate research design when using qualitative methods. Finally, the use of the 
triangulation of qualitative methods appeared valuable, as using multiple methods allowed the 
researchers to capture additional detail on important issues. It seemed apparent therefore, that 
an inductive and exploratory approach to qualitative study was that which was most 
beneficial.  
3.3.2 The use of qualitative research to improve recruitment to randomised controlled 
trials  
Although qualitative research has been used extensively in health services research, for 
example in the development and evaluation of healthcare interventions (see Hart et al., 2005; 
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Schulze and Angermeyer, 2003), this review focuses specifically on how qualitative methods 
have been used to understand RCT recruitment. There is a growing body of health services 
research that focuses on using qualitative approaches to identify potential barriers to RCT 
uptake, in the context of patient recruitment to trials being challenging, and patient numbers 
being lower than required. A search of the literature was undertaken to retrieve examples of 
these papers, with a total of ten being discussed.  
Most studies captured through the search were undertaken as part of an ongoing RCT. The 
studies used qualitative research to explore recruitment processes, with the aim of identifying 
factors that facilitated or prevented uptake to RCTs, and generating suggestions for 
improvements to recruitment processes generally. Although these recruitment papers had 
similar objectives to one another, different qualitative methods were used, including semi-
structured interviews, in-depth interviews, focus groups, observation, and the triangulation of 
these methods. As with the previous review, the studies are compared according to the 
methods undertaken. 
Two studies used semi-structured interviews (Eborall et al., 2011; Gopinath et al., 2013) to 
identify reasons for non-participation in RCTs from the perspective of patients who decided 
not to participate. Both studies generated findings on barriers to recruitment and suggestions 
to improve uptake. However, the deductive approach adopted by Gopinath et al. (2013) 
limited research conclusions, as the paper focused on exploring pre-existing barriers to 
recruitment, producing findings on patient treatment preferences that only reaffirmed those of 
previous studies. The focus on confirming rather than generating theory also inhibited 
exploration of patients’ feelings around the issue of treatment preferences, as reasoning was 
explored in limited depth, and preferences were assumed to be ‘non-modifiable’. Eborall et al. 
(2011) generated additional themes on barriers to recruitment through a more inductive 
approach, finding too that patient treatment preferences were responsible for non-participation 
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in RCTs. However, the authors asked informants closed-ended questions, questioning 
informants directly about their thoughts on potentially participating in the trial and not 
knowing which treatment they would receive. It is possible therefore that the style of 
questioning adopted may have influenced the themes and outcomes of this research. 
Studies using in-depth interviews benefited from informants’ detailed and lengthy discussions 
on recruitment. Das Nair et al. (2014) used focus groups to capture informants’ views on the 
recruitment process planned for an upcoming RCT. The study found altruism to be a 
motivator for trial participation and thus the findings of informants’ detailed discussions were 
used to update patient information resources to include the benefits to others of medical 
research. Two papers based on the same qualitative studies used in-depth interviews to 
understand recruiters’ involvement in, and experiences of, recruitment (Donovan, 
Paramasivan, et al. 2014; Donovan, de Salis, et al. 2014). Both studies found that encouraging 
recruiters to speak in-depth and personally about their roles led to discussions over feelings of 
discomfort around recruiting patients. The benefits of an exploratory approach to research 
were demonstrated, as informants did not immediately recognise these feelings as potential 
barriers to recruitment. When asked directly about issues around recruitment, informants only 
identified organisational difficulties and patient treatment preferences as problematic. The 
studies determined that recruiters required further training and support to improve 
recruitment, aimed at helping recruiters to engage more comfortably with potential 
participants, and discuss trial participation more confidently.   
Studies by Wade et al. (2009) and Mills et al. (2011) used observation of recruitment 
appointments (recordings) to gain insight into interaction between recruiters and patients. 
Wade et al. (2009) used conversation analysis to investigate whether patients appeared to 
understand recruitment information. In comparing conversational exchanges, the authors 
found the most ‘successful’ appointments in terms of uptake were those that allowed patients 
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to express their views and address participation concerns. The researchers observed patients 
moving from having set preferences for a particular treatment, to consenting to a trial and 
randomisation after this style of discussion. Mills et al. (2011) aimed to explore how patients 
communicated treatment preferences, finding that patients expressed strengths of preference, 
in that whilst some individuals were sure of the treatment that they wanted, others were less 
convinced, and changed their minds after detailed discussions with recruitment staff. The 
findings of the above studies were in contrast to those of Gopinath et al. (2013), who 
concluded that treatment preferences could not be changed, but who also did not capture the 
nuances associated with patients’ opinions on recruitment. Both observational studies 
suggested that RCT uptake could be enhanced through improvements to communication with 
patients. 
The remaining papers used a triangulation of methods. Through the use of in-depth interviews 
and observation of recruitment appointments, Paramasivan et al. (2011) identified a number 
of recruitment challenges, including recruiter difficulty with explaining trial design to 
patients, due to the complexity of the information involved. The recruiters interviewed 
reported such problems themselves, and were also observed struggling to convey recruitment 
information to patients concisely. These collective findings provided increased justification 
for clearer patient information within the trial. Hamilton et al. (2013) used semi-structured 
interviews with recruiters and observation of recruitment appointments. In contrast to the 
previous study, the triangulation of methods generated conflicting findings, in terms of what 
was observed as problematic during observation of appointments, and the reasons that 
recruiters gave for poor recruitment in their interviews. The authors found that recruiters were 
reinforcing their own perceptions of why patient uptake was low onto patients during 
recruitment consultations. The recruiters expressed the view that patients considered one 
treatment option to be less acceptable than the other, but were actually emphasising this 
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stance to patients, thus not presenting treatment options in an equivalent way. These findings 
highlight the potential for alternative qualitative methods to capture different interpretations 
of the same phenomenon.  
Donovan et al. (2002) used semi-structured interviews with patients, and observation of 
recruitment appointments to explore how patients interpreted study information. Patients were 
asked to discuss their experiences of recruitment, and the authors ‘matched’ patient comments 
to the information delivered during RCT consultations. The data generated gave the authors 
some indication of why patients held particular views on recruitment, such as patient concern 
with the ‘conservative monitoring’ arm of the trial, which was presented as an inactive option 
compared to others, and thus perceived by patients to mean ‘no treatment’. The use of 
interviews and observation in conjunction allowed the authors to explore the findings of one 
method, using the other. All of the above papers and those using observational methods have 
highlighted the additional insight that the study of communication in the RCT recruitment 
process was able to provide.  
The review of this literature has demonstrated how qualitative methods have been used to 
understand recruitment issues in RCTs, and suggest ways to improve uptake. Again this 
provides support for the use of qualitative methods to understand and identify improvements 
to modelling processes, by speaking to and observing those involved. A number of the 
recruitment studies emphasised the importance of using observation to capture 
communication between patients and recruiters, and in terms of the implication of this 
research for the modelling work proposed, it is probable that communication between those 
involved in model development could have a similarly important effect on the modelling 
process and final model.  
Arguably, and similar to the conclusions of the preference-based valuation studies, the RCT 
papers using methods that allowed for deeper exploration of informants’ feelings and the 
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recruitment context, provided the opportunity to investigate the more nuanced but important 
issues associated with RCT uptake. Further, the studies using triangulation highlighted the 
benefits of using multiple qualitative methods, in generating support for research findings, but 
also different insights into a particular phenomenon.  
3.3.3 The use of qualitative research to explore decision-analytic model development 
A systematic review was undertaken to explore how qualitative methods have been used to 
understand decision-analytic model development. This review was important in identifying 
similar work to that proposed within this thesis, and therefore highlighting whether further 
research is required and justified. The next sections describe the methods used within the 
systematic review.  
3.3.3.1 Review question 
How have qualitative methods been used to understand and/or improve health economic 
modelling? 
3.3.3.2 The search strategy 
The systematic review was undertaken in line with guidelines from the CRD (2008). Prior to 
undertaking the systematic review, a search was carried out in the Cochrane Database of 
Systematic Reviews, to check that there were no existing reviews on the use of qualitative 
methods in model building. Despite searches of the database using a number of different 
search terms, no relevant reviews were retrieved. Next, a full systematic review was 
undertaken, involving a number of stages and approaches to identify relevant material and 
ensure thoroughness. Wider searches are advised to identify different types of relevant 
literature, and to avoid publication bias (CRD, 2008). The search involved the following 
stages: 
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 The searching of major electronic bibliographic databases for potentially relevant 
papers 
 Forward citation searching within electronic databases 
 The systematic scanning of the reference lists of key papers 
 Online searches using Google Scholar.  
The electronic bibliographic databases searched were MEDLINE®, EMBASE and HMIC. A 
pilot search was undertaken within these databases to test the sensitivity of search terms in 
capturing papers relevant to the research question. The initial search indicated that terms had 
to be broad, but specific in relation the context of the papers being searched for as, when 
‘qualitative’ and ‘modelling’ were searched for in combination, many irrelevant papers were 
returned. Therefore, the format followed in the main search focused on dividing the research 
question into three components: context (health economics), subject (modelling) and 
methodology (qualitative research). These components were expanded on during the review 
process to include synonyms and variations of the original search terms. The search strategies 
tested and undertaken as part of the review process are recorded in Appendix 4. 
Forward citation searching was used to find papers that had referenced those identified 
through electronic database searching. This was undertaken using the ‘find citing articles’ 
feature available in MEDLINE®. This approach to identifying relevant papers was important, 
given that authors may have cited others’ work to justify the methodology that they were 
using in their own. The reference lists of all papers retrieved through electronic database or 
forward citation searching were also thoroughly searched for other relevant research. These 
approaches were used in an iterative manner, in that at the point at which a key paper was 
identified, forward citation and reference list searching was undertaken on the publication. 
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Finally, online searches were undertaken in Google Scholar, to identify any further and 
relevant work by key authors and by using key search terms.    
3.3.3.3 The selection of literature 
All relevant material was considered for inclusion in the review, including full papers, reports, 
conference abstracts and theses. Where papers or material were not accessible through the 
electronic databases or online searches, authors were contacted for a copy. All material 
returned through the various search strategies was screened using pre-defined inclusion and 
exclusion criteria. These criteria were intentionally broad so as to attract as many relevant 
papers as possible. The exclusion criterion was implemented for practical reasons.  
 Inclusion criteria: Any form of literature that has used qualitative methods to 
investigate the elements or processes involved in the development of health economic 
models. 
 Exclusion criterion: Non-English language papers. 
The selection of papers for the final review was iterative, in the sense that the collected 
material was reviewed a number of times against the inclusion criteria. At the point at which 
papers were initially identified, their title and abstracts were checked for eligibility, with only 
material that was clearly not relevant being excluded. Material that appeared to be related to 
the research question then progressed to the second stage of the screening process, where it 
was reviewed in full-text format. Papers that were not excluded at this point were included in 
the final review. 
3.3.3.3.1 Quality of papers 
The CRD (2008) state that papers collected in a review should be assessed for quality. As this 
review was focused on methodology, studies could be critically assessed according to how 
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appropriate and robust their uses of qualitative methods appeared. Papers were compared 
broadly against the relevant criteria outlined in the British Medical Journal (BMJ) editor’s 
qualitative research checklist (BMJ, 2015).   
3.3.3.4 Data extraction and synthesis  
To facilitate data analysis and synthesis, a data extraction form was developed to record the 
details of the papers retrieved. The information taken from the papers was that which was 
considered most important to the research question, namely the aims of the study, the 
qualitative methods used, and the nature of the findings that the author(s) had generated. A 
copy of the data extraction form is given in Appendix 5. Narrative synthesis was used to 
compare the key components of the papers. The research protocol in Appendix 6 details all of 
the methods used within the review.  
3.3.3.5 Results of the review 
In total, 376 papers were identified for potential inclusion in the review. After screening of the 
titles and abstracts of these papers, 365 were excluded for not meeting the inclusion criteria. A 
large number of papers were removed at this stage, given that it was easy to see from the 
methods section of the abstracts whether, or in what context, the authors had used qualitative 
research. Eleven papers reached the second stage of the screening process, which involved 
evaluating the text of the papers to check that their content met the inclusion criteria. One 
paper was excluded at this point, because, although the paper was focused on identifying 
errors in model building, the authors had not used qualitative methods, but had only cited 
others’ uses of them. Three further papers were removed for being earlier versions of full-text 
papers also captured in the review (i.e. abstracts and unpublished discussion papers). Given 
that these papers were referring to the same research study as the published full-text versions, 
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and did not contribute any additional information, they were excluded for ease and 
readability.  
The systematic review therefore retrieved seven relevant papers. Of these, three were found 
through searching the electronic databases, one was retrieved through online searches using 
Google Scholar, and two were identified using reference list searching. The remaining paper 
(Squires, 2014) was retrieved through contacting the author directly, as a conference abstract 
of her PhD thesis was identified in a Google Scholar search, which then prompted a request 
for her full work. Although identified via a reference list search, Paisley (2012) also had to be 
contacted for her PhD thesis. The search process is demonstrated in the QUOROM flow 
diagram represented in Figure 2.  
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Figure 2: QUOROM flow diagram of study selection (Moher et al., 1999). Numbers represent 
the papers retrieved via database searching + those retrieved using other search strategies 
 
The numbers in each of the boxes of the flow diagram represent the papers retrieved through 
electronic database searching, plus (+) those that were found via other strategies i.e. reference 
list searching, searches in textbooks, and online searches. A full version of the systematic 
review is given in Appendix 4. 
3.3.3.5.1 Characteristics of the papers   
Of the seven papers retrieved through the review, five were full-text papers and two were PhD 
theses. The papers included the work of only four lead authors, with four of the papers being 
written by the same author, and all papers originating from the same UK University. Further, 
Kaltenthaler et al., (2014, 2013) were papers derived from the same qualitative study. This all 
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suggests that there has been minimal work using qualitative methods to explore modelling 
processes. In the next sections, the papers are compared according to their aims, methods and 
the nature of their findings. The characteristics of these papers are summarised in Table 2. 
Aims of the qualitative research 
All of the papers retrieved had similar aims, seeking to explore model development processes, 
mostly from the perspective of those involved. For the majority, model development referred 
to models that compared clinical technologies, although one paper focused on model building 
within a public health context (Squires, 2014). Similar to the research proposed within this 
thesis, all of the empirical studies had an objective to explore model development and/or 
highlight issues with current methods and processes. Further, the majority of these studies had 
been justified on the basis of poor practice in the finished product or written processes of 
existing decision-analytic models, or a lack of guidance on good practice. All of the papers 
appeared to aim to generate findings that would be of assistance to modellers. 
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Table 2: Summary of paper characteristics 
 






Aims of the paper Methods  Findings  
 
 
Summary of quality 
concerns 




To explore modeller 




differences in practice, 
and how errors might 





Description of the 
modelling process, 
including methods 
used in each stage 
and advice on how 
to avoid common 
errors.  
Sample size fairly 
small (12 modellers), 


















To report on 
suggested methods for 
structuring a model, 
and methods for the 
identification of 
evidence to inform 
model parameters.  
Focus group Paper provided 
detailed methods on 
how to conceptualise 
a structure, and for 
identifying evidence 
to populate data 
parameters, on the 




available on research 
methods. Only one 
focus group 
undertaken. Unclear 
how many people 
were involved and 
what their 
backgrounds were.  
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Aims of the paper Methods  Findings 
 
 
Summary of quality 
concerns 
Kaltenthaler 








To highlight common 
issues identified by 
ERGs during analysis 
of manufacturer’s 







A list of research 
recommendations 
for manufacturers, 
aimed at improving 
the quality of 
manufacturers’ 
submissions. 
Sampled only the first 
thirty ERG reports of 
those available. 
Therefore, questions 












To report on findings 
from the focus group 
on what might 
constitute a systematic 
and transparent 





Focus group Findings presented 
as issues of 
importance when 
using evidence to 
populate models, 
and paper provides 
advice on each of 
these. 
Findings based on one 
focus group with 18 
experts. Experts had 
different areas of 
expertise related to the 




comments of the 
informants on the 
themes generated. 
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To explore the issues 
concerned with the 
identification and 
use of information 
for model 
development.  
Focus group The paper reported on 
key issues of 
importance in the 
identification of 
evidence for models, 
and included guidance 
on good practice, and 
areas that require 
future research.  
Findings based on 
one focus group with 
13 experts. The 
authors reported 
reaching saturation 










requirements for the 













suitable approaches to 
the retrieval of 
evidence for models. 
Recommendations 
were based on 
methods used and 
problems reported by 






involved case studies 
of the development 
of two models. 
However, it was 
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Aims of the paper Methods  Findings  
 









To explore the 
methods used and 
issues encountered in 
the development of 











Research generated a 
conceptual 
modelling 





Research followed the 
development of only 
one model in a single 
organisation. Three 
observations of 
meetings and two 
interviews were 
undertaken with the 
modellers involved. 
Focus groups were 
with only 5 
informants, although 
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Five of the seven papers focused on investigating particular stages or aspects of model 
building (Kaltenthaler et al., 2014, 2013, 2011, 2012; Paisley, 2012), whilst the remaining two 
papers undertook research on processes of model development (Chilcott et al., 2010; Squires, 
2014). The majority of the former group of papers used qualitative methods to explore how 
evidence was identified and/or retrieved to inform decision-analytic models. For Paisley 
(2012) and Kaltenthaler et al., (2011) this included evidence for the structure of the model, in 
addition to data parameters. The paper by Kaltenthaler et al. (2012) focused on the end stage 
of model development, specifically the submission of a model to the NICE STA process. The 
authors’ aim was to identify common concerns with manufacturers’ evidence submissions. 
Chilcott et al. (2010) and Squires (2014) both aimed to capture data on the process of model 
building, with the former authors concentrating on the entire process of modelling, and the 
latter particularly on structural development.  
The qualitative methods used 
A variety of qualitative methods were used to explore model development. Of the seven 
papers retrieved, one used documentary analysis, three used focus groups, one used in-depth 
interviews, and two used a combination of observation, focus groups and interviews. The 
papers differed in terms of how much they reported about the methods used, which was 
seemingly due to whether the publication was focused on the methods and findings of the 
qualitative study, or the recommendations made as a result. Of the papers that discussed the 
methods in any depth, most involved conducting primary research with the individuals 
involved in model development. The exception was the work of Kaltenthaler et al. (2012), 
which used documentary analysis to categorise ‘key elements’ of ERG reports regarding the 
aspects of manufacturer’s submissions that the ERG identified as problematic.  
The remaining studies differed in terms of whether they aimed to capture the opinions of 
those involved in model development, their behaviour, or both. Focus groups were used 
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within three papers (Kaltenthaler et al., 2014, 2013, 2011), as Kaltenthaler et al. (2014) 
suggested that this method was appropriate because of an objective to identify consensus 
between informants, and synthesise data according to the themes that individuals agreed were 
most important to modelling practice. Chilcott et al. (2010) were the only authors to use in-
depth interviews alone, as the aim was to gain a detailed and ‘personalised view’ of the 
processes that modellers used to develop models. Chilcott et al. (2010) were interested in 
understanding how model development differed between modellers, and where informants 
considered errors were likely to occur in the process.  
Squires (2014) and Paisley (2012) used interviews in combination with focus groups and 
observation. The authors both aimed to capture the behaviour of modellers, in addition to their 
opinions, to explore how particular aspects of model development were undertaken. Squires 
(2014) and Paisley (2012) also included their own modelling experiences and reflections as 
methods of investigation. Squires (2014) analysed notes from her involvement in a previous 
public health modelling project, to identify what she had deemed to be important to the 
development of a model structure, and Paisley (2012) undertook her study within an action 
research framework, implementing different approaches to identifying evidence within her 
role as an Information Scientist, and reflecting on the usefulness of the alternative searches 
used.  
The findings of the qualitative studies 
The findings of studies differed according to the objectives and contexts within which they 
were undertaken. However, common themes could be identified in terms of the nature and 
type of findings that the methods were able to generate. This was valuable in evaluating the 
usefulness of the different qualitative approaches, but also in determining the overall attitude 
within this literature towards modelling practices. The qualitative studies generated two 
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themes: (1) that current modelling practices require improvement, and (2) that further research 
and guidance is needed on model development. 
Current practice requires improvement 
All seven of the papers retrieved found problems with current methods of model 
development. Kaltenthaler et al. (2012) concluded that the general quality of manufacturers’ 
submissions to the NICE STA process required improvement. The authors found through 
analysis of ERG reports that problems with submitted models were common, including the 
lack of detail available in submissions on modelling decisions, and the appropriateness of the 
data used to populate model parameters. Paisley (2012) concluded that the Cochrane style 
approach to evidence retrieval was not suitable for the requirements of decision-analytic 
modelling. These findings were based on the opinions and comments of informants, and 
Paisley's (2012) observations of informants’ information seeking behaviours. The three papers 
using qualitative focus groups (Kaltenthaler et al., 2014, 2013, 2011) also suggested that 
methods for identifying evidence to develop and populate decision-analytic models required 
improvement. For example, Kaltenthaler et al. (2014) reported that focus group informants 
were uncertain about how they should search for data to populate certain parameters, 
particularly probabilities for rare adverse events.  
Kaltenthaler et al., (2011), Chilcott et al. (2010) and Squires (2014) argued that improvement 
was required to model development on the basis of inconsistency in modelling methods. 
Chilcott et al., (2010) and Squires, (2014) found that the modeller informants interviewed 
and/or observed were undertaking different stages to one another in structural development. 
This disparity in informants’ methods was viewed as problematic, as Squires (2014) 
interpreted these differences as uncertainty among modellers regarding good practice, and 
Chilcott et al. (2010) suggested that subjectivity in structural decision-making invited 
criticism around whether credible methods were being used across all modelling processes.  
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Guidance and further research is needed  
In light of findings relating to problems with current modelling methods, the papers suggested 
that guidance and/or further research on model development was needed. As a result, all 
papers provided some advice to modellers, ranging from highlighting the issues that appeared 
most important to model development (Kaltenthaler et al., 2014, 2013), to a list of research 
recommendations (Kaltenthaler et al., 2012; Paisley, 2012), to good practice modelling 
processes (Chilcott et al., 2010; Kaltenthaler et al., 2011; Squires, 2014). Arguably, the style 
of advice offered by the latter set of authors provided the most in-depth and detailed guidance 
for modellers. Whilst Squires (2014) offered a conceptual modelling framework to guide a 
modeller stage by stage through the development of a public health model structure, Chilcott 
et al. (2010) presented a synthesised version of the modelling process as given by the 
interview informants, with advice on how to avoid common errors at various stages. 
Similarly, Kaltenthaler et al., (2011) gave detailed methods on how to conceptualise a 
structure, and identify appropriate evidence to populate model parameters. Although 
Kaltenthaler et al. (2013) and Kaltenthaler et al. (2014) provided numerous suggestions on 
good practice and issues to be aware of when identifying evidence for cost-effectiveness 
models, detailed methods and guidance on the processes involved with this aspect of model 
development were not given.  
For Kaltenthaler et al., (2012) the level of detail and, arguably, the usefulness of the research 
output was restricted by the methodology chosen. Kaltenthaler et al. (2012) limited the scope 
of their research to identifying issues with manufacturers’ submissions from ERG reports, 
rather than involving manufacturers and/or ERG members to collect data on how or why the 
problems recorded were occurring. The consequence of this was uncertainty and a lack of 
guidance on how modellers should change current modelling methods to ensure that they 
meet the standards expected by the ERGs.  
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Quality of the papers 
The quality of the papers was assessed against the BMJ editor’s qualitative research checklist 
(BMJ, 2015). When compared against the quality checklist criteria, the sampling and 
recruitment strategies used in the studies invited most concern. The BMJ checklist states that 
the sampling undertaken in qualitative research must be justified and ‘theoretically 
comprehensive to ensure the generalisability of the conceptual analysis’ (BMJ, 2015). 
However, the majority of the studies had relatively small sample sizes, with Kaltenthaler et al. 
(2013) and Kaltenthaler et al. (2014) undertaking one focus group with eighteen and thirteen 
informants respectively, and Chilcott et al. (2010) undertaking interviews with only twelve 
modellers. Squires (2014) followed the development of only one model, carrying out three 
observations of meetings and two interviews with the modellers involved. Paisley (2012) 
observed practice and undertook interviews on the development of two models, however, it 
was unclear how many observations and interviews were undertaken throughout the two case 
studies. Only two of the studies reported reaching saturation in terms of the themes generated 
(Kaltenthaler et al., 2014, 2013). Kaltenthaler et al., (2011) reported their methods in very 
limited detail, stating only that a focus group with participants from one academic modelling 
organisation was undertaken, and thus making it difficult to assess the quality of the study.  
Although qualitative research is not typically concerned with the number of informants 
sampled, the importance of capturing a range of perspectives and generating findings that are 
generalisable is emphasised (BMJ, 2015; Mays and Pope, 2000; Merkens, 2004). While some 
of the studies offered purposive and reasonably justified sampling strategies, such as the focus 
group studies (Kaltenthaler et al. 2013; Kaltenthaler et al. 2014) and Chilcott et al. (2010) 
who each aimed to sample a diversity of modelling experts, others did not. Kaltenthaler et al. 
(2012) sampled the ‘first thirty ERG reports’ with no justification as to why. In terms of 
achieving a typical set of findings, it would have been more robust to sample letters over a 
    
93 
 
period of time, given that issues identified within manufacturer’s submissions are likely to 
evolve with changing modelling approaches. Further, both Squires (2014) and Paisley (2012) 
based their research on model development within one academic institution, specifically their 
own, which raises questions around the generalisability of findings, given that 
recommendations are based on the practice of a single team of modellers. Squires (2014) did 
however, sample modellers outside of her institution for the focus group, although this only 
involved five informants. None of the studies, to the author’s knowledge, sampled the 
clinicians involved in model development, or modellers or other experts based outside the 
UK. 
3.3.3.6 Conclusion of review  
The review of the literature into the use of qualitative methods to explore model development 
has demonstrated that only very limited research has been undertaken within this area. 
However, the studies have indicated a need for changes to current modelling practices, and 
further guidance and research on modelling processes. The papers appeared to consider 
different aspects of model development important as the focus of research, although the 
majority concentrated on evidence retrieval and/or structural development. Only a few studies 
researched the entire modelling process. Most papers were concerned with exploring 
modelling from the perspective of those involved, although none of the studies included 
clinical experts. All of the papers reviewed were able to generate output to help modellers in 
their model development, and thus potentially improve the general standard of models. 
However, those using less exploratory qualitative approaches did not appear as able to 
produce detailed forms of guidance and recommendations as output. Concerns around the 
quality of existing studies have been raised, as the majority of the papers had relatively small 
samples, and lacked a clear and purposive sampling strategy.  




The review of the health services research and health economics literature within this chapter 
has demonstrated the ability of qualitative methods to explore healthcare related processes, 
and to generate data that can help researchers to understand methodological issues. The 
findings of these qualitative studies facilitated the development of recommendations around 
the methodological issues present in preference-based valuation tasks and RCT recruitment, 
to potentially improve processes and limit future problems. The review of these areas of 
research suggested that qualitative methods could also be useful in exploring modelling 
processes, and in understanding how and why problems occur within model development.  
The systematic review undertaken within this chapter identified studies that have used 
qualitative research to explore model development, and generate recommendations around 
good practice in model building. The findings of all of the studies indicated that future 
research and guidance were needed to improve modelling processes. However, the review 
also demonstrated that only a limited number of qualitative modelling studies had been 
carried out, and that those that had generally lacked quality in terms of the sampling strategies 
employed. Further, a potentially important omission from existing research was the 
involvement and role of clinicians in the modelling process. These findings suggest that 
qualitative research can be used, and is needed, to understand and address methodological 
issues in model building, but also that broader sampling and more robust qualitative 
approaches should be undertaken in future studies.  
A consistent theme running through all of the literature reviewed was the strength associated 
with the use of more exploratory qualitative approaches, and the triangulation of qualitative 
methods. The general impression from the papers was that those using more inductive and in-
depth approaches were able to generate a more detailed and nuanced understanding of the 
phenomena under study. The papers also demonstrated that using a combination of qualitative 
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methods was beneficial in providing potentially different insights into a phenomena, and 
emphasised the importance of choosing an appropriate research design, for example, using 
observational methods to capture communication where this might contribute to the conduct 
and results of a particular process. Drawing on the lessons learnt through the review of the 
qualitative studies within this chapter, this thesis aims to use a combination of in-depth 
qualitative methods to explore and document current processes of model development, using 
the findings to generate suggestions for improvements to modelling practices. The next 
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CHAPTER 4: METHODS 
4.1 Introduction 
This chapter reports on the qualitative methods used in each phase of the empirical research 
undertaken for this thesis. The research was divided into two phases: qualitative interviews 
with modellers and modelling case studies with teams of modellers and clinicians. The 
purpose of both stages of the research was to explore the processes used to develop decision-
analytic models, including the methods followed, examples of good practice, opinions on 
poor practice and any problems encountered. The overall objective of the research was to 
generate findings highlighting the current processes used by modellers, and to make 
recommendations for aspects of model building that could be improved through further 
research or guidance.  
Ethical approval was sought and granted for both phases of the research from the Science, 
Technology, Engineering and Mathematics Ethical Review Committee at the University of 
Birmingham (reference: ERN_12-1533). Approval was also obtained from the University of 
British Columbia Behavioural Research Ethics Board for the Canadian phase of the research 
(reference: H13-01796). Evidence for the ethical approvals for the UK and Canadian phases 
of the research is given in Appendices 7-9.  
4.2 Overview of research design 
The theoretical framework applied to the research was one of constructivism-interpretivism, 
which assumes a relativist ontology and subjectivist epistemology, specifically that there are 
multiple realities, and that the ‘reality’ captured through research is one created through the 
combined understandings of the researcher and informant (Denzin and Lincoln, 2000). The 
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methodological position was one of naturalistic inquiry, which typically uses strategies such 
as ethnography and case studies to explore the empirical worlds of informants (Denzin and 
Lincoln, 2000).  
The research undertaken within this thesis used qualitative methods to explore decision-
analytic model development from the perspective of those involved. Based on the findings of 
the previous chapter, in-depth and exploratory methods were selected due to their ability to 
produce detailed and nuanced data on the experiences, opinions and behaviour of informants, 
in relation to model building. The research used in-depth interviews in its first phase, and case 
studies using non-participant observation, think-aloud and qualitative interviews in its second 
phase. The research sampled those currently working in the area of model building, 
specifically modellers and clinical experts. The sampling strategy undertaken in the research 
was to recruit informants who could provide a broad range of perspectives. Therefore, the 
modelling experts interviewed in phase one were from a variety of backgrounds, including 
academics and non-academics, and individuals from the UK and Canada. The modelling 
teams sampled for the case studies were also intentionally diverse, one being academic, and 
the other policy-based. The research used constant-comparison and framework methods for 
analysis. 
4.3 Phase one: Qualitative interviews with modellers 
4.3.1 Research design 
Qualitative interviewing is the most commonly used qualitative method within health research 
and the social sciences (Green and Thorogood, 2009; Legard et al., 2003; O’Reilly, 2009). 
Interviews are generally used to explore phenomena that cannot be observed, such as a 
person’s thoughts, opinions and past behaviours (Patton, 2002). The aim of qualitative 
interviewing, also referred to as in-depth interviewing, is to produce ‘rich, detailed accounts’ 
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of the research topic under study ‘from the perspective of the interviewees’ (Green and 
Thorogood, 2009, p.95).  Legard et al (2003) suggest that the key to generating personal and 
detailed informant accounts is to be flexible in allowing informants to freely discuss 
important issues, and to encourage informants to give in-depth responses to questions. As the 
objective of the research was to capture in detail the model development processes used by 
modellers, in addition to their individual perspectives on current modelling methods, 
qualitative interviews were considered optimal. 
All qualitative interviews were conducted face-to-face, to facilitate the interactivity required 
to generate in-depth interview data (Legard et al., 2003). O’Reilly (2009) argues that 
establishing good rapport and trust with an informant is essential to the richness and quality of 
the data collected. Legard et al. (2003, p.143) suggest that rapport can be developed through 
the researcher ‘demonstrating a real desire to understand from the perspective of the 
interviewee’, while Coffey (1999) similarly argues that good data relies on an interviewer’s 
willingness to invest in an informant. Therefore Rubin and Rubin's (2005) approach of 
responsive interviewing was used. This involved the researcher formulating future questions 
based on informants’ previous answers, demonstrating awareness and interest in what the 
informant was discussing, but also gaining more depth and detail on matters that they 
considered important. 
4.3.2 The sampling and selection of informants for interview 
To enhance the credibility of research, Rubin and Rubin (2005) suggest selecting informants 
based on their knowledge and experience of a topic, choosing those who have a first-hand and 
in-depth understanding of the phenomenon under study. Informants were therefore selected to 
take part in the qualitative interviews on the basis of their experience of building decision-
analytic models, and their perceived ability to offer opinions on the model-building process. 
This is referred to as purposeful sampling, which focuses on choosing ‘information-rich’ 
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cases ‘from which one can learn a great deal about issues of central importance to the purpose 
of the inquiry’ (Patton 2002, p.230). Merkens (2004, p.167) also draws attention to the 
importance of having a sample that represents as many ‘facets’ of a particular group of 
informants as possible. Mays and Pope (2000, p.51) argue that the validity and credibility of 
qualitative research depends on the researcher ensuring ‘that the research design explicitly 
incorporates a wide range of different perspectives so that the viewpoint of one group is never 
presented as if it represents the sole truth about any situation’. Firestone (1993, p.17) also 
contends that sampling for different opinions on the same research issue can promote 
generalisability, stating that ‘similar results under different conditions illustrate the robustness 
of the finding’. Therefore, modellers were also approached and sampled according to the 
different experiences of modelling that they possessed, their seniority and the context in 
which their modelling work was conducted.  
Sampling was continuous and purposive in the sense that the background and outlook of 
previous informants influenced the selection of informants for the next round of interviews. 
This is also referred to as gradual selection, and involves assessing who to approach next 
based on the nature of the data previously collected, and the desire to gain a range of 
perspectives (Flick, 2009). The informants eventually sampled were modellers working in 
either an academic or non-academic role. The academic modellers sampled worked for 
universities either in the UK or Canada, and the non-academic modellers were working for a 
modelling consultancy, pharmaceutical company, or policy institute in the UK. Snowball 
sampling was used to gain access to most of the non-academic and Canadian academic 
informants with whom the author or her supervisors did not have existing links. Snowball 
sampling involves asking existing informants to recommend individuals whose experiences 
are related to the research (Kuper et al., 2008). The non-academic and Canadian academic 
informants were in each case mostly identified through one key informant.  
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4.3.2.1 Sample size  
In line with the ongoing sampling approach (O’Reilly, 2009), informants were recruited to the 
interviews in waves, to allow future data collection to be informed by the themes emerging in 
previous findings. For example, it was suggested in the first wave of interviews with UK 
academics that the modelling processes and methods used by those in industry might differ 
from their own. Therefore, going forward, it was considered important to recruit non-
academic modellers to ensure a representative view of model development.  
Sample size was not decided in advance of the research, with sampling instead continuing to 
the ‘point of diminishing return, where increasing the sample size no longer contributes new 
evidence’ (Richie et al. 2003, p.83). This was determined as the point at which informants 
were continually offering similar accounts and opinions of the model-building process, for 
example, repetition of the stages, issues and methods used. It was also considered important 
that enough data were collected for each of the different groups of informants, and that 
saturation was occurring across all interview accounts. This view of saturation of data 
categories is aligned to that defined by Bowen (2008, p.148), who argued that sampling 
should continue until the interviewer ‘hears the same comments from different participants in 
different places’.  
4.3.2.2 Recruitment 
Methods of recruitment differed depending on the type of informant sampled. Searching staff 
profiles on various university websites was the strategy used to identify UK academics. The 
first step was to compile a list of UK universities that undertook modelling work, identifying 
potential informants within these universities whose role involved decision-analytic 
modelling. From this list, a shortlist of informants to approach was decided on in conjunction 
with the research supervisors. This decision was based on the information given within an 
informant’s staff profile, with the aim of sampling those working within different size teams, 
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in different disease areas and at different levels of seniority, and to obtain a geographical 
spread of informants.  
Rubin and Rubin (2005) suggest that informants are more likely to agree to participate in an 
interview if they have a shared background with the interviewer, for example, a mutual 
contact. Therefore, all UK academic informants on the initial shortlist were initially emailed 
by one of the research supervisors who had existing connections with the individual. Potential 
informants were sent an introductory email outlining the research, introducing the author, and 
drawing attention to email attachments. The attachments included an official letter inviting the 
informant to take part in the research, and an information sheet that outlined research 
objectives, data collection and storage and ethical considerations. Copies of a sample 
invitation letter and the informant information sheet are provided in Appendix 10 and 
Appendix 11. Potential informants were asked to reply to the author directly if they were 
interested in participating, and were sent a follow-up email after seven days if they had not 
responded.  
Non-academic UK informants were almost all identified through a key informant, who was an 
existing contact of one of the research supervisors. The key informant was approached for 
interview because he worked for a modelling consultancy, and was able to suggest other 
modellers working for consultancies and pharmaceutical companies who could be sampled. 
Policy informants were recruited directly by the author through an established contact, who 
took part in the interview himself but also recommended a further policy informant. Potential 
non-academic informants were contacted by either the author or key informant with an 
introductory email, official invitation letter and information sheet.  
The interviews with academic modellers in Canada were facilitated by funding gained 
through the Universitas 21 Doctoral Scholarship Programme. This programme allowed the 
author to travel to a university outside the UK, where research was similarly being undertaken 
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using decision-analytic models. Canada was specifically chosen because it shares a similar 
regulatory structure and health technology assessment process to the UK, meaning that the 
data generated between the informants in Canada and the UK were comparable. It was 
anticipated that interviewing Canadian academic modellers on their model development 
processes would provide an international perspective, and could highlight differences to the 
methods used by UK modellers. The author was assigned a research supervisor at the host 
university who assisted with the recruitment of modellers to interviews. This research 
supervisor identified and recruited a key informant, and the key informant then identified 
other informants to be contacted to take part. Canadian informants were selected on the same 
basis as those in the UK, on their knowledge and experience of decision-analytic modelling. 
The key informant was also asked to identify a diverse group of modellers in terms of the 
context of their work and their seniority. Academics from a number of different institutions 
affiliated to the host university were therefore considered as potential informants. In the same 
way as with the UK academic informants, all Canadian academic informants were initially 
contacted through the research supervisor in Canada, and sent an official invitation letter and 
information sheet.   
4.3.3 Data collection 
For those interested in participating in an interview, a convenient date and time was arranged 
via email. Most interviews took place at the informant’s place of work, as this was considered 
a setting where an informant would feel comfortable and relaxed, facilitating the development 
of rapport (Green and Thorogood, 2009). However, one interview was conducted in a café, as 
this was identified as the most convenient place by that particular informant. All of the 
interviews, with the permission of the informant, were recorded using a digital audio-recorder, 
to allow the interviewer to focus full attention on the interview exchange (Legard et al., 
2003), and provide a rich source for data analysis. Written notes were taken to remind the 
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author of issues to follow-up with informants later in an interview. All of the interviews were 
undertaken by the author. 
The questions asked in the interviews followed the framework proposed by Rubin and Rubin 
(2005, p.152), namely ‘a balance of main questions, follow-up questions, and probes’. The 
main questions were prepared prior to the interview and were designed to explore the issues 
perceived to be important to the research topic, including the processes used to develop 
decision-analytic models, and informant opinions on the methods used. Main questions were 
phrased in an open-ended way in order not to influence responses, and to encourage 
informants to discuss issues most salient to them (McNamara, 2009). Follow-up questions 
were devised during the interviews and in response to what informants had said. The purpose 
of these questions was to gain a deeper understanding of issues that informants raised when 
answering main questions (Creswell, 2013). Probes were used to encourage the informant to 
expand on specific points, for clarification or to facilitate the flow of the interview. Many of 
the probes used were non-verbal and were to reassure the informant that they were discussing 
issues that were important and interesting to the research, for example, ‘leaning forward to 
express interest, and…taking notes in ways that signal the interviewee to keep talking’ (Rubin 
and Rubin, 2005, p.164).  
An interview guide was developed to remind the author of important questions to ask. 
Questions were ordered according to the funnelling technique, which involved moving from 
‘general enquires to more specific and focused questioning’ to allow informants ‘to relax into 
the interview’ (Wilkinson and Birmingham, 2003, p.47). Questions were initially focused on 
asking for background information from the informants on their modelling experiences, and 
moved on to detailed issues, such as informant opinion of current model-building guidance. 
However, the use of the interview guide was flexible in the sense that questions, and their 
order, were influenced by topics that informants wanted to discuss. Informants were free to 
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introduce and discuss ideas that were not in the interview guide, and these were followed-up 
for depth and detail in the same way as answers to planned questions. Further, questions at the 
end of the interview focused on asking for suggestions for future research, and on ensuring 
that the informants had nothing else that they wanted to contribute (Legard et al., 2003). The 
interview guide was modified a number of times over the course of the interviews to 
encompass additional issues that informants raised. A copy of the interview guide is provided 
in Appendix 12. 
4.3.4 Analysis 
All of the interviews were analysed by the author. Interviews were transcribed verbatim to 
ensure a reliable account of the informants’ thoughts and opinions (Green and Thorogood, 
2009). Analysis drew on grounded theory procedures (Strauss and Corbin, 1990) and the 
method of constant comparison (Glaser and Strauss, 1968; Glaser, 1965). Data collection and 
analysis occurred simultaneously, as analysis of the data collected influenced the sampling of 
further data (Strauss and Corbin, 1990), and continued analysis allowed a deeper 
understanding of the data categories emerging. Interview transcripts were coded individually 
in the first instance, with ‘open coding’ used to ‘break down’ and ‘conceptualise’ data into 
incidents that could be assigned a representative label (Strauss and Corbin, 1990).  
Open coding of transcripts was initially undertaken using line-by-line analysis; however, as 
coding continued and categories were identified and became well-established, transcripts were 
coded by sentence or paragraph, as focus moved toward developing a deeper understanding of 
existing themes (Strauss and Corbin, 1990). As required by the constant comparative method, 
data coded with a particular label or within a particular category were continually ‘compared 
with the previous incidents coded in the same category’ (Glaser 1965, p.439). This allowed 
the author to begin to understand the properties of a category, and how emerging categories 
related to one another (Glaser, 1965; Strauss and Corbin, 1990). As analysis progressed, new 
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instances of data were compared to the properties of emerging categories, to further make 
sense of how concepts were connected. Comparisons were facilitated through continuous 
questioning of what each instance of data meant, and how it was similar or different to 
previous incidents, and concepts presented within categories as a whole (Strauss and Corbin, 
1990). The use of questioning also improved the theoretical sensitivity of the analysis, as data 
were examined for additional meanings and relevance (Strauss and Corbin, 1990).  
Coding was initially carried out on the first three interview transcripts (referred to as I1, I2 
and I3). As comparisons continued within and between these transcripts, data were sorted and 
reduced into first and second level codes. These codes were noted and applied to each of the 
initial three interview transcripts in their entirety. Further coding and revision of the data, 
referred to as ‘axial coding’ (Strauss and Corbin, 1990), was carried out to establish 
hierarchical relationships between codes, forming categories and sub-categories of data. 
Written and diagrammatical coding structures were developed to record this hierarchy. A 
descriptive account was generated for the first batch of interviews, to facilitate analysis and 
comparison of informant responses and synthesise the data within each category.  
Interviews continued to be undertaken and analysed in batches of three to seven, with 
informants being grouped according to their backgrounds, rather than order of interview. The 
coding structure developed through the full analysis of the initial batch of interviews was 
applied to the transcripts of the second batch, and a descriptive account was produced. This 
continued for all batches of interviews, as the analysis of previous transcripts updated and 
revised the categories and sub-categories that were applied to future batches. Collecting and 
analysing the data in this way allowed for previous analyses to influence the questions asked 
in future interviews, and facilitated the author’s understanding of the important issues that 
were emerging from the data. For example, clinician involvement in the modelling process 
was perceived to be important after two interview batches; therefore, in future interviews 
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informants were probed to give greater depth and detail on this aspect. Comparison of the 
coding structure diagrams developed at the beginning and end of analysis demonstrate that as 
analysis progressed, some original codes were combined, whilst others were divided to form 
distinct categories. For example, ‘integrity’ was originally represented as a category in its own 
right, but was later understood to be an aspect of what informants considered as good practice 
in model development. Likewise ‘clinician involvement’ became a first level code, as it 
became apparent that there were many issues around their involvement in model 
development. The initial and final versions of the coding structure diagrams are available in 
Appendix 13 and Appendix 14, and the final version of the coding structure definitions is 
available in Appendix 15. 
The final stage of analysis involved combining all descriptive accounts to display all 
informants’ thoughts and opinions under each category and sub-category of data (Richie et al., 
2003b). The comments of the informants were compared for similarities, and specific 
attention was paid to any circumstances indicative of differences in opinion or practice. Given 
that a focus of the research was to investigate how modellers typically undertake their 
modelling processes, matrices were developed to compare and contrast informant responses, 
specifically to see which stages of model development were most commonly followed, and 
where there were differences in methods used. An excerpt from these matrices is available in 
Appendix 16.  
The coding of the interview transcripts was carried out both manually and electronically for 
thoroughness. Codes were noted in the margins of hard copies of transcripts, and then later in 
the comments section of electronic copies in Microsoft Word. To improve validity, the coding 
and analysis of the interview transcripts were challenged in various ways by the research 
supervisors. Each of the research supervisors independently coded the first interview 
transcript, and their insights were incorporated into the development of initial data categories. 
    
107 
 
The original coding structure was also developed in conjunction with research supervisors, 
who read the coded versions of the first three interview transcripts and offered their 
understandings of how the data were related and what appeared important. The research 
supervisors also read each descriptive account thoroughly and gave opinions on the 
appropriateness of the content of data categories, and feedback on analysis technique.  
4.3.5 Ethical considerations 
Ethical issues were considered prior to commencement of the interviews, and ethical conduct 
was maintained throughout the research. Much time was spent at the planning stages 
considering any potential risks to informants, and although there appeared to be little risk of 
harm due to the professional rather than personal nature of the research, precautions were still 
taken. Given that informants were being interviewed in a professional capacity, there was a 
possibility that discussion of their work could make them identifiable. Therefore, to safeguard 
informants’ identities and guarantee anonymity and confidentiality, interview transcripts were 
anonymised, and all data were stored in a secure way. Any information that could potentially 
identify an informant, for example, the informant’s name, details concerning their work 
history, modelling projects and modelling teams, were removed from the transcripts and 
replaced with a code. All data were stored on a secure, password protected computer network 
that could only be accessed by the author. The personal information of the informants was 
stored separately from their interview transcripts.  
Gaining the informants’ consent to take part in interviews was seen as a continuous process, 
rather than a single event, due to the right of the informants to reconsider their involvement in 
the research at any time (The Research Ethics Guidebook 2015). Informed written consent 
was taken from each informant prior to their interview, after they had been ‘informed fully 
about the purpose, methods and intended possible uses of the research, [and] what their 
participation in the research’ entailed (The Research Ethics Guidebook 2015). Informants 
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were encouraged to read the informant information sheet prior to consenting to participate in 
the interview, and to ask the author any questions that they had. Importantly, the informant 
information sheet (see Appendix 11) outlined the informant’s right to withdraw from the 
research at any time, even after providing written consent. Karnieli-Miller et al. (2009) 
stressed the importance of the contributions and rights of informants being respected 
throughout the research process, and as a result informants were reminded just before their 
interview that they still had the right to withdraw during or after data collection. A copy of the 
written consent form is available in Appendix 17. 
4.3.6 The interview informants 
A total of twenty-four interviews were undertaken with health economic modellers from 
various backgrounds. Table 3 shows the basic characteristics of these informants, in addition 
to comments on their interviews. The informants were almost evenly distributed between 
academics working in the UK, academics working in Canada and non-academic UK 
informants. Sixteen of the informants were male and eight were female, however, the gender 
of the informants was not considered to be important to this research. The interviews aimed to 
sample a mixture of senior and more ‘junior’ informants. Senior informants were defined as 
those who worked in a managerial role and were largely overseeing the work of others. The 
ratio of senior to junior informants was nine to fifteen; however, there were varying degrees 
of experience among the junior informants. While some appeared to have been modelling for 
a number of years and worked on numerous models, others had worked on only one or two. 
Capturing this range of informant experience was seen as beneficial in gaining a breadth of 
perspective on the modelling process. The differences in the informants’ experiences of 
modelling are examined in more detail in the next chapter. The average interview lasted for 
around one hour, and most took place in a quiet location. A few of the interviews suffered 
from interruptions such as background noise or telephone calls; however, these did not 
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prevent the interviews from continuing. Some of the informants were more difficult to engage 
than others, appearing nervous or tending to offer short answers to the questions asked. 
However, in most cases the informants became more relaxed as the interview progressed, and 
the open-ended style of questioning and prompting encouraged the informants to speak for 
longer and in more depth. 
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Comments on interview 







1 hour  
 
Informant was very talkative 
and spoke in-depth in 
response to most questions. 










Informant seemed nervous 
before the interview but was 
fine answering the questions. 
He remembered a lot of 
information toward the end 
of the interview that he had 
not said during. 










Interview flowed well, the 
informant spoke for long 
periods of time on each topic 
without being prompted. 
 











1 hour Interview went well. 

















Comments on interview 















Some of this informant’s 
answers to questions 
were fairly short and 
required further 
prompting. 













1 hour, 20 
minutes 
Interview went well but 
felt long and the 
informant spent a long 
time discussing the 
context of his work. He 
spoke freely and at 















The informant appeared 
to be nervous. He 
required prompting and 
further questioning to 
gain clarification on his 
points.  































1 hour, 10 
minutes 
Good interview, very 
informative, although the 
informant spoke rather 
technically at times.  










Informant was very easy to 
chat to and rapport was 
quickly established.  
I10 Male Academic UK Senior 
Informant's 








times was a 
little 
disruptive. 
1 hour, 15 
minutes 
The interview seemed to 
last quite a long time but 

















This informant gave fairly 
short answers to all of the 
questions asked.  
 













































The informant was 
enthusiastic and 
talkative, giving detailed 














1 hour, 20 
minutes 
 
This informant was very 
enthusiastic and led a lot 
of the discussion and the 
direction of the 
interview. 













1 hour, 45 
minutes 
The interview lasted for 
almost 2 hours and I felt 
very tired towards the 
end. The informant 
spoke freely and 
confidently about all 
topics, although rather 
technically at times. 





















UK Junior  
In a cafe, 











1 hour, 15 
minutes 
Interview was quite long 
but informant often did 
not provide a lot of depth 
and explanation to the 













Informant was very 
informative and clear in 
all of his answers. 
I18 Male Academic Canada Junior  
The 
author's 






This informant struggled 
to recall some of his 
modelling practices, 
making the interview 
difficult at times. 
I19 Male Academic Canada Junior 
The 
author's 







The informant gave a lot 
of background to his 
projects and the 
interview was slow to 
'get started'. 
  


















Comments on interview 
I20 Male Academic Canada Junior 
The 
author's 





40 minutes Interview went well.  
I21 Male Academic Canada Junior 
The 
author's 






The informant was 
enthusiastic and 
provided in-depth 
answers to most 
questions. 
I22 Male Academic Canada Senior 
The 
author's 






The interview went well, 
the informant was very 
talkative. Rapport was 
quickly established. 
I23 Female Academic Canada Junior 
The 
author's 





40 minutes Interview went well.  
I24 Male Academic Canada Senior 
The 
author's 






Interview was slow at 
first with the informant 
giving fairly short 
answers to the questions 
asked. However, answers 
became more 
informative as the 
interview progressed. 
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4.4 Phase two: Model-building case studies with modellers and clinicians 
4.4.1 Research design 
The second phase of the research involved model-building case studies with teams of 
modellers and clinicians. The case studies and the methods used within them were designed to 
complement and broaden the findings of the first phase of the empirical research: the 
qualitative interviews with modellers. The case studies aimed to complement the findings of 
the qualitative interviews in two ways. Firstly, the findings of the case studies could either 
support or challenge the accounts of modelling processes given by the interview informants. 
Secondly, and due to the observational methods used, the case studies could generate findings 
on what people do, in addition to what they say they do (Green and Thorogood, 2009). Mays 
and Pope (2000) argue that comparing the findings of two or more different data collection 
methods can ensure comprehensiveness in the research conclusions. The case studies could 
also expand on the findings of the qualitative interviews, as they allow for the first-hand, close 
and detailed exploration of the ‘real-life situation’, i.e. the model-building process, under 
study (Flyvbjerg 2006, p.223).  
The literature offers different definitions of a case study, with some defining it as the sample 
of people or phenomena being studied (Hammersley, 1992; Stake, 2003), and others 
identifying it as a methodological approach to research (Yin, 2014). From either perspective, 
a case study is concerned with gathering ‘comprehensive, systematic, and in-depth 
information about [the] case of interest’ (Patton 2002, p.447). For this research, the case of 
interest referred to the model-building process, and the stages and methods that the modellers 
and clinicians were undertaking. Considering the case study as a methodological approach to 
research, Yin (2014, p.4) argues that it is an important method when an answer to a ‘how’ or 
‘why’ question is required, and when ‘an extensive and in-depth description of some social 
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phenomenon’ is needed. Indeed, the objective of this research was to explore how decision-
analytic models were being developed in practice, and to capture any problems that occurred 
within the model-building process. If any problems were observed, the research aimed to 
explore why these occurred, in addition to how they were resolved. Therefore, the case study 
‘method’ lent itself well to the questions being asked around the modelling process, and also 
addressed the need to generate a ‘thick description’ of the ‘issues, contexts, and 
interpretations’ involved with model development (Stake, 2003).  
Yin (2014, p.17) identifies the use of ‘multiple sources of evidence’ as being fundamental to a 
case study inquiry, and advocates the combination of methods such as interviews, collection 
of documentary information, and observations. Although case studies are not essentially 
qualitative (Stake, 2003), all of the methods used within this research were. The case studies 
used non-participant observation, qualitative interviews and think-aloud interviews to gather 
data on the model-building process. These methods were selected with the aim of collecting 
data on as many of the stages undertaken in model development as possible, with reflections 
from those involved. Non-participant observation was used to observe the meetings that took 
place between those working on the model, whilst the qualitative interviews allowed the 
author to question those involved on aspects of the model’s development and the process in 
general. Data collection also extended to emails that were sent between the modellers and 
clinicians, and any documents that were used or discussed within the meetings that were 
observed. The think-aloud interviews were used to elicit data on specific stages of the 
modelling process that typically involved the modeller working independently.  
Using these methods in conjunction with each other was expected to give a breadth and depth 
of understanding of the way in which modellers and clinicians undertake stages of the 
modelling process, and their opinions on the methods used. Stake (2003, pp.446-448) 
identified the value of case studies as being an ‘opportunity to learn’ from the study of a 
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particular phenomenon and to suggest ‘complexities for further investigation’. The research 
aimed to provide full and analytical accounts of the model-building process that those 
working within the field could potentially take guidance from, and also make 
recommendations for future research that could enhance the methods of model development.  
4.4.1.1 Case study selection 
Two case studies were selected for analysis, with the focus being on the process used to 
develop a decision-analytic model. The decision to undertake two case studies appeared 
optimal given the desire to maximise the generalisability of the research conclusions within 
the time available. Schofield (2000, p.79) argues that ‘a finding emerging repeatedly in the 
study of numerous sites would appear to be more likely to be a good working hypothesis 
about some yet unstudied site than a finding emerging from just one’. Each case study aimed 
to capture the stages involved in the development of one health economic model from 
beginning to end, involving multiple exposures to model development to ensure that a 
representative perspective was being captured (Krefting, 1991).  
The case studies were selected on the basis of the information that they could generate, and 
the potential implications of their findings more generally. Flyvbjerg (2006, p.230) suggests 
that sampling for ‘critical cases’ provides a more useful insight into a particular phenomenon, 
and enhances the generalisability of conclusions. Critical case sampling involves looking for 
cases that permit ‘logical deductions of the type’ i.e. ‘if this is valid for this case, then it 
applies to all cases’ (Flyvbjerg 2006, p.230). Therefore, the aim was to sample modelling 
teams which had a particularly good reputation for model building, on the assumption that 
any problems or issues that were encountered within their modelling processes were also 
likely to be encountered by modellers with less experience. The aim was also to sample a 
range of model development processes, on Polit and Beck's (2010, p.1454) recommendation 
that replication of findings between similar ‘cases that vary on attributes likely to affect 
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conceptualization can…strengthen generalization’. Therefore academic and policy-based case 
studies were sampled, referred to as Case Study A and Case Study B respectively. This was 
on the assumption that they might take alternative approaches to, and use different methods 
in, model development given the different contexts of their work. It was anticipated that the 
recommendations made from the case study findings, would focus on the issues that were 
most challenging in model development, and would be applicable to multiple model 
development settings. 
4.4.1.2 Recruitment 
The two case studies were selected and recruited using the suggestions of the interview 
informants, as they were asked towards the end of their interviews to suggest teams of 
modellers who would be an interesting focus for the research. As a result, many informants 
recommended undertaking case studies within institutions that had a good reputation for 
model development, and a number suggested sampling models that were being developed in 
different contexts to one another, in anticipation of capturing a broader perspective. Also, 
some informants offered modelling projects that they were due to work on as potential case 
studies. Based on these recommendations and ease of access, two of the modelling case 
studies offered by the interview informants were selected. 
The two interview informants who set up the case studies were asked to distribute an 
information sheet to those involved in model development, to ensure that they were fully 
informed and happy to take part. The information sheet outlined the methods of the case 
studies, how informant data would be used and managed, and ethical aspects such as the 
informant’s right to withdraw. The information sheet also stated that the informants might be 
asked to take part in an interview during the case study, to give their opinions on the 
modelling process. Written informed consent was obtained from those involved, with 
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additional written consent being taken later for those who agreed to be interviewed. The 
informant information sheet for the case study research is available in Appendix 18.  
4.4.2 Methods and data collection 
4.4.2.1 Non-participant observation  
Patton (2002, p.262) argues that directly observing phenomena has the advantage of allowing 
the researcher to understand the context of an interaction, and observe aspects that an 
informant would not necessarily be aware of or discuss. The aim of using observations was to 
gain a deeper insight into the model development processes being used, including the nuances 
of how those involved contributed and communicated. Non-participant observation was 
selected as it was not deemed necessary for the author to have an active role in the research 
setting. Glesne (2006, p.50) refers to this position as ‘participant as observer’ on ‘the 
participant-observation continuum’; defined as such because ‘the researcher remains primarily 
an observer but has some interaction with the study participants’. The aim of the non-
participant observation was, as far as possible, to capture the typical processes used by 
modellers and clinicians, without any influence from the author. In addition, it was not 
considered practical for the author to be involved in the model building given the professional 
nature of work undertaken.  
The observation of the modelling processes involved observing all meetings between the 
modellers, and the modellers and clinicians. This included the observation of face-to-face 
meetings, documents referred to within discussion, and email communication between those 
involved. For Case Study A, the author was permitted to audio-record all meetings, which 
provided a rich and detailed source for analysis. Field notes were taken in addition to the 
meeting transcripts to record details of the setting and the author’s perceptions and thoughts. 
Data collection for Case Study B relied mostly on field notes, as the author was not permitted 
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to audio-record meetings and had limited access to the modellers’ own recordings. The field 
notes taken therefore had to be very thorough to ensure that enough detail was captured on 
every interaction. On the recommendations of Patton (2002), both descriptive and analytical 
field notes were recorded, with the former involving a description of the setting and what was 
being observed, in addition to direct quotations from the informants, and the latter involving 
the author’s interpretations of what was happening. Silverman (2000) refers to the latter as 
‘expanded field notes’ and suggests that that these provide an important basis for data 
analysis. Expanded field notes were taken in the form of ‘contact summary sheets’ (Miles and 
Huberman, 1984, p.25) that were created for each observation of a meeting, and summarised 
the main issues that were emerging from the data, including any ‘new hypotheses or 
speculation’. Miles and Huberman (1984, p.25) argue that data that are analysed as they are 
collected are ‘radically more analysis-rich’, and the analytical field notes generated allowed 
the author to develop a deeper understanding of important issues as the research progressed. 
The descriptive notes were recorded separately from the author’s interpretations. Field notes 
were handwritten but typed up as soon as possible after each observation.  
4.4.2.2 Qualitative interviews  
Face-to-face or telephone interviews were conducted with the modellers and clinicians 
involved in both case studies. Most of the interviews were face-to-face and took place in the 
case study setting; however, the interviews with the clinicians in Case Study B were by 
telephone, due to their busy work schedules. Although there are concerns among qualitative 
researchers that it is more difficult to develop rapport with informants and collect rich data 
using telephone interviews, it is also argued that telephone conversation may put people at 
ease ‘and allow [them] to disclose sensitive information more freely’ (Novick, 2008, p.8). 
Therefore telephone interviews were seen as a fruitful and practical method of data collection. 
The interviews took place at various points in the models’ development and were designed to 
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capture the reflections of the case study informants on aspects of the development processes 
that had been observed thus far. 
The interview guide contained questions that were specific to the models being built, in 
addition to questions about the general processes. The intention was to gauge from the 
modellers or clinicians what they felt was good about the current model and processes, and 
what they felt was not as good. This was designed to generate findings on methods that might 
be considered as good practice, and aspects that might require improvement. The interview 
guide also asked the informants for their opinions on issues that had emerged from the 
findings of the qualitative interviews in the first phase, such as the suggestion of guidance for 
clinicians.   
The qualitative interviews undertaken within the case studies were more structured than those 
in the first phase of the research. There was less flexibility in terms of the topics discussed, as 
much of the interview focused on asking informants about issues that had emerged during the 
observations. These questions were prepared in advance of the interviews and typically 
involved checking the author’s interpretations of observations, and asking informants to 
expand on model development activities and aspects of their role. However, informants were 
still given the opportunity to introduce and discuss issues that they considered important, as 
follow-up questions were asked to gather further detail on comments and opinions, and all 
informants were asked at the end of their interviews whether there was anything else they 
wanted to contribute that they felt was relevant. A copy of the interview guide for the case 
study interviews is available in Appendix 19. 
Informants were asked prior to their interviews to fully read through the interview information 
sheet, ask the author any questions that they had, and sign the additional interview consent 
form (copies of which are available in Appendix 20 and Appendix 21 respectively). All of the 
interviews for both case studies were audio-recorded with the permission of each informant.   
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4.4.2.3 Think-aloud  
Think-aloud generates data on the ‘reasoning processes’ that individuals use to undertake 
particular problem solving tasks (Fonteyn et al., 1993). More specifically the method works to 
‘identify the information that is concentrated on during problem solving and how that 
information is used to facilitate problem resolution’ (Fonteyn et al. 1993, p.430). Data are 
obtained by asking informants to ‘talk aloud’ while performing cognitive tasks, capturing 
verbalisations of their thought processes (Ericsson and Simon, 1984). The focus of the think-
aloud used in this case study research was to explore how modellers completed stages of the 
modelling process that were undertaken individually and implicitly. Think-aloud therefore 
allowed the author access to processes within modelling that could not be explored through 
observation alone. Further, think-aloud was considered a more appropriate method than 
qualitative interviews, as rich and detailed data could be captured on the entire stage of model 
development under study, without the concern of recall bias (van den Haak et al., 2003).  
Think-aloud was carried out within one of the two case studies and focused on following and 
exploring the methods that the modeller used to test the model results, specifically the 
sensitivity analysis. This aspect of the process was selected not only because the modeller was 
working independently, but also because in-depth data could be generated on the cognitive 
processes that the modeller used to interpret analyses (van Someran et al., 1994). The aim was 
to learn about the type of sensitivity checks carried out, but also about how the modeller 
understood and made sense of the test outputs. In line with the suggestions of Fonteyn et al 
(1993), think-aloud was undertaken in a quiet location, specifically in the informant’s work 
office, with as little interaction from the author as possible to avoid interruption to the 
informant’s thoughts. The informant was instructed prior to the think-aloud to ‘speak 
constantly without regard for coherency’ whilst completing the sensitivity analyses, and was 
only communicated with to be reminded to ‘keep talking’ after periods of silence (Boren and 
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Ramey, 2000). The think-aloud was audio-recorded with the permission of the informant, and 
the recording was transcribed verbatim. The author also took note of any questions or 
clarifications that seemed important during the think-aloud, so that these could be discussed 
with the informant after the session.  
4.4.3 Analysis  
Case study analysis followed the framework method outlined by Richie and Spencer (1994). 
Framework was selected because it facilitates a combined approach to deductive and 
inductive thematic analysis, allowing existing and specific issues to be explored, but also 
providing an opportunity for new experiences and interpretations to emerge (Gale et al., 
2013). This was essential given that the aim of the case studies was to look for support for, 
but also expand on the findings of the qualitative interviews. The method is also orientated 
towards the management of large data sets, and promotes ‘within-case and between-case 
analysis’ (Srivastava and Thomson, 2009, p.77). This meant that informant experiences and 
opinions on particular modelling stages could be compared within the same case study, and 
similarities and differences in modelling practices across the two case studies could be 
explored. The framework method involved undertaking five key stages of qualitative data 
analysis: 
 familiarisation, 
 identifying a thematic framework, 
 indexing, 
 charting, 
 mapping and interpretation (Richie and Spencer, 2002). 
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Familiarisation was the first step of analysis, and required the researcher to become 
‘immersed’ in the data that were gathered from each case study (Richie and Spencer, 2002). 
Case studies were analysed individually and all collected material was revised. This 
specifically involved reviewing meeting and interview transcripts, re-reading observational 
field notes, and in some cases listening to original audio-recordings. This was whilst creating 
‘memos’ on the ideas and themes that appeared important and were recurrent throughout the 
data. For example, as memos were generated for Case study A, it became apparent that 
miscommunication and misunderstanding between the modellers and clinician was an issue at 
a number of stages of the modelling process. 
From the ‘key issues, concepts and themes’ identified through review of the case study 
material, the next stage of analysis involved the development of a ‘thematic framework’, used 
to sort and label the data (Richie and Spencer, 2002, p.313). This coding framework was also 
informed by themes raised in the first phase of the research, and by issues covered on the case 
study interview guide. This was important given that the aim of the case study research was to 
further explore issues that were identified as important in the in-depth interviews, whilst also 
seeing whether similar modelling methods were used across the interviews and case studies. 
The first version of the thematic framework therefore contained codes indicative of the overall 
stages of the modelling process demonstrated in the qualitative interviews and case study 
material, in addition to codes for issues that were important in the first phase, such as clinician 
involvement.  
Consistent with the findings of Richie and Spencer (2002), the thematic framework was 
refined as it was applied to the case study data, as new codes, particularly those at the 
secondary level, emerged and were added. The fluidity of the thematic framework therefore 
allowed new and important issues to be explored, and provided an overview of how the case 
study data were related to the findings of the qualitative interviews with modellers. For 
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example, the framework initially contained and coded data according to the three broad 
elements of model development that were generated in the first phase of the research, namely 
structural development, populating the model and model checking. However, it became clear 
after reviewing the case study material that there were data available on the results stage of 
model development, indicating the need for an additional first level code. Similarly, as the 
data were coded, further lower level codes were added to the framework to account for the 
description of model development stages and richness of data that the case study methods 
were able to generate. The sub-categories of ‘where patients go and why’, ‘decisions on how 
to model pathways’, and ‘outcomes of pathways’, developed from the ‘drafting the structure’ 
code generated through the qualitative interviews, as observation allowed the author to learn 
in detail of the information that appeared most important in developing the pathways of the 
model.  
The thematic framework generated through the review of all case study material, and the 
coding of Case Study A was then applied to Case Study B. Although no first level codes 
changed, indicating similarities in the overall model development stages undertaken between 
the case studies, some lower level codes were added. Where existing lower level codes could 
not be applied to Case Study B data, it was often indicative of a difference in methods and 
practice between the two case studies. The final thematic frameworks for both case studies are 
available in Appendices 22 and 23.  
The next stage of analysis, undertaken alongside the development and refinement of the 
thematic framework, was indexing. Indexing referred to the application of the codes outlined 
in the framework to the case study data, including interview transcripts, observational 
transcripts and field notes, and documents such as presentations and emails between 
informants. Materials were coded by line or passage, with consideration of the meaning of 
each instance of data and how it related to the thematic framework and data coded previously. 
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Indexing was carried out through the use of NVivo software, which facilitated the 
organisation and coding of large amounts of data (Srivastava and Thomson, 2009) and easily 
allowed data to be compared within codes, to explore whether existing labels were 
appropriate and whether further lower level codes were required. This comparison of data also 
allowed the author to gain an early overview of the findings generated within each theme, 
particularly the methods used to complete each stage of the modelling process, and 
differences in informants’ opinions on particular issues.  
The penultimate stage of the framework analysis involved charting the data, specifically 
‘lifting’ it from its original context and rearranging it with reference to the themes identified 
during indexing (Richie and Spencer, 2002). The charts in this research were organised 
according to the codes in the thematic framework, and entries were made for the relevant data 
generated via each method of data collection, i.e. observations, interviews, documents and 
‘other’, including think-aloud and diagrams. This typically allowed what had been observed at 
each stage of model development to be directly compared to specific comments informants 
made in interviews. The author was therefore able to compare informants’ reflections on 
particular aspects of model development, and also confirm that the practices observed had 
been understood and interpreted correctly. In each section of the chart appeared a summary of 
the data captured by each type of method in regard to a particular stage or issue. Data were 
typically summarised according to key information on practices used to complete stages of 
model development, problems that occurred, and informants’ reflections on both. The charts 
also contained a summary section for each code, synthesising all important information 
gained. Separate charts were created for the two case studies, although the codes used were 
almost identical, so findings were easily comparable. An excerpt from the framework created 
for Case study A is demonstrated in Figure 3. 
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Figure 3: Excerpt of framework for Case Study A 
 
 
The final stage of analysis was mapping and interpretation. Richie and Spencer (2002) 
referred to this as the process of ‘detection’, where the author interprets the data collected in 
relation to the original objectives of the research. This involves reviewing and comparing 
aspects of evidence, and structuring it according to underlying, important issues (Richie and 
Spencer, 2002). Although the objective of the case study research was to record and compare 
the processes and methods used by different modelling teams, it was also to explore why 
modellers and clinicians undertake particular practices and encounter certain problems. 
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4.4.4 Ethical considerations 
Ethical considerations for the case study research followed similar processes to those outlined 
for the qualitative interviews. Again any potential risks to informants were assessed prior to 
commencement, with ethical issues being discussed with those involved. As with the first 
phase of the research, informants were not deemed to be at risk of any harm from 
participating, but steps had to be taken to protect the identities of the modellers and clinicians 
involved, and the modelling organisations. Due to the volume and richness of data collected, 
there was a risk that individual or combined aspects of evidence could reveal the identity of 
the modelling team under study. Hopf (2004) argues that particular care is needed when 
disseminating the findings of empirical research undertaken within an organisation, ensuring 
that workplace or regional contexts are not recognisable to the public. Therefore within all 
written reports of the data, including thesis chapters and publications, all characteristics that 
could potentially identify the context of the case studies were anonymised and replaced with a 
code. This included informants’ names and job titles, the names of others involved in model 
building, and the details of the medical conditions that were the subject of the models. The 
organisations were referenced to only as academic (university) for Case study A, and policy-
based for Case study B. To ensure further that the organisations remained anonymous, case 
study informants were asked to review thesis chapters for identifiable information that should 
be removed. This step was also important to the ethics around informant ownership of data, 
and the credibility of research, as Baxter and Jack (2008, p556) suggest that ‘member 
checking’ allows informants to discuss what has been written, and whether they feel that 
findings are a fair and accurate representation of what was observed.  
Raw data, such as observational and interview transcripts, were anonymised as far as possible. 
This involved coding the identities of informants, locations and disease references. As a 
precaution, all data and documents were stored on a secure, password protected computer 
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network that could only be accessed by the author. Further, the personal information of the 
informants was stored separately from any transcripts. With the qualitative interviews, 
informed consent was viewed as a continuous process, whereby separate consent was taken 
for the observation and interview elements, and informants were reminded each time that they 
were free to withdraw from the research.  
4.4.5 The case study informants  
Two case studies were carried out with teams of modellers and clinicians. Case Study A 
involved the development of a model within a UK university. Those immediately involved in 
model development were two health economic modellers (I25 and I1) and one clinical expert 
(C1). The modellers held different roles in model development and were identified as having 
different levels of expertise. Whilst I25 undertook the ‘hands on’ model building, I1’s role 
was in a supervisory capacity. Although I1 did not get involved in the ‘technical’ 
development of the model, she took an active role in clinical meetings with C1 and modelling 
meetings with I25, and in the model’s structural development. I25 identified this as the first 
modelling project that he had worked on, whilst I1 had supervised the development of many 
models previously. C1 had no previous knowledge or experience of health economics, but 
was Principal Investigator (PI) on a clinical project that required modelling expertise. I25 and 
I1 were therefore recruited by C1 to develop a model, as the required economics element of 
the clinical study. Immediate model development involved an additional member of the team, 
referred to as Modeller 2, who was identified as an expert modeller. A wider team of clinical 
collaborators and statisticians were also involved in the RCT and model development, 
providing clinical input and statistical expertise where necessary. The informants referred to 
in Case Study A and Case Study B are presented in Table 4. 
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Table 4: Case study informants with their roles in model development 
Case Study Informant Role in model development 
Case Study A: I1 Modeller (supervisory/senior 
modeller) 
I25 Modeller (main modeller) 
C1 Clinician 
Modeller 2 Modeller (ad-hoc involvement) 
Case Study B: I8 Modeller (supervisory/senior 
modeller) 
I26 Modeller (main modeller) 
R1 Researcher  
C2 Clinician (interviewed) 
C3 Clinician (interviewed) 






C10 Clinician  
The focus of Case Study B was the development of a model in a UK policy context. The 
modelling team consisted of two health economic modellers, two project managers and three 
researchers, whose roles were focused on identifying data for the model. The two modellers 
held different roles in model development and had different levels of expertise. Whilst I26 
reported this to be the first model that he had worked on since his Master’s degree, I8 had 
developed many more and thus was supervising I26 who undertook the ‘hands-on’ modelling. 
The clinicians involved held various clinical roles within Medical field 2. The extent of a 
clinician’s involvement in model development was subject to their ability to attend meetings 
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and contribute to discussions. Although model development involved twenty clinical experts, 
the research focused on the opinions and reflections of three clinicians (C2, C3 and C4) and 
two modellers (I8 and I26). The three clinicians interviewed each had some experience of 
health economics, with C3 having been involved in the development of other models, and C2 
and C4 having worked on projects with a cost-effectiveness element.  
4.4.6 Presentation of findings 
The findings of the qualitative interviews and case studies are presented in the next two 
chapters of this thesis. Chapter 5 provides the analysis of responses of the interview 
informants on the model-building process, and issues around model development. Chapter 6 
presents the findings of the two model-building case studies, including analysis of 
observational data on the stages undertaken in model development, and interviews with 
modellers and clinicians for their reflections on the practices used. In these chapters, 
quotations from informants or observational data are presented verbatim. Ellipsis (…) is used 
to indicate where any text has been omitted to shorten or simplify quotes. ‘Umms’, ‘errs’ and 
repeated words were omitted without the use of ellipsis.  
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CHAPTER 5: QUALITATIVE INTERVIEWS 
WITH MODELLERS ON THE MODEL-
BUILDING PROCESS 
5.1 Introduction 
This chapter presents the analysis of the responses of the modeller informants on the model-
building process. It covers the informants’ experiences of modelling, accounts of the 
modelling process, clinician involvement in model development, reflections on model 
building, opinions on modelling guidance, and avenues for future research. Given that 
clinician involvement appeared to be such an important issue, it is discussed in relation to the 
relevant stages of the modelling process, but also considered in-depth as a separate theme. 
Suggestions for future research related to what the informants thought it important to explore 
within the model-building case studies, presented in chapter 6. The implications of the 
findings of these interviews in relation to the case study research are considered in the 
Discussion chapter (7). 
5.2 Experience of modelling 
Differences between informants’ experiences of modelling, other than those that were 
purposively sampled for, became apparent through the analysis of their responses. These 
differences are demonstrated in Table 5, and displayed by number of informants.
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In terms of informant background, most were economics or mathematics related; however, a 
small number originally studied a clinical discipline. Informants were divided between those 
who learnt to model whilst in employment and those who learnt on a postgraduate 
programme. The nature and purpose of the modelling work undertaken varied, as academic 
informants typically engaged in research-orientated activities, and the non-academic 
informants mostly worked for modelling consultancies. The aim of the work of the 
consultancy informants was to develop models for submission to decision-making bodies, on 
behalf of pharmaceutical companies. One informant, I16, worked directly for a 
pharmaceutical company, where his role concentrated on the design of models, and ensuring 
that structures were fit for submission to decision-makers. Two of the non-academic 
informants, I7 and I8, worked for UK policy institutes, and generated research to directly 
inform healthcare policy.  
The strategy of sampling for senior and junior modellers generated a divide between 
informants typically modelling in a supervisory capacity, and those doing 'hands on' model 
development. Senior academic informants were mostly in a ‘supervisory only’ role, focused 
on overseeing the development of a model without being involved in its programming, whilst 
the role of the junior informants was typically concerned with the ‘everyday’ conceptual and 
technical development of a model. However, most senior non-academic informants appeared 
to still engage in some ‘hands on’ modelling, although their role mostly involved supervising 
and contributing to the work of others. Similarly, there were a few junior informants who 
undertook some supervision of others. 
Informants’ working environment and seniority seemed to affect how much their current role 
focused on modelling. The non-academic and junior informants were more likely to be 
working on model based projects only, whilst senior academics typically reported having to 
undertake projects in additional research areas. Collectively the informants had modelled in a 
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range of disease areas. The non-academic consultancy informants discussed developing 
models in a variety of conditions, whilst over half of academic informants' modelling work 
appeared to focus on a specific disease area. Unsurprisingly, those who had built models in a 
number of disease areas also tended to have more experience of working with different model 
types. Generally the non-academic informants had worked on higher numbers of models than 
those in academia.  
5.3 The modelling process 
Informants offered descriptions of the typical processes that they used to develop a decision-
analytic model. Their processes appeared to follow the same three broad elements: developing 
the structure, populating the model and model checking. The first section looks at the 
informants’ definitions of the structure of a model. Presented next are the stages and methods 
referred to by informants in structural development.  
5.3.1 Defining model structure 
Most informants offered a similar definition of the structure of a model. Almost all referred to 
the structure as the pathways or the health states and outcomes that were related to a patient’s 
experience of a particular disease and its treatment. 
I7: “that particular intervention and its effects and if there are any adverse effects that 
come along…” 
I8: “… a pathway of different events in the correct way for a given population or 
treatment” 
Most informants gave the impression that the pathways and health states used in a structure 
should reflect what happens to patients in reality, including the intermediate and long term 
outcomes that result from disease progression or treatment.  
I19: “...we are trying to mimic the human physiology” 
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I10: “…a set of intermediate outcomes, so change in blood pressure, a set of final 
outcomes, death or heart attack” 
However, a few of the non-academic, consultancy informants suggested that although based 
on clinical reality, their structures reflected the health states and outcomes considered most 
important. I14 and I11 both implied that this referred to the health and quality of life 
outcomes that were likely to have the greatest impact on patients, but also on the health 
economics output.  
I14: “...what’s important clinically...or it can be what’s important because it clearly 
matters to the patient...” 
I11: “a patient reported outcome study found the thing that made the biggest 
difference for the patient and their quality of life was actually whether they were in a 
wheelchair or not, so the structure ...[was based on] wheelchair use because that’s 
what’s relevant”  
While most informants confined their definitions of structure to a representation of patient 
pathways and health states, a few informants, both academic and non-academic, suggested 
that the structure should incorporate the data used to populate it.  
I6: “I see it as one big thing, you’ve got your data and you’ve got a mechanism for 
synthesising that data and turning lots of parameters into costs and QALYs...” 
5.3.2 Developing model structure  
Informants discussed using other model structures, clinical literature and clinical data to 
inform and develop their own model structures. However, there were some differences in 
opinion among the informants as to how much influence these sources do or should have. The 
next sections outline the methods used by informants to gather information that would form 
the basis of model structure. 
5.3.2.1 Other model structures 
Over half of informants discussed using existing model structures to inform structural 
development. Most informants mentioned using other structures as a source of inspiration for 
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their work, generating ideas about how other modellers had represented a particular disease or 
intervention, and what appeared to be good and poor practice.  
I6: “the easiest way to get a handle on a condition and how you’re going to model it is 
to see if there have been any other models developed…” 
I12: “NICE criticise models and so you take those on board and you develop your 
model to take into account those criticisms” 
However, a smaller number of informants discussed using existing structures more 
prominently in their work, taking an existing structure and developing it further, rather than 
building an entirely new model. Both of the informants below suggested that using existing 
models was a more efficient way of working.  
I10: “sometimes there’s a model that’s already there, we have complete access to it… 
[We] don’t reinvent the wheel” 
I2: “you can use other models, improve on them, develop them, and re-parameterise 
them…you don’t want to reinvent the wheel”  
This said I17 and a few others gave the impression that the need to use other structures 
depended on the complexity of the disease area being modelled, and the quality and standard 
of other models available.   
I17: “[if] they don’t look like they’ve been really well accepted or we don’t believe 
that they are robust then we would start with a blank piece of paper…” 
Just under half of informants who discussed using other structures, thought that the search to 
retrieve them should be systematic. I21, for example, argued that a robust search of the 
literature should be undertaken to ensure that the new structure is valid in light of the work 
that others have done.  
I1: “We do a [systematic] review of the papers out there, looking at different model 
structures, always…” 
I21: “people ask you ‘how valid is your model?’ and you have to have some 
convincing answers, when you've gone through all the literature you will know what 
all the papers have done so far…”  
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5.3.2.2 Clinical literature  
Over half of informants referred to using the clinical literature as a resource to inform 
structural development. This referred to clinical information on the natural history and 
treatment of a disease. Sources included clinical papers, clinical patient information, and 
NICE clinical guidelines. Most of these informants gave the impression that reviewing such 
material gave them an initial and essential understanding of the disease that they were 
modelling.  
I7: “you have to research the clinical area first; you can’t just make a stab in the 
dark…” 
I19: “...delved into reading about a disease itself...studying it to the point where I feel 
like I’m good enough, well-versed in the natural history of that disease”  
Other informants discussed using the clinical literature to directly inform structures, looking 
for and including information such as disease symptoms, health outcomes and adverse events 
to represent states or pathways. 
I14: “…looking for what are the symptoms of these things, what adverse events are 
important to a patient?” 
I10: “what are the long-term outcomes of a child having a [particular infection 
type]…they might get [serious health outcome], those are things that you want the 
model to be able to cope with” 
From a non-academic consultancy perspective, I13 discussed using the clinical literature to 
determine the model population, looking for the patient group in which an intervention is 
most clinically and cost-effective.   
I13: “you often find people are using the drug in other countries in a particular 
setting, that’s a good indication of what their clinicians think is their best subgroup” 
5.3.2.3 Use of clinical data 
Just under half of informants used clinical data in the development of their model structures. 
This referred to the data on the treatment and intervention effectiveness, and the probabilities 
    
140 
 
associated with patients experiencing particular patient pathways, health states, outcomes and 
adverse events. These informants implied that they would build a structure using only the 
health states or pathways that they had clinical data for. These were almost all Canadian 
academic or UK non-academic, consultancy respondents.  
I21: “…you build your model based on your data” 
I11: “… first step is sifting through the data, seeing what we can do [with the 
structure]” 
In contrast, the remaining half of informants appeared to develop their structures prior to 
knowing the data available to populate them. In reference to the earlier comments of these 
informants when defining model structure, the suggestion was that they believed that a 
structure should be based on the health events that could happen to a patient in real life, rather 
than those for which there were available data. Some of these informants then talked about 
having to make simplifications to their structures after later realising that they do not have the 
data needed to populate the original pathways or states (see section 5.3.2.7). 
 I10: “then you begin looking around for the data to fill the model that you’ve 
created” 
I3: “you build a model and then you start checking whether the data you have, to what 
extent it can fit the model that you have built” 
A few informants discussed whether they considered it appropriate to develop a structure 
based on the data used to populate it. While I6 appeared to be of the opinion that it was a 
standard and inevitable practice, I17 argued that it could bias the results of a model as the 
structure would include only selected health events and outcomes. I17 seemed particularly 
wary of developing the structure on the basis of data provided by the pharmaceutical 
company, as this would likely favour their intervention. This said, I17 also stated that 
structural development had to be pragmatic, and that a structure may have to be modified in 
light of the data available to populate it.  
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I6: “people get really hung up on having a structure and having the data... I think our 
attitude is slightly different, the data informs certain things so you may be adapting 
the model, changing the structure to reflect that data...” 
I17: “I’m never a fan of building models just around the data you’ve got because that 
can lead to all sorts of biases especially if the data is provided by the manufacturer of 
the product you’re evaluating...that said if you don’t have any data available then you 
have to be quite pragmatic” 
5.3.2.4 Drafting the structure 
Most informants suggested that they drafted a structure before implementing it into a software 
platform. A number of informants described the methods used to develop an initial structure, 
indicating that they linked relevant clinical and quality of life outcomes to the pathways and 
health states that patients had to experience to reach them.  
I8: “I try and match up [the] key events that would get to [primary] outcomes…” 
Most informants indicated that they drafted a structure in diagrammatical format, to record 
how health events and outcomes linked together, and to facilitate making early changes to the 
structure. The majority of informants seemed to design their initial structures using pen and 
paper. 
I13: “map out the health states that you are interested in modelling and that are 
relevant to your question and then the relationships between them, this is a really 
rough bubble and arrow kind of diagram” 
I20: “just sitting down with a bunch of sheets of scrap paper and drawing and 
crossing out and redesigning” 
Model specification 
A quarter of informants discussed developing a model specification document as part of 
designing the initial structure. The specification document typically outlined how the 
modellers planned to develop a structure, including what information the structure was based 
on, and the data necessary to populate it. Only one informant who referred to this stage was an 
academic modeller.   
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I11: “…introduction and background and then a proposed model structure with a 
diagram explaining where we are going to get the data sources from, [and] how we 
have arrived at that structure…” 
The model specification document appeared as a formal aspect of most non-academic 
processes, used to communicate the planned development of a structure to a client and other 
parties involved. I14 stressed the importance of clients agreeing to the document’s content, to 
prevent them from wanting to change aspects of the structure after the model had been 
developed. 
I14: “… the client will sign it off, the reason is you’ve signed it off you can’t then 
come back to us and say, ‘I want you to do it all again’…”  
The specification document appeared central to I16’s involvement in model development.  I16 
gave the impression that he used the document to communicate with model consultancies 
about the important aspects to capture in a structure, for example, where different groups of 
patients required different pathways or health states.  
I16: “we think there might be a differential response rate between patients so [we say] 
‘you’re going to have to build that in somehow’…so the spec is what we think needs to 
be captured…” 
There were some contrasting opinions of the benefit of model specification documents among 
those who used them. Most informants seemed to perceive it as a necessary stage, including 
I12, who suggested that it facilitated understanding between those involved in model 
development. However, a few informants viewed the document as restrictive in the sense that 
it required a lot of work and information to be available at the beginning of the process. I17 
indicated that “signing-off” the structure at such an early stage was impractical as it was likely 
to have to change in light of data available. 
I12: “you’ll have difficulty explaining to the client what a model does if you’ve not got 
a document there that details the processes…” 
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I17: “…it’s no good finalising your protocol, signing it off and then six months later 
finding ‘oh right, we haven’t got a utility for that health state’” 
5.3.2.5 Clinician involvement  
Almost all informants involved clinical experts in their structural development. Informants 
suggested that the role of clinicians was to inform the modeller about the pathways that 
patients typically followed or health states that they experienced when they had a particular 
disease. This included providing information on the interventions and treatments that patients 
received, and the outcomes of these.  
I18: “get some expert clinical input into the…different pathways that patients could go 
through”  
I16: “find out about what happens in this particular condition so ‘how is pancreatic 
cancer, for example, managed currently? What’s a typical patient course from 
diagnosis to treatment to treatment failure to progression…?’”   
A number of informants, including I9, additionally implied that it was the clinician’s role to 
converse with the modeller over how disease pathways or states could feasibly be represented 
within a model framework. Informants suggested that this involved the clinician informing 
the modeller of the clinically important events and outcomes to include.  
I9: “simplify reality in a way that’s simple enough but not too simple, you need a 
clinician to help you out with that” 
I5: “clinical input would guide you as to what might be the important factors to 
include in your model” 
However, there were differences in practice between the informants, regarding when and how 
clinical input was sought. Just over half of informants gave the impression that they drafted a 
structure in conjunction with clinicians, whilst others suggested that an initial structure was 
developed independently, later receiving expert validation. Almost all of the Canadian 
academics used the latter practice. 
I6: “it’s getting the clinicians into a room, drawing lots of diagrams...” 
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I15: “I build a framework of the structure…and then I go to the clinician and I 
arrange a meeting and we go over the model…” 
Most informants gave the impression that they met clinicians face-to-face when developing 
the initial structure. The methods used by a number of them appeared to be rather formal, with 
discussion of setting up focus groups and workshops to determine aspects of a structure. Two 
informants, both UK academics, discussed on occasion using a Delphi style format, which 
involved structured methods for retrieving and combining clinical opinion on what a model 
structure should include. One informant suggested that Delphi was required where there was 
variation in treatment practice, whilst another implied that Delphi was necessary when 
developing structures in complex disease areas. I9 suggested that the Delphi methods that she 
had used had been very formal on the one hand, using recommended techniques and 
processes, and less formal on the other, using a Delphi type approach to contact a broad range 
of clinicians for ad-hoc input.  
I5: “getting small focus groups together of clinicians, toing and froing about 
structure...” 
I9: “…some of the early economic models we’ve done, talking to the clinicians we’ve 
actually formalised that, we’ve done some Delphi processes because the current 
practice is so disparate that it’s actually quite difficult to actually get your 
comparator set… or surveys, we’ve used surveys as well just to get an idea of what we 
were looking at…so we just wanted a snapshot of how people use that particular 
drug....”   
A few informants, who discussed involving clinicians in initial structural development, also 
discussed situations in which they would not involve clinician input, namely if building a 
model in a disease area that had numerous previous structures. Of note, this mostly applied to 
the non-academic, consultancy informants. 
I17: “If it was a really well established disease area… we probably wouldn’t speak to 
a clinician at all at the model design stage” 
I14: “if there’s nothing that has been done before or if what has been done before 
doesn’t make sense, it is then, ‘okay we’ll talk to the clinicians’…”  
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Only two informants, both Canadian academics, appeared to never involve clinicians at the 
conceptualisation stage. Both informants implied that a clinician’s first involvement was after 
a structure had been populated. I21 perceived this to be the most relevant time to ask for their 
feedback, whilst I19 attributed this practice to his clinical background. However, I19 implied 
that he did not consider it to be good practice generally to seek clinical expertise at such a late 
stage in the process.  
I21: “you don’t speak to them because you first have to have something to show them. 
Their job is to validate your model or to suggest something but as long as you don’t 
have any data it doesn’t make sense to go [and get them involved]” 
I19: “… I do model building with a pretty good knowledge of the clinical know how’s 
that go into the health condition I am modelling…people expect of me and I expect of 
myself to be good in the natural history of the disease… [I involve clinicians] very late 
in the model development process, that’s probably not good practice, but it has 
worked for me that way…” 
5.3.2.6 Model type 
Most informants discussed selecting an appropriate model type for their decision problem 
based on the timeline associated with the disease being modelled. The general opinion was 
that decision trees were used to represent short-term conditions, whilst Markov structures 
were used in chronic conditions, where there were repeat events. The use of individual 
sampling models was discussed less by the informants but also referred to, with the 
implication that such models would be required in the modelling of complex diseases, to 
encompass a larger number of health states and events. 
I10: “the primary consideration is first of all the time span of the outcomes, so if it’s 
a…simple treatment, no long-term harms to think about it might be best to be a simple 
decision tree… [if] you’re talking about a chronic issue where someone might be 
somewhat better by three months, much better by six months and then the device needs 
replacing at twelve months…‘okay this ought to be a Markov model’” 
I11: “I can remember we had one in [Condition 9] where we had so many states at 
that point we realised we needed a discrete event simulation…” 
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The most commonly used model type was a Markov structure, with a third of informants 
giving the impression that due to personal preference or requirements of decision-making 
bodies, they would default to a Markov structure provided it was suitable. 
I4: “the usual approach would be if you can get away with doing a Markov model in 
Excel, get away with doing a Markov model in Excel, because it’s simple...” 
I8: “because the NICE reference case specifies a lifetime approach, you generally 
start off with the assumption it will be a Markov model unless you can talk yourself 
out of it” 
Two informants discussed whether they considered choice of model type to be important in 
structural development. I1 was of the opinion that model selection was important, as it could 
affect the outcomes and results that a model generated. I24, however, argued that model type 
only impacts on the time and resources used, stating that different models were capable of 
representing all decision problems, but in a more or less efficient way.  
I1: “understanding the disease is important, and the fact that model type can make a 
difference...” 
I24: “there isn’t a right or wrong, there’s a more appropriate. There’s an [infectious 
disease] model that I’ve been involved in, which is a crazy Markov structure and I 
think it’s got a million tunnel states, it’s ridiculous, they’d have been much better off 
doing an individual sampling model. The model works but it’s just not a very efficient 
way of doing it”  
5.3.2.7 Making structural assumptions 
A third of informants discussed having to make structural assumptions within their models. 
The majority of these informants gave the impression that assumptions were made in 
collaboration with clinical experts. Informants cited different reasons for making structural 
assumptions including lack of data to populate a structure, a lack of knowledge of the disease 
being modelled, and a need to simplify patient pathways to make them feasible to model. The 
informants implied that making an assumption often involved removing a part of the original 
structure, or predicting unknown aspects.  
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I1: “…we realise that we haven’t got data for all points of the pathway; we try and 
make a shortcut, an assumption…” 
I5: “some diseases are pretty well defined and you know what’s happening, whereas 
the natural history of some diseases is so unknown…so you’re making huge 
assumptions…” 
I7: “we have to make them because otherwise the model becomes unwieldy and a little 
bit crazy…” 
However, a number of these informants stated that they would only make an assumption on 
the basis that it would not affect the results and overall outcome of a model. This appeared to 
involve ensuring that any changes to the model structure would not lead to any important 
costs or clinical outcomes being missed. 
I20: “we assumed that nobody had an occurrence of [specific disease outcome], we 
knew that was not reflective of reality but we also knew that would add so much 
complexity to the model. Because it’s a rare outcome and a low cost intervention, it 
was very unlikely to change the decision point…”  
5.3.2.8 Implementation 
The majority of informants referred to an implementation stage in structural development, 
which involved programming a structure into a software platform. Most informants gave the 
impression that they drafted their structures entirely on paper prior to implementation; 
however, a few suggested that they used software as a tool to develop their structures. The 
latter informants implied that the software facilitated their understanding of how the model 
was working, and the way in which patients were progressing through a structure.  
I13: “I’m not one of those people who likes to put everything down on paper massively 
first before I start putting it into Excel because I find it a lot easier to try and link 
things and see how they work and develop the structure that way” 
I19:”…I have used Excel to get a sense of what are the stages, what are the transition 
probabilities and ‘if I apply this transition probability to these disease states, what 
would happen down the road?’…”  
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The most commonly used software package among the informants was Excel, although 
TreeAge, R and WinBUGS were also mentioned. Informants tended to have preferred 
software that they consistently used, although a few implied that usage would depend on the 
type of model being built. A number of informants complained that modelling software 
tended to be difficult to run. 
I20: “the program that we used was really slow, it took twenty hours to run and it was 
a hellacious experience”  
5.3.2.9 Iterative  
Almost all informants commented or gave the impression that structural development was an 
iterative process. The iterative aspect appeared to be in terms of the involvement of clinicians 
and the cyclical process of having them check a structure, and the modeller making required 
changes.  
I15: “… first meeting and then going back, change the information from the first 
meeting and then arrange another meeting until we are happy with the structure of the 
model”  
For the non-academic consultancy informants, structural development also appeared to be an 
iterative process, with this iterative process particularly formed on interaction with their 
clients. 
I13: “…All iterations of the model go to the client, for their feedback…” 
5.3.2.10 Summary: developing model structure 
Informants appeared to follow similar processes in the development of their model structures. 
This included the use of other model structures, clinical literature and clinician opinion to 
inform their models. However, informants held contrasting opinions on how some of these 
stages should be undertaken, for example, whether existing structures should be used to 
directly inform a new model. Further, although most informants involved clinicians in 
structural development, there were different perspectives on when and how clinical opinion 
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should be sought. Two of the Canadian academic informants did not involve clinicians at all 
at the structural stage. Informants held different opinions on whether clinical data should be 
used to inform a model structure, and it was largely UK informants who suggested that a 
structure should initially be developed without prior knowledge of the clinical data available. 
In addition, informants used contrasting methods to plan their structures, as most discussed 
drawing it on paper prior to implementation, but others stated that they initially developed the 
structure in modelling software. In terms of the differences between informants’ practices in 
relation to their backgrounds, the processes of the non-academic informants largely included 
an additional step, involving the development of a model specification document. Further, a 
few of the non-academic consultancy informants offered a different definition of model 
structure to the majority, implying that a structure should aim to incorporate only the health 
events that were of the greatest clinical and economic importance.  
5.3.3 Populating the model 
All informants discussed the typical processes used to populate a model. This included 
methods for identifying and collecting data inputs. The first sections look at the methods for 
identifying evidence for the clinical parameters of the model, and then report on the sources 
used to retrieve economic inputs, for example, costs and utility estimates. The remaining 
sections explore how data assumptions were made, and the typical involvement that clinicians 
had in data identification.   
5.3.3.1 Identifying data 
Informants provided a variety of different methods for identifying data to populate their 
models. These included literature searches, primary data collection and use of existing 
models. Sources of data appeared to be project and context dependent. Whilst non-academic 
consultancy informants were more likely to have access to primary evidence provided by 
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pharmaceutical clients, most Canadian informants were able to use government administrative 
data. The majority of informants though, particularly UK academics, used a combination of 
primary data and literature sources. 
Clinical evidence 
Just under half of informants suggested that they conducted a systematic review to inform the 
clinical parameters of their models.  
I22: “start with a systematic literature review of the clinical effectiveness literature”  
Informants who did not undertake a systematic review for clinical parameters still tended to 
carry out fairly thorough searches, or looked for existing meta-analyses. One informant stated 
that he did this because he considered the accuracy of the clinical parameters to be more 
important than others.  
I24: “treatment effects...we rely on meta-analysis and stuff like that for those 
parameters that we deem to be most important”   
For those who did not undertake a systematic review or carried out less thorough searches, the 
most commonly cited reason was a lack of time or resources. 
I15: “there's no time or money to do it in a systematic way...” 
I2: “you don’t have to do a systematic review because that does take some time…” 
A number of informants cited problems with identifying clinical data to populate the 
comparator (current practice) arm of the model structure. These informants suggested that 
data on the effectiveness of current clinical practice was difficult to obtain, because clinical 
trials tended to focus on the efficacy of new interventions, often against placebo or other new 
interventions.  
I21: “we didn’t have transitioning rates for the status quo. Nobody gives you the 
transition rates for the status quo because all the clinical trials follow the patients 
who… they impose medication on…”  
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I13: “the comparator that’s used in real life, there’s no evidence for that, [it] happens 
frequently…” 
Economic evidence 
Clinical evidence searches seemed to be more systematic than those used to identify cost and 
utility data. Searches for economic evidence appeared mostly to be unsystematic, as 
informants reported using ad-hoc searches to retrieve utility data, and specific sources to 
obtain costs and resource use. A number of informants discussed searching for relevant 
economic evaluation papers to inform utility values. However, only a few informants 
suggested that this search involved a systematic review of the literature, and these tended to 
be non-academic, consultancy or policy informants, who were following practice 
recommended by NICE. 
I19: “… start from previous published cost-effectiveness papers to see what values 
they have used…” 
I8: “we do a systematic search to get an idea of quality of life”  
I17: “we’re obliged to do a systematic review because we have to follow the NICE 
Methods Guide” 
Informants reported mostly identifying costs via government websites and databases, giving 
the impression that this aspect of data collection was straightforward.   
I14: “it is NHS reference costs, it is BNF or EMIT for costing, costs are usually fairly 
standard”  
However, a few informants reported having difficulty identifying resource use data, with 
informants implying that data were not specific enough, or were not generally available.  
I4: “for time that people spend in the clinic, actually going, because they don't publish 
much detail on it” 
5.3.3.2 Making data assumptions 
Most informants mentioned having to make data assumptions to populate parameters for 
which there were no data available. Data assumptions typically involved the use of clinical 
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opinion; however, other methods were mentioned such as the use of proxy values for utility 
parameters.  
I7: “if you didn’t have quality of life data for a particular condition, whether a similar 
condition would be a good proxy for that” 
A number of informants stated that assumptions should be validated by clinicians and tested 
using a sensitivity analysis. Many informants also stressed the importance of assumptions 
being transparent. 
I1: “[We] tested the assumptions afterwards to say 'well look, if we'd assumed 
something else what difference would it make?'…” 
I5: “if assumptions are made they are documented as assumptions and we tend to do a 
huge amount of sensitivity analysis around them” 
5.3.3.3 Clinician involvement 
Around half of informants stated that they involved clinicians in identifying and/or collecting 
data to populate models. A number of informants gave the impression that it was the 
clinician’s role to provide data, or indicate where they could find values themselves.  
I10: “drilling into their expert knowledge of the clinical literature to find a particular 
bit of information”  
I23: “they can provide data if it’s an area that they’ve worked in a lot before” 
Clinician opinion was most commonly used to inform data assumptions. The informants 
reported on a variety of different methods for gaining clinical input on assumptions, ranging 
from informal to very formal techniques. It was suggested that the method used could differ 
according to a particular project, and was dependent on factors such as time and budget. 
Illustrative of the approach taken by the majority of informants, I19 and I24 described asking 
clinicians in an informal and ad-hoc manner for data values to populate parameters.   
I19: “it has been fairly unstructured…asking through email or phone call ‘what do 
you think the impact of this treatment is?’” 
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I24: “I would go to physicians and say…‘what is the max it could be, what’s the min it 
could be?’ and fit some distributions around that” 
Of the informants who discussed having used formal expert elicitation methods, for most this 
appeared to be in the context of one-off projects. However, there were a few informants who 
gave the impression that they always take a formal approach. The formal aspect seemed to 
refer to how data were collected and validated, and the methods used to combine clinician 
opinion.  
I15: “I build a spreadsheet telling the experts what is asked of them … once I've 
collected the data… I’ll show everyone 'these are the anonymous results of your 
answers and these are the combined estimates’…and ask if there's anything that they 
would like to change…I use a different process of combining the experts' data together 
that captures the wide range of opinions…it doesn't reduce the uncertainty across all 
the different experts…” 
However, a number of informants were sceptical of the use of clinical opinion to inform 
parameters, and suggested that it would only be used as a last resort. One informant seemed to 
question the validity of clinician responses, questioning how experts select values in these 
contexts.   
I22: “I am deeply sceptical about expert opinion, deeply sceptical, so because I know 
a little bit about behavioural economics, I know expert opinion can be wildly 
wrong…” 
5.3.3.4 Summary: populating the structure 
Informants’ methods for identifying data seemed dependent on the nature of their work, and 
who the model was for. Searches for clinical evidence appeared to be more robust than those 
used to identify cost and utility data, as most informants reported using systematic methods or 
existing evidence reviews. Utility and cost data were mostly retrieved through ad-hoc 
searches, with few informants stating that they undertook a systematic review for economic 
evidence. Those who did were mostly non-academic informants, and were doing so to adhere 
to the NICE Methods Guide. Time and lack of resources appeared to be factors in the 
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modellers’ decisions to use less thorough methods. Informants reported using specific sources 
to identify cost data, but implied that these did not include enough detailed information on 
resource use. Clinician involvement again appeared to be important in this aspect of model 
development; however, some informants criticised the use of clinical opinion to make data 
assumptions. This was in the context of the majority of informants currently using informal 
and unstructured methods to collect the clinicians’ inputs.  
5.3.4 Model checking 
All informants discussed undertaking checking activities within their model development. 
Most described model checking as a process, involving a number of different stages, namely 
sensitivity analysis, internal validation, external validation and structural validation. These are 
reported on next, as are findings related to the involvement of clinicians and other experts in 
model checking. 
5.3.4.1 Sensitivity analysis 
Almost all informants discussed undertaking sensitivity analysis on the results of their 
models. The majority of informants implied that they applied sensitivity analysis to uncertain 
data parameters, including data assumptions.  
I18: “[we carried out] sensitivity analysis…because we had no great confidence in 
that initial estimate” 
A number of informants stated that they would vary all parameters to note the effect that it 
would have on model results. The majority of these informants indicated that this would 
involve a full probabilistic sensitivity analysis. 
I12: “sensitivity analysis throughout all of the parameters that you entered into the 
model” 
I3: “…we made it probabilistic so all the variables that at the beginning were point 
estimates, we just included the corresponding distribution that was associated to each 
one of them…” 
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5.3.4.2 Internal validation 
Internal validation was the most talked about and, seemingly, the most undertaken check 
among the informants. Internal validation appeared to involve testing for errors within a 
model, to ensure that everything was working as it should be. Informants referred to this as 
‘debugging’ or ‘internal consistency checking’. 
I15: “it's a matter of looking for bugs, doing internal validity…” 
Run the model 
Many informants suggested that they ‘run’ models within a software platform as a validation 
check. This involved programming ‘extreme values’ into model parameters, and ensuring that 
the model results changed in an appropriate way.  
I6: “stick in massive numbers and small numbers and see what happens… see if the 
results go the way you expect”  
A few informants stated that they run their models to confirm that they are working, and that 
patients are progressing through the structure as intended. 
I12: “making sure it works as it’s supposed to work…’are patients going through the 
health states as they are supposed to or is something happening, are you losing 
patients?’” 
‘Eyeballing’ 
Just under half of informants indicated that they check their models by examining in detail the 
inputs and formulas that have been programmed. Most suggested that this was an exhaustive 
visual check of the data within the software platform.  
I2: “make sure you’ve typed the right things, the right numbers into the right places 
on your spreadsheets” 
I11: “go through on a sheet by sheet basis…‘does this formula make sense, does this 
one make sense?’” 




A number of informants discussed looking for face validity within a model, apparently 
assessing whether clinical inputs were a valid reflection of what happened to patients in 
reality. This appeared to require knowledge of the nature of a clinical condition, and the 
prognosis of a typical patient.   
I13: “we will look for face validity, so we will look for whether utilities look sensible 
given the context of the disease” 
Reprogramming the model 
A few informants stated that they will program a model twice, checking for inconsistencies 
between the two versions. Any discrepancies may highlight errors in the original model. For 
most this involved building a second model in alternative software.  
I9: “if I build it in Excel, if I can and if it’s feasible I will try and build it in something 
like TreeAge as well to check the simple maths is working right....” 
I21 was the only informant to state that he reprogrammed aspects of his model in the same 
software. 
I21: “I double up some codes and run my model simultaneously on different 
computers, and then I compare the results…” 
Most of these informants gave the impression that this is not an activity that they carry out on 
every model due to a lack of resources.  
I24: “I don’t do it all the time because of time and resource constraints”  
Plausible results 
Around a third of informants included a stage of model checking that involved an explicit 
assessment of whether a model’s results seemed sensible. This was described as a phase of 
reflection in terms of whether informants felt that results were consistent with what they were 
expecting. Similar to face validity, this check appeared to require the informant’s knowledge 
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of the disease and interventions being modelled. It was implied by the majority of these 
informants that if the results were not as expected they would undertake further checks on 
their models.  
I19: “always make sure that I am getting some results that are sensible to me, it is 
very important in detecting bugs in your model…” 
I2: “if you see a result that you don’t believe, the first thing to do is to check to make 
sure the model’s working right” 
5.3.4.3 External validation  
Less than half of informants discussed external validation, which involved confirming a 
model’s results against relevant clinical and economic sources. Around half of these 
informants suggested that if differences were found between the model results and other 
clinical findings or economic studies, they would need to be justified. 
I20: “make sure that the findings that you get are in line with the findings from the 
medical literature, so if you find that people who have taken drug X vs. drug Y live an 
average of six months longer and the finding in the literature is that they live two 
years longer, you’ve done something wrong …” 
I1: “produce results that aren’t wildly different from someone else’s, and understand 
if they are different what was new that we put in our model that was likely to drive the 
difference” 
I3 was the only informant to refer to an alternative method of external validation, which 
involved presenting and comparing model results to the opinion of experts working on similar 
projects. She implied that this was to identify discrepancies and possible errors.  
I3: “in the last two years I attended at least ten conferences with the research of the 
project presented…I discussed the results of my model with people who are working in 
…other areas in similar topics, so this is a way to compare the results we are 
gaining…it helps us if there is something that is not right, someone may say something 
or give us comments that will identify these things”  
Of the informants who did not undertake external validation, a few indicated that this was due 
to this type of check being too difficult and time consuming.   
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I20: “there are some models that are built that are widely valued against external 
data and that’s what you should do, but that’s an incredibly laborious process 
especially when data are not available or accessible”  
5.3.4.4 Structural checks 
Only one informant discussed undertaking analysis on the structure of a model as a means of 
addressing uncertainty. However, this informant gave the impression that this was a one-off 
because she was unsure about particular model findings. The nature of the specific check 
carried out was, however, unclear as it was conducted elsewhere.  
I11: “recently we sent one to [Modeller 23] at [University F] because they are quite 
heavily involved in structural uncertainty, to get her opinion on it” 
One further informant referred to structural sensitivity analysis but only to indicate that he did 
not undertake it. This was due to the apparent difficulty associated with doing so.  
I17: “always do lots of sensitivity analysis on the numbers within a model but we 
never do sensitivity analysis on the structure of a model because it’s too hard and it 
takes too long”  
5.3.4.5 Clinician involvement 
All informants referred to clinician involvement in validating their models, and for most this 
was the only form of structural checking undertaken. For many informants this involvement 
was iterative in the sense that clinicians were validating models at the structural development, 
data population and results stages. In terms of checking model structure, the implication from 
a number of informants was that a clinician would feedback on various drafts until they 
reached a version that they were happy with.  
I8: “I’m taking notes on what I’m interpreting from that meeting and then I’ll follow it 
up with a more specific meeting, ‘I’ve understood this to be the case, do you agree?’”  
It was suggested by a few informants that receiving clinician ‘sign-off’ on a structure was an 
important stage of the process. These informants suggested that formal clinician agreement 
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was a method of structural validation, to ensure that the clinical aspects of the model were 
robust to external critique. 
I24: “I don’t do too much on the structure of a model if I’ve got sign off from the 
clinician about how it’s working…” 
I4: “the main thing from our perspective is to be able to justify it; if you’ve got some 
justification for the clinical parts of your model…I’m covered....” 
In terms of checking the data used to populate a model, around half of informants indicated 
that clinical opinion was used to validate data inputs or assumptions. As with the development 
of structure, the impression from a few informants was that it was important to have formal 
‘sign-off’ from clinicians on these values. 
I12: “…clinical opinion, you’d be foolish just to make an assumption and not have 
anything to back it up”  
I1: “…I got her to put in an email ‘these are the assumptions we had to make’, and 
they’ve emailed back ‘yeah that assumptions fine, we can live with those 
assumptions’” 
Most informants indicated that clinicians were involved in checking the results of their 
models. The clinician’s role appeared to involve confirming the clinical findings, ensuring 
that results were intuitive to their knowledge and practice.  
I23: “we initially run the model and take the preliminary results back to the 
clinicians…” 
I20: “it’s whether or not the result completely violates [their] clinical experiences…” 
As one of few informants to involve clinicians only at the results stage of model development, 
I19 reflected on this practice, explaining that at times, errors have not been identified until 
very late in the process. 
I19: “…it was pretty much at a production level that one of the [clinical] co-
investigators said ‘I19, the -medications that you have put in your model as a 
treatment, the costs are way too low…’ so that was a big wake-up call at the last 
minute that we were using [the] wrong values from a wrong source…” 
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In terms of methods used to gain clinical feedback, all of the non-academic consultancy 
informants discussed using advisory boards. For most of these informants, this stage occurred 
when a model structure had been developed and populated, although a few informants 
suggested that their advisory boards happened after results were generated. The typical format 
appeared to involve the presentation of a model to clinicians, clients and other experts, 
followed by discussion of the model’s validity and any suggested changes. 
I11: “an advisory board would generally come at the stage when we’ve got a structure 
in place and we are just looking to firm things up” 
I14: “we’ll have the company present the clinical data…then we will present the 
model, ‘this is what it is, these are the methods, this is where the data comes from, 
these are the results…’” 
5.3.4.6 Other involvement 
Almost half of informants discussed the involvement of other experts, aside from clinicians, 
in model checking. For most informants this referred to other health economists, typically 
colleagues, who were external to model development. The involvement of these experts 
tended to be ad-hoc and informal, focused on checking the technical aspects of a model. A lot 
of these informants suggested that they involved a health economist more senior than 
themselves. 
I4: “…look at a model together and spot stuff because it’s quite easy to make basic 
errors like using a standard deviation instead of a standard error when you’re 
sampling from a distribution, just bits and bobs that you don’t really notice because 
you’re in the zone doing modelling…” 
I3: “and then you speak to people who are experts, who have been working for a long 
time... just by having a glance they will see something immediately, identify ‘this is not 
right’…” 
The non-academic, consultancy informants however, involved external health economists 
formally through advisory boards. Again the suggestion was that it was the health economist’s 
role to validate and feedback on the economic and technical aspects of a model.  
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I14: “then the economist will ask his questions and then there will be a big discussion 
as to whether the model is right…” 
I13: “… they let us know whether they think what we’ve done is sensible and if there’s 
any additional sensitivity [analysis] we should do” 
A few informants also discussed the involvement of patient representatives in model 
checking, implying that this aimed to ensure that a model structure reflected the patients’ 
experiences of a disease and its treatment. However, most of these informants suggested that 
patient involvement occurred only rarely within their modelling processes.  
I3: “I have gone as far as speaking to people who have had that condition in the past 
and went through the treatment...” 
5.3.4.7 Summary: model checking 
Sensitivity analysis and internal validation checks were those most commonly and frequently 
undertaken by informants. This was in contrast to external validation, which was reported by 
under half of informants, and structural checking, which was not personally undertaken by 
any modeller. Informants suggested that the reason for not carrying out these types of checks 
was a lack of time and resources. Clinician involvement appeared essential in validating a 
model structure, data and results. The non-academic consultancy informants used formal 
advisory boards with clinical experts to discuss and encourage feedback on all aspects of a 
developed model. A few informants emphasised the importance of clinicians validating and 
formally agreeing to the inputs and results of the model for justification purposes. Informants 
also suggested that the support of other health economists, either formally or informally, was 
important in terms of checking the technical aspects of a model. Patient involvement in 
structural validation was seen to be valuable although few informants actually used patient 
opinion in structural development. 
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5.4 Clinician involvement  
Informants’ discussions of the clinician’s role in developing, populating and checking a 
model structure suggested that clinician involvement was an important aspect of model 
building. Informants spent considerable time during their interviews discussing issues around 
clinician involvement. The next sections cover clinician recruitment, number recruited and 
communication between the modeller and clinician(s), particularly focused on clinician 
engagement. 
5.4.1 Recruitment 
Just over half of informants discussed the recruitment of clinicians to their modelling work. 
For half of these modellers, clinicians were the Principal Investigators (PIs) on projects, with 
the informants therefore being recruited by the clinician(s) to undertake model development. 
These informants were almost all UK academics. 
I2: “when it comes to health economists very often we don't come up with the research 
question, it'll be clinicians…it'll only be later that the health economist will come onto 
the bid…” 
One of these informants reflected on being involved in a project with this set up, implying 
that when clinicians are co-investigators it is easier to engage them in model development. 
I5: “it was really helpful and it moved things along very quickly, you didn’t feel 
worried about asking the clinicians and you didn’t feel as if you were badgering 
them...” 
The remaining half of the informants implied that they recruited clinicians to their own 
projects and modelling work. For almost all of the academics in this group, this appeared to 
involve rather informal methods. 
I21: “I talk to my supervisor and he talks to them…” 
I9: “we did cold call people…” 
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Most of these informants spoke of the difficulty of gaining a clinician’s input to a modelling 
project that they are not formally involved in, due to clinicians’ workloads.  
I4: “it’s often quite difficult to get a clinician’s time full stop…especially if they have a 
lot of clinical time with patients, it’s almost impossible to get hold of them...” 
The non-academic consultancy informants in this group however, appeared to use more 
formal methods of recruitment, having access to clinicians who worked for their clients. 
Similarly, the two non-academic policy informants stated that their clinicians were recruited 
through formal advertisement. 
I14: “…one who is working for the company that you’re working with because they 
are quite easily accessible” 
I7: “it’s advertised by the [policy institute]…” 
Around a third of informants discussed the type of clinician that they recruited or worked 
with, with most suggesting that projects involved leading experts. One non-academic, 
consultancy informant inferred that recruiting senior clinicians to model development leaves a 
model less open to change and criticism when it is submitted to a funding body.   
I1: “there were three key clinicians who were really specialist…” 
I13: “you want as many of the leading people in the field as possible because 
hopefully you have got all the opinions out prior to the [submission] meeting so you’re 
not going to have some clinician turning up and saying something completely 
different…” 
5.4.2 Number recruited 
Almost all informants discussed the number of clinicians typically involved in model 
development, ranging from zero up to twelve. Most informants involved two clinicians on 
average, with three and then four being the next most common practice. Only three 
informants, all non-academic, indicated that they typically involved more than four clinicians. 
Two informants, I15 and I17, discussed involving only one clinician; however, only I15 gave 
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the impression that this was the norm. I17 implied that he only involved one clinician in 
situations where he was building a simple model in a non-complex disease area. 
I17: “so typically two or three I would say but in some cases one, if we’ve spoken to 
one clinician and it’s appeared to be relatively straightforward…it’s not always been 
the case that we’ve spoken to a second” 
I22 was the only informant to discuss having no clinician involvement in the entire modelling 
process, however; he gave the impression that this practice occurred on very few projects.  
I22: “… about 95% of the projects that I’m on there are clinicians involved on the 
project…” 
A number of informants discussed involving different numbers of clinicians on different 
modelling projects, with the final number determined by the complexity of the disease area or 
research question being modelled. One informant suggested that additional clinicians were 
required for models in disease areas where there was variation in treatment practice. 
I20: “depending on the complexity of the question it can be as few as two…other times 
when we’ve had more complex models we sent them out [to additional clinicians]…” 
I9: “… depends very much on the disease and the intervention...I would argue that 
[Disease area 1] is the area where you have the biggest variation in clinical practice 
and I think you need bigger numbers there because even within a hospital trust you’d 
see different practices in terms of current care…” 
One informant mentioned using additional clinicians where treatment effectiveness data was 
limited.  
I13: “… for a standard model that’s got good clinical trial evidence I would want to 
speak to somewhere between two and four, for a model that has practically no clinical 
trial evidence I would want to speak to more like six to eight…” 
Informants discussed the optimal number of clinicians to involve, with many believing that 
involving only one limited the generalisability of the model.   
I7: “…you’re asking one person to make an assumption for you; in their experience it 
may be completely different than someone else’s…” 
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I12: “you could have a rogue, which has happened to a colleague of mine…one 
clinician view, fine, went to the board and they said ‘no that’s not right, the way he 
treats patients is completely different to how we do’…” 
However, a few informants also discussed problems associated with involving too many 
clinicians, namely that it was difficult to manage and include numerous opinions in structural 
development. 
I17: “…things quickly get very complicated because you end up with eight clinicians 
who have eight different views and you go away and try and design a model that takes 
all of those views into account, and you end up with an over-elaborate model that 
becomes a bit meaningless if you can’t populate it properly…”  
A small number of informants talked about how they synthesise information given by 
clinicians if there are disagreements. All of these informants suggested that they would 
encourage the clinicians to agree on a particular aspect amongst themselves. 
I7: “… so they’ll sit and argue for ten, fifteen minutes on particular fine little points 
for you”  
I6: “often they just disagree and you say well ‘do you feel that actually you're wrong 
on one of these or the other one's wrong?'” 
Only one informant discussed the importance of having a range of clinicians involved in 
model development. 
I8: “… an A and E nurse, a consultant, maybe a surgeon for the onward treatment, 
they try to get a big range of clinicians all involved with the pathway…”  
In addition, none of the informants indicated that they recruited clinicians from a range of 
geographical areas or medical centres. Despite this, a number of informants suggested 
potential issues with the generalisability of model results if model structures were developed 
without consideration of the practice of different medical teams.  
I6: “I found that with [Chronic condition 2], different teams do very different 
things....” 
    
166 
 
I4: “there’s about five different ways of classifying the disease, and different regions 
of this country, different people use different classification systems…and they don’t 
really map well together...” 
5.4.3 Communication 
Almost all informants discussed issues around communication with clinicians. This included 
the format for meetings between the modeller and clinician, their typical working relationship, 
and informant opinion and experiences of clinician engagement in the modelling process. 
These issues are discussed next, with the inclusion of informants’ accounts of methods used 
to encourage clinician involvement in model development.    
5.4.3.1 Meetings 
Just under half of informants discussed the typical nature of meetings with clinicians. For all 
of these informants meetings were entirely face-to-face, or involved a combination of face-to-
face, telephone and internet correspondence. 
I21: “most of the time face-to-face meetings” 
I8: “… formal face-to-face meetings, but in between is constant email correspondence 
going backwards and forwards” 
Two informants suggested that the format of communication depended on the stage of model 
development being undertaken. It was seen as important by these informants that meetings 
were face-to-face when developing or checking the structure of a model, with I10 suggesting 
that this stage required a clinician’s complete attention. I17 gave checking data assumptions 
as an example of where telephone contact would be appropriate. 
I10: “there’s no substitute for face-to-face meetings for…the structure of a model as a 
whole, that conversation doesn’t work via email because people don’t read their 
emails as carefully as they should do…” 
I17: “we do it by telephone call anyway if it was just a case of checking a few data 
assumptions”  
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The majority of informants discussed having regular and structured meetings with clinicians, 
with further ad-hoc involvement where necessary. However, a number of these informants 
implied that the frequency of meetings was dependent on the project, specifically the 
preferences of the PI and complexity of the disease being modelled. 
I5: “… the PI on this one was very good and just set up weekly [meetings]…” 
I13: “the [complex disease area] model that I’ve been working on, we had three or 
four rounds of clinician review, because that one was really very dependent on the 
clinician opinion of how it was modelling survival” 
5.4.4 Relationship 
Over a third of informants offered insight into the working relationship between modeller and 
clinician. There appeared to be a divide in opinion and practice among informants regarding 
how much negotiation a clinician had over a final model structure. Almost all of these 
informants suggested that although they would take into account a clinician’s opinion on 
structure, as the modeller, they would make the decision as to the information that informed 
the final model. 
I22: “although it’s essential to incorporate them into the process, you do have 
to…protect your role on the project and basically that’s done via direct 
rationalisation of the inputs…” 
I8: “I think they need to be guided personally…I feel like well it’s my role to tell them 
what’s important or not”  
The majority of these informants implied that the modeller must have the final decision on 
structural development because clinicians were not typically aware of which information was 
important to model. Both I20 and I4 suggested that clinicians often wanted to include every 
conceivable clinical event within a structure, rather than just those that were common and 
would impact on the model results and overall outcome.  
I20: “clinicians will always look to the edge cases…there’s some negotiation about 
which of those differences [between a typical and less typical patient]are necessary to 
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include, and which of those differences are so rare that they will only overcomplicate 
the structure and not give you any new information…” 
I4: “they'll suggest you put this in the model and it's like 'I can't do that', I can't take 
every possible adverse event and put everything into the model, that's just not 
possible...”   
In contrast to the practice of others, one informant gave the impression that the clinicians had 
the final say on what a structure encompasses.  
I7: “as the health economist you look and go okay ‘this…it’s going to be quite 
important’ and they come back to us and say ‘no that’s not that important’ or ‘this 
is’”  
I7, a non-academic policy modeller, offered further context to this by implying that clinicians 
should dictate the inputs to a model because they have to be happy with using its results in 
practice.  
I7: “they make [the] decisions because at the end of the day a doctor in a hospital can 
look at the [model results] and just ignore [them]…” 
5.4.5 Engagement 
The engagement of clinicians in model development was an important issue for almost all 
informants. These informants gave the impression that they had experienced difficulty in 
engaging clinicians fully in model building. Many informants implied that a clinician’s lack 
of engagement was problematic in terms of receiving required information from them. 
I9: “if clinicians aren’t engaged it’s impossible because you can’t possibly understand 
all the nuances of what you’re trying to model”  
5.4.5.1 Understanding 
Most informants gave the impression that a lack of clinician engagement in the modelling 
process was related to a lack of clinician understanding of modelling and health economics. 
The suggestion was that clinicians struggled to understand models and the assumptions 
attached to them. According to informants, clinicians had difficulty discussing the experience 
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of an average patient, whose treatment pathways are represented within a model structure. A 
number of informants suggested that clinicians tended to discuss the experiences of patients 
on an individual basis, similar to how they assess and treat them. 
I11: “this concept of ‘we are massively oversimplifying what happens in this disease 
and we’re assuming every patient is the same’, that’s quite difficult for clinicians” 
I14: “the hard thing with clinicians is getting them to abstract because they see 
individuals, they don’t see a group…” 
I10: “…so you might be saying ‘how great a probability of infection would a patient 
need to have before you gave them [treatment]?’, GPs just don’t think like that, you 
need them to think like that for the model but it’s not how they’re used to thinking” 
Related to the tendency of clinicians to discuss the individual experiences of patients, a few 
informants suggested that clinicians typically emphasised rare and uncommon patient events, 
which for economic reasons would not be included in a structure.  
I4: “they'll talk about really rare events and really special cases that in their thirty 
years of experience they've witnessed once and they'll suggest you put this in the 
model…” 
I12: “there’s always a case where ‘oh I had a patient who didn’t behave like that’ or 
whatever, you’re going to get that…”  
However, around a third of informants discussed working with clinicians who had a good 
understanding of models and the information required for their development. Most of these 
informants suggested that clinicians had been more engaged and helpful, if they had previous 
experience of health economics and/or modelling.  
I20: “[structural development] is an ongoing process that depending on how much 
familiarity the clinician has with modelling…it can take a long time or a very short 
time” 
One informant discussed clinicians being more engaged if they had received relevant training. 
I24 implied that the clinicians who had training tended to understand how models worked, 
and the key information that was required to build a clinically representative but economically 
important structure.  
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I24: “…clinicians who have got training in it, who just totally get it and they’re really 
involved and they just really describe what your assumption is, they understand it 
implicitly, they know which ones are a big deal and which ones don’t really matter as 
much, or aren’t really going to influence your results…” 
It was implied by many informants that clinician understanding of modelling facilitated 
structural development. However, I20 was the only informant to equally stress the importance 
of the modeller understanding the clinical condition being represented. 
I20: “the only way to make [structural development] easier is for the modeller to have 
a really strong understanding of the clinical reality before trying to build the model… 
for both sides to have more understanding of what the other party is trying to 
accomplish” 
5.4.5.2 Personality 
Around half of informants implied that personality and attitude affected how much a clinician 
engaged with model development. A quarter of these informants suggested that engagement 
was wholly related to a clinician’s enthusiasm and motivation to work on a particular project.   
I21: “some people put more time [in] and they spend more time on your work” 
I9: “it depends on the clinician, how interested they are…”  
However, the remaining informants suggested that a lack of engagement was often related to a 
negative attitude towards modelling. Informants implied that clinicians were reluctant to 
contribute to models as they were distrusting of how they worked. 
I7: “some clinicians are very anti health economics; I’ve actually had one ask me why 
we bothered, which was lovely, ‘what was the point in health economics because it’s 
too new of a science to be of use…’” 
I24: “I’ve found there are two types of clinician…one just distrusts the whole thing 
anyway and doesn’t really buy into it and thinks modelling is somehow a quirk, quack 
science…” 
5.4.5.3 Vested interest 
Informants suggested that while some clinicians will not engage, others become 
‘overinvested’ in model development. Around a quarter of informants reported working with 
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clinicians who had a ‘vested interest’ in seeing a particular outcome from a model. This 
resulted in clinicians being difficult to work with, if the model was not generating desired 
results. The implication from many informants was that clinicians wanted to see a ‘cost-
effective’ outcome for the intervention being represented. 
I15: “clinicians are fine as long as if they think it’s cost-effective and it’s cost-
effective, great, that’s brilliant, if it’s not cost-effective it’s a big problem, that’s when 
you have the issues…”  
I23: “…it was difficult to work with some clinicians because they had very strong 
opinions about what the outcome should be, so when it came to build the model and 
present the results they weren’t really approaching it from…an unbiased position. 
That was challenging because it became difficult for us to engage them in the process 
because those strong opinions were so prevalent…” 
A few informants, including I16, stated that they had to reiterate to clinicians during the 
process, the importance of being objective in model development, and having an outcome 
based on unbiased evidence.  
I16: “you may have medical colleagues who think the new drug is the bee’s knees and 
my role is to kind of dampen that enthusiasm a little bit or…to justify it, so maybe it is 
the bee’s knees but you have to get the evidence to show it…” 
5.4.5.4 Methods of engagement 
Many informants implied that a lack of clinician engagement in the modelling process made 
model development difficult. In response to this, almost half of informants discussed the 
methods used to attempt to engage clinicians further in model building. For two modellers, 
this referred to activities taking place prior to model development, namely offering clinicians 
training in health economic modelling to increase understanding and acceptance. I7 stated that 
this involved outlining the health economic context of models to clinicians and similarly to 
I24, explaining how models worked and why they were necessary. I24 suggested using 
existing model structures to allow clinicians to visualise how models synthesise information. 
    
172 
 
I7: “it’s telling them why health economics is important, especially in the NHS, and 
how we do things, how models work…” 
I24: “…I choose one that has lots of states, inputs and transitions and say ‘this is a 
previous model that we did in disease X, and to choose what the best treatment is you 
need evidence, and this is beyond most human minds to be able to do that internally 
and so modelling is a framework to do that’, and they generally buy into it” 
The remaining informants referred to methods used during model development to engage 
clinicians. For a few informants this referred to techniques used during communication, 
namely asking them questions in a direct way to ensure a specific answer.  
I12: “you’ve got to make sure that you keep the questions direct so that they can’t 
divert off into ‘yes there are 99% of people that die within 5 years, however, there’s 
one patient who lived for 20 years’…” 
For an additional few informants, showing clinicians a diagram of the model, or its structure 
within the software, appeared to encourage clinicians to take a more detailed interest. 
I13: “when you’re going through the model physically they get a bit more involved, so 
it’s just like ‘oh can you click that, can you show me the other’…” 
One of the informants however, reflected that despite efforts to engage clinicians further in 
model development, they often do not want to spend time learning about models. 
I23: “the feedback that we got from clinicians was…they didn’t really feel like it was 
necessary to know all that much about models in their day to day practice…they 
weren’t really interested in pursuing more in that area”  
5.4.6 Summary: clinician involvement 
Informants’ methods for recruiting clinicians appeared related to the context of their projects, 
with some modellers reporting difficulty with gaining external clinical input. Questions were 
raised regarding the appropriate number of clinicians to include in model development, and 
whether, for reasons around generalisability of structure, modellers should be looking to 
involve clinical experts working in different roles and for different healthcare practices. 
Informants typically involved two clinicians in structural development, giving the impression 
    
173 
 
that speaking to only one would bias a model, and too many would overcomplicate a structure 
and the development process. However, a few informants suggested methods for managing 
clinician discussion and disagreement, proposing that clinicians should negotiate amongst 
themselves on the content of a model.  
The majority of informants gave the impression that clinician engagement in model 
development was problematic, as modellers discussed clinicians who distrusted or who did 
not understand modelling. Informants talked about having to manage and ‘filter’ information 
given by clinicians into states or pathways that were suitable or important in informing model 
structure. Some informants suggested that offering clinicians a background or training in 
modelling would improve their knowledge of the information needed in a model, and may 
encourage them to trust and invest further in the process. Informants stated that formal face-
to-face meetings were optimum in facilitating communication with clinicians, whilst visual 
aids and ‘hands-on’ involvement may help to enhance clinician understanding. However, 
some informants suggested that experts might not welcome or have time for training and 
further engagement in model development.  
5.5 Model reflection 
All informants offered reflection on what they perceived to be good and poor practice within 
the modelling process, and what they considered as a good and poor modelling outcome. 
Informants also offered opinions on the feasibility of developing an ideal model. These issues 
are reported on next. Perhaps not surprisingly, informants tended to refer to their own 
practices when discussing good processes, and the practices of others when referring to poor 
processes or outcomes.  
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5.5.1 Good and poor modelling practice 
Informants offered similar opinions of what constituted good and poor modelling practice 
within the modelling process. Good and poor process elements were reflective of one another 
i.e. poor practice was apparent where good practice was lacking. Informants discussed the 
involvement of experts and also rigour in model development. 
5.5.1.1 Expertise 
Two thirds of informants cited expert involvement in model development as good practice. 
For half these informants, this concerned the regular involvement of clinicians. The general 
impression from many was that having this support facilitated model building and led to a 
more robust model outcome. Most informants implied however, that regular and engaged 
clinician involvement was an ideal rather than a typical aspect of their modelling processes. 
I23: “we had ‘buy in’ from clinicians …they were really interested in what was going 
into the model and what was coming out…” 
I19: “… that was my best modelling practice because I had a lot of interaction with 
experts in the field and everybody put in a lot of effort, it was very rigorous. I still love 
that model and results that we generated, I believe in them more than other results”  
Around a quarter of informants cited other expertise, such as the involvement of additional 
health economists, as beneficial to the process. Again, many informants gave the impression 
that their involvement facilitated the process and improved the quality of the model.  
I22: “the most successful process included the health economists from the get go… 
making sure you have the right type of data…and then throughout the process being 
involved…” 
In terms of poor modelling practice, over a third of informants cited a lack of expert 
involvement, with most informants implying that limited expertise affected model validity. 
One informant, I20, described his own experience of having difficulty developing a model 
without assistance from others. 
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I22: “a process where there are no other experts on the team who are thoroughly 
going through and validating the results…that’s when I start to have concerns” 
I20: “…I was using the wrong program, I didn’t know what I was doing…that was my 
first model and I was operating without a net, I didn’t have a modeller working with 
me…” 
5.5.1.2 Rigour 
A few informants referred to a good modelling process as one that was robust, defined as such 
because it included multiple model checking activities.   
I12: “good review processes and good quality control….help eliminate as many errors 
as possible…” 
I23: “making sure that it’s validated against clinical opinion…all assumptions are 
valid”  
In contrast, a poor process was identified as one using unsystematic methods to identify data, 
and too few model checking activities. Over a third of informants commented on problems 
associated with models being populated with unrepresentative data that could bias results. 
I15: “why is it so common to find just one data source per parameter? It opens the 
model to selection bias…”  
I9: “it’s about cherry picking the values, I’ve seen that happen and have had quite 
robust arguments with people about why they shouldn’t do that...” 
I19 gave the impression that it was easy for modellers to bias model outcomes through their 
choice of data inputs, and a perceived lack of scrutiny from others.  
I19: “…I feel like I can get any results from my model, I have so many degrees of 
freedom, so many parameters to vary, I can vary them still in a plausible range, no 
one will criticise me to ‘why did you pick that value for instance, that value?’ but 
internally I know this value is going to give me the results that are publishable…the 
aspect of modelling that has put me off is the amount of subjectivity that goes in…” 
Just under a quarter of informants suggested that a lack of model checking was definitive of a 
poor process, and often a poor model. 
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I5: “…they don’t do any good consistency or validity checks or sensitivity analysis at 
the end…” 
I6: “…you look at the published results and they just don't make any sense, validation 
is a big issue...” 
5.5.2 Good and poor modelling outcomes 
Almost all informants commented on good and poor model outcomes. The outcomes 
concerned whether finished models had been built with integrity, had representative 
structures, and could provide an answer to a specified research question. These issues are 
explored next. 
5.5.2.1 Integrity 
Just under half of informants implied that a good model would result from a model structure 
that had been developed with integrity. For most this involved following an objective and 
transparent process, to avoid bias, but to inform the audience of biases that were unavoidable. 
I19: “… a structure that represents a quantified knowledge in the evidence base, has 
been impartial, objective and transparent”  
I17: “we’d always want to be utterly transparent about what goes into the model so 
anybody seeing it for the first time can understand exactly what’s in there and where 
the biases might be” 
A few non-academic informants emphasised the importance of maintaining integrity and 
avoiding bias when developing models on behalf of pharmaceutical companies, due to client 
preferences towards a cost-effective model outcome.  
I16: “…sometimes global teams want to have an optimistic model but UK people like 
me say ‘well no that’s, NICE will see through that, I’m not going to put my name to 
that’, you have to make the inputs credible, non-biased, defensible…” 
A third of informants implied that a lack of transparency in model reporting may lead others 
to question the quality of a model. The attitude was that modellers do not write-up their 
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modelling processes in enough detail, leaving users unsure of whether they can trust model 
results. 
I15: “there’s no information in terms of how did he come up with the other 
parameters of the model…I find that quite disturbing…And then you have no 
comments about ‘has the model been internally tested for validity?’” 
I8: “their reporting, I don’t know if it’s reporting or the construction is so poor that 
we can’t use them, and that’s a shame…” 
However, a number of these informants suggested that the word limits of journals may 
account for a lack of reporting, rather than poor practice. 
I18: “my default position is it’s not the author’s doing and it’s on the journal’s side 
because you are so restricted” 
5.5.2.2 Representative structure  
Around a quarter of informants considered a good modelling outcome as the development of a 
structure that replicated the reality of a disease, thus generating meaningful clinical and 
economic outcomes. 
I21: “….it should fit the real world according to my knowledge…” 
I23: “a good outcome would be one that we are confident that it reflects practice” 
Over a third of informants suggested that a model structure and its results must be checked by 
relevant experts, particularly clinicians, before an outcome can be assumed valid.  
I18: “… I require different people to be happy with the structure, the people that build 
it but also that validation from technical colleagues…to trust what comes out…” 
I2: “a model that the clinicians are actually happy with, because it doesn't really 
matter if the modeller is happy with it, if it's not like real life you're stuffed” 
In terms of a poor outcome, a quarter of informants referred to this as the use of an 
inappropriate structure. This was defined as either the wrong type of model or the 
development of a structure that did not reflect clinical reality. A number of these informants 
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implied that the use of an inappropriate structure related to a modeller’s lack of understanding 
of a disease and associated treatment.   
I1: “they had done a simple decision tree, which doesn’t capture the effects of an 
infectious disease properly” 
I14: “it didn’t reflect what patients went through, people were put on something that 
cost £6000 a month and in the UK that doesn’t happen, it was the wrong 
comparator…” 
I24 was the only informant to suggest that an inappropriate structure may be the result of 
modellers’ developing structures based on available evidence, rather than clinical reality.  
I24: “people don’t include a state because there’s no evidence for it…I feel like then 
the model has been built based on the evidence rather than the clinical pathway, I 
think it’s a major limitation, and quite common”  
5.5.2.3 Answer 
Almost half of informants argued that a good model provided an answer to a specified 
research question. Whilst a few academic informants suggested that the direction of the 
answer was not important, the majority indicated that they would be looking for a ‘cost-
effective’ outcome. Interestingly, this mostly related to the non-academic consultancy 
informants, who on behalf of their clients were aiming to demonstrate an intervention to be 
cost-effective. 
I12: “for the client is an ICER which is less than whatever the threshold” 
I13: “I know how my clients would define a good modelling outcome, ‘drug 
approved!’” 
A number of informants additionally indicated that the outcome of a model should prove 
useful in practice, and further, that model users should be able to make decisions from it.  
 I16: “…the people making the decisions feel that the model was sufficient to guide 
them with the decision”  
I14: “it informs a decision, if it doesn’t inform a decision then what’s the point?” 
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A few informants suggested that model structures and outcomes that were not generalisable 
were problematic. I23 implied that generalisability was an issue given that model structures 
typically reflected the practices undertaken by particular experts in a particular location. 
I23: “…limitation in terms of making models that are reasonably applicable in 
different contexts…if you’re reading a paper and you see a model structure and 
you’re like ‘oh that’s not what we do here so there’s no point in continuing to 
read...’” 
5.5.3 Ideal model 
Informants were asked about whether they thought it possible to develop an ‘ideal model’. A 
few informants suggested that there were ideal aspects of a modelling process, such as regular 
clinician involvement, validation and model checking activities.   
I7: “check it with clinicians as you go along and then obviously it’s validated by 
someone else who understands the clinical area and understands health economics” 
However, the majority of informants suggested that either there was not the time or the 
resources for an ideal model development process, or that it would never be possible to 
develop an ideal model.  
I22: “…re-program the model that’s an ideal for me… I have to admit that’s not 
always done, that’s just a constraint in resources…” 
I19:  “of course that’s wishful thinking, these people are busy, clinicians are busy, and 
they are not going to spend [more] time with you…” 
The informants who stated that an ideal model was not possible implied that a structure could 
never perfectly reflect clinical reality, and that model development was too subjective to 
generate one ideal model for any decision problem. 
I11: “models are inherently such a simplification that you couldn’t get an ideal”  
I20: “short of recreating the universe, there will never be a perfect model…” 
I15: “I feel it might be a lot of an art, some science frameworks behind sections of it 
but it still feels so much like an art that I’m unable to see what an ideal model would 
be” 
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Two informants gave the impression that it was not efficient to aim for an ideal, implying that 
extra time and resources spent on model building may not deliver increased accuracy in a 
model outcome. 
I14: “for the amount of time we spend getting the most we possibly could, to do 
anymore would take a lot more”  
I16: “it’s striking that balance between striving for perfection, as close of an 
approximation to reality as possible, within practical constraints of going to the nth 
degree and beyond a certain point, you put more in but it’s false precision, you’re 
conning yourself that you’re getting better results”   
5.5.4 Summary: model reflection 
A good modelling outcome was identified as a structure that was clinically representative, had 
been developed with the regular involvement of clinical experts, and followed a robust 
process. Only the non-academic consultancy informants gave a preference for a particular 
answer arising from the model, implying that their clients favoured a cost-effective outcome. 
Informants felt that modellers could improve their processes generally by using more 
thorough methods for identifying data inputs, and undertaking further model checking 
activities. Other improvements concerned taking measures to ensure that model structures and 
outcomes were generalisable. One informant was of the opinion that subjectivity in model 
development was problematic, implying that modellers were potentially able to influence 
model results. However, informants also emphasised the importance of modeller integrity in 
model development. Despite informants being generally of the attitude that modelling 
practices needed to improve, a few questioned the practicality and efficiency of committing 
further resources to model development.  
5.6 Modelling guidance 
All informants discussed their knowledge of, use of, and attitudes towards published 
modelling guidance. This was related to the aims of the research, which were to establish how 
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modellers used existing guidance, and highlight where further guidance might be needed. The 
research also sought to gauge what guidance the modellers regarded as most useful. These 
issues around modelling guidance are all reported on next.  
5.6.1 Use of guidance 
Table 6 provides a summary of the type of guidance used or referred to by the informants. 
The most commonly cited guidance was the ‘ISPOR-SMDM’ modelling guidelines, followed 
by checklist guidance and modelling textbooks.  
Table 6: Summary of type of guidance used or referred to by informants 
Type of guidance Number of informants who had used or 



























Around half of informants suggested that they used guidance regularly, although in different 
contexts. Whilst a few of these informants, all junior academics, gave the impression that they 
used it to assist their model building, the majority implied that its purpose was to justify their 
model development. The latter informants suggested that they adhered to and cited the 
recommendations of well-known guidelines and checklists, to demonstrate that they had 
followed good practice. These informants were mostly senior, with the majority being non-
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academics, adhering to the NICE methods guide whilst developing models for submission to 
NICE.  
I24: “If I’m going to try and publish this I’ll probably cite that I’ve used the ISPOR 
guidance, so I just want to make sure that I follow it” 
I17: “the NICE reference case is obviously something that we’d have to adhere to for 
modelling so it’s really looking through the report and making sure that everything is 
matching what NICE wants” 
Around a third of informants stated that they never, or very rarely, use modelling guidance. 
These were almost all senior informants, with the non-academic ones suggesting that they 
used ‘in-house’ checklists, ostensibly in place of published guidance. 
I1: “I haven’t looked at guidance. I have my way of doing things and it’s worked for 
me”  
I11: “we’ve got quite a comprehensive checklist that we use here…” 
5.6.2 Attitude towards guidance 
Around a third of informants appeared to be of the opinion that the current modelling 
guidance was useful. Most of these informants referred specifically to the ISPOR guidelines, 
which were considered helpful because they guided the modeller though the entire modelling 
process, and reminded them of the specific stages and methods that they should undertake. 
I9: “it’s providing a framework to the process of the project…it’s like having a 
skeleton to hang everything onto to make sure you cover all the right areas” 
I12: “…used the ISPOR taskforce publications before… [it tells you] make sure 
you’re including ‘x, y and z’ …” 
However, a few informants suggested that they found methodological papers most useful, 
given that they provided specific and detailed guidance on aspects of model building. 
I6: “one thing that is good…the [NICE] DSU does technical report documents…a lot 
of them are focussed on things like evidence synthesis…not focussed on modelling as a 
whole but on aspects of it” 
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The most common criticism made by almost a third of informants was that guidance was too 
fragmented. Many of these informants implied that it would be useful if there was more 
relevant and concise guidance in one place.  
I23: “there’s a lot of material out there, a bit of a more condensed version at a more 
introductory level would have been helpful” 
I3: “I haven’t found many guidelines …like something that you get one document, ‘oh 
here it is’, you know?” 
Around a quarter of informants were of the opinion that there was not enough guidance 
available. Informants most commonly referred to a lack of guidance on structure, clinician 
involvement and the modelling process.  
I4: “there isn't that much to accompany you in the process of building the model” 
I8: “…I haven’t seen anything to say…‘how do you think about a structure of a 
model’, how do you think about how many states?’…” 
I13: “The [clinical] interpretation step is the bit I think is more difficult and makes a 
model structure relevant or not, so that’s the really key bit and there really isn’t any 
guidance…” 
5.6.3 Summary: modelling guidance 
The informants’ use of guidance appeared to vary according to their seniority and the context 
of their work. Junior academic informants were more likely to use published guidance in their 
everyday practice, suggesting that these were the modellers who found it most useful. Senior 
and non-academic informants tended to use guidance as justification for aspects of their 
modelling work, particularly in demonstrating adherence to good practice processes. This 
seemed particularly important for non-academic informants, who had to follow guidelines 
outlined by the funding bodies to which they were submitting models. All informants 
appeared to value process guidance, such as the ISPOR-SMDM guidelines, above any other 
type. A number of informants gave the impression that current guidance could be improved 
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with the development of further process guidance, with more detail on structural 
development, and how clinician opinion should be used.   
5.7 Future research  
Informants were told at the end of their interviews that the next stage of the research would be 
case studies with teams of modellers and clinicians, undertaken with the aim to further 
explore modelling processes and investigate aspects of model development that would benefit 
from further research and guidance. Informants were asked to identify areas of model 
development that they considered important to focus on in the case study research, such as 
stages that they found difficult or where they felt current practice could be improved. 
Suggestions for future research were entirely from the perspective of the informant, without 
prompt from the author. Informant suggestions are categorised in Table 7.  
Most informants proposed that structural development required further research. These 
informants gave the impression that modellers did not focus enough on the conceptualisation 
of a structure, and ensuring that it included all important states or pathways. A number of 
informants commented on a lack of knowledge regarding how clinicians should be involved 
in structural development, specifically the process used to translate clinical opinion into 
structure. 
I24: “…coming up with those diagrams is the most important part and I don’t think 
that we spend enough time on it…” 
I13: “the current area that is lacking is knowledge about the translation of the clinical 
evidence into the model itself” 
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Table 7: Informant suggestions for future research 
Suggestions for future research Number of informants 
How to design and conceptualise a model 
structure (in conjunction with clinicians) 
11 
Model validation 6 
Communication and engagement between the 
modeller and clinician 
5 
How data parameter inputs were selected 5 
Evidence synthesis of parameter data 3 
Structural uncertainty  3 
How to make structural assumptions with 
clinicians 
2 
How to elicit expert opinion (including how 
many clinicians to involve) 
1 
 
Clinician involvement appeared central to informants’ suggestions for further study. As well 
as clinician involvement in making structural and data assumptions, informants considered it 
important to explore how the working relationship between modeller and clinician could be 
facilitated.  
I2: “…the communication between the clinicians and the modellers. I think that’s 
quite important…” 
One informant suggested that future research should focus on developing guidance to assist 
clinicians in model development.  
I23: “the feedback that we got from clinicians was that they like the idea of models but 
they don’t really trust them…if there was a lay guide to models that would be really 
helpful” 
Other suggestions concerned exploring good practice for identifying evidence to populate a 
model, and which model checking activities were most important to carry out.  
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I5: “which evidence you incorporate into your model, be it for parameter inputs or 
structure…it needs more investigation as to what the best ways of doing that is...”  
I22: “…what is best practice for validating a model?” 
5.8 Conclusion 
The model diagram outlined in Figure 4 demonstrates the typical process that informants 
followed when developing a decision-analytic model. Although the overall stages were 
similar, the diagram illustrates the differences in the methods used within these stages. 
Differences referred to the information that the modellers used to define a model structure, 
how clinician opinion was sought, the number of clinicians involved, the steps undertaken to 
plan and draft a structure, and how data were identified to populate the model. Some 
differences in practice appeared related to the context of the modellers’ work, but others 
seemed indicative of contrasting perspectives over the methods that should be used. 
Similarities in informants’ processes highlighted aspects that might generally require 
improvement, namely the use of systematic methods to identify economic data, and the 
undertaking of further model checking activities, particularly external validation and 
structural checking. When discussing the shortcomings of model development, informants 
stated that more robust methods of data collection and model checking were needed, albeit 
mostly in relation to other modellers’ practices. Informants also raised issues around the 
generalisability of model structures. 
The overarching issues related to informants’ modelling practices were clinician involvement, 
and a lack of time and resources. Informants suggested that clinician involvement was 
essential to model development, but also discussed problems with clinicians’ understanding 
of, and attitudes towards modelling, which impacted on the modellers’ ability to conduct the 
process. 




Figure 4: Diagram of the typical model-building process with questions raised 
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However, informants also proposed that holding face-to-face meetings with clinicians, using 
model diagrams during conversations, and offering clinicians training in modelling may 
encourage them to engage further. The second issue was the lack of time and resources 
available to build models. Informants tended to cite resource constraints as a reason for 
undertaking less robust practices. This finding suggested that further resources may be 
required in modelling processes, but informants also argued that it was impractical and 
inefficient to dedicate additional time and expense to model development.  
There were a number of implications from these findings for the second phase of the research. 
Informants made direct suggestions as to where they felt further research should be focused, 
including exploring how structural development should be undertaken, and communication 
between the modeller and clinician managed. Differences in informants’ practices raised 
questions around whether some informants were using more appropriate methods than others, 
suggesting that further consideration is required in regard to what constitutes good practice in 
these areas. 
The next chapter presents two complete model-building case studies, which followed the 
modelling processes of two different teams of modellers and clinicians. The chapter provides 
step-by-step accounts of the stages and methods undertaken to develop two separate models 
within different model settings. In addition to the modelling practices carried out by the 
modelling teams, the case studies explore the overarching issues highlighted in the in-depth 
interviews, and investigate whether similar processes, methods and issues were encountered.  
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CHAPTER 6: RESULTS OF MODEL-
BUILDING CASE STUDIES WITH 
MODELLERS AND CLINICIANS 
6.1 Introduction 
The two model-building case studies presented in this chapter aimed to explore and compare 
the modelling processes used by two separate teams of modellers and clinicians. This phase of 
the research was designed to build on the findings of the qualitative interviews with modellers 
presented in the previous chapter, whilst gaining additional insight into how clinicians were 
involved in model development. Two modelling case studies were selected on the basis that 
both modelling teams had good reputations for model building (as recommended by the 
qualitative interview informants), and could potentially provide different perspectives on the 
modelling process, due to the different contexts in which the models were developed. Whilst 
Case Study A was concerned with the development of a model in an academic context, Case 
Study B followed the development of a model designed to inform healthcare policy. Both 
aimed to compare the cost-effectiveness of alternative diagnostic pathways, within Medical 
conditions 1 and 2 respectively. The findings for Case Study A are presented first and cover 
the background to the model, development of model structure, data and populating the model, 
results, model checking and clinician involvement. The findings of Case Study B are then 
presented under similar headings.  
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6.2 Case Study A – Diagnostic model in Condition 1 
The next sections present the findings of the non-participant observation, semi-structured 
interviews and think-aloud interviews undertaken within Case Study A. The research 
concentrated on those immediately involved in model development, but those who 
contributed to the model more broadly are also referred to. The background to the model is 
explored first, including who was involved in the process and the model objectives.  
6.2.1 Background 
Case Study A followed the development of a model within a UK academic context. Those 
immediately involved in model building were two modellers (I1 and I25) and one clinician 
(C1). An extra member of the team, Modeller 2, was identified as an “expert modeller” and 
held an ad-hoc role in the process.  
The modelling element of this study was part of a larger project focused on the conduct of an 
RCT. C1 was PI of the study and a consultant in the clinical condition being modelled. A 
wider team of clinical collaborators and statisticians were involved in the RCT and model 
development, providing clinical input and statistical expertise respectively. The role of the 
clinical collaborators will be considered in more detail later in the chapter.  
The objective of the model was to compare the cost-effectiveness of three diagnostic 
strategies for identifying problems related to Condition 1 (current practice, Strategy D and 
Strategy E). The decision problem was modelled in the context of doubt among the clinical 
community as to the usefulness of the current practice test, which had previously been 
considered to be the gold standard. C1 believed that Strategy E was the optimum strategy 
instead.  
 “…why bother doing a test if you're going to treat patient symptoms, why put them 
through [an] invasive test and the…result [is] we are still going to treat that [patient 
reported symptom]” (C1, clinical meeting 1) 
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6.2.2 Structural development 
Most of the time that the modellers and clinician spent together was focused on designing and 
discussing the model structure. The next sections report on the communication between the 
two parties, focusing on how the pathways of the model were developed.  
6.2.2.1 Beginning structural development 
Prior to any formal structural development meetings, I25 reported visiting C1 and the clinical 
collaborators to gain an understanding of how the current practice option worked in its 
diagnosis of Condition 1. I25 also undertook general research into the condition, and specific 
reading into the patient pathways represented in the NICE guidelines. On the basis of this 
research, I25 developed an initial diagram of the current practice treatment pathways, for 
discussion in the first structural meeting with C1.  
“Initially I met with C1 and other clinicians to make sure I had an idea about what 
they are doing and after that I did some readings to see what…NICE suggests for the 
treatment of the specific disease…” (I25, interview) 
6.2.2.2 Pathway plotting 
Most meetings between the modellers and C1 focused on translating patient treatment 
pathways into model structure. Communication involved a mixture of open discussion from 
C1 regarding how patients were treated, and clarification and follow-up questions from the 
modellers. From C1 the modellers learnt the order of treatments that a particular diagnosis 
resulted in, and what led patients to receive different treatments to one another. 
“I wanted to understand what follows what and…what drives the decisions made in 
the clinical pathway…” (I25, interview) 
In the first clinical meeting, I1 requested that C1 discussed freely what happened to each 
group of patients after they had been diagnosed using the current practice test. 
“It’s important to find out from you what the patient pathway would be, as in the 
patient would have this and then this treatment…” (I1, clinical meeting 1) 
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The modellers asked C1 questions to establish why patients were given particular treatments 
at various points, and learnt that factors such as the result of a test, clinical diagnosis and 
patient choice would determine the decision, dividing patients in terms of pathways followed. 
C1: “…it’s patient choice”   I1: “…patient choice…it’s not the best treatment for 
what you’ve got is [Minor surgery 1], it’s you can have [Minor surgery 1] or you can 
try this…okay”  
(Clinical meeting 1) 
The modellers were next interested in learning about possible outcomes of treatments, 
seemingly to identify subsequent pathways, and the patients who should be following them.  
I25: “… is having [Symptom 1] but cured of the [Symptom 2] after [Minor surgery 1] 
considered a successful treatment?”  C1: “yes, yes” 
 (Clinical meeting 2) 
Most discussion and questions asked by the modellers concerned establishing the 
chronological order of treatments, particularly whether treatments were sequential or not. 
These questions were related to the apparent need to simplify pathways.  
Modeller 2: “…the question is whether we actually need to model those alternatives 
or whether we can…”  I1: “…put one in and do a weighted average of it, I think it’s 
the latter from what C1’s saying, it sounds like you’re sending them for minor surgery, 
it could be [Minor surgery 1] or the other one… the fact is they are substitutes for 
each other…you don’t do [Minor surgery 1] and then the other”  
(Clinical meeting 1) 
Also as a means to simplify the pathways included, the modellers emphasised the need to hear 
about the pathway of an average patient. 
“Is there a general case that we could have, assume that everyone will go forward after 
two treatments unless they're a special case and go out of our model?….”   
(I1, clinical meeting 1) 
The meetings between the modellers and C1 were focused on determining the pathways for 
current practice, whilst the pathways for the two comparator arms (Strategy D and Strategy E) 
were discussed between the modellers only. The modellers developed the comparator 
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pathways to be analogous to the patients’ true conditions, as defined by the current practice 
test. This was to account for the consequences of patients receiving a misdiagnosis. 
I1: “The test found them positive for [Problem 1] even though we know that's going to 
be a false positive…and the test found them negative to [Problem 2] so we know that's 
a false positive, is that how it should be?”  Modeller 2: “It's what determines the 
effectiveness of the treatments...”                        
(Modelling meeting 1) 
6.2.2.3 Boundaries of model structure  
Decisions regarding the boundaries of model structure were made in conjunction with C1, and 
concerned the population of the model, the patients excluded, model type, model outcomes 
and time horizon. Although there was some discussion between the modellers and C1 
regarding these elements, it was typically the modellers who made the final decisions on what 
was included in the structure. 
The model population was determined by the RCT study, but also limited by the modellers. 
This was in terms of the modellers opting to exclude ‘smaller’ groups of patients from the 
model, seemingly to avoid having to include additional patient pathways to represent 
exceptional patients. However, the exact proportion of patients who were considered 
exceptional appeared to vary. In one example the modellers discussed the importance of 
keeping 10% of the patient population in the model, but then later excluded up to 25%, 
despite C1’s request to keep them in. Although C1 appeared reluctant to lose this particular 
group of patients from the main model, I1 made the decision that they should only be 
accounted for in the sensitivity analysis, which they later were not.  
C1: “…no they are more than an exception to the rule…in the prevalence studies they 
are quoting that 12 to 25% of the population have [Problem 3]…”  I1: “so my 
suggestion to you is that our main model excludes this specialist patient group but in 
the sensitivity analysis we allow the 25% because there are data in the literature….”                                  
(Clinical meeting 1) 
    
194 
 
However, there were also examples of C1 wanting to include very small groups of patients in 
the model, seemingly not recognising the requirement for the pathways of the average patient. 
C1: “…I would include them because in my daily clinical practice in the last six years 
as a consultant I have only seen maybe one a year that they’ve had [Problem 3] and 
they’ve had [Major surgery 1], so they’re a quite small proportion…”  I1: “Right, so 
we just want to be trundling along as if most people are the general case, so actually 
although you’ve said include them I think we probably mean exclude them because 
they’re such a minority amount” 
(Clinical meeting 1) 
The two outcomes of the model, clinical effectiveness in natural units and quality-adjusted 
life years (QALYs), were selected by the modellers and influenced by the outcomes used in 
similar models. The time horizon was determined through discussion between the modellers 
and C1, although again the modellers made the final decision regarding this element. The 
conversation quoted below demonstrates I1 encouraging C1 to agree to a shorter time horizon 
than she initially appeared to consider appropriate, due to a perceived lack of data to model a 
lengthier timeframe.   
I1:“…shall we just assume arbitrarily five years…would that be a good time 
horizon?”  C1:  “five years would be in the medium term, which would be the 
minimum they would need”  I1: “so is five years long enough? I mean after that we 
are not going to get much data”  C1: “no we're not”  
(Clinical meeting 1) 
The selection of a decision tree structure was justified on the temporary nature of the 
condition.  
 “Given the short-term nature of the decision problem, the appropriate model 
structure…is a decision tree” (Final model report) 
6.2.2.4 Basis of model structure 
In addition to C1’s input, other sources such as the NICE guidelines influenced the 
development of model pathways. However, there was inconsistency in opinion and practice as 
to when and how the guidelines should be used in structural development. I25 gave the 
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impression that the structure should fundamentally represent clinical practice as described by 
the clinician, and that a secondary analysis should be undertaken to assess the effect of any 
variation in practice suggested in the guidelines.  
“[the] pathway would be what C1 said is happening, [that] clinical practice involves 
several current practice tests but we’d do a secondary analysis with what NICE says, 
which is only one test in the beginning” (I25, interview) 
However, there were examples where the NICE guidelines were used in the main model in 
place of C1’s experience, as a means of simplifying the structure.  
C1: “…if that’s becoming too complicated you can just say what NICE is saying…we 
should be giving everybody [Measure 1] of [Minor surgery 1], but we…are giving 
them a lesser dose…”  I1: “…so there would be no repeat [Minor surgery 1] in that 
because you would have already done it. That would make it simpler and it’s the NICE 
recommendation” 
(Clinical meeting 1) 
In another example, the guidelines were used to exclude the effects that rationing would have 
on the treatments that patients received.   
Cl: “….because we are struggling with the NHS funds, we don’t necessarily send 
everybody to [Major surgery 1] because it costs £10,000 per patient…so a lot of our 
patients drop out…”  Modeller 2: “…for modelling purposes I don’t think we 
should…”  C1: “yeah, because in an ideal world we should be giving everybody 
[Major surgery 1]…”  I1: “…so let’s follow NICE guidelines in the model and show 
the impact of it in terms of cost-effectiveness” 
(Clinical meeting 2) 
I1 was very clear however, that clinical probabilities and treatment effectiveness data used to 
populate the model should not be used to inform pathways. She felt that this could bias the 
structure, as the modeller would then be aware of how the inclusion of particular pathways 
could impact on the cost-effectiveness result. I1 argued that a modeller should only have a 
general idea of the clinical data available to populate a model, to know whether model 
development was feasible.  
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“…you should know what type of data you’ve got when you’re making the model 
structure but you shouldn’t actually see it in terms of probabilities, see it in terms of it 
giving away information that will lead you to the answer…” (I1, interview) 
I1 suggested that developing the structure on the basis of available evidence was not a 
credible method, with good practice being to draft a structure first and then populate it. 
“…it’ll be right up the street of people doing it wrong to see the data and change the 
question… first you need to populate the model as is”  (I1, modelling meeting 2) 
6.2.2.5 Making structural assumptions 
Making structural assumptions appeared iterative and in response to the need to simplify the 
model structure, usually due to lack of data. Assumptions were typically suggested by the 
modellers and confirmed by C1. A major assumption made was that patients would proceed 
from receiving the least to most invasive interventions, despite this not being reflective of 
clinical practice. I25 stated that no data were available to estimate the effectiveness of 
sequential treatments, namely patients receiving conservative treatment after invasive 
interventions. 
“…If you continue to put conservative treatments in the pathway then what would be 
the effectiveness of the conservative treatment at that point? Do you have that 
information? You don’t have it…” (I25, interview) 
The modellers and C1 also agreed that there would be no recurrence in the patients’ 
conditions. Again this was not reflective of real life but was seemingly related to a lack of 
long-term follow-up data, and the shorter time horizon agreed for the structure. 
I1: “so they remain symptomatic”  C1: “and they go back through the loop again”  
I1: “yeah [but] that's the end of what we're doing, we put them through it once…” 
(Clinical meeting 2) 
Asking C1 to ‘sign-off’ on assumptions appeared to be an important part of the structural 
process. The assumptions were emailed to C1 after meetings for official agreement.  
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I25: “I sent the assumptions to C1 to finalise them and she got back to me and all of 
them are fine”  I1: “good, did she come back on an email with that?”  I25: “Yeah”  
I1: “keep that email”                                              
(Modelling meeting 3)  
I1 suggested that assumptions must be agreed to and documented to avoid the clinician 
questioning them later in the process. I1 implied that clinicians often wanted to change 
assumptions after knowing the results of a model, and argued therefore that clinicians should 
not be aware of how assumptions might impact on model outcomes at any point prior to 
agreeing to them.  
 “…never tell her how the assumptions are going to change the answer, ever, because 
that’s not what it is about. So I have known people in the past to say ‘oh I’ve seen that 
answer, let’s have a re-look at that assumption, that was silly’ and you’re thinking 
‘well no it was fine when you looked at it not knowing the answer’” (I1, interview) 
6.2.2.6 Communication in structural development 
Communication between the modellers and C1 in structural development involved either face-
to-face meetings or email correspondence. Most pathway plotting occurred in face-to-face 
meetings with C1, whilst emails were used for ad-hoc queries about the structure, and to 
confirm assumptions made. Both parties reflected that this format was optimal due to C1’s 
busy schedule.   
“this format works very well because me being a busy clinician I don't have time for 
face-to-face meetings all of the time, so most problems are sorted over email but there 
might be a couple of things that really we need to sit down face-to-face to explain and 
understand…” (C1, interview) 
Both I1 and I25 stressed the importance of pathway plotting taking place in face-to-face 
meetings. I25 indicated that he struggled when asking and receiving answers to structural 
development questions via email, seemingly due to the complexity of information involved. 
“I tried emails, asking questions and I understand that her time is valuable, [but] 
some of her responses were very brief, more brief than I was expecting, or wanted…I 
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had to think about….better ways to get the answers….that were relevant for the model. 
So that’s why we had more meetings and more illustrative things… (I25, interview) 
Communication focused on the modellers asking C1 questions about the pathways that 
patients followed. C1 often answered the modellers’ questions in terms of the proportion of 
patients affected, and this appeared to be helpful to the modellers, as it led to discussion over 
whether groups of patients were large enough to be included in the model. 
I25: “…after the [Major surgery 2] can they develop [Symptom 3]?”  C1: “10%”  
(Clinical meeting 2) 
Both parties reflected on the use of the model diagram as a key communication tool, giving 
the impression that it provided a tangible resource for them to relate their discussions and 
understandings to.  
 “…just for the sake of the conversation…it is difficult when I’m discussing something 
and they don’t have the idea, but more helpful when they had the picture” (I25, 
interview) 
Problems with communication concerned C1’s lack of understanding of the economic terms 
used by the modellers, which stalled communication between the two parties.  
I25: “are the utilities, after the surgery…”  C1: “…sorry?”  I25: “…if the person has 
[Major surgery 1] for example, the utility might be different then, does the surgery…”  
C1: “…the, what will be different sorry?”  I1: “…the quality of life, so do we assume 
it’s full health when they’ve had surgery…?” 
(Clinical meeting 2) 
6.2.2.7 Role of the clinical collaborators  
The role of clinical collaborators in structural development appeared to be ad-hoc and 
typically at the request of C1. C1 gave the impression that she felt more comfortable gaining 
consensus from the collaborators on some issues, particularly where she seemed uncertain or 
suspected that practice might be different in other clinical centres. 
I25: “so what would we do at this point, [Major surgery 2]?”  C1: “I’ll discuss it 
[with the clinical collaborators], share the burden” 
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(Clinical meeting 1) 
Although C1 appeared keen to gain the input of the clinical collaborators during pathway 
plotting, I1 suggested it more appropriate to involve them when the structure had been 
established, and only in a model checking capacity.  
“…we wouldn't want to get them to join in at this point because we're still working out 
what makes sense, so we'll get a model from beginning to end…and then present it” 
(I1, clinical meeting 1) 
6.2.2.8 Location of treatment pathway 
Relating to the generalisability of the developed structure, and the apparent lack of clinical 
collaboration in structural development, C1 mentioned a number of times during pathway 
plotting that the practices that she was describing to the modellers may not be the practices 
that were undertaken in every medical centre.  
“…they will have a [Test 1] to begin with, that’s in our centre though it’s not a 
standard practice everywhere” (C1, clinical meeting 1) 
C1 also seemed to be concerned about which treatment pathways to describe to the modellers 
given that she had worked in two different centres, which had each undertaken different 
practices.  
“…I am pondering over it because…in [Location 1] the consultant would treat the 
current practice treatment  result rather than treating the patient and the symptoms 
…but in the [Location 2] because we have facilities for [Test 1]… if we can find 
[Symptom 2] then we will do [Minor surgery 1]” (C1, clinical meeting 2) 
The modellers addressed this issue by stating that they would use the most typical practice in 
the primary model and test exceptions in a sensitivity analysis. However, this raised the issue 
as to whether C1 would be aware of what the most common practice was across various 
medical centres. Additionally, alternative practices were ultimately not tested within a 
sensitivity analysis. 
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“If your centre is the exception we’ll go with the typical case…we can do sensitivity 
analysis with exceptions to see what impact it has.” (I1, clinical meeting 1) 
6.2.2.9 Implementation  
The implementation of the model structure into the software occurred after it had been fully 
developed and signed-off by C1. I25 suggested that it was optimum to have a ‘good’ diagram 
of the model structure on paper prior to translating it into the software, as changes could be 
made on paper with less effort. 
“…for me it’s easier to draw it down just to make sure ‘yeah that’s what I want’ and 
then put it on TreeAge….it’s easier than to work on the decision tree diagram itself 
because you can just write and erase… (I25, interview) 
6.2.2.10 Reflections on structure 
All informants were asked for their reflections on the model structure. Opinions appeared 
generally positive towards the standard of the model, although C1 had some doubt over the 
assumptions used. Whilst I25 gave the impression that the structural assumptions had made 
little difference to the overall clinical representativeness of the model, C1 appeared less 
comfortable with having to simplify some of the clinical aspects. C1 expressed concern that 
patients with coexisting conditions had been excluded, and therefore the true costs associated 
with some of the treatments had not been captured.  
“…we modelled clinical practice as accurately as we could, we didn’t have to 
sacrifice assumptions to sacrifice the quality of our model…it is a more simplified 
version of what happens in practice” (I25, interview) 
 “In the model we are mostly concentrating on [Symptom 2] and no [Symptom 2] but 
then there are some patients who have coexisting conditions like [Symptom 1]… [that] 
are not being accounted for in the sense that these people will need extra [Medical 
device treatment]…and things like some of the [Medical devices] might be more 
expensive than others, those kind of minutiae are not [there]” (C1, interview) 
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6.2.2.11 Summary of structural development 
The model structure was developed through discussion between the modellers and C1, with 
the focus being on learning the treatment pathway of the average patient receiving the current 
practice test. The modellers were interested in knowing about the interventions that particular 
groups of patients received, and how health outcomes and other factors affected future 
treatment. Communication was facilitated through face-to-face meetings, diagrams of the 
model structure, and a mixture of open discussion by C1, and clarification questions from the 
modellers. In addition to C1’s clinical experience, the modellers used the NICE guidelines to 
inform the structure, although there appeared to be uncertainty around how these two sources 
should be used in conjunction. However, I1 felt strongly that available data should not 
influence the structure.  
The modellers undertook various approaches to simplifying pathways as structural 
development progressed, including the merging of non-sequential treatments in the structure, 
and the exclusion of exceptional groups of patients. However, decisions regarding model 
boundaries and simplifications of pathways were sometimes inconsistent, and were mostly 
undertaken by the modellers, involving limited negotiation with C1. C1 did not appear to fully 
comprehend the need to include the pathways of only the average patient, and later expressed 
feeling uncomfortable with some of the structural assumptions and simplifications made. This 
raised the issue of whether communication could have been managed more effectively 
between the two parties, including further explanation and discussion of structural 
assumptions with C1. Additional problems with communication referred to C1’s lack of 
understanding of the economic terms being used during discussions. Finally, issues around 
generalisability of structure were highlighted, as C1 talked about her clinical practices being 
different to others, and appeared concerned that the information that she was giving to inform 
pathways may not be representative of the experiences of all clinicians.  
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6.2.3 Data and populating the model 
The data used in the model originated from various sources including the RCT study, 
literature, relevant registries or databases, and clinician opinion. Presented next are the 
methods used to identify and check the clinical and economic data used to populate model 
parameters.  
6.2.3.1 Clinical data 
The clinical data used to populate the model comprised: 1) the prevalence data that 
represented the proportion of patients with each of the problems related to Condition 1; 2) the 
accuracy data that informed the probability of patients being correctly diagnosed with one of 
these problems; and 3) the effectiveness of treatments given a patient’s true condition. Most 
of these data were informed by the RCT study, specifically the prevalence data and the 
accuracy of the diagnostic strategies. These data were therefore collected by the clinical trial 
team and given to I25 in their appropriate form by the statistician. The treatment effectiveness 
data were informed by clinical literature or expert opinion. The data parameters requiring 
clinical input were those that referred to patients receiving treatment after a misdiagnosis. I25 
stated that despite a review of the literature, there were no robust data on the effects of 
patients receiving inappropriate treatments. I25 undertook detailed reviews for all of the 
clinical parameters of the model that were not informed by the RCT, ensuring that he was 
using the best data available, preferably values from systematic reviews or meta-analyses.  
“…it wasn’t a systematic review…but it was thorough. I found some studies and then I 
tried to see which were the most relevant and appropriate sources of information. 
Thankfully most of them were systematic reviews or meta-analyses of clinical trials, so 
we had good data” (I25, interview) 
6.2.3.2 Economic data  
The economic data used to populate the model comprised utility data, which referred to the 
quality of life of patients, and cost and resource use data. The model used two utility values 
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within each model pathway, related to the patients’ quality of life before and after they had 
received treatment. The initial utility values originated from the RCT and differed depending 
on the specific problem that a patient had. The utility values after treatment were an outcome 
of the model pathways, and referred to whether or not patients were “subjectively” cured of 
their symptoms. These endpoint values were informed by the literature due to a lack of long-
term follow-up data. I25 first undertook a systematic review of the literature, but after finding 
no suitable studies, searched the ‘Cost-Effectiveness Analysis Registry’ for appropriate utility 
weights. This search was not systematic, but used relevant search terms to identify eighteen 
studies that could potentially inform QALY values for patients cured of their symptoms. I25 
used a weight from only one study because the others were deemed inappropriate. 
“Utility weights from other studies were not considered either because they were 
focused on a population with [Problem 4] who were undergoing [different 
treatments], or because they were focused on a [different population]” (Final model 
report) 
I25 reported being unable to find appropriate utility values for patients not cured of their 
symptoms. Therefore, the modellers made the assumption that patients maintained the initial 
QALY value taken at the beginning of the RCT study. 
I25: “… [the population] in the beginning of the study have [Problem 1]”  I1: “…of 
course they do”  I25: “If they remain with [Problem 1] they will have the same 
quality of life”  I1: “…but if they get better you take them to full health?”  I25: “No 
0.92 and this is from the literature”   (Modelling meeting 4) 
I25 gave the impression that identifying utility values had been difficult and reported being 
unable to find and include quality of life decrements, which referred to patient utility after 
receiving appropriate or inappropriate treatments.  
“I couldn’t find decrements for the interventions; the best thing I could do is assume 
that if they are still with [Problem 1] they have a quality of life of 0.87…” (I25, 
modelling meeting 4) 
    
204 
 
Identifying appropriate cost and resource use data to populate the model appeared to begin at 
the pathway plotting stage. On a number of occasions, I1 asked for more information or 
clarification on treatments, particularly on the resources used and staff time involved, to 
determine costs. 
I1: “Do they have to have an anaesthetic?”  C1: “…we are doing it under local 
anaesthetic now increasingly, but some patients will still go to theatre because they 
want a general anaesthetic…”  I1: “…like a minor…”  C1: “…operation…”  I1: 
“…in terms of costs anyway, once you’ve given somebody a local anaesthetic they’re 
a day case, it’s a minor operation?”  C1: “Correct”  (I1, clinical meeting 1) 
Cost and resource use data were identified using the HRG (Healthcare Resource Groups) 
database. I25 discussed searching for specific HRG cost codes informed by a review of the 
NICE guidelines, and also searching the database manually.  
 “…I did a literature search to see what NICE suggested, they had some HRG codes 
in their reports so most of them came from there, and then if I couldn’t find a cost I 
did some searching within the HRG database” (I25, interview) 
The information gathered about the treatments appeared to assist I25 in determining which of 
the HRG categories were most suited to the data requirements of the model.  
“…so within its HRG category they have all the surgeries for example, they all fall 
within [the same category] so I searched there to make sure ‘this one’ was the type I 
wanted…” (I25, interview) 
However, I1 implied that when using HRG codes to identify costs, it was not necessary to 
know too much detail on an intervention, as the categories each represented a broad definition 
of a particular treatment.   
I25: “Do we need to ask what surgery is?”  I1: “No, let's just call it surgery for 
now…it's surgery…in that area, in terms of a cost you're going to be looking at minor 
surgery or major surgery so you don't need to know what it is, you need to say 'is it 
defined as minor or major?’ because when you look at the HRG costs it will be 
merged…”  (Modelling meeting 1) 
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6.2.3.3 Data and clinician involvement 
C1 and the clinical collaborators were involved in identifying and providing data to populate 
the model, with C1 offering references for clinical data not available in the RCT, and a 
number of the treatment effectiveness values being informed by the opinions of C1 and the 
collaborators. I25 elicited the effectiveness values from the clinicians via email, asking for the 
mean, mode and confidence intervals for each treatment effect estimate. He gave the 
impression that expert opinion was not a preferred method of data collection. 
“Because I couldn’t find anything in the literature I [sought clinical opinion]…the 
reason is that it had to be in the structure of the model and we needed that value…it 
was a last resort really” (I25, interview) 
In terms of the cost data, C1’s role appeared to be more in a model checking capacity. I25 
reported presenting C1 with relevant HRG cost categories and asking her to select the most 
appropriate. He implied that this method worked well.  
“…because I had the description and comments about the HRG categories, that 
helped her realise ‘okay yeah it’s not that’ or ‘this intervention takes more than 20 
minutes’ for example, and so it was very easy for her to say ‘yeah, that’” (I25, 
interview) 
However, C1 did not appear to be involved in identifying or checking utilities. Perhaps related 
to C1’s lack of involvement in this aspect, I1’s comment below appeared to be indicative of 
what she considered to be a clinician’s role in populating the model. 
 “when it becomes utilities I’d say ‘yes that is your (I25) responsibility’ because the 
clinicians won’t know where utility data come from, or cost data or resource data, but 
[treatment] effectiveness data, the fact that they are doing this study means that that 
effectiveness data is buzzing around in their heads…where there’s a gap it’s their job 
to plug it” (I1, modelling meeting 1) 
6.2.3.4 Summary of data and populating the model 
I25 reported robust methods for identifying data to populate clinical parameters, with data 
originating from either the RCT or detailed literature reviews. The only exception to this was 
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the treatment effectiveness values informed by expert opinion. The economic data were 
informed almost entirely by the literature, either using utility values from relevant studies or 
costs from the HRG database. The processes undertaken to retrieve these data did not seem to 
be as thorough as those used for the clinical parameters, as non-systematic searches were 
ultimately used to identify values, and assumptions around utility data were made without 
validation from C1. However, I25 reported difficulty with finding relevant and appropriate 
quality of life values. The modellers and C1 seemingly held different roles in data collection, 
with I1 implying that it was the clinician’s responsibility to identify clinical data, but that the 
clinician’s role was limited in terms of the data used to populate economic parameters.  
6.2.4 Results 
After the model was populated with the clinical and economic data it was ‘run’ in TreeAge 
software to generate results, which were then presented to C1 for her feedback. For context, 
the model found the current practice test to be the most cost-effective. Whilst I25 expressed 
that the results were in the direction expected, C1 appeared surprised and unhappy with the 
outcome.  
“This is not what I was expecting, I was hoping my hypothesis was right that the 
current practice test doesn’t add much to our management and it’s just a time wasting 
step” (C1, clinical meeting 3) 
I1 reported that after hearing the result, C1 wanted to use new data in the model, to see how it 
would affect the model result. However, both modellers were strongly of the view that 
alternative data could not be used, as it would mean changing structural assumptions around 
the model population that had previously been agreed on. I1 suggested that C1 was unhappy 
with this decision.  
“…there were some new data [but] it wasn’t appropriate for us to put in our 
model….and C1 just didn’t understand why we couldn’t update our model with this 
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new data, and what it was, the data she’d found…applied to a different 
population…and she had forgotten that” (I1, interview) 
However, a secondary analysis was undertaken to further test C1’s hypotheses and seemingly 
address her concerns. 
 “…so we did a secondary analysis to see whether the interventions were more cost-
effective in subgroups…patients with [Problem 4], Strategy E is not cost-effective, but 
it is cost-effective when you give it to patients with [Problem 1]… C1 was happy with 
that” (I25, interview) 
In addition to the result not being as C1 had expected, further discussions between her and I25 
identified disagreement and apparent miscommunication over how the Strategy E comparator 
was defined.  
C1: “See this is what I disagree with because…Strategy E is not what the clinicians 
are saying, this is what the patients are saying…I don’t know whether I have been on 
the same page here?”  I25: “I thought it was…”  C1: “No…the patient tells us what 
they have and we just tick it”  (Clinical meeting 3) 
6.2.5 Model checking 
Most checking activities were undertaken by I25 after the model results had been generated. 
These checks focused almost entirely on sensitivity analysis. The sensitivity analyses 
undertaken were mostly on the data in the model, and included increasing the cost of current 
practice, and reducing the test’s accuracy. The analyses appeared aimed at gauging whether 
the direction of results would change if data values were varied to be less favourable towards 
current practice. I1 stressed the importance of the sensitivity analyses being sensible and 
justified, based on alternative relevant sources of data or using other legitimate scenarios 
supported by C1.  
“But that's only if patients can be asymptomatic and actually everyone thinks that they 
are unlikely to become asymptomatic. You can always find a scenario that makes 
something better off…you do a sensitivity analysis to assess the robustness of the 
assumptions you've made, not change the assumption to something less robust…” (I1, 
modelling meeting 5) 
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The sensitivity analysis also tested uncertain data parameters, particularly those informed by 
clinical opinion. Only one of the sensitivity analyses involved a change to the structure of the 
model, in terms of seeing the effect that having only one diagnostic test in each treatment 
pathway had on the model result. This was to take into account the practice outlined in the 
NICE guidelines. The think-aloud interview demonstrated how I25 worked through each of 
the sensitivity analyses, stating what he expected to happen to the cost-effectiveness results of 
the model prior to running each scenario.   
“By lowering current practice sensitivity…in [Outcome 1]…I’m still expecting this 
effectiveness to be higher than Strategy E but the cost-utility might come down to .50, 
.40, it will still be dominating but at a higher cost…Let’s see, so current practice test, 
lower cost, less effective…Makes sense doesn’t it? Yep. I mean it was dominating but 
now it is less dominating…” (I25, think-aloud) 
Whilst some results of the analyses appeared intuitive to I25, he struggled with the 
interpretation of others. For example, in realising that where all patients were assumed to 
receive the same intervention for a particular problem, the effectiveness of Strategy E 
increased because misdiagnosed patients now received more appropriate treatment.   
“Why did current practice become less effective? [Long pause] There was a high 
likelihood of a wrong diagnosis for Strategy E, but if you assume now that these 
patients will be getting [Minor surgery 1] instead of having the option, patients 
receive the intervention they would get if they were correctly diagnosed. So you would 
expect the effectiveness to increase…” (I25, think-aloud) 
I25 did not only use the sensitivity analyses to test the effect of alternative data and scenarios 
on the results, but also as a means of internally validating the model and checking that it was 
programmed correctly and working as it should. 
“Run something just to see if the model works… that’s a check, whether it happened 
as expected…” (I25, think-aloud) 
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6.2.5.1 External validation 
Despite considerable internal validation of the model, I25 discussed not undertaking any 
external validation due to a lack of similar models to compare the structure and results to.  
“…there was a decision tree in similar symptoms but in a different population group; 
[there] wasn’t something similar so I didn’t do any external validation” (I25, 
interview) 
6.2.5.2 Clinician involvement in model checking  
The model checking undertaken by C1 took place throughout the development process, in 
terms of her informing and checking iterations of the model structure, confirming data values 
and giving feedback on results. However, C1’s opinions appeared to become less influential 
as model development progressed, with I1 implying that the results were only presented to C1 
to see if there were any further sensitivity analyses that could be undertaken.  
“The only reason for doing it…they might say something that we ought to test…so it’s 
worth them seeing the results…” (I1, modelling meeting 4)  
6.2.5.3 Summary of results and model checking 
The presentation of the results demonstrated a breakdown in communication between the 
modellers and C1, in terms of the definition of Strategy E and C1’s lack of understanding and 
acceptance of the model conclusions. C1 appeared to have somewhat of a vested interested in 
the model outcome, in not wanting the current practice test to be cost-effective, and also 
appeared unaccepting of the fact that structural assumptions could not be changed after they 
had been agreed. Model checking focused on sensitivity analysis, with the checks aimed at 
exploring whether the results were robust to less optimal scenarios. However, the sensitivity 
analyses undertaken were almost all on the data in the model, despite discussions with C1 
over the testing of alternative structures and the inclusion of additional patients. In addition to 
undertaking limited structural checking, I25 stated that he did not carry out any external 
validation due to a lack of similar models and studies in the literature.  
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6.2.6 Clinician involvement in model development 
Clinician involvement was determined to be a key factor in the model’s development, 
particularly in pathway plotting. However, problems were encountered and reported with their 
participation in the modelling process. The next sections explore issues around C1’s and the 
clinical collaborators’ involvement, specifically the number of clinicians involved, clinician 
understanding of modelling, and the potential for training clinicians in model building.  
6.2.6.1 Number of clinicians 
The involvement of only one clinician in immediate model development raised issues around 
the generalisability of the structure. I1 suggested that involving more clinicians would have 
allowed the modellers to learn about alternative clinical practices that could have potentially 
informed the model.  
“The more people you involve, the more heterogeneity you get and that’s important 
because you’ve got to know that there are other ways of skinning a cat or whatever” 
(I1, interview) 
This said, I1 defended the practice of working with only one clinician, arguing that there were 
other factors that informed the development and validation of the structure, including the 
NICE guidelines and the treatment pathways followed in the RCT. 
“…it’s not based on just one person’s idea ever. There’s historical models to look 
at…there’s evidence from the literature and there’s a trial that has already been peer 
reviewed” (I1, interview) 
I1 also referred to the involvement of the clinical collaborators as being important to the 
validity of the structure, and indeed their opinion was sought at various points of model 
development. However, collaborator input appeared inconsistent, as I25 reported only 
receiving contributions from eight of the twenty-two collaborators. Further, C1 suggested that 
she struggled to get comments from the collaborators on structural issues, which often led to 
her reluctantly making decisions alone.  
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“…everybody's so busy it's difficult to get colleagues to respond and sometimes 
because of the time pressures I have to make executive decisions, and I wish this was 
not just left to me…” (C1, interview) 
6.2.6.2 Clinician understanding of modelling 
On a number of occasions, C1 appeared to have difficulty understanding and accepting 
aspects of model development. For example, she seemed unhappy with having to exclude 
patients from the model, having to make structural assumptions, and struggled with the 
interpretation of the model results. Despite C1 sometimes appearing confident in her 
understanding of modelling, expressing the view that making assumptions was necessary 
where there were limited data, she gave the impression more frequently that she found it 
difficult to comprehend how the model was working. 
 “…sometimes there are uncertainties that can't be resolved with the existing evidence 
and then you just have to make a lot of assumptions. It's not a weakness of the model; 
it's the weakness of the available literature” (C1, interview) 
“I don't know anything…I don't have any knowledge of health economics so if you 
guys (I1 and I25) think it's okay then that's fine, whatever you explain to me seems 
fine” (C1, clinical meeting 3) 
6.2.6.3 Guidance for clinicians  
Without prompt from the interviewer, C1 suggested that clinician guidance would be a useful 
addition to the modelling process. C1 reflected that it would have been beneficial to have had 
some information prior to model development, on health economic terms, how a model 
works, and what her role would entail. 
“it's quite easy to presume that the clinician knows about health economic modelling 
when I'm just ignorant of even the basic terminology and so I don't know whether…we 
could have a one or two hour brief in the beginning to explain what health economics 
is, what modelling is, and what they expect from us…” (C1, interview) 
The modellers appeared to have different attitudes towards the suggestion that guidance 
should be given to clinicians. Whilst I1 gave the impression that she thought it unnecessary 
for clinicians to understand the model, at least not until they needed to use the results, I25 
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argued that the clinicians should know what information is important to communicate and 
include in the structure, particularly what will impact on the cost-effectiveness result.  
“The difference is we had to understand their bit to do our bit, they can do their bit 
and assume that we know what we are doing for our bit, where it becomes an 
issue…we come up and say it’s cost-effective, it should be done in practice and then 
they think ‘God we need to understand how you can say this’…” (I1, interview) 
“ I think it is necessary for them to understand…the health economics pathway and 
mostly what drives the costs and what is important in the clinical effectiveness of the 
treatment…the adverse events, things that drive the costs or the outcomes” (I25, 
interview) 
The modellers’ opinions on the necessity of clinician training appeared to be related to their 
perspectives on whose role it was to train the clinicians. Whilst I25 stated that it was the 
modellers’ responsibility to guide clinicians through model development, I1 suggested that 
the clinicians should be educating themselves, giving the impression that it would be too 
much of a commitment to provide guidance to every clinical expert.  
“…it’s our responsibility; we should be guiding the discussion…” (I25, interview) 
“If she was motivated to, she could come on our courses and learn about modelling… 
there are ways of them finding out without me having to teach them, you don’t want to 
meet every collaborator you’ve got and sit down and tell them why you’re needed on 
their study…” (I1, interview) 
6.2.6.4 Summary of clinician involvement in model development 
Issues around clinician involvement in the process concerned the lack of clinical contribution 
to structural development, and C1’s lack of understanding of various aspects of model 
building. C1 stated that she struggled to follow the model’s development, and indeed, later 
had difficulty understanding and accepting the model results. Again, problems around the 
generalisability of the structure were raised, as both I25 and C1 reported limited collaborator 
involvement in the process, and gave the impression that more immediate clinician 
involvement would have been beneficial. Further, C1 suggested that she would have found 
her role in the process easier if she had previously received some training in health 
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economics, to allow her to understand model development as it progressed. Although I25 
agreed that it would have been useful for C1 to have known which information was most 
important to communicate when developing the structure, I1 argued that offering training to 
clinicians was impractical, unnecessary and outside of the modeller’s role. 
6.2.7 Conclusion 
The first part of this chapter has presented the findings of the model development undertaken 
within Case Study A. The analysis of the observations and interviews has highlighted the 
stages and methods used, in addition to the issues and problems encountered. These are 
demonstrated in the diagram in Figure 5.  
The issues that appeared most important were those related to structural development and 
clinician involvement in the process. Much of the structural development focused on 
discussion between the modellers and C1, with the pathways being drafted according to C1’s 
experiences of clinical practice, in addition to the NICE guidelines and other clinical 
literature. The modellers and clinicians had open discussions around model structure, and 
commented that face-to-face meetings and reference to a diagram of the model facilitated 
structural development. C1 and the clinical collaborators were also involved in identifying 
some of the clinical data for the model, and C1 had the task of checking the cost inputs used. 
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Figure 5: Modelling process for Case Study A, with issues highlighted 
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Issues included inconsistency in the sources used to inform model pathways, questions around 
whether involving only one clinician in structural development was generalisable, and 
communication between the modellers and clinician. Communication was problematic in a 
number of respects, with the modellers not negotiating with C1 over model boundaries, and 
C1 not being accepting of the actions undertaken to simplify the structure. Further, there was 
some inconsistency in how model boundaries were being applied. C1 also struggled to follow 
model development, and found interpretation of some of the economic terms difficult. It 
became apparent that both C1 personally, and the development of the model would have 
benefited from greater communication from the modellers, potentially beginning with some 
form of training prior to the process.  
Instances of the modellers using less robust practices were also identified. Economic data 
used to populate the model were retrieved through unsystematic searches, and structural 
assumptions and clinical opinion were used in the place of arguably more reliable sources. 
Further, I25 undertook limited structural analysis, and no external validation on the model and 
its results. However, some of these practices were not intentional, but instead based on a lack 
of suitable data and literature. For example, the modellers could not identify relevant utility 
data to populate the model, particularly long-term quality of life outcomes, making structural 
assumptions necessary. I25 also reported being unable to undertake external validation due to 
a lack of similar economic studies. 
The modelling process conducted within Case Study B is explored next, under the headings of 
background, structural development, data and populating the model, model checking, results 
and clinician involvement in model development.  
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6.3 Case Study B – Diagnostic model in Condition 2 
The next sections present the findings of the non-participant observation and semi-structured 
interviews undertaken within Case Study B. The background to the model is explored first 
and covers the objectives of the model, who was involved, and the training that clinicians 
received prior to model development. 
6.3.1 Background 
The focus of Case Study B was the development of a model in a UK healthcare policy 
context. Those involved in immediate model development were two modellers (I8 and I26), 
two project managers, three researchers and around twenty clinical experts. For the purpose of 
this research, the reflections and opinions of the two modellers and three of the clinicians (C2, 
C3 and C4) were concentrated on. The remaining members of the modelling team and 
clinicians were referred to in terms of their contributions to model development meetings. 
The objective of the model was to compare the cost-effectiveness of five alternative 
diagnostic strategies for identifying Condition 2 (current practice and Diagnostic strategies 2, 
3, 4, and 5). Each strategy used a different combination of Diagnostic tests A, B and C. The 
medical condition in which the model was developed was selected because it was considered 
a priority by the modelling team and clinicians. The clinicians reported variation in the way 
that Condition 2 was treated, and suggested that current practice was inefficient and had 
questionable accuracy. It was mooted that identifying the most cost-effective strategy for 
detecting Condition 2 would result in important cost savings for the health service.  
 “[Condition 2] was picked because it was quite a high prevalence so it could have a 
big impact [financially]…” (I8, interview) 
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6.3.1.1 Clinician training 
Training was offered to all clinicians involved in model development. Clinicians were given 
the option to attend a training session prior to the modelling process, and were also able to 
access the material online. Training focused on giving the clinicians a background and context 
to modelling, and information on how models worked and generated cost-effectiveness 
recommendations. The training was delivered through presentations given by the modellers, 
and included tasks for the clinicians to complete. The background information covered why 
health economics and cost-effectiveness were important, and explained how models trade-off 
the costs and health benefits of interventions. The presentation seemed to be directed at 
addressing any apprehension that the clinicians had around using cost-effectiveness, and 
addressing the ‘myth’ that modelling was only concerned with costs.  
“Myth 1: ‘Health economics is about saving the government money’ 
 Health economics helps the NHS use its limited budget to maximise health 
outcomes for the whole population [and] identify interventions offering the best 
value for money” 
(Clinician training presentation) 
The tasks were aimed at providing the clinicians with an understanding of how model 
structures were developed, as clinicians were asked to populate a structure, calculate cost and 
QALY output, and determine the resulting ICER. The clinicians also had to identify the 
potential impact of assumptions made in a hypothetical model. An example assumption and 
the associated implication are given below: 
Assumption Implication 
“The model has a time horizon of 1 
year” 
“By accepting this analysis, we accept that the 
relative and cumulative difference in costs and 
difference in QALYs will not change after one 
year of the intervention…a potentially serious 
limitation” 
  (Clinician training booklet) 
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At the end of the session, clinicians were given an additional booklet, which contained 
definitions of a number of economic concepts, including terms referring to the effectiveness 
of interventions, for example, utilities, and those necessary in the interpretation of model 
results. 
6.3.2 Structural development 
The design and development of the model structure was initiated by I26, and discussed and 
validated by the clinicians. Most discussion regarding pathway plotting took place within one 
clinical meeting, although checking and changes to the structure were addressed in future 
meetings within the process. The next sections report on how the pathways of the structure 
were generated.  
6.3.2.1 Beginning structural development 
The initial development of the model structure was embarked on by I26 prior to any specific 
discussions with the clinicians. I26 drafted the structure based on the findings of an economic 
literature review, using existing model structures in Condition 2 to inform how patients were 
divided in terms of the model pathways. This involved separating patients first by their true 
conditions, and next by whether or not their conditions were identified by the relevant 
diagnostic test. The impression was that beginning a decision tree by delineating patients 
according to their true diagnosis was a common way to structure diagnostic models.  
“…based on what I’d seen with other diagnostic models…so splitting out the 
population by whether they’ve got [Problem A] or not, and then if that’s identified or 
not….” (I26, interview) 
I26 modelled the remaining patient pathways on the information provided in the clinical 
literature, looking particularly at which treatments patients received after a positive or 
negative diagnosis for Problem A. I26 implied that the treatment branches of the pathways 
were important in representing the consequences associated with patients receiving 
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misdiagnosis and mistreatment. 
“…with a diagnostic model it’s basically just looking at the costs of who gets 
identified, and the main things are missed [Problem A] and the people who you are 
over-treating” (I26, interview) 
6.3.2.2 Pathway plotting 
After developing a draft of the model structure, I26 presented it to the clinicians for their 
feedback. Using a diagram of the model, he guided the clinicians through the progression of 
patients in each arm of the decision tree. 
“…so initially patients are split by whether they’ve got [Problem A] or not, and then if 
they’ve got [Problem A] whether they have [Symptom A], and then comes in the 
Diagnostic test B or C, so whether it’s positive or negative, and then treatment follows 
on from that. So if they’ve got a positive diagnosis and they’ve got [Problem A], they 
have [Treatment 2] followed by [Treatment 1]…” 
(I26, Clinical meeting 2) 
The clinicians were then asked a number of questions on the structure. Initial questions 
focused on the nature of treatments that different groups of patients received. This was 
particularly to establish how interventions should be represented in the tree, but also where 
there were differences in patient costs and outcomes, pertaining to where patients needed to 
be divided within the structure.  
I26: “… (for patients with) missed [Problem A]…will [Treatment 2] be required, so 
would that be different [Treatment 2] for those identified with [Problem A] or would it 
be reduced outcomes for delayed [Treatment 2]?”  C5: “….the [Treatment 2] is much 
more complicated….because you go onto get secondary problems… and (there are) 
major cost implications for treating those, and loss of quality of life…” 
(Clinical meeting 2) 
Further questions were aimed at confirming whether pathways were valid in terms of the way 
in which patients were treated at various points. 
I26: “…is there a reason why we don’t have a no further treatment option, so after the 
initial indeterminate Diagnostic test A, we just take that to be negative and send 
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people home?”  C4: “…well if it’s negative but you’re still suspicious clinically then 
you can’t discharge that patient, that patient has to go through a patient pathway” 
(Clinical meeting 2) 
Discussion in pathway plotting   
Discussion between clinicians over model structure allowed for further validation of the 
patient pathways, and highlighted variation and disagreement in the clinical practices 
undertaken. The excerpt below demonstrates clinician disagreement in terms of defining the 
current practice pathway.  
C5: “when they come through the department I think ‘well the Diagnostic test A is 
positive, there’s a [Problem A]’, is it [Symptom A] or not? Or the Diagnostic test A is 
negative and I’ve got a low level of clinical suspicion, in which case there’s a pathway 
back out the door really…”  C3: “…from [my] point of view once you’ve [tested] 
someone for [Problem A], we are obliged to put them on a pathway…I don’t think it 
would ever be ‘you’ve had a negative Diagnostic test A, go home’ because you need to 
take the negative findings and determine them”  C5: “… you always refer the patient 
into some form of follow-up?!”  C3: “Yeah...” 
(Clinical meeting 2) 
On a number of occasions the clinicians reported using different practices to one another in 
terms of how they treated patients. When determining which clinical experience should be 
represented within the model structure, the clinicians often decided amongst themselves on 
the most common practice to include.  
C9: “…. it varies from clinic to clinic as to whether they come back, have an 
examination and then Diagnostic test A or whether they come back, complete 
[Treatment 1], have Diagnostic test A and then get an examination….But I think quite 
a lot of people get a second Diagnostic test A even if they are asymptomatic because 
they are not examined until Diagnostic test A is done…”  C3: “So I think the answer is 
‘yes, the second Diagnostic test A gets done before the negative clinical examination, 
and in the presence of two negative Diagnostic test As and a negative examination and 
follow-up, those patients will get discharged” 
(Clinical meeting 2) 
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6.3.2.3 Boundaries of model structure 
The boundaries of the model structure were determined at the beginning of the process, 
alongside the development of a model protocol. The protocol was generated through 
discussion between the clinicians, and designed to capture the components that the clinicians’ 
considered important to include in the structure. The population was determined to be patients 
who had suspected Condition 2 and had received an indeterminate first Diagnostic test A. The 
clinicians determined this to be the point at which adverse events could be avoided if patients 
were given optimum treatment. Clinicians were instructed by the modellers to capture all 
relevant comparators, and the five diagnostic strategies included represented all of the 
possible combinations of diagnostic tests that patients with suspected Condition 2 could 
receive.  
The time horizon and type of model used were determined by the modellers, although the 
former was discussed with the clinicians for their agreement. The important factor in 
determining the time horizon appeared to be the nature of the condition, and how long the 
symptoms or the outcomes of the treatments remained.    
I26: “about the time horizon, so in the original protocol… [We had] [condition 
specific] outcomes, so does the model need to have a long time horizon to incorporate 
those?”  C5: “Yeah but I’d have no idea what that time horizon should be”  I26: 
“Lifetime?”  C3: “I think lifetime”  C5: “I think lifetime would be the sensible thing 
to go on….even people with subtle [condition specific outcomes] allegedly go onto 
have quite significant disability later on in life…”  (Clinical meeting 2) 
The use of a decision tree structure appeared to be at the preference of I26, who suggested 
that he selected the simplest structure that was able to represent the decision problem.  
 “…I thought about the progression of [Condition 2], which makes you think about a 
state transition model, but then it was going to be quite difficult to identify different 
states… I thought the decision tree captured the main important aspects” (I26, 
interview)  
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6.3.2.4 Basis of model structure  
The model structure was based on a combination of I26’s research of the literature, clinician 
input, and knowledge of the data available to inform parameters. C4 was of the opinion that 
pathways should reflect clinical experiences and how patients were treated in reality. 
“….it’s feeding in your own personal experience of working through that medical 
process in real life….it’s deconstructing what you do on a day to day basis and trying 
to codify that in terms of the model” (C4, interview)  
However, C2 suggested that pathways, even if reflective of clinical practice, should still be 
supported by evidence.  
 “…that tension between what I think is happening, what I think is feasible and 
actually….will there be the evidence to support that?” (C2, interview) 
When determining the focus of the model, clinicians were encouraged to consider whether 
there was evidence to inform the structure, and a search was undertaken to check for relevant 
data. 
 “…we had looked through the literature so we knew what the evidence base was for 
the question and that’s where we said ‘we have some evidence for this but perhaps 
this is where we should build a model so we’ve got more evidence…’” (I8, interview)  
However, the general attitude was that the structure should not be influenced by the clinical 
evidence available, as C9 relayed the importance of the boundaries of the structure being 
agreed upon prior to model development, to avoid bias. Similarly, I8 gave the impression that 
structural development must prioritise developing pathways that are clinically representative 
from the perspective of the clinicians.  
“We have to define the protocol first and then go away and find the clinical literature; 
otherwise it will be biased by the literature” (C9, clinical meeting 1) 
 “…I don’t care if there are data available because I think ‘well that can be sorted 
out’…you can put a data entry in at zero to 1 and just ignore that part of the structure. 
But if [an aspect of the structure] suddenly becomes important you can’t just add it in, 
so I also feel for completeness, for representation to the people who are trying to 
understand this problem… [It’s] quite important…” (I8, interview)  
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There were circumstances during pathway plotting where the clinicians suggested excluding 
pathways from the model, on the basis that there would be no evidence to populate or support 
them. However, I8 emphasised the importance of keeping pathways in the structure that might 
impact the overall cost-effectiveness result. In the example below, I8 stressed the need to 
maintain the aspect of the structure that accounted for the adverse events associated with each 
comparator, despite the clinicians’ perception of a lack of evidence on this element. The 
impression was that I8 considered this important for the comparison of the differences in cost-
effectiveness between the strategies. 
I26: “Can those with a false positive diagnosis have [Treatment 2], those that don’t 
have [Problem A]?”  C4: “It could happen; it’s a bit of a whoops moment”  C10: 
“For the purposes of evidence I think you can say no…”  C5: “…I’ve certainly heard 
of a case though…like hen’s teeth, rare, but the ones you see stick in your mind”  
C10: “I think on the basis of evidence you can say no….”  I8: “…but that box still 
needs to be explored to compare Diagnostic test C against how many people would 
end up there with Diagnostic test B or Diagnostic test A”  C9: “Yeah with Diagnostic 
test A you’d get people in that box…”   (Clinical meeting 2) 
6.3.2.5 Making structural assumptions  
I26 suggested potential structural assumptions to the clinicians for their feedback. Most 
structural assumptions appeared necessary due to a lack of long-term outcome data, 
particularly on quality of life. The modellers proposed limiting the structure and finishing 
patient treatment and recovery at the point at which there were no longer data available to 
populate parameters.  
I26: “… assume that everyone with [Condition 2] has a quality of life based on that 
patient reported [Measure] of [Value 1] for the first year and then they go to perfect 
health if it is identified, if it is not identified then assume [Value 1] for the lifetime…”  
C10: “So does that make the assumption that treatment works and continues to work 
for the rest of that patient’s life?”  I26: “Yeah so with missed [Problem A], patients 
will stay at the 1 year [score] for the rest of their life” 
(Clinical meeting 4) 
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Clinicians discussed the validity of the suggested assumptions, and in most cases agreed with 
what the modellers were proposing. Where there was disagreement between the clinicians, 
there were instances of the modelling team making the final decision on the assumption used. 
In this example, the modellers opted to include the perspective that seemingly allowed for the 
consequences of misdiagnoses in the current practice arm to be accounted for, instead of 
patients receiving further testing as argued by C6.  
I26: “Another assumption was that in current practice if patients had an 
indeterminate Diagnostic test A…. [If] they needed [Treatment 2] then they were 
considered to be missed and they would have continued reduction for their lifetime”  
C3: “…there is the potential for them to be erroneously discharged because the 
Diagnostic test A is not 100% sensitive...”  C6: “Is there? Because a lot of centres 
including us do initial Diagnostic test A, follow-up Diagnostic test A and then on to 
Diagnostic test C…”  C3: “But it is done on clinical grounds so if it’s tender you 
[keep them in], if it’s not tender and you’ve got two negative Diagnostic test As you 
discharge them…”    (Clinical meeting 4) 
Despite clinicians being generally accepting of the assumptions proposed, I8 emphasised the 
importance of having them officially ‘signed-off’. The clinicians were therefore asked to 
agree to relevant sections of previous meeting minutes. 
“we've got to get all the clinicians to buy in and so that's why we use our meeting time 
because that's the only time we're on record…and when they all say ‘yes’ as a group 
that means we can sign it off and we've got agreement on that particular assumption 
from the entire group” (I8, interview)  
I8 gave the impression that clinicians were asked to sign-off on assumptions because they had 
a tendency to question them at the results stage.  
“… That’s when it all comes out of the woodwork, until they’ve seen those results and 
they disagree with those results, they don’t question what’s going in and then all of a 
sudden you get a flurry…” (I8, interview) 
6.3.2.6 Communication in structural development 
Communication in structural development worked in terms of the modellers asking the 
clinicians questions to check aspects of the structure, and the clinicians subsequently 
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discussing the validity of the pathways. I26 suggested that he used the method of developing 
the structure and presenting it to the clinicians because it was the most efficient approach in 
the context of his workload and limited clinician contact time.  
“I’ve just tried to do it as quickly as I can really because we are doing [numerous 
models]….I just present as much as I can to them in each meeting” (I26, interview) 
There were issues with gaining access to clinical opinion in structural development, 
specifically in terms of establishing an economic subgroup. The modellers reported that a 
subgroup would typically involve three to four clinicians, who would offer more in-depth 
advice on, and validation of, structural inputs. However, I26 reported only being able to 
recruit one individual, due to the clinicians’ conflicting schedules.  
“…I haven’t had a huge amount of contact; it’s been mostly with C5 because it’s been 
difficult to get people together at the same time…” (I26, interview) 
Despite this, both I8 and I26 suggested that C5’s sole involvement in the subgroup was 
unlikely to have a negative impact, given that C5 typically took on a leading role in 
discussions. However, the lack of negotiation with others was sometimes problematic, as C5 
made suggestions for the comparators of the model that other clinical experts later disagreed 
with.  
“… people mentioned that we should look at a strategy of immediate Diagnostic test C 
or Diagnostic test B without the initial Diagnostic test A, C5 thought this was wrong 
[because] the patient [would] have to go home and come back for an additional visit. 
This was raised with [the other clinicians] (and they) said these were feasible 
strategies” (I26, interview) 
Other issues with communication concerned the clinicians’ lack of understanding of the initial 
nodes in the decision tree, which divided patients according to their true conditions. This was 
clarified through an explanation from I26.  
C3: “I’m not sure you need the negative nodes in this pathway because if it is 
[Problem A] it’s either [Symptom A] or not [Symptom A] and then they go on to the 
[different treatment] options…” I26: “the first bit is whether they’ve got a true 
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[Problem A] or not, that’s what you know, so then the positive [Diagnostic test] is 
whether it’s picked up”  C3: “So you have an Diagnostic test C or Diagnostic test B, 
the patient really has [Problem A] but there’s a possibility that the [Diagnostic tests] 
might not have picked that up”  I26: “Yep”   (Clinical meeting 2) 
6.3.2.7 Implementation 
I26 suggested that he planned the structure on paper prior to its implementation in the 
modelling software. I26 stated that developing a plan and protocol of the model at the 
beginning of the process ensured that he had a complete structure to later program.  
“…it’s planning for problems, I find it hard to look ahead at things that are going to 
crop up, that’s why I think it’s important to have a plan of the model….rather than just 
start doing it and see what happens” (I26, interview) 
6.3.2.8 Reflections on model structure  
All informants were asked to reflect on the model structure. The attitude of the modellers 
seemed positive, as both I8 and I26 gave the impression that they were happy that the 
structure was providing a clinically valid representation of the decision problem. However, 
C4 suggested that he was struggling to understand why the structure was representing clinical 
events that in his opinion were unlikely to occur.  
“some of those scenarios seemed to be things that just wouldn’t happen in real life i.e. 
if you went down a certain pathway you could perhaps end up in a scenario in which a 
surgeon would operate on a [Problem A] that didn’t exist…” (C4, interview) 
6.3.2.9 Summary of structural development 
Structural development was generally initiated by the modellers, and reviewed and discussed 
by the clinicians. The modellers tended to ask questions aimed at validating pathways, and 
I26 reflected that this method was efficient in the context of limited time and access to clinical 
opinion. Discussion between clinicians appeared to be a key communication tool in terms of 
ensuring the clinical representativeness of the pathways, but also intrinsically addressing the 
generalisability of the structure, as the clinicians resolved disagreements by negotiating on 
what they considered to be the most common or valid clinical practice. The process appeared 
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to benefit from the large group of clinicians involved in immediate model development, but 
having only one clinician involved in the subgroup demonstrated that one opinion may not be 
representative of all. Some tension was identified between the modellers and clinicians in 
terms of the aspects that were included in the structure. Whilst the clinicians were 
fundamentally concerned with ensuring that the structure was clinically valid, the modellers 
additionally were striving to keep pathways that could potentially demonstrate the 
comparative cost-effectiveness of the strategies being evaluated. The clinicians appeared, at 
times, to struggle with understanding the components of the structure that were important to 
the economics of the model.  
6.3.3 Data and populating the model 
Data used to populate the model were identified using various means, including systematic 
reviews of the literature, ad-hoc literature searches, searches in relevant databases, and 
clinician opinion. The next sections report on the methods used to identify and check the 
clinical and economic data in the model.  
6.3.3.1 Clinical data 
The clinical effectiveness data, which referred to the diagnostic accuracy of the three tests 
used in the strategies, were searched for using a systematic review. The accuracy value for the 
first diagnostic test was taken from a relevant paper retrieved. The modelling team had to 
undertake further ad-hoc searches to identify a value for the second diagnostic test, as this did 
not feature as a comparator in the original paper. The third test, Diagnostic test C, was 
assumed to be the reference standard, and as such the sensitivity and specificity values were 
set to 100%.  
The probability values originated from a variety of sources. Two of the values, including the 
prevalence of Condition 2, were informed by clinical papers identified through general 
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searches, whilst the remaining inputs came from clinician opinion. I26 gave the impression 
that the use of unsystematic searches for these values was not ideal, but necessary due to time 
constraints.  
“….we don’t really have time to do a systematic search for each parameter in the 
model so we just do a general search and try and find the best evidence we can, that’s 
the main thing I would improve” (I26, interview) 
6.3.3.2 Economic data 
The process for identifying costs and utilities for the model was initiated with a systematic 
review aimed at finding economic evaluations to inform the structure of the model, and 
potentially data to populate parameters. However, the search returned only one relevant paper, 
which included no quality of life outcomes. Utility data were therefore identified using a 
“quick search” of the literature, retrieving a relevant patient reported value to inform the 
quality of life of a patient one year post Condition 2.  Due to a lack of long-term quality of life 
values, it was assumed that patients would remain with the one-year value for life if their 
problem was not identified, or return to full health if they were diagnosed appropriately. 
Although these values and assumptions were reviewed by the clinicians, I26 later identified 
the lack of appropriate utility data as the greatest source of uncertainty in the model. 
 “I think the long-term benefits, the health outcomes, they came from papers but they 
were small studies and it was based on assumptions from the clinicians as well, so in 
assuming that the health state carries on…” (I26, interview) 
Cost and resource use data were identified using NHS reference costs and the HRG database. 
I26 searched for relevant costs within the database according to the condition being modelled 
and type of medical care. The cost data were presented to the clinicians and questions were 
focused on whether the clinicians recognised the costs to be valid, and whether appropriate 
HRG codes had been used. The clinicians who answered these questions seemed familiar with 
the codes, and were aware of the differences between cost categories. 
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I26: “…there are two different costs, there’s category 1 and category 2. I’m not sure 
what the difference is. I was hoping someone here might know?”  C10: “It is 
comorbidities, so the comorbidities push you into category 2…”  I26: “So do we want 
category 1 or?”  C5: “Category 1 would be more representative…” 
(Clinical meeting 4) 
While most of the cost values were considered appropriate, some of the clinicians questioned 
the transparency and accuracy of the NHS reference costs. However, all parties seemed to 
accept that these data and the data source were the best available. 
C7: “For Diagnostic test C does it refer to [Type 1] Diagnostic test C or [Type 2] 
Diagnostic test C? There will be a cost difference.”  I26: “In the costs it just says 
Diagnostic test C, it doesn’t specify”  C8: “It’s interesting though because it would be 
significant”  C10: “Significant on every level because the [Type 1] is cheaper to 
maintain”  C8: “Well actually … the capital costs are lower but the running costs are 
the same or higher”  I26: “So you think that cost would be more?”  C10: “No I think 
that the figures you’ve found are what we should use, there’s nothing better 
published” 
(Clinical meeting 4) 
6.3.3.3 Data and clinician involvement 
Clinician involvement in populating the model mostly concerned the checking of data values, 
with all of the clinical and economic data inputs being reviewed by the clinicians prior to their 
inclusion in the model. Clinicians were also asked to recommend sources for data parameters, 
mainly in circumstances in which a systematic review had not been undertaken. I8 gave the 
impression that the clinicians would have more confidence in the model results after being 
involved in data collection.  
“If you have any papers around this then please add them on, we are not doing a 
systematic review and so if we have other numbers these will impact on the 
results…I’d hate to think that you won’t believe in the model outcome because of the 
numbers being used” (I8, clinical meeting 3) 
In circumstances where data were not available in the literature, clinicians were asked to 
provide data estimates for parameters. Around one third of the base case inputs were informed 
by clinician opinion. The modellers asked open questions regarding the values to use, and 
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based final estimates on consensus among the clinical experts. Where there was disagreement, 
as in the example below, the modellers eventually used the suggestion supported by most 
clinicians, including C5, in the main model, and increased the accuracy of the follow-up test 
in the sensitivity analysis.  
I26: “…so we don’t have data on the accuracy of follow-up Diagnostic test A, can we 
make assumptions about that?”  C5: “I’m not aware of any evidence to show that the 
follow-up Diagnostic test A is any more accurate than the first”  C3: “It’s probably a 
little bit more sensitive because you do get some [Problem As] that don’t show up and 
then do show [at the follow-up]”  C5: “Do you? After eight years of looking for them 
I never saw one…. [I’d] assume that the second Diagnostic test A is no more accurate 
than the first” 
(Clinical meeting 2) 
6.3.3.4 Summary of data and populating the model 
The modelling team used a combination of systematic reviews, general searches and clinician 
opinion to identify parameter inputs for the model. Systematic reviews were used in the first 
instance to search for clinical effectiveness data and economic evaluations that could 
potentially inform economic data parameters. However, both searches were limited by a lack 
of relevant evidence. General searches were undertaken to retrieve clinical probabilities and 
utilities and cost data. Collecting quality of life data was problematic, as I26 stated that the 
lack of long-term utility data was the greatest source of uncertainty within the model. Further, 
the clinicians were concerned with the accuracy of NHS reference costs, although they were 
also of the opinion that the HRG database was the best and most practical resource currently 
available. The clinicians were involved in checking data, highlighting relevant data sources to 
inform parameters, and making data assumptions for the model where there was no literature 
available. Discussion between the clinicians appeared to be essential in ensuring the validity 
of data assumptions.  
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6.3.4 Results  
After populating and running the model, the model results were presented to the clinicians. 
I26 initiated the presentation with a reminder of the data inputs to the model, and an 
explanation of the concepts used to interpret the results.  
“…often we present cost-effectiveness as a cost-effectiveness ratio and compare it to 
the £20,000 per QALY threshold set by NICE, but to present it in a simpler way using 
the net benefit approach, we take that £20,000 QALY threshold, multiply it by the 
number of QALYs we have for that strategy and that gives us what we value those 
QALYs at in monetary terms. Then we take off the cost of the strategy and the optimal 
strategy will be the strategy with the highest net benefit” (I26, clinical meeting 5) 
For context, the main model demonstrated that Diagnostic strategy 5 was the most cost-
effective. The modellers discussed the results with the clinicians, allowing them to ask 
questions to aid their understanding of the findings, and explaining how the differences in 
costs and effectiveness between the strategies impacted cost-effectiveness overall. However, a 
number of the clinicians appeared to struggle with interpretation, specifically of the research 
and economic terminology. As a result, the modelling team had to provide clarification. 
I26: “…this is the base case analysis… the maximum net benefit is from the 
Diagnostic strategy 5, so that’s based on the analysis where missed [Problem A] has 
reduced quality of life over a lifetime....”  C9: “So base case analysis means?”  I26: 
“…not the sensitivity analysis”  C2: “can I ask why the Diagnostic strategy 2 and 
Diagnostic strategy 3 cost is higher? Is that presuming there is a follow-up 
appointment as well…?”  I26: “…they have another attendance”  I8: “Your 
Diagnostic strategy 5 accuracy estimates are incredibly high because that is your 
reference standard, so you’re avoiding having people go off on the wrong route… 
that’s worth the additional cost of Diagnostic test C”  C9: “…I may be being stupid 
here….tell me what base case means….?”  I8: “….base case is based on your best 
possible estimate…then what you do is change a parameter a little bit either way just 
to see how the conclusions might change ….”   
(Clinical meeting 5) 
The model results seemed unexpected to the clinicians as they questioned the differences in 
cost-effectiveness between strategies, and subsequently the data inputs used. The clinicians 
appeared unhappy with the value used for the accuracy of Diagnostic test B, and the 
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assumption that Diagnostic test C was the reference standard. These were inputs that the 
clinicians had previously agreed to. As a result, the clinicians requested that the accuracy of 
Diagnostic test B was increased to 100%, and the impact of this tested in a sensitivity 
analysis.  
C9: “I’m surprised that Diagnostic test B was so poor?”  I26: “Diagnostic test B was 
poor based on missed [Problem A] because it was 86% sensitive”  C10: “…only 86% 
sensitive?” C5: “Compared to Diagnostic test C but you could argue Diagnostic test 
C over-diagnoses”  C10: “So should we say actually Diagnostic test B is 100% 
sensitive for [Condition 2]?”  C5: “…You can do that on the sensitivity analysis…” 
(Clinical meeting 5) 
Other issues were not as straightforward to resolve; during a preliminary results meeting, 
clinicians questioned the validity of the model pathways, specifically the current practice arm. 
The clinicians were concerned with the credibility of the assumption that patients would leave 
the model after receiving a second negative diagnostic test, thus experiencing permanently 
reduced health outcomes. Interestingly, this was the structural assumption that had earlier 
caused disagreement among the clinicians (see section 6.3.2.5), with the final decision being 
made by the modellers, rather than explicitly between the clinical experts.  
C9: “[Current practice]…if you just do that alone then we are going to miss people, 
that’s what we are saying isn’t it? In practice I don’t think that happens because most 
people would never do just Diagnostic test A and follow-up…”  C9: “… [If] you’re 
still symptomatic you’re going to go on and [have]… Diagnostic test C”  C10: “so 
this model is saying that we are not doing that, this is saying that we accept the 
findings of the follow-up Diagnostic test A and send them home”  C9: “…if we are 
saying that normal practice misses [Problem A] and someone says ‘well how do you 
know that?’, we’ve got no evidence…what we have got evidence to say is that up to 
the point that you’ve taken the second Diagnostic test A you may not have found 
everything, but normal practice isn’t to discharge at that point unless there’s no 
clinical problem…” 
(Clinical meeting 6) 
The clinicians’ concern appeared to be that the clinical evidence did not adequately support 
the developed pathways, and subsequently the adoption of a new diagnostic strategy. 
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However, the clinicians were happy that the result could be justified on the basis of cost 
difference alone.  
R1: “we have done our best to find how many patients would have been missed in the 
current practice strategy; we would have included it if we found it…. [But] it looks 
like current practice is more expensive anyway…”  C9: “So we can justify it on the 
basis of the cost without looking at the long-term consequences?”  I26: “Yeah”  C9: 
“And if there are long-term consequences because we miss some people who go 
through without ever having [further diagnostic testing] then that would only be to 
our advantage.”  
(Clinical meeting 6) 
6.3.5 Model checking 
Most model checking was undertaken by I26, and mainly involved sensitivity analysis. I26 
undertook deterministic sensitivity analysis on almost all of the data parameters, to test the 
impact that it would have on the model results. Many of the alternative values used were 
informed by clinician opinion, and some of the scenarios tested were at the clinicians’ request, 
for example, increasing the accuracy of Diagnostic test B to 100%. The clinicians appeared to 
benefit from the opportunity to discuss the outcome of the sensitivity analyses with each 
other, seemingly aiding their acceptance and interpretation. The excerpt below demonstrates 
the clinicians’ discussion of the effect that decreasing patients’ reduced quality of life had on 
the model. 
C10: “at the moment we are saying that patients had a [false negative] diagnosis, 
they remain with these symptoms. But then I26 has modified that by saying for only 1 
year, or 2 years….”  C9: “…basically the long-term effects are not in play?”  C10: 
“Well they’re just in play for current practice really”  C2: “so the difference between 
Diagnostic strategy 4 and Diagnostic strategy 5 is just the difference between the 
costs, they’re both the same as each other, the mean cost is just lower for Diagnostic 
test B…And that’s why Diagnostic strategy 4 is coming out better”  C10: “And the 
longer you say the harm lasts, Diagnostic strategy 5 comes out better” 
(Clinical meeting 6) 
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The clinicians appeared to have little problem with the interpretation of the sensitivity 
analyses, and a few of the clinical experts demonstrated the ability to predict the effect that 
changes would have on the results prior to the check being undertaken.  
“ And if you put that at 100% the results would change…the sensitivity analysis is 
going to turn it on its head, so that Diagnostic strategy 5 looks great if you use the 
base case but as soon as you say that Diagnostic test B is more sensitive, Diagnostic 
strategy 4 becomes more cost-effective…” (C4, clinical meeting 4) 
I26 also undertook extreme value analysis as a means of internally validating the model. 
Following a validation checklist, I26 populated clinical and economic parameters with “null 
and extreme values” to ensure that when the model was run, the cost-effectiveness result was 
changing in the direction expected. Other internal validation checks involved ensuring that 
data inputs were consistent with clinical outcomes, and that the modeller was able to explain 
model results.  
6.3.5.1 External validation 
External validation checks were also included on the checklist, with I26 comparing the 
outcome of the current model with the results of the published economic evaluation retrieved 
through the systematic review. It was reported that the conclusions of the published model 
were consistent with those in the published paper, although the identified study had not 
compared all five of the diagnostic strategies that had been included in the current model. 
6.3.5.2 Clinician involvement in model checking 
Clinician involvement featured as a fundamental aspect of model checking, as the clinicians 
were given the task of validating pathways, data inputs, model results and sensitivity analyses. 
In terms of structural validation, the impression given was that it was the role of the clinicians 
to ensure that the structure represented the clinical problem appropriately. It was stated in the 
model report that the structure had been clinically validated through continuous and iterative 
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consultation with clinical experts. The perspective that the clinicians were responsible for 
structural validation was also mirrored in comments from the modellers. 
“Structure…I see that as a planning one, just through looking at it with the clinicians 
and trying to sort it out…through presenting ‘this is where I’ve got to so far, this is 
what’s coming out so far, what do you think?’” (I8 interview) 
“…all I’ve done is taken the structure to the clinicians and used their knowledge to 
make sure that the structure is what it should be” (I26, interview) 
However, I8 implied that further structural validation and sensitivity analysis should have 
been carried out, but that it was not because the checks were very difficult to undertake.  
“…actually that’s one thing that we test the least because it’s so complicated and yet 
the structure dictates so much in terms of what is important, so I find that quite, but 
it’s just a really complicated issue…” (I8, interview) 
6.3.5.3 Summary of results and model checking 
The model results were presented to the clinicians for their feedback, with opportunity for the 
clinicians to clarify the findings with the modellers and each other. The clinicians gave the 
impression that the model result was unexpected, and subsequently questioned the data inputs 
and structural assumptions used. It appeared that there was some breakdown in 
communication between the modellers and clinicians over what was considered valid to 
include in the model, perhaps caused by a lack of explicit agreement on structural 
assumptions. However, discussion between the two parties facilitated a solution in terms of 
identifying a justification for the model results, and the clinicians’ requesting that alternative 
values be tested in the sensitivity analysis. Further, although initially a problem, the 
clinicians’ understandings of economic terms used in the interpretation of the results were 
enhanced through the clinicians’ ability to seek clarification from the modellers. 
Model checking mostly focused on sensitivity analysis, with clinician understanding of the 
results of analyses again being enhanced by the opportunity for discussion with others. I26 
undertook some external validation, and structural validation was carried out through iterative 
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checks of the structure with the clinicians. However, I8 suggested that further structural 
checks should have been undertaken, but stated that these were avoided because of their 
complex nature.  
6.3.6 Clinician involvement in model development  
The clinicians were involved in the structural, data and results stages of model development. 
Their involvement appeared to be valuable to the construction and checking of the model, but 
there were also some problems in communication between the modellers and clinicians. The 
next sections explore issues around the clinicians’ involvement, and reflect on the number of 
clinicians involved, their understanding of modelling and the usefulness of clinician guidance.  
6.3.6.1 Number of clinicians  
The entire process of model development involved up to twenty clinicians, but the number 
attending each meeting varied. Nevertheless, there were a number and variety of clinicians 
involved in each of the decisions around the structure and inputs to the model. Both the 
clinicians and modellers were of the opinion that this was essential to the model’s validity, 
credibility and generalisability. 
“There’s a good mix of people, we’ve got people who specialise in all areas” (I26, 
interview) 
“It’s clear from discussions around the table that things are very different across the 
whole country and I think…it’s actually a really important part of it in terms of  
validating the outcome, which is actually the strength and breadth of both experience 
and geography of clinicians”  (C2, interview)  
“…it would immediately undermine the credibility of what we do so I think it’s 
important to have these discussions, even though they can feel quite uncomfortable at 
times” (C3, interview) 
C3’s comment suggested that discussions between larger groups of clinicians could be 
difficult, as it appeared to increase the likelihood of disagreements. Although discussion was 
deemed to be valuable, the modellers gave the impression that the clinicians’ conversations 
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could sometimes be difficult to manage. Both I8 and I26 reflected that there tended to be a 
few clinicians who regularly dominated discussions. I26 suggested that further measures 
needed to be taken within modelling meetings to ensure that every clinician had the 
opportunity to contribute. 
“We’ve got a couple of argumentative clinicians in there….there’s always one or two 
like that in every group” (I8, interview) 
“We get one person who specialises in a certain area and has a lot more input than 
other people, so I suppose it would be better if we tried to make sure that more people 
had an input. I don’t know how we could do that. We’d have to sort of make people 
say something …” (I26 interview) 
6.3.6.2 Clinician understanding of modelling 
On occasion, the clinicians appeared to have difficulty in understanding aspects of the model 
building, for example, the economic components included and the terminology used. The 
clinicians also suggested that they struggled to understand how structural development 
worked and why the model was being developed as it was. C4 thought that his lack of 
understanding would later impair his ability to interpret the model result.  
“… understanding about how it’s all pulled together, I’m not clear whether that’s 
something I’ve missed or something that I would never be expected to be told” (C2, 
interview) 
“…. those models are such an unfamiliar way of looking at information for me. The 
feeding the information in is something that I can understand, I don’t have an 
understanding of the shape that the model is taking yet and I suspect that even when 
the finished product comes out that it’s going to take some explaining…” (C4, 
interview) 
I26 also suggested that the clinicians struggled to follow model development, particularly in 
understanding why certain aspects had been included in the structure. He proposed that the 
clinicians had this difficulty because they were only asked questions on specific aspects of 
structural development. I26 gave the impression that building and conceptualising the 
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structure in conjunction with the clinicians would have enhanced the clinicians’ ability to 
understand the model. 
“[getting] the structure to match what the issues are…I think the problem is the 
difference between the understanding of the clinicians and the modellers, and they 
don’t always know what we are doing” (I26, interview) 
“You do get some good feedback on specific bits of it but then they don’t see the 
actual thing happening, so maybe if they did actually see it being built as it goes then 
that might [help]” (I26, interview) 
6.3.6.3 Guidance for clinicians  
All of the clinicians were offered training prior to commencing their roles, but none of the 
three clinicians interviewed attended due to work commitments. C3 gave the impression that 
it would have been useful if the training were more flexible and potentially web-based, to fit 
in with their schedules. While C3 suggested that knowledge of how models worked would 
have been helpful, C2 stated that she required clarification of economic concepts.  
“…a dictionary of terms, almost a glossary of terms….” (C2, interview) 
“I think some sort of interactive online training or a video might be quite useful, just 
about health economic models and the rationale of using different types with some 
examples, that would be quite good I think because then it would be something we 
could do in our own time rather than having to come down for a day’s training” (C3, 
interview) 
Both C4 and I26 also stressed the importance of the clinicians receiving continuous training, 
and being reminded of important aspects at various points of development.  
 “…they basically just forget when they’ve seen it once, so they need to keep going 
over it...” (I26, interview) 
…I’ve heard the technical terms used lots of times and I understand what most of the 
terms mean …but until you start using something all of the time you never understand 
it…” (C4, interview) 
C2 gave the impression that the nature and amount of training that clinicians required would 
depend on their previous experience of health economics and modelling.  
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“I think I’ve probably come into it a bit more confidently than others because of my 
research background, because one of the projects that I’ve been involved with…it 
includes health economics, an economic analysis section, so I’m used to the 
terminology. I think otherwise if someone was talking about QALYs and I’d never 
done any work on that before it would have been completely over my head” (C2, 
interview) 
6.3.6.4 Summary of clinician involvement 
The large number and diversity of clinicians contributing to model development was 
perceived to be essential to the validity and generalisability of the model, but the modellers 
gave the impression that it was more difficult to manage discussion between larger groups of 
clinical experts. The clinicians stated that they struggled to follow structural development, 
particularly why the model was being developed as it was. I26 proposed that the clinicians’ 
comprehension of what was important, and occurring in model building, could be improved 
through their involvement in the conceptualisation and development of the entire model 
structure. The clinicians interviewed thought that training would have further aided their 
understanding of model development, but none of those interviewed attended the training 
offered due to work commitments. The suggestion from the clinicians and the modellers was 
that training should be flexible, preferably web-based, and given throughout model 
development.  
6.3.7 Conclusion 
The second part of this chapter has presented the modelling process used by the modellers and 
clinicians in Case Study B. The findings of the observations and interviews have highlighted 
the modelling practices undertaken, and the issues and problems encountered in model 
development. These are demonstrated in the diagram in Figure 6.  
Issues highlighted concerned the clinicians’ involvement in structural development. Although 
clinician input was fundamental to various aspects of model development, there were 
problems around the clinicians’ understanding of modelling. The clinicians questioned the 
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inclusion of economic components to the structure, and struggled with the interpretation of 
some of the economic concepts used. I26 attributed this lack of understanding to the 
clinicians’ limited overview of the model-building process, and how the model was put 
together as a whole. Other issues related to communication, as clinicians questioned structural 
assumptions and model pathways fairly late on in the modelling process. This was seemingly 
due to the lack of explicit agreement between clinicians over structural assumptions earlier on 
in model development. Although discussion between clinicians was seen as beneficial to the 
model and clinician understanding, a further problem with communication concerned 
managing discussions between large groups of clinical experts. 
Problems related to the data used in the model included the use of general and ad-hoc 
searches as opposed to systematic reviews. The modelling team undertook general searches 
on a number of parameters within the model, recognising this as a limitation of their practice 
due to the lack of time available. The modellers reported on the lack of long-term quality of 
life data, giving the impression that this was the source of the greatest uncertainty within the 
model. The clinicians were also concerned with the accuracy of the cost data used, suggesting 
that the NHS reference costs did not highlight the differences in cost between similar types of 
treatment. In terms of model checking, the modellers undertook structural validation only 
insofar as asking the clinicians to check various elements of the structure, with I8 suggesting 
that further structural checks could have been carried out. However, I8 also stated that 
alternative forms of structural validation were too complex to include in the process. A final 
practical issue in terms of the overall process related to the inability of the clinicians 
interviewed to attend the training offered by the modelling team. 
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Figure 6: Modelling process for Case Study B, with issues highlighted  
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After reviewing the processes used by the modellers and clinicians in Case Study A and Case 
Study B, the next chapter looks at their practices in relation to one another, to gauge whether 
the teams used similar methods and encountered the same problems and issues. There is also a 
focus on what can be inferred from the similarities and differences in the practices 
undertaken. The next chapter summarises the findings of both stages of the qualitative 
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CHAPTER 7: DISCUSSION OF FINDINGS 
7.1 Introduction 
The objective of this research was to explore the processes used to develop health economic 
decision-analytic models. These are models used by healthcare decision-making bodies such 
as NICE, to assess the costs and outcomes of health interventions, and provide an assessment 
of which offer the most value for money (NICE 2013). The research was undertaken in light 
of literature that highlighted errors in the processes and results of published decision-analytic 
models (Chilcott et al., 2010; Karnon et al., 2007; Roberts et al., 2006), and a systematic 
review suggesting that there was limited guidance available on particular aspects of model 
development (see chapter 2). The aims of the thesis were therefore to investigate good 
practice in model building, and explore issues and problems that were occurring in the 
process. Further, the intention was to examine model development from the perspective, and 
through the experiences, of those who were involved, namely modellers and clinicians. This 
was possible through the use of qualitative methods, specifically in-depth interviews with 
modellers, and case studies with teams of modellers and clinicians, involving non-participant 
observation, think-aloud and qualitative interviews. A qualitative approach was selected 
following a review of qualitative studies in other areas of health services research and health 
economics (see chapter 3), which suggested that in-depth and exploratory methods were 
particularly useful in highlighting and understanding methodological issues occurring within 
healthcare processes. 
This chapter begins by presenting a summary of the results of each of the two phases of 
qualitative research undertaken within this thesis, and provides a synthesis of the main 
findings across the in-depth interviews and case studies. The findings of this thesis are then 
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discussed in relation to the results of similar qualitative studies, and following this, the 
implications of the findings for various aspects of model development are considered, and 
recommendations for good practice are made. The final sections of the chapter outline 
suggestions for future research and reflections on the methods used. 
7.2 Summary of findings of the qualitative interviews with modellers 
A total of twenty-four in-depth interviews were conducted with modellers in the UK and in 
Canada. The modellers interviewed included those from academic and non-academic 
backgrounds, and those who were in senior and more junior roles within their organisations. 
Interviews were detailed and inductive in that informants were encouraged to talk at length 
about their experiences, and raise issues that they felt were important to the aims of the 
research. The use of constant comparative methods of analysis allowed the practices of the 
informants to be compared for similarities and differences in terms of the methods 
undertaken; common problems were also examined.  
The interviews captured rich data on the processes used by individual informants. Modellers 
were following similar stages in model development, and clinician involvement was 
considered to be a key aspect of the process, particularly in receiving input to model structure. 
Although modellers undertook similar stages within structural development, different 
approaches were taken to these stages. Informants discussed different ways of involving 
clinicians, including when they sought clinician opinion, and how many clinicians they talked 
to. A few modellers did not involve clinicians until late in model development, which was 
reflected on as poor practice. While most informants involved only two clinicians in model 
development, some spoke to just one, or even no clinicians, with the latter practices raising 
concerns among the informants around the generalisability of developed structures. This was 
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in addition to the lack of measures reported by informants to ensure that a range of clinicians, 
i.e. those from a variety of backgrounds and locations, were involved.  
Other differences in structural development related to the sources used to inform model 
structure. Modellers had conflicting opinions about whether the data used to populate a model 
should influence structural development, and whether existing structures should be used to 
directly inform a new model. The academic and non-academic consultancy modellers had 
slightly different foci in terms of what they considered important to include in a structure. 
Academic informants suggested that the structure should be based on all clinically valid 
health states, whilst some non-academic informants implied that the structure should contain 
the states that were most important to patients, namely those that had most impact on their 
clinical and quality of life outcomes. 
Common problems were identified through informants’ discussions of their practices, and 
their perceptions of where and how processes could improve. The overarching issues that 
were reported related to communication between modellers and clinicians, and a lack of time 
and resources to undertake robust practices. Informants cited problems with engaging 
clinicians in model building, suggesting that clinicians’ lack of understanding and acceptance 
of modelling made it difficult to involve them in any depth. Informants also criticised aspects 
of others’ processes, such as using less robust methods for identifying data to populate a 
model, and carrying out limited model checking activities. However, some of the modellers 
interviewed appeared to lack robust practices in these areas, as external validation was carried 
out by fewer than half of informants, and structural checking (outside of clinician validation) 
was not undertaken at all. Those who gave a reason for their limited model checking cited a 
lack of time to carry out additional activities.  
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7.3 Summary of findings of the case studies with modellers and clinicians 
Two case studies were undertaken with two teams of modellers and clinicians, to observe 
modelling processes, and identify any issues with the methods used. The case studies were 
selected because they offered insight into potentially different processes, capturing the 
development of an academic model and policy model from beginning to end. The teams of 
modellers sampled were from among those who had a good reputation for model building, on 
the basis of recommendations from the interview informants. It was anticipated that problems 
encountered by these modelling teams were also likely to be experienced by others. Both case 
studies used non-participant observation and qualitative interviews to gain a detailed 
understanding of each model’s development. Case Study A additionally used the think-aloud 
method to explore thought processes around model checking. 
The approach to inquiry was inductive; however, the case studies were also designed to 
investigate further the issues raised during the first phase of the research. Particular attention 
was paid to the role and contribution of clinicians in the modelling process, given that this 
was identified in the qualitative interviews to be an important but problematic aspect of model 
building. The use of the framework method for analysis allowed case study data to be coded 
according to pre-existing concepts, in addition to permitting the development of new codes 
and themes. Case studies were analysed separately, but framework analysis facilitated the 
comparison of the modelling methods used, highlighting similarities and differences in 
practices, and common problems identified. Although the findings of the individual case 
studies provided useful insights into issues with model development (see chapter 6), 
comparing the findings allows broader inferences to be made about the potential benefits and 
drawbacks of the different modelling approaches taken. These are explored in the next 
section. 
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7.3.1 Comparison of the case studies  
The case studies were similar in terms of the overall stages of model development followed. 
The modelling processes included initial structural development by the modeller, clinician 
discussion and checking of pathways, populating the model with data, model checking 
activities and presenting the results to the clinician(s). However, different methods and 
approaches were undertaken by the two modelling teams.  
Modellers from both case studies used similar methods to inform their model structures, as 
initial structures were developed with reference to clinical literature and/or other economic 
models. In both cases, structures were drafted into diagrams of patient treatment pathways, to 
be discussed with the clinician(s). Clinical input was then used in both case studies to verify 
and develop model pathways, with the NICE guidelines additionally being drawn on by the 
team in Case Study A.  
Much of structural development in both case studies focused on gaining clinician opinion and 
feedback on model pathways. In Case Study A this input came from just one clinician, whilst 
up to twenty clinicians were involved in discussions of model structure in Case Study B. 
Modellers’ discussions with clinicians addressed similar structural issues; however, clinician 
opinion was sought in different ways. In Case Study A modellers asked the single clinician to 
talk through and clarify all patient pathways, whilst Case Study B modellers concentrated on 
asking questions on specific aspects of structure.  
Both teams of modellers developed the structure prior to using the data that would populate 
the model, with the impression from both case studies being that the structure would be biased 
if it were to be based on this data. For this reason, the team in Case Study B decided on the 
boundaries of the structure prior to knowing the data available. In Case Study A, structural 
boundaries were applied iteratively, with modellers, for example, excluding groups of patients 
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as model development progressed. However, these boundaries were applied rather 
inconsistently, as the modellers varied their definitions of what they considered to be a non-
typical patient.  
The approach to communication with clinicians differed across the two case studies, as 
modellers in Case Study B encouraged clinical experts to have an influential role in decisions 
around model development. Clinicians were asked to determine model boundaries and discuss 
and validate structural assumptions. This contrasted with Case Study A, in which the clinician 
was permitted little negotiation about, and given limited explanation of, simplifying 
assumptions made. This approach to communication seemed to impact the clinician’s 
understanding and acceptance of the model, as she later reported feeling unhappy with the 
clinical representativeness of the structure.  
Discussions between the clinicians in Case Study B seemed to work well in enhancing the 
generalisability of structure, as variation in clinical practice among the clinicians was 
highlighted. The involvement of only one clinician in immediate structural development in 
Case Study A raised issues around generalisability, as the clinician found it difficult to give a 
representative overview of treatment pathways. In contrast to Case Study B, discussion 
between clinicians could not be used to resolve uncertainty around treatment pathways, or to 
enhance the clinical validity and generalisability of structure. Although a wider group of 
clinical collaborators were involved in Case Study A, these experts were reported to have had 
limited input to pathway plotting.  
The methods used to identify data to populate the models differed according to the context of 
the projects; however, there were similarities in the search strategies employed, as both 
modelling teams attempted systematic or ‘thorough’ searches of the literature to identify 
clinical (effectiveness) and economic data. General searches were used in Case Study B to 
find clinical probabilities, with the main modeller commenting that the team did not have the 
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time and resources to conduct systematic searches for all parameters. The teams encountered 
similar problems in being unable to find appropriate utility values for their models, and as a 
result incorporated a similar assumption that patients who were not cured of their conditions 
would maintain their initial quality of life for the entire model. Cost data were identified 
through NICE reference costs in both processes, with the clinicians in Case Study B 
criticising this resource, implying that cost figures were not specific enough.  
Most model checking within both case studies focused on sensitivity analysis, with internal 
validation also carried out. External validation was undertaken in Case Study B, but not in 
Case Study A due to a reported lack of relevant economic studies. In both case studies, 
limited or no structural checking was undertaken outside of clinicians’ structural validation. 
The modellers in Case Study A discussed undertaking various structural sensitivity analyses, 
but only eventually tested one alternative structural scenario. In Case Study B, the senior 
modeller stated that alternative structural checks should have been carried out, but were not, 
due to their complexity.  
When the results of the models were presented to the clinician(s), both case studies 
encountered problems with the clinicians’ understanding and acceptance of the outcome. In 
both cases, this appeared to be connected to problems with communication between modellers 
and clinicians. In Case Study A, the clinician expressed dissatisfaction over the results, stating 
that the outcome was not as she was expecting. Although this appeared partly due to the 
clinician’s preference for a particular result, factors pertaining to the modellers’ lack of 
negotiation with the clinician over important structural decisions, and the clinician’s lack of 
understanding of the model and its development throughout, may have contributed to her 
inability to accept and perhaps also anticipate the model results. When the preliminary results 
were presented to the clinical experts in Case Study B, the clinicians questioned pathways 
included in the model, and it became apparent that there had been a lack of explicit agreement 
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between clinicians on an important structural assumption. Although the clinicians had 
discussed the validity of this assumption during structural development, there was outstanding 
disagreement between them, with the modellers eventually making the final decision on what 
was included in the model. This issue would have likely been avoided if the modellers had 
encouraged clinicians to come to an agreement on this assumption earlier on in model 
development.  
Clinician understanding of model development was an overarching issue in the two case 
studies. Both sets of clinicians struggled to follow model development, and there was 
evidence in both case studies that a lack of understanding about what was important to include 
in the structure hindered discussions around pathway plotting. In Case Study A, there were 
examples of the clinician asking to include rare patient pathways, with the main modeller later 
implying that structural development would have been more straightforward if the clinician 
had been more aware of the information that was important to model. The Case Study B 
clinicians struggled to understand the inclusion of economic components in the structure, 
specifically the aspects that were considered by the modellers to have the potential to 
demonstrate the comparative cost-effectiveness of strategies. The main modeller from Case 
Study B later reflected that using conceptual modelling methods, and developing the structure 
in conjunction with clinicians, would have enhanced the clinicians’ ability to understand the 
model. An additional problem with clinician understanding in both case studies concerned 
confusion among the clinicians over the research and economic terminology used during 
discussions. 
Whilst clinician training formed the initial stage of model development in Case Study B, the 
modellers and clinicians in Case Study A were divided about its value. The clinician from 
Case Study A introduced the idea of clinician guidance without any prompt from the author, 
stating that it would have been beneficial to have had some background information on how 
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model development worked, so that she was aware of what she was expected to contribute. 
The main modeller had a similar view that it would be useful to provide clinicians with an 
understanding of what information was important to communicate during pathway plotting. 
However, the senior modeller argued that it was not the modellers’ responsibility to provide 
training for the clinician, suggesting that this was unnecessary and too resource intensive.  
7.4 Synthesis of findings from the different aspects of the research 
A number of similar overarching themes were raised across the two phases of the qualitative 
research. These were issues around structural development, clinician involvement and the lack 
of time and resources available to model.  
The findings collectively demonstrated that modellers followed similar stages in their 
modelling processes, but used different methods for structural development. Informants 
discussed, and/or were observed, using a variety of sources to inform structure, including 
clinician opinion, other model structures, NICE guidelines, and clinical data. This called into 
question whether there needs to be an agreed hierarchy of sources for informing model 
structure. Within the case studies, modellers used diverse methods to determine structural 
boundaries, with the Case Study A modellers applying restrictions iteratively during pathway 
plotting, and those involved in Case Study B agreeing on boundaries prior to model 
development. Arguably, the latter practice appeared more robust, as inconsistent criteria 
appeared to be used in Case Study A to exclude patient groups from the model. Modellers 
across both phases of the research drafted their structures differently. Interview informants 
were split as to whether they produced an initial draft of the structure in conjunction with 
clinical experts, or they first developed a structure alone, to later receive clinician validation. 
Both case studies used the latter method, although they undertook different approaches to 
discussing the initial draft with clinicians. Despite the different approaches taken, most 
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modellers engaged in a number of stages of planning before software programming, 
suggesting that model conceptualisation prior to implementation was important. 
A final structural issue identified in both phases of the research was the generalisability of 
model structures. Many interview informants commented that involving too few clinicians in 
pathway plotting would bias the structure, but typically included two or even fewer clinicians 
in their processes, and did not discuss recruiting clinicians from diverse locations. The 
involvement of only one clinician in immediate structural development within Case Study A 
was problematic, as it was unclear how typical the practices of this clinician were in relation 
to other clinical centres. In Case Study B, there were numerous differences in the treatment 
pathways followed by the clinicians involved, which led to discussions among the clinical 
experts to determine the most representative practices to include in the model. This raised 
questions around whether good practice should constitute the involvement of a minimum 
number of clinicians, purposively selected to cover a variety of contexts. 
Clinician involvement was a major theme of the research, with the importance of the 
clinicians’ role in pathway plotting being highlighted initially in the qualitative interviews, 
and explored further within the case studies. However, clinician involvement was presented 
and observed as problematic within both phases, particularly in terms of clinician engagement 
in the process, and communication between modellers and clinical experts. Interview 
informants referred to experiences of working with clinicians who had a negative attitude 
towards cost-effectiveness modelling, and those who struggled to understand the importance 
of communicating the pathway of an average patient during structural development. The case 
study research identified similar issues, with clinicians in both case studies having difficulty 
understanding and accepting the developed models. However, observations made within the 
case studies suggested that more could have been done to aid clinician understanding. In Case 
Study A, the clinician was given very little direction from the modellers regarding what 
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information was important to communicate and include in structural development, and in 
Case Study B, clinicians were not given an overview of how the structure was developed, and 
why particular elements had been included. This raised questions as to whether modellers 
should be approaching structural development differently, perhaps involving clinicians in the 
initial conceptualisation of a model, and offering clinicians training as a standard element of 
the modelling process.  
Observation and insight into communication between modellers and clinicians indicated that 
modellers held different views on the role that clinicians should have in model development. 
The majority of qualitative interview informants gave the impression that clinician input was 
important to structural development, but that it was the modeller who had the final say over 
what was included in the structure. The role of the clinicians differed in the two case studies, 
with a greater role for the group in Case Study B. The modellers limited negotiation with the 
clinician in Case Study A appeared problematic, which raised questions around how 
communication and decision-making should work between modellers and clinicians in model 
development.  
The issue of the time and resources available to undertake modelling was emphasised in both 
phases of the research. During interviews, modellers suggested that they did not have the 
capacity to carry out external validation and structural checking, or systematic searches for 
economic data. The case study research similarly found that data inputs were not from 
systematic searches, although this was mostly as a result of a lack of available data, 
particularly on quality of life. On this note, further consideration may be required as to the 
impact of structural assumptions made in both processes due to the lack of available utility 
data. As with the interviews, model checking in the case studies focused on internal 
validation, as both sets of modellers carried out limited structural checking, and external 
validation was not undertaken in Case Study A. These findings raise questions around 
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whether modellers are prioritising the most important aspects of model development in the 
face of limited resources. In Case Study B, clinicians questioned the accuracy of NHS 
reference costs, suggesting that it may be important to consider whether existing and 
commonly used data sources are sufficient for model development. 
7.5 Findings compared to existing literature 
The systematic review undertaken in chapter 3 demonstrated that there was a limited number 
of papers that had used qualitative research to understand methodological issues within 
decision-analytic modelling. Of these, only two studies focused on exploring the entire 
model-building process (Chilcott et al., 2010; Squires, 2014).  
The findings generated within this thesis both contribute and differ to those reported in other 
qualitative studies. Similar to this research, Chilcott et al. (2010) and Squires (2014) found 
that modellers were using different methods to one another in the development of their model 
structures. Chilcott et al., (2010) noted that modelling practice varied in terms of how far 
modellers planned and conceptualised a structure prior to software implementation, and 
Squires (2014) observed that modellers had different approaches to deciding which factors 
should be represented within the structure of a public health model. The findings of these 
studies, and of this thesis, may also potentially be related to the outcome of the systematic 
review presented in chapter 2, which found that there was little detailed guidance available for 
modellers on how to plan and develop model structures.  
A major concern of a number of the qualitative papers therefore was the lack of a standard 
and explicit model conceptualisation stage within modelling processes (Chilcott et al., 2010; 
Kaltenthaler et al., 2011; Squires, 2014). This thesis has similarly highlighted a number of 
arguments in favour of using conceptual modelling methods. The thesis finds reasons in 
support of those given for conceptual modelling in the other qualitative studies, specifically 
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that the use of conceptual modelling methods can enhance the validity and credibility of a 
model, and improve communication and understanding of model development between the 
parties involved (Chilcott et al., 2010; Kaltenthaler et al., 2011; Squires, 2014). However, as a 
result of the exploration of communication between modellers and clinicians, the findings of 
this research additionally suggest that conceptual modelling techniques are important in the 
engagement of clinicians in model development. The research found that clinicians lacked 
understanding and acceptance of models and model results, perhaps in part due to their lack of 
involvement in model conceptualisation and decisions around model structure. Further 
discussion and recommendations around the use of conceptual modelling methods are given 
in section 7.6.1. 
An additional finding of this research present in other qualitative papers was the 
acknowledgement of time and resource constraints on model development. A number of 
qualitative studies also reported that a lack of time and resources were limiting the practices 
of modellers, as Kaltenthaler et al. (2013) and Kaltenthaler et al. (2014) suggested that 
modellers were using ‘rapid review methods’ rather than systematic searches to identify 
evidence for model parameters. Squires (2014) found that the complexity of a structure was 
dependent on how much time a modeller had, and Chilcott et al. (2010) reported that 
modellers were not carrying out more complicated model checking activities, such as 
reprogramming and structural sensitivity analysis. Most of these papers gave the impression 
that time and resource restrictions, and their effect on the practices undertaken by modellers, 
were an inevitable aspect of model development. However, similar to the conclusions drawn 
from this research, Chilcott et al. (2010) questioned whether modellers were prioritising the 
most appropriate modelling activities in the time available. This thesis has provided insight 
into why modellers are using less robust practices, with modellers either perceiving particular 
tasks to be too complex, or being unable to find appropriate evidence for the model. 
    
256 
 
Discussion and recommendations around the lack of time and resources available in model 
development are given in section 7.6.3. 
This research has made an original contribution in relation to its exploration of the 
involvement of clinicians in model development. Other qualitative studies commented 
relatively little on the role of clinical experts, and none involved clinicians directly in their 
research. Additionally, the systematic review of modelling guidance found that that there was 
very little guidance available on the role of clinicians in the modelling process, particularly on 
how modellers should communicate with clinicians, and how many clinicians should be 
involved in model development. Most qualitative papers that mentioned clinicians, referred to 
their input very briefly, in stating that their input was important to structural development and 
model checking, and also that it was beneficial to have their contribution to the modelling 
process early on (Kaltenthaler et al., 2014, 2013, 2011). Chilcott et al. (2010) and Squires 
(2014) expanded on this, emphasising the advantages of using conceptual modelling methods 
as a means of facilitating communication with clinicians in structural development. However, 
the observation of communication between modellers and clinicians in this research has 
permitted new insights into what worked well, and arguably not as well, in terms of clinician 
input to structural development. Further, the observations and interviews with clinicians and 
modellers identified problems related to clinician understanding of model building, and 
generated suggestions around the potential benefits of including clinician training as a 
standard element of the modelling process. Recommendations on communication and training 
for clinicians are given in section 7.6.2.2. 
Another important finding of this research was that modellers may be involving too few 
clinicians in model development. Again, few of the other qualitative papers discussed the 
appropriate number of clinical experts to include in the modelling process, and of those that 
did, recommendations seemed vague or impractical. Chilcott et al. (2010) noted that several 
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of the modellers interviewed demonstrated a preference for involving multiple clinical 
experts, and Squires (2014) suggested that involving as many stakeholders as possible 
(including clinicians) in the development of public health models was optimal. The latter 
recommendation raises questions around how feasible it is to attempt to recruit ‘as many 
experts as possible’ within a time and resource constrained environment. Discussion and 
recommendations around numbers of clinicians are given in section 7.6.2.1.  
7.6 Implications of the findings for model building practice 
The objective of the research was to make recommendations for improvements to model 
development, and highlight where future research was required to encourage good practice in 
modelling processes. The aim was not to provide prescriptive or all-encompassing 
recommendations for improvements to current modelling methods, but to consider whether 
conclusions can be drawn from the research that can assist modellers in their practices. 
Although this research has involved both a broad assessment of perceptions, and a detailed in-
depth analysis of the processes used to develop decision-analytic models, the findings will not 
be representative of the practices of all modelling teams, and it is likely that further primary 
research would highlight alternative perspectives on optimum methods and approaches to 
model development. However, inferences can be drawn about which practices appeared better 
within the processes that were observed, and according to the informants’ opinions. The next 
sections consider the implications of the findings for structural development, for clinician 
involvement, for the lack of time and resources available in model development, and for 
future modelling guidance. 
7.6.1 Implications for structural development 
Both phases of the research have demonstrated that modellers and modelling teams are using 
different methods and approaches to developing their model structures. Recommendations 
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made as a result of the research concern the use of conceptual modelling methods, and offers 
a suggested hierarchy of sources to inform model structure.  
7.6.1.1 Model conceptualisation: planning the structure and determining model boundaries  
The differences in the structural development methods used by informants, in addition to their 
reflections on the different approaches to drafting the structure, have given some indication of 
what might be considered good practice in this aspect of model building.  
First, the majority of informants engaged in some form of structural planning, producing 
model specification documents and/or early diagrams of model structure, indicating that this 
was a standard and good practice element of model development. Informants reflected that 
these documents and diagrams were important in facilitating the discussion of a model 
between modellers and clinicians, to assist understanding of what a structure encompasses and 
to gain clinician agreement on a proposed structure. 
Second, gaining input from clinicians early on in the modelling process was perceived as 
good practice, as the majority of informants involved clinicians from the outset of structural 
development. The few interview informants who did not reflected on this as being poor or 
unusual practice. However, modellers followed different practices in terms of whether they 
drafted an initial structure in conjunction with clinical experts, or developed a structural 
diagram first, to be validated by clinicians. To suggest which of these approaches constitutes 
better practice is difficult, as informants discussed the advantages of having an initial 
structural diagram, but the case studies suggested that clinicians struggled to understand and 
engage in model development because they had not been involved in initial model 
conceptualisation and structural decision-making. For the benefits associated with both 
approaches, modellers could, prior to their first meeting with clinicians, draft a broad outline 
of their understanding of what happens to a patient with a particular disease, and discuss each 
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aspect thoroughly with the clinical experts, to further develop the structure according to the 
clinicians’ knowledge and experiences. This is largely similar to the practice undertaken in 
Case Study A.    
Third, the modelling teams in the case studies took different approaches to determining 
structural boundaries. In Case Study A, applying boundaries to the model as structural 
development progressed highlighted inconsistency in practice, as the modellers applied 
contradictory criteria to exclude patients from the model. This inconsistency has potentially 
undermined the model’s quality, as the modellers would have difficulty justifying their 
decision to exclude larger patient groups, but keep smaller patient numbers in the model. 
Arguably, it would have enhanced the credibility of the process if modellers had determined 
the proportion of patients that they considered to be exceptional in advance of model 
development. It is thus recommended that model boundaries are defined at the outset of the 
modelling process, as was observed in Case Study B, to avoid opportunities for, and 
accusations of, bias and lack of rigour.  
Finally, the modellers in the qualitative interviews were found to be using and prioritising 
different information in the development of structure. This referred particularly to the divide 
between the academic informants who stated that they structured their models to reflect 
patients’ experience of a disease, and non-academic consultancy informants who suggested 
that they developed a model to include the pathways and health states that were most 
important to a patient. Clearly, there is subjectivity in how modellers choose to build their 
models, and this is not necessarily poor practice; however, it can lead to modellers generating 
different cost-effectiveness results for similar decision problems. As a result, it seems 
important to recommend that modellers acknowledge the effect that decisions around 
structure can have on the outcomes of their models.  
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To incorporate these good practice recommendations, this research advocates the use of 
model conceptualisation methods. Conceptual modelling involves the separation of the 
problem-orientated model from the design-orientated model, as all factors potentially relevant 
to a decision problem are understood and represented in a conceptual diagram, prior to the 
development of the structure that will directly inform a cost-effectiveness recommendation 
(Kaltenthaler et al., 2011). The process of development from the problem-orientated model to 
the design-orientated model is documented, and the conceptualisation of the problem-
orientated model, and decisions around the boundaries of a design-orientated model, are made 
in conjunction with clinical experts (Kaltenthaler et al., 2011). In line with the 
recommendations of this research, conceptual modelling methods thus facilitate the 
involvement of clinicians from the beginning of structural development, and require model 
boundaries to be determined explicitly, and at the outset of the development of the design-
orientated model. Further, conceptual modelling necessitates that modellers are transparent 
about how they decide what to include in model structure, and the comparison of the problem-
orientated and design-orientated model facilitates discussion around the impact of the 
exclusion of particular patient groups, pathways and health states from the final model 
(Kaltenthaler et al., 2011). Using conceptual methods, modellers can therefore continue to 
develop structures on the basis of the information that they perceive to be important, but 
should be open about how what has been included in and excluded from the structure, may 
influence model results. Modellers should read existing guidance on conceptual modelling 
methods (Kaltenthaler et al., 2011; Roberts et al., 2012; Squires, 2014). 
7.6.1.2 Basis of structure 
The majority of informants across both stages of the research suggested that the pathways or 
health states within a model should represent a patient’s experience of a disease. Informants 
indicated that knowledge of a particular clinical condition to inform model structure was 
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generated through familiarisation with the clinical literature and discussions with clinicians. 
In terms of poor practice, many modellers were of the opinion that the evidence used to 
populate the model should not influence structural planning. Despite this, there was a fairly 
large group of Canadian modellers from the qualitative interviews, who stated that they 
developed their structures based on available data. With clear opinions from informants on the 
appropriateness of competing sources to inform model structure, but notable inconsistency in 
practice, this research has generated a suggested hierarchy of sources for structural 
development, similar to those that rank the validity of clinical evidence (Evans, 2003). A 
diagram of a suggested hierarchy of sources to inform model structure is given in Figure 7. 
At the top of this hierarchy, as observed in the practice of the majority of informants, is the 
use of clinical literature and clinician experience to inform model structure. Second in the 
hierarchy are the NICE guidelines, which modellers in the UK can use to gain knowledge on 
treatments that patients receive within current practice. To promote consistency, it is 
suggested that modellers avoid using clinician input and the NICE guidelines interchangeably, 
as was observed in Case Study A. It is instead recommended that modellers use the NICE 
guidelines in support of clinicians’ versions of patient treatment pathways, and where the 
NICE guidelines suggest alternative pathways, test the impact of these in a structural 
sensitivity analysis. This approach should generate a more representative model, and valid 
cost-effectiveness recommendation, as the primary model is developed, and results calculated, 
on the basis of what is happening in actual clinical practice.  
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Figure 7: A suggested hierarchy of sources to inform model structure 
 
Informants in both stages of the research discussed using existing models to inform their own 
model structures; however, informants were split as to how much influence existing structures 
had. The majority of interview informants used other structures as an inspiration rather than a 
basis for their models, but the modellers in Case Study B, for example, drafted the first 
version of their model entirely on previous work. Given this difference in methods, and thus 
the lack of clarity regarding what constitutes best practice, it is recommended that, rather than 
basing new models on existing structures, modellers use others’ models to validate and justify 
decisions in structures that they have already drafted. If, as a result, modellers felt that they 
were missing important information from their model design, they could add to their 
structures accordingly. These methods will prevent new models being developed wholly on 
the basis of existing structures that may be outdated, be of poor quality and/or contain 
methodological errors. 
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Finally, the clinical data being used to populate the data parameters in a model should only be 
referred to after a structure has been developed. Developing a structure on the basis of 
available data was seen by informants as having the potential to bias a model result, as 
modellers could become aware of how including certain elements in the structure would 
impact the model outcome. Basing a model on only the data available will also likely lead to 
important components of a decision problem being absent from a structure. The sentiment 
from the majority of informants was that a structure should be developed initially on the basis 
of clinician experience, and structural and/or data assumptions should be made later in the 
process if data are unavailable to populate existing parameters.  
7.6.2 Implications for clinician involvement  
A number of problems were highlighted with clinician involvement in the modelling process. 
These specifically referred to the generalisability of model structures, the number of clinicians 
involved in structural development, and clinicians’ lack of acceptance and understanding of 
modelling, seemingly related to communication between modellers and clinicians. The 
implications of these issues for modelling practice are considered next. 
7.6.2.1 Number of clinicians  
The findings of this research suggested that some modellers were involving too few clinicians 
in their processes; however, there was no indication from the research as to an ideal number 
of clinical experts to include. There were clear advantages to involving a large and diverse 
group of clinicians in the modelling process, as demonstrated within Case Study B. This was 
as discussions between clinicians could be used to resolve uncertainty and increase the 
representativeness of structural pathways, in addition to the validity and generalisability of the 
model. However, there are practical implications associated with involving greater numbers of 
clinicians in model development, including difficulties with managing discussion between 
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large groups, and recruiting (additional) clinical experts to a project. Arguably, the former can 
be addressed through greater facilitation from modellers within clinical meetings; however, 
the latter needs further consideration, particularly given clinicians’ busy workloads. In the 
face of difficulty in involving larger numbers of clinicians in model development, it may be 
more efficient to recommend that recruiters strive to include a purposive sample with 
maximum variation, as sometimes advocated within qualitative research, thinking about all of 
those that can give a knowledgeable but potentially different perspective on the same issue 
(Merkens, 2004).  
7.6.2.2 Communication and training for clinicians   
The direct observation of meetings and discussions within the case studies, and the in-depth 
interviews undertaken with modellers, provided detailed insight into communication between 
modellers and clinicians. In terms of what worked well, face-to-face meetings, and the use of 
visual methods, such as diagrams of model structure, were reported as useful for engaging 
clinicians and enhancing their understanding. Likewise, discussions between clinicians, and 
the ability to have their questions answered by modellers, helped clinical experts to overcome 
difficulties with their interpretations. However, the findings highlighted a number of problems 
with how communication was facilitated in model development, and the clinicians’ lack of 
understanding and acceptance of modelling.  
To address these problems, conceptual modelling methods are again recommended to 
facilitate communication and the engagement of clinicians in the modelling process. As both 
sets of clinicians in the case studies struggled to follow model development, it was suggested 
by the clinicians and modellers that greater clinician involvement in designing the model 
would have improved clinicians’ understanding, and thus made structural development easier 
for both parties. Further, conceptual modelling facilitates the involvement of clinicians in 
determining the boundaries of structure, providing that clinicians’ have input both to the 
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problem-orientated and design-orientated model. Modellers in both phases of the research 
involved clinicians in structural decision-making to different extents, but the observation of 
communication, and the interview with the clinician in Case Study A, suggested that this 
clinician struggled to engage with the model because she had been permitted limited 
negotiation over what was included and excluded from the structure. For reasons around 
clinician engagement, and given the emphasis in both phases of the research on the 
importance of clinical experts offering sign-off on the clinical validity of a model, it seems 
essential that clinicians are involved in all decisions around structure. To facilitate this, 
clinicians can be offered training in model building, to teach them about the information that 
is important to represent in a cost-effectiveness model, and to provide them with the capacity 
to discuss and negotiate with modellers over structural inputs. 
7.6.2.2.1 Clinician training 
The suggestion that clinician training could be used to increase clinician understanding and 
engagement in the modelling process was made within both phases of the research by both 
modellers and clinicians, and was also an established aspect of model development in Case 
Study B. The usefulness of clinician guidance was mostly mentioned in relation to problems 
around communication between modellers and clinicians, as modellers suggested that it 
would be advantageous for clinicians to know what information was important to contribute 
to discussions. The clinicians also gave the impression that they had difficulty following and 
engaging with model development due to a lack of understanding of how a model was put 
together. The potential benefits of offering clinicians training are that clinicians may be more 
trusting of, and engaged in, model development, and have a greater understanding about what 
they need to contribute, leading to model development being carried out more efficiently. The 
recommendations for guidance for clinicians that emerged from both phases of the research 
were: 
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 An outline of what health economics is, why cost-effectiveness models are needed, 
and how models work, for example, how they synthesise cost and effectiveness 
information 
 An outline of the typical stages involved in model development, for example, through 
a diagram of the modelling process 
 The information that is important to a model in terms of the cost-effectiveness result, 
for example, the structure needs to be based on the clinical pathways of the average 
patient, rather than very rare clinical pathways, but also needs to include potentially 
important economic events 
 Why assumptions need to be made and what is their potential impact (as outlined in 
the training for clinicians in Case Study B) 
 A ‘dictionary of terms’ that gives definitions of the economic and research 
terminology commonly used in model development.  
However, there was some resistance from informants regarding the introduction of clinician 
training to the modelling process. While some questioned the practicality of offering guidance 
to all clinicians because of time and resource constraints, others queried the likelihood of 
clinicians committing to undertaking training. The research findings have demonstrated that 
the clinicians interviewed were keen to receive some form of training, but that this training 
needed to be flexible. There were suggestions from the clinician informants that initial 
training sessions could be available online for them to access at their leisure. It was also 
suggested that training be offered throughout the process, for example, by reminding 
clinicians of the important information to include in a structure prior to structural discussions, 
and by developing a document of economic and research terminology that clinicians can refer 
to within meetings. Further, it may be most effective to develop ‘universal’ training for 
clinicians that could potentially be used within any modelling process, to prevent modellers 
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from having to spend time preparing training material for every model’s development. Future 
research should focus on developing training and guidance material that is accessible, and that 
will facilitate model building for both modellers and clinicians. 
7.6.3 Implications of a lack of time and resources for model development 
Modellers in both phases of the research discussed being unable to undertake particular 
aspects or stages of model development due to a lack of time and resources. The modellers 
typically prioritised structural development, internal validation and sensitivity analysis on 
their models, and were less likely to carry out systematic reviewing for economic data 
parameters, external validation, and structural checking of the model. Further, modellers 
within the qualitative interviews gave the impression that they had to weigh up the benefits of 
carrying out additional modelling activities against the costs associated, and how far 
undertaking the task was likely to improve the quality of a model. The tasks that modellers 
were least likely to carry out thus appeared to be those that they perceived as the most 
difficult and/or time consuming. The implication of these findings is that modellers would 
benefit from an increase in the time and resource available for model development, however, 
given that this is unlikely to be feasible, future research should focus on exploring whether 
modellers are prioritising the aspects of model building that are the most important to the 
validity and robustness of a model. 
Modelling practices were also limited by the data available. In the case study research, 
modellers discussed attempting to carry out good practice methods, for example, systematic 
searches for clinical and economic data, but finding no suitable evidence. This particularly 
applied to long-term quality of life data, with both sets of modellers having to make structural 
assumptions to account for this, specifically that patients who were not cured of their 
conditions maintained their initial quality of life for the entire model. As an area for further 
research it would be interesting to look at how commonly this assumption is made in 
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modelling, and whether it is, in general, consistent with clinical reality. Further, it seems 
important to raise awareness within the health economics and wider academic community 
regarding the shortage of relevant evidence, particularly long-term quality of life data, and 
whether this can somehow be considered and addressed within future research studies.  
Finally, a number of modellers questioned the validity of, and level of detail offered within, 
traditional data sources for decision-analytic models, specifically the use of NHS reference 
costs. An alternative would be for modellers to use ‘bottom-up’ or micro costing methods, 
which require primary data collection, and the identification of costs and resource use at the 
unit level i.e. for individual patients (Morris et al., 2007). However, the micro costing 
approach is time consuming and resource intensive, and thus the benefits of its use in model 
development will again need to be considered against the importance of carrying out other 
modelling activities.  
7.6.4 Exploration and documentation of the practices of modellers  
Alongside the objective to highlight issues and problems being encountered within model 
development, this research has sought to explore and provide accounts of the current 
processes and methods used by modellers. The systematic review in chapter 2 found that 
current guidance on model building was generally lacking in detail, and particular aspects of 
the process were missing from the advice given, including methods for translating clinical and 
economic information into a model structure, and how to involve clinical experts in model 
development. In response, this thesis has presented an in-depth insight into how modellers 
carry out these, and other aspects of model development, which in the face of limited 
methodological guidance, could provide a useful resource for modellers. Those looking for an 
accompaniment to model building could potentially use informants’ accounts of their 
methods, particularly for advice on what each stage of the process typically encompasses, 
what modellers perceived as good and poor practice, and the problems that they may 
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encounter. The think-aloud and observations undertaken of modelling processes in the case 
studies have also allowed for the documentation of the more nuanced aspects of model 
development, such as the techniques modellers used to communicate with clinicians over 
model pathways, and how modellers might interpret the results of sensitivity analyses.  
Rather than offering prescriptive guidance and/or a summary of recommendations, a useful 
output of qualitative research into model building may be ‘guidance’ in the form of the 
reporting and/or a synthesis of model development processes, with some analysis and 
reflection from the researcher as to what appears to be good practice, and what common 
problems are. The benefit of this is that the level of detail captured on the modelling methods 
discussed and/or observed can be maintained as a resource for the reader. This case-study 
style guidance is likely to be valuable to anyone who is new to modelling, and who requires a 
thorough overview and insight into how the stages of model development work. Equally, this 
format may be more appealing to those who are experienced in modelling, providing a means 
for these modellers to compare and assess their processes against those of others. This is 
given that many of the senior modellers interviewed in the first phase of the research 
suggested that they did not (need to) use modelling guidance. However, the practicality of 
publishing such an in-depth and detailed resource would require further consideration. 
The idea that modellers can potentially learn from the documentation of others’ processes 
suggests that it would also be beneficial for modellers to provide a more in-depth write-up of 
their methods, particularly on the aspects that are missing or lacking in detail within current 
guidance. This would be a useful and straightforward way for modellers to share and reflect 
on their modelling processes, and facilitate discussions around good practice, and the 
constructive criticism of the methods that modellers are using. Again, the practicalities of this 
would need consideration, given the restricted word limit of journals and other publications; 
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however, the creation of a separate online forum for modellers to share their methods is a 
potential starting point.  
7.7 Future research 
The findings of the qualitative research undertaken within this thesis have given rise to 
recommendations for future work. These include how to involve greater numbers of clinicians 
in model development, developing clinician training and guidance material, ascertaining 
which aspects of model development should be prioritised, and the practicalities of how 
detailed guidance on modelling processes can be shared. These suggestions have largely been 
based on issues that informants have discussed as being important, or which were repeatedly 
observed to be a problem within the modellers’ processes. However, an important 
requirement for the validity of qualitative research is to also pay attention to ‘negative cases’, 
or findings that differ from the main themes that have emerged (Mays and Pope, 2000). An 
example of this was the suggestion by a few informants within the qualitative interviews that 
involving patient representatives in model development, particularly in checking model 
structure, was potentially important. Although patient involvement was carried out very rarely 
within informants’ processes, and discussed by only a few modellers, the suggestion was that 
gaining the input of patients may improve the validity of a model, and thus it is recommended 
that future research explores how patients can be incorporated into everyday modelling 
practice. This avenue for future work also seems key, given the increasing emphasis on 
patient and public involvement within health research and in the development of clinical 
guidelines (INVOLVE 2015; NICE 2015). 
7.8 Reflections on the method 
Having considered how the findings of this thesis both support and add to those of other 
studies, and the implications for modelling practice and future research, this thesis will next 
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reflect on the methods that have been used. This section will consider the appropriateness of 
the research design, including its strengths and limitations, and reflections on the way in 
which the researcher, and the approach taken, may have impacted on the research findings. A 
full description of the methods used within this research is available in chapter 4. 
The first phase of the research was qualitative interviews with modellers from various 
backgrounds, whilst the second phase involved two case studies with teams of modellers and 
clinicians, using semi-structured interviews, non-participant observation and think-aloud as 
methods of data collection. A clear strength of this approach was the level and breadth of 
detail that the combination of these methods were able to capture, thus allowing a thorough 
understanding of how model development was being undertaken, and what the common 
problems were within the modelling process. These rich insights have enabled 
recommendations to be made for modelling practice on the basis of considerable evidence, 
and permitted the in-depth documentation of informants’ modelling activities, which could 
provide a valuable resource for modellers. In addition, the detailed presentation of the data 
collected within the thesis, and the analysis and interpretations that the researcher made as a 
result, are important requirements for demonstrating rigour in qualitative research, in allowing 
others to see how important themes, and the conclusions of the research were generated (Pope 
and Mays, 1995). 
An in-depth and exploratory approach to research was taken to enhance the validity of the 
research findings. The research was designed to facilitate a broad and deep understanding of 
model development and the issues associated, through information on, and exposure to, as 
many aspects of the modelling process as possible. Thus, the qualitative interviews 
undertaken in the first phase of the research were face-to-face and flexible, to allow rapport to 
be established between the researcher and modellers, and to encourage informants to speak at 
length about their modelling experiences and the issues that they felt to be important. In both 
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case studies, the aim was to gather data on all stages of model development, and thus all email 
correspondence, documents and meetings between modellers and clinicians were observed. 
The use of observation allowed the communication between modellers and clinicians to be 
studied, which provided an original insight into how their discussions contributed to model 
development, and highlighted a number of problems with the way in which communication 
was managed. In Case Study A, the novel method of think-aloud was additionally used to 
generate data on tasks that modellers worked on independently, specifically the interpretation 
of sensitivity analyses.  
However, a limitation of the case study research was that the researcher was unable to observe 
all aspects of model development within the two processes, particularly stages that the 
modellers undertook individually. Although attempts were made by the researcher to be 
present for these modelling activities, this proved difficult, as individual tasks tended not to be 
pre-planned. This was particularly an issue within Case Study B, as the modellers were 
involved in multiple model-based projects, and thus were unable to specify in advance when 
they would be working on a particular project and activity. Due to time constraints, the 
modellers tended to carry out stages of the process in a fragmented and ad-hoc manner, and as 
a result, think-aloud was not used within Case Study B, as the method requires that an 
informant invests time in verbalising their thought processes whilst completing a task (van 
Someran et al., 1994). The impact of observing mostly planned modelling activities was that 
more in-depth data were collected for particular stages of the modelling process, specifically 
for structural development, which involved regular meetings between modellers and 
clinicians. However, the qualitative interviews undertaken with modellers in the case studies 
allowed for the detailed exploration of the stages that could not be observed, through in-depth 
discussion of the methods used.  
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The triangulation of different qualitative methods was a further strength of this research. This 
is in relation to the combination of methods used within the case studies, and across the two 
phases of the empirical work. The use of non-participant observation in addition to the 
qualitative interviews in the case studies allowed the researcher to question the informants on 
what was observed, to gain their reflections on the methods used, and an impression of what 
they considered to be good and poor practice. Additionally, it was possible to relate 
informants’ comments during interviews to the observations of what had occurred within 
actual modelling practice, offering context to, and possible explanation for, informants’ 
perspectives. For example, in Case Study A, the clinician stated that she was unhappy with 
the representativeness of the model, and on review of the discussions between the modellers 
and clinician, it became apparent that this disapproval was likely to be connected to her lack 
of involvement in structural decision-making. The additional use of observational methods 
therefore allowed inferences to be made about why issues were occurring, which facilitated 
considerations around how problems could be addressed.  
In terms of the overall research, the combination of interview and observational based 
methods has enhanced the breadth and validity of findings, as the case studies were able to 
capture data on issues that informants may forget or decide not to discuss during interviews. 
Within the case study phase, more data were collected on problems associated with the 
modelling process, as the modellers interviewed within the first phase of the research tended 
only to discuss issues with other people’s processes in any depth. The triangulation of 
qualitative methods has provided a comprehensive evidence base for the research findings and 
its implications, as the main themes and issues that emerged were corroborated across both 
phases of the empirical work (Mays and Pope, 2000).  
A robust sampling strategy was employed for both phases of the research, as twenty-four 
modellers from different geographical and professional backgrounds were interviewed in 
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phase one, and the case studies were carried out within diverse contexts. The aim was to gain 
a breadth of perspective, but also select informants and case studies that were ‘information-
rich’, and thus able to generate detailed and credible data on model development (Patton, 
2002). A strength of this research was that it went outside of the UK, permitting an 
international perspective, and outside of academia, as around a third of interview informants 
were from policy or consultancy backgrounds, and one of the case studies was undertaken 
within a policy environment. This gives the research an advantage over the qualitative 
modelling studies reviewed in chapter 3, as these mostly concentrated on academic modelling 
processes, and did not involve modellers from other countries. Further, none of the other 
papers included clinical experts in their studies, which has enabled this research to make an 
original contribution in terms of its focus on, and recommendations for, clinician involvement 
in model development. Arguably, this research represents the most extensive qualitative 
analysis of the model-building process undertaken to date, as other studies used relatively 
small sample sizes, and/or did not specify a sampling strategy that was aimed at ensuring that 
findings were transferrable across modelling teams and processes. The broad sampling 
strategy adopted within this research has enhanced the generalisability and transferability of 
its conclusions, as the recommendations have been generated across a number of different 
contexts (Firestone, 1993; Krefting, 1991).  
A possible criticism of the case study research, however, is that further insights and 
potentially different processes and issues may have been highlighted if additional case studies 
had been carried out. For example, both case studies followed the development of decision 
tree models, meaning that some of the explanation of the methods used in model development 
will be specific to this type of structure. Although it would have been advantageous to have 
had the time to undertake a further case study, the research was successful in achieving 
diversity in the case studies selected, which allowed inferences to be made around the benefits 
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and drawbacks of the different approaches used in their model development. Additionally, the 
modelling teams in the case studies were chosen because they were recommended by the 
interview informants as having a good reputation for model building. In terms of the 
generalisability of the research recommendations, it was anticipated that issues present in both 
of these case studies were also likely to be problematic for modellers and modelling teams 
who were less experienced at modelling.  
A rigorous approach was taken to analysis in both stages of the research. All interview 
recordings were transcribed by the researcher verbatim, line-by-line coding of interview 
transcripts was carried out, and analysis was undertaken in conjunction with the research 
supervisors to enhance the thoroughness and reliability of the research findings (Krefting, 
1991; Pope and Mays, 1995). Additionally, grounded theory procedures were drawn on, and 
methods of constant comparison used, for the systematic analysis of data, as all new data were 
compared to the properties of emerging categories to enhance understanding of research 
themes, and increase the validity and sensitivity of the meanings assigned to the data (Kolb, 
2012; Strauss and Corbin, 1990). In the case studies, the framework method was used, with 
the initial stage of analysis requiring the researcher to become ‘immersed’ in the data to 
ensure understanding, and the coding and charting stages providing a detailed and systematic 
process for categorising and comparing case study findings (Gale et al., 2013).  
A strength of the analytical approach undertaken throughout the research was the use of 
inductive reasoning, alongside an exploratory approach to data collection. The use of the 
constant comparison method for the analysis of the qualitative interviews, specifically the 
continual comparison of data, facilitated the emergence of important themes and issues, and 
allowed future sampling and data collection to be aimed at generating a deeper understanding 
of these (Strauss and Corbin, 1990). The use of the framework method for the case study 
analysis then enabled these themes to be explored further using additional exploratory 
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qualitative methods, whilst also permitting new issues to arise. The inductive approach thus 
ensured that rich data were available on the issues most important to the research, as 
discussed by, or observed in, the practices of informants. This enhanced the credibility of the 
research, as findings and recommendations were defined by and closely related to the data 
(Kolb, 2012).  
Finally, reflexivity is an important consideration of qualitative research, in terms of assessing 
how the background and preconceptions of a qualitative researcher affect the process and 
conclusions of a piece of research (Malterud, 2001). Haynes (2012) suggests that a researcher 
should question and be aware of their motivations for undertaking particular research, and 
how any existing assumptions or connections to the topic of study might be impacting on 
empirical practice and findings. As a PhD student undertaking a doctoral project, the research 
had an academic objective, aimed at increasing my own knowledge of modelling practice and 
issues, and contributing to any existing literature around good practice in model building. 
With no previous experience as a health economic modeller, only knowledge gained from a 
Health Economics and Health Policy MSc course, I feel that I had no preconceptions of how 
model development should be undertaken, only a general idea of the stages involved.  
Prior to starting the research, I had some experience of interviewing gained through a 
dissertation undertaken on a previous Master’s course. However, I feel that my interview 
technique improved significantly whilst carrying out the qualitative interviews, as I became 
more confident in forming probing questions and using non-verbal cues, to encourage the 
informants to speak in more depth about particular topics. Further, I felt that it generally 
became easier to establish rapport with informants after I had undertaken a couple of 
interviews, as by then I knew the topic guide well, and so could therefore concentrate on 
listening and developing future questions based on informants’ responses (Rubin and Rubin, 
2005). The implication of this is that as I became more practiced and confident in conducting 
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the interviews, and also in my modelling knowledge, it is likely that richer data were collected 
for informants. Therefore more detailed data may be available for modellers interviewed later 
in the research. 
Finally, it is important to acknowledge that my presence during the observations for the case 
studies may have affected the practices that informants carried out, given that the informants 
were aware that they were being observed. Although informants may have actively engaged 
in more robust practices because of their involvement in the research, the case studies both 
still generated data on problems occurring within model development. 
7.9 Conclusion 
The aim of the research undertaken within this thesis was to explore decision-analytic 
modelling processes, and investigate both good practice, and common problems, in model 
development. This research has made a number of original and important contributions to the 
health economics modelling literature, both methodologically, and in terms of its 
recommendations for future model development and for further research.  
To the author’s knowledge, this research has been the most extensive qualitative exploration 
of the modelling process undertaken to date, making its findings generalisable and useful to 
modellers and model building across different professional and international contexts. The 
research has used a robust and novel combination of qualitative methods, and demonstrated 
the benefits associated with using a qualitative approach to understand issues in model 
development. This thesis therefore provides an established and rigorous methodology for 
those wanting to undertake further research to improve the methods used in modelling 
processes and/or to develop modelling guidance. The research has also expanded on the 
papers available on good practice in the modelling guidance literature, and previous 
    
278 
 
qualitative studies aimed at exploring and identifying issues with decision-analytic model 
development. 
The research contained within this thesis has resulted in findings on, and implications for, 
structural development, clinician involvement, and addressing the lack of time and resources 
available for model building. Outputs include recommendations for the use of model 
conceptualisation methods, the development of a hierarchy of sources to inform model 
structure, and suggestions for future research around improving model data sources, and for 
exploring which modelling activities to prioritise in the face of limited resources. The 
involvement of clinical experts in this research has been particularly novel, and has generated 
a number of recommendations aimed at facilitating and optimising the input of clinicians to 
future model development. These include recommendations around the number of clinicians 
that should be involved in model building, and suggestions for improving communication 
between modellers and clinicians in structural development, specifically through the use of 
model conceptualisation, and the introduction of clinician training to modelling processes. 
The in-depth and detailed exploration of the processes used by modellers has additionally 
provided a resource to guide other modellers in model development, as rich data were 
generated on modelling methods, reflections on good practice, and problems encountered 
during model building.  
The contribution of this research is important in the context of the reliance of organisations 
such as NICE and CADTH on the cost-effectiveness results generated by decision-analytic 
models. The outputs of economic models are used by these organisations to inform decisions 
around the allocation of finite healthcare resources, and therefore there is a requirement for 
these models to be valid, and of good quality, to produce optimum cost-effectiveness 
recommendations. Modellers may also require guidance in their everyday modelling 
practices, to ensure that all models potentially informing healthcare decision-making are 
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developed to a high standard. This thesis has made a substantial contribution to this 
endeavour by generating recommendations for model building practice, aimed at enhancing 
the quality and validity of future models and modelling processes. 
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Appendix 1: Search strategy for the 
systematic review of modelling guidance 
 
1.1 Searching of the Electronic Bibliographic Databases: 
1.1.1 The Cochrane Database of Systematic Reviews:  
This initial search was iterative in that where too few or too many reviews were recovered, the 
search terms and strategy was altered to find more relevant reviews.  
1st August 2012 
Search 1:  
Searched: ‘health economic model building’ (retrieved 2 articles, none of which relevant to 
the proposed research topic) 
Search 2:  
Searched: ‘modelling guidance’ (retrieved 8 articles, none of which were relevant to the 
proposed research topic)  
Search 3:  
Searched: ‘modelling’ (retrieved 15764 articles, the majority of which were likely to be 
irrelevant to the context of the proposed research topic)  
Search 4:  
Searched: ‘modelling’ and then for articles under the subheading ‘methods studies’ (retrieved 
1443 articles, 1of which were deemed relevant to the proposed research topic)  
24th September 2015 
Updated search: Searched: ‘modelling’ and then for articles under the subheading ‘methods 
studies’ (retrieved 1445 articles, 2 of which were deemed relevant to the proposed research 
topic)  
1.1.2 Search of the electronic bibliographic databases for relevant articles:  
The search strategy for each of the electronic bibliographic databases was iterative, as search 
terms were developed to retrieve an optimum number of relevant papers. Only the final 
(original and updated) searches for the MEDLINE® and HMIC databases is documented 
below, although the development of the final search terms followed a similar process to that 
of EMBASE. 
1.1.2.1 Original searches: EMBASE (EMBASE Classic + EMBASE 1947 to 2012 July 
31) 
Search 1: 
1. Health economics or health technology assessment or cost-effectiveness analysis 
2. Model building or modelling process 
3. Guidance or guidelines or best practice or methodology 
4. 1 and 2 and 3. 
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The search returned 16 papers. 
Search 2:  
1. Health economics or health technology assessment or cost-effectiveness analysis 
2. Model building or modelling process 
3. Guidance or guidelines or best practice or methodology or methods or procedures or 
checklist or critical appraisal 
4. 1 and 2 and 3 
The search returned 38 papers. 
Search 3: 
1. Health economics or health technology assessment or cost-effectiveness analysis 
2. Model building or modelling process or decision-analytic modelling or decision-analytical 
modelling 
3. Guidance or guidelines or best practice or methodology or methods or procedures or 
checklist or critical appraisal  
4. 1 and 2 and 3 
The search returned 112 papers. 
Original search of EMBASE returned total of 112 papers. 
1.1.2.2 Updated search: EMBASE (EMBASE Classic + EMBASE 1947 to 2015 
September 24) 
Search 1:  
1. Health economics or health technology assessment or cost-effectiveness analysis 
2.Model building or modelling process or decision-analytic modelling or decision-analytical 
modelling 
3.Guidance or guidelines or best practice or methodology or methods or procedures or 
checklist or critical appraisal  
4. 1 and 2 and 3 
The search returned 144 papers. 
Updated search of EMBASE returned total of 144 papers. 
1.1.2.3 Original searches: Ovid MEDLINE® (1946 to July Week 4)  
Search 1:  
1. Health economics or health technology assessment or cost-effectiveness analysis or 
Economics, Medical 
2. Model building or modelling process or modelling or modelling or decision analysis or 
decision support techniques or model 
3. Guidance or guidelines or practice guideline or best practice or methodology or methods 
or checklist or critical appraisal or modeling methodology 
4. 1 and 2 and 3 
    
283 
 
The search returned 431 papers. 
Search 2:  
The search aimed to identify papers related to Chilcott et al (2010), which was identified in 
MEDLINE.  
The search returned 3 papers. 
Original search of Ovid MEDLINE® returned a total of 434 papers 
1.1.2.4 Updated searches: Ovid MEDLINE® (1946 to July Week 4) 
Search 1:  
1. Health economics or health technology assessment or cost-effectiveness analysis or 
Economics, Medical 
2. Model building or modelling process or modelling or modelling or decision analysis or 
decision support techniques or model 
3. Guidance or guidelines or practice guideline or best practice or methodology or methods 
or checklist or critical appraisal or modeling methodology 
4. 1 and 2 and 3 
The search returned 664 papers. 
Search 2:  
The search aimed to identify papers related to Chilcott et al. (2010) using the Ovid Medline® 
‘find citing articles feature’. 
 
The search returned 3 papers. 
Search 3:  
The search aimed to identify papers related to Philips et al. (2006) using the using the Ovid 
Medline® ‘find citing articles feature’. 
The search returned 39 papers. 
Search 4:  
The search aimed to identify papers related to Roberts et al. (2006) using the using the Ovid 
Medline® ‘find citing articles feature’. 
The search returned 29 papers. 
Updated search of Ovid MEDLINE® returned a total of 735 papers. 
1.1.2.5 Original search of HMIC Health Management Information Consortium (1979 to 
July 2012)  
Search 1: 
1. Health economics or health technology assessment or cost-effectiveness analysis 
2. Model building or modelling process or decision-analytic modelling or modelling or 
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modelling or decision analysis or model 
3. Guidance or guidelines or best practice or methodology or methods or checklist or critical 
appraisal 
4. 1 and 2 and 3 
Original search of HMIC Health Management Information Consortium returned 148 papers. 
1.1.2.6 Updated search of HMIC Health Management Information Consortium (1979 to 
September 2015)  
Search 1: 
1. Health economics or health technology assessment or cost-effectiveness analysis 
2. Model building or modelling process or decision-analytic modelling or modelling or 
modelling or decision analysis or model 
3. Guidance or guidelines or best practice or methodology or methods or checklist or critical 
appraisal 
4. 1 and 2 and 3 
Updated search of HMIC Health Management Information Consortium returned 265 papers. 
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Appendix 2: Data extraction form - 
systematic review of modelling guidance 
Description: 












Type of publication  
 
 
Source of finding 

















Stages referred to: 
Understanding the 




Structuring the model  
 
 
















    
286 
 
Appendix 3: Research protocol for the 
systematic review of modelling guidance 
 
No. Criteria 
1 Review question: 




2 Inclusion criteria: 
Any paper or form of literature that is focused on offering some level of advice 
(i.e. guidance, guidelines, methods, critical appraisal, or checklist) on at least 





Identifying the research evidence 
a) Electronic databases: Cochrane Library (Cochrane Database of 
Systematic Reviews (CDSR)), MEDLINE®, EMBASE and HMIC. 
b) Forward citation searching on key papers within electronic databases 
c) Reviewing reference lists of relevant papers for further relevant key 
papers (systematic)  
d) Searching of published textbooks for relevant information 
e) Searching the NICE and CADTH websites guidance. 
  
4 Potential search terms: 
Health economics, cost-effectiveness analysis, model building, modelling 
process, guidance, guidelines, best practice, critical appraisal, checklist. 




5 Paper selection: 
Paper selection will be based on the inclusion criteria. The initial selection will 
be made based on the title and abstract. The full-text version will be obtained 
for papers that appear to meet the inclusion criteria or avoid the exclusion 
criteria. This also applies where a decision could not be made on the basis of 
the information available in the title and abstract. 
 
  
6 Data extraction: 
Publication information, study characteristics and findings related to the 
research question will be recorded in a data extraction form. 
 
  
7 Synthesis of results: 
Narrative synthesis will be used. 
 
  
8 Exclusion criteria: 
Papers that simply compare different methods for model building are to be 
excluded from the review, as are those that comment only on the mathematical 
construction of decision-analytic models. For practical reasons, the exclusion 
criteria extends to articles published in a language other than English. 
 Miscellaneous  
9 Documenting the searches: 
All of the electronic database searches are documented in Appendix 1. 
10 Protocol modifications: 
Any modifications to the protocol will be recorded in the report. 
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Appendix 4: Search strategy for the 
systematic review of qualitative modelling 
studies 
1.1 Searching of the Electronic Bibliographic Databases: 
1.1.1 The Cochrane Database of Systematic Reviews (Search for title, abstract and 
keywords (searched July 2015)). 
Search 1: Qualitative modelling – returned 11 papers, 0 relevant (Cochrane Database of 
Systematic Reviews: Issue 7 of 12, July 2015) 
Search 2: Qualitative modelling – returned 72 studies, 0 relevant (Cochrane Methodology 
Register: Issue 3 of 4, July 2012) 
Search 3: Qualitative model building – returned 0 studies (Cochrane Database of Systematic 
Reviews: Issue 7 of 12, July 2015) 
Search 4: Qualitative model building – returned 3 studies, 0 relevant (Cochrane Methodology 
Register: Issue 3 of 4, July 2012) 
1.1.2 Systematic search of relevant electronic bibliographic databases 
EMBASE Classic and EMBASE 1974 to 2015 July, Ovid MEDLINE ® 1946 to July Week 4 
2015 and HMIC Health Management Information Consortium 1979 to May 2015. 
Pilot search 1: Qualitative AND Modelling  
Returned 1971 results, search terms were considered to be too broad. 
Pilot search 2: Qualitative research AND Health economic modelling 
Returned 2 results, none of which were relevant, search terms considered too narrow. 
Pilot search 3: Health economics or cost-effectiveness analysis or health technology 
assessment 
AND 
Qualitative research or qualitative analysis or qualitative or qualitative methods 
AND  
Model building or modelling process 
The search returned 3 results, with 1 paper meeting the inclusion criteria at the title/abstract 
stage of the screening process. Search terms were broadened for this search to involve the 
context of the research question however; it was proposed that expanding the search terms 
might result in further relevant papers being identified.  
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Main search 1: Find citing articles search on Chilcott et al. (2010) [paper identified in 
previous electronic database search] 
Returned 3 results, none of these papers were relevant to the research question.  
Main search 2: Reference list searching of Chilcott et al. (2010).  
Search returned 0 relevant papers. 
Main search 3: Health economics or cost-effectiveness analysis or health technology 
assessment or cost-effectiveness modelling or cost-effective  
AND 
Qualitative research or qualitative analysis or qualitative methods or qualitative  
AND 
Model building or modelling process or modelling or modeling  
Returned 105 papers, 4 of which were identified as relevant to the research question at the 
title/abstract stage of the screening process.  
 Kaltenthaler et al. (2014) ‘Identification and Review of Cost-effectiveness Model 
Parameters: A Qualitative study’ 
 Chilcott et al. (2010) ‘Avoiding and identifying errors in health technology assessment 
models: A Qualitative study and Methodological review’  
 Kaltenthaler (2011) ‘The UK NICE single technology appraisal process: A qualitative 
study based on manufacturer’s submissions’ (Conference abstract)  
 Kaltenthaler et al. (2013) ‘Reviewing the Evidence to Inform the Population of Cost-
effectiveness Models within Health Technology Assessments’   
 
Main search 4: Find citing articles search on Kaltenthaler et al. (2014).  
 
Search returned 0 papers. 
 
Main search 5: Reference list searching of Kaltenthaler et al. (2014). 
 
Search returned 3 relevant papers, however two of these were duplicates of those already 
retrieved through electronic database searching. The remaining paper was original and 
relevant to the research question. 
 Kaltenthaler (2011) NICE DSU Technical Support Document 13: ‘Identifying and 
reviewing evidence to inform the conceptualisation and population of cost-
effectiveness models.’ 
Main search 6: Web searches for other relevant papers by Chilcott et al. (as lead or co-
author). 
Search returned 0 additional and relevant papers. 
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Main search 7: Web search using Google Scholar for other relevant papers by Kaltenthaler 
(as lead or co-author). 
Search returned 3 original and relevant papers. 
1. Kaltenthaler et al. (2012) ‘A qualitative study of manufacturer’s submissions to the 
UK NICE single technology appraisal process’  
2. Squires et al. (2013) ‘Health Economic Modelling: A Conceptual Modelling 
Framework for Public Health Economic Models’ (conference paper) 
3. Chilcott et al. (2010b) – ‘Choice and judgement in developing models for health 
technology assessment; a qualitative study’. Discussion paper. (Unpublished). 
Hazel Squires was contacted directly for source of conference paper, which returned Squires 
(2012) ‘A methodological framework for developing the structure of public health economic 
models’ (PhD thesis). Conference paper therefore considered superseded by thesis as on same 
piece of research. Kaltenthaler (2011) conference abstract also superseded by Kaltenthaler et 
al (2012) full-text paper. Chilcott et al (2010b) superseded by full text HTA report. 
Main search 8: Reference list searching of Squires (2012). 
The search returned 2 relevant papers, 1 of which was a duplicate. The second paper was a 
PhD thesis and the author was contacted for a copy. 
Result: Paisley (2012) 
Total of 7 papers retrieved after removing work that was superseded by full-text papers. 
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Appendix 5: Data extraction form - 




Record number  
 
 
Author and year  
 
 










Type of publication  
 
 
Source of finding 




















Guidance and further 
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Appendix 6: Research protocol for the 
systematic review of qualitative modelling 
studies 
No. Criteria 
1 Review question: 




2 Inclusion criteria: 
Any form of literature that has used qualitative methods to investigate the 




Identifying the research evidence: 
 The searching of major electronic bibliographic databases for 
potentially relevant papers 
 Forward citation searching within electronic databases 
 The systematic scanning of the reference lists of key papers 
 Online searches using Google Scholar.  
 
  
4 Potential search terms: 
Health economics, cost-effectiveness modelling, health technology assessment, 
qualitative research, qualitative analysis, qualitative methods, modelling 
process, model building. 
 




5 Paper selection: 
Paper selection will be based on the inclusion criteria. The initial selection will 
be made based on the title and abstract. The full-text version will be obtained 
for papers that appear to meet the inclusion criteria or avoid the exclusion 
criteria. This also applies where a decision could not be made on the basis of 
the information available in the title and abstract. 
 
  
6 Data extraction: 
Publication information, study characteristics and findings related to the 
research question will be recorded in a data extraction form. 
 
  
7 Synthesis of results: 
Narrative synthesis will be used. 
 
  
8 Exclusion criteria: 
Non-English language papers. 
 
 Miscellaneous  
9 Documenting the searches: 
The electronic database searches are documented in Appendix 4. 
 
10 Protocol modifications: 
Any modifications to the protocol will be recorded in the report. 
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Appendix 7: Ethical Approval for phase 
one of the research  
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Appendix 8: Ethical Approval for phase 
two of the research  
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Appendix 9: Ethical approval for the 
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Appendix 10: Sample invitation letter to 
modellers – phase one 
 
  




Health Economics Unit 










I am a PhD student at the University of Birmingham conducting research on best practice in 
decision-analytic model building. As part of my research I am carrying out a number of short 
interviews with expert modellers to gain insight and opinion on the current process of model 
development.  
I would be very interested in speaking to you given your experience of developing decision-
analytic models. I am looking to gain a greater understanding of the methods used to develop 
the structure of a model and your opinion on which aspects of the process require improvement 
and further investigation. This is with an overall objective to develop best practice guidance.  
If you agree to take part in the interview it will last approximately one hour and can be 
conducted at a time and in a location most convenient to you [most likely at your place of work]. 
I have attached an information sheet which will provide you with further information about the 
research. 
 I will follow up this letter with an email in 7 days’ time to see if you would like to participate.  





Health Economics Unit 
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Appendix 11: Informant information sheet 
– phase one  
  




Best Practice in Decision-analytic Model Building Study - Information 
Sheet 
Information for the participant 
We would like to invite you to participate in our research study. This information sheet has 
been designed to help you to decide whether you would like to take part. It will explain the 
purpose of the research, what will be required of you as a participant, and how the data gathered 
from you will be managed. Please take a couple of minutes to read through the information 
below and ask any questions about the research that you may have.  
Information about the research  
This research study is being carried out and funded by the University of Birmingham. The 
overall objective of this research is to develop best practice guidance for building the structure 
of a decision-analytic model, in conjunction with the opinion and work of expert modellers and 
clinicians.  
This study has been approved by the Science, Technology, Engineering and Mathematics 
Ethical Review Committee at the University of Birmingham.   
Why have I been invited to take part? 
You have been invited to take part in this research due to your expertise in modelling and 
experience of developing decision-analytic models for the purpose of economic evaluation. 
Your views on the model building process will be central to enhancing understanding about 
where and how it can be improved, and will result in guidance on how to achieve an optimum 
structure and cost-effectiveness recommendation.   
Do I have to take part? 
No, you are under no obligation to participate. Your involvement is completely voluntary, but 
would be very beneficial to this research.  
What is the research about? 
With an aim to develop best practice for building a decision-analytic model structure, in this 
initial phase of the research we are asking you to take part in a face-to-face, in-depth interview 
to learn of your experiences of modelling. We are especially interested in your opinion on 
current practice in model building and your opinion on aspects of the process which require 
further investigation and development. This is with the intention of exploring and potentially 
improving these aspects through case study research with teams of modellers and clinicians.   
How will the data from my interview be used? 
It will be used to inform the remaining phases of the research as well as the overall objective of 
developing best practice for building a model structure. The second phase of the research 
involves case studies with a number of modelling teams and clinicians. The aim of this 
interview is to highlight issues relevant to the modelling process which can then be observed 
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and discussed further within the case studies, with the intention of developing suggestions for 
improving methods of model building.   
The findings of this research will form an integral part of a PhD thesis, with key results being 
presented through seminars, academic journals and conferences.  
What will happen if I take part? 
Should you agree to take part, the interview will last up to one hour. During this time you will 
be asked to discuss a series of topics relevant to the model building process. The questions will 
ask you to draw upon your own modelling experiences and your knowledge of the field. 
Although the interview will follow a broad topical structure, please feel free to contribute any 
information which you believe to be relevant to the research objective. 
Can I withdraw from the research? 
Yes, at any time. You are not obliged to provide a reason for your decision to withdraw. Upon 
withdrawal you will have the option to request that any existing data you have given be 
destroyed. If you decide to withdraw we ask that this request is given within one week of the 
interview’s completion, to avoid the data being analysed and used to inform future interviews 
and phases of the research. 
Is the research confidential? 
Yes, the research is confidential. Any data you give will be entirely anonymised and assigned 
a unique identity code to enable us to store your data safely and keep your personal information 
and digital recordings separate. All personal and interview information will be kept on a secured 
computer network which only the lead researcher will have access to. Data will be stored at the 
University of Birmingham for 10 years. Any writing or publications relevant to this research 
will not include any information that can identify you.  
Where can I get more information about the study? 
If you require any further information about the research please contact Sam Husbands on  
  
What if I have a complaint about the research? 
If you want to raise any concerns about the research please contact Professor Joanna Coast at 
  
What now? 
Please take your time to decide whether you would like to take part in this study and ensure that 
you ask any other questions that you may have.  
If you would like to take part in the research please sign the consent form.  
Thank you. 
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Appendix 12: Interview guide – phase one 
  






 REPEAT PURPOSE OF 
THE RESEARCH 
 INTRODUCE TAPE 
RECORDER 
 CONFIDENTIALITY AND 
ANONYMITY 
 RIGHT TO WITHDRAW 
 TRANSCRIPTS 




-Can you think of an example of a model which you have worked on, where its development process was done 
particularly well?  
 Can you tell me about the process used? 
 Why was it good? 
-Can you think of any examples of modelling processes which contrast with this? [i.e. examples of bad 
modelling processes] 
-Have you found the process easier/harder depending on the particular disease area that you are working in? 
-Have you found the process easier/harder depending on the clinician that you speak to? 
•The number of clinicians that you speak to? 





-What is your experience of modelling? 
 How did you begin? 
 What is your current 
role? What does it 
involve? 
 Have you worked on 
many models? 
 What type of modelling 
have you done 
previously? Disease 
areas? Model types? 
 Have you ever done work 





-Do you or have you ever used modelling guidance to assist you in model building? 
 Which guidance? 
 How did you use it? 
-What do you think to the published modelling guidance as a whole? 
 What does it do? What does it not do? 
 In terms of structure?  
 Are there any that are particularly good? Particularly bad? 
-Do you think that it is possible to develop “a one size fits all” guidance for the process of developing the 
structure of a model? Why? 
- Have you read the newest version of the ISPOR-SMDM Task Force modelling guidance? What do you think? 
 Do you believe that it is sufficient to assist modellers in developing a model structure? 
 Where is it sufficient/good? Where is it lacking? 




-Can you talk me through the process by which you usually develop the structure of a 
decision-analytic model? 
 Why do you include this particular stage? Are there any other stages which 
you could include? 
-Do you speak to clinicians? 
 How many? At what stage(s)? How do you ‘recruit’ them? 
-What model checking activities are carried out? 
 In terms of the model structure? Who is involved in this? 




REITERATE THE OBJECTIVE OF THE RESEARCH 
PROJECT 
-Which aspects of the model building process do you think 
require further investigation [for the purpose of developing 
best practice guidance]? 
-Can you think of teams of modellers who would provide 





-What would you define as the structure of a model? 
 What are the boundaries? 
-What would you define as a structural model error? 





Is there anything else you would like to add which could 
contribute to this research? 
    
307 
 







                                                                                                                                   
    
308 
 
       
    
309 
 
            
    
310 
 
Appendix 14: Final version of coding 
structure – phase one  
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Appendix 15: Final version of coding 
structure definitions  
 
1. Experience of modelling – In reference to the informant’s background in modelling 
and current skills and experience.  
1.1 First modelling experience – In reference to the very first experience that the informant 
had of building a model 
1.2 Context – Referring to the circumstances around the informant becoming a modeller and 
their past and current modelling projects 
1.2.1 Background – Reference to the nature of an informant’s background, which may affect 
the way in which they model 
1.2.2 Developing skills – Referring to how the informant built up modelling abilities 
1.2.3 Current role – Informant is referring to the context of their current role and what it 
involves 
1.2.3.1 Hands on Modelling – Where the informant refers to their role as one of physically building a 
model 
1.2.3.2 Supervision – Where the informant refers to their role as a supervisor of the building of a 
model. 
1.2.3.3 Seniority – How senior a modeller is or appears in relation to others working within their 
organisation or in the context of the modelling field 
1.2.4 Models worked on/previous models – Reference to past models that the informants have 
worked on 
1.2.4.1 – Disease area – Reference to the disease areas that the informants have built models in 
previously  
1.2.4.2 – Model type – Reference to the types of models that the informants have built previously 
1.3 Commissioning body – Informants discuss the requirements of different commissioning 
bodies for the models that are submitted to them 
1.3.1 NICE - The informant's discussing any modelling work that they have specifically done 
for NICE  
1.3.2 Other decision-making bodies - The informant's discussing any modelling work that they 
have specifically done for other decision-making bodies (outside of NICE), such as CADTH 
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1.4 Training and guidance – Where informants discuss any training they have given or 
guidance they have produced themselves specific to modelling 
1.5 Model reviewing – Any reference to model reviewing work that the informants may have 
carried out 
 
2. Modelling process – The informant makes reference to the stages that are involved in 
developing a model 
2.1 Understanding – A stage of the modelling process of understanding the 
intervention/problem to be modelled 
2.2 Establish the research question – A stage of the modelling process as determining the 
research question 
2.3 Other models - Reference to the use of other people's models to inspire a new model being 
built 
2.3.1 Structure – how informants use other models to influence the structure of their own 
models 
2.3.2 Data – how informants use other models to influence the data used in their own models 
2.3.3 Use – Informants’ comments on how far they will use other people’s models to inform 
their own 
2.3.4 Identifying other models – Discussion of the methods used to identify existing models 
2.4 Literature – Reference to using the clinical and/or economic literature to determine the 
structure of a model 
2.5 Review - Reference to conducting some sort of review prior to the development of a 
model structure 
2.6 Model specification/protocol - Reference to the development of a model specification 
document prior to or alongside the development of a model structure 
2.7. Structure – Direct reference to establishing/building the structure of the model 
2.7.1 Data vs structure – Discussion on how far available data should influence the 
development of a structure 
2.7.2. Model type – Comments on the types of models used and how a particular model is 
selected to represent a problem  
2.7.3. Simplicity vs complexity – Comments on how simple/complex a model structure needs 
to be to address a particular decision problem 
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2.8 Data – reference to the use of data in a model 
2.8.1 Lack of data - Discussion of what happens when there is a lack of data available to 
populate a model 
2.8.2 Quality of data – Discussion of what happens when the data available is of low quality 
2.9 Making assumptions - Reference to the stage of creating model assumptions where data or 
information is not available in the literature 
2.10 Implementation – Reference to building the model in a software platform 
2.10.1 Software – Reference to the use of a particular software in the development of a model 
2.11 Iterative - Reference to the modelling process as being one that is iterative (involves 
backward and forward movement between stages in the modelling process) 
2.12 Advisory board – Informants’ reference to a stage in the process involving the 
undertaking of an advisory board 
2.13 Model checking activities – Reference to activities that are carried out to ensure that a 
model is as it should be 
2.13.1 Validation – Reference to the activities carried out under the umbrella term of 
validation – involving making sure that a model is a true representation of the 
disease/problem/intervention 
2.13.1.1 Internal validation - Reference to the activities carried out under the umbrella term internal 
validation- ensuring that the internal workings of a model are performing as they should be 
2.13.1.1.1 Run Model - Where informants discussing running a model to ensure it is working correctly and 
producing sensible and intuitive results  
2.13.1.1.2 Eyeballing - Checking the mathematical aspects of the modelling by ensuring that the correct values 
have been entered into the software/spreadsheet 
2.13.1.1.3 Face validity – Checking whether a model appears valid in the face of what is already known about 
the nature of a particular disease 
2.13.1.1.4 Reprogramming (software) - Building the model in an alternative software program or in the same 
software again to check if same model result is achieved  
2.13.1.1.5 Sensible results? - Checking the model results by ensuring that they stand up against existing similar 
models and also intuition 
2.13.1.1.6 Log changes – where informants discuss formally noting all the changes that they make to the model 
as a means of checking that these have occurred 
2.13.1.2 External validation – Reference to activities which involve checking a model and its finding 
against sources that are external to it  
2.13.2.1 Dissemination strategies – Reference to a means of checking the model which involves presenting the 
findings to outside parties (aside from clinicians) for their feedback 
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2.13.1.3 Structural validation – Reference to checks that are carried out on the structure of a model 
2.13.2 Sensitivity analysis - Reference to checking the model results through the use of 
sensitivity analysis i.e. changing a parameter(s) to study its impact on the results of a model 
2.14 – Other interaction – Reference to getting other people outside of the modelling team 
involved in the modelling process 
2.15 Interpretation – Reference to an explicit stage in the process in which an informant 
translates the model results into overall findings 
2.16 Presenting results - In reference to the way in which the model results are handed over to 
the decision-makers, project commissioners or disseminated to others 
 
3. Model reflection – In reference to an informant’s evaluative comments on aspects of 
the modelling process. 
3.1 Project - Where informants' discuss the modelling process being different according to the 
particular project that they are working on  
3.1.1 Different areas - Informants' suggesting that model structures may be developed 
differently depending on the area of the country in which the study is undertaken 
3.1.2 Different diseases - Reference to the informants' belief that some diseases are more 
difficult to model than others and require different modelling techniques and pathways 
3.1.3 Individual modellers - Individual modellers and their aptitude for modelling may affect 
the way in which they build models  
3.2 Structure definition – reference to how the informants define the structure of a model 
3.3 Error definition – reference to how the informants define error in the structure of the 
model 
3.4 Good model [Process] – Reference to what the informant believes constitutes a good 
model and outcome 
3.4.1 Clinical input - A good model is one that has had input from people with clinical 
expertise 
3.4.2 Other input – A good model is one that has had input from people with relevant 
expertise, aside from clinicians 
3.4.3 Model specification – A good modelling process is one that includes the development of 
a model specification document 
3.4.4 Realistic – A good model is one that has a realistic structure in relation to the disease 
that it is representing 
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3.4.5 Confirmation - A good model (outcome) is one that has been validated by the relevant 
people or information  
3.4.6 Model checking activities – A good model process is one that contains sufficient model 
checking activities 
3.4.7 Answer – A good model is one that is able to provide an answer to the decision problem 
3.4.8 Highlighting gaps – A good model is one that can be used to highlight gaps in the 
literature and/or existing knowledge 
3.4.9 Providing information – A good model is one that can be used to generate information 
on a particular issue or problem  
3.4.10 Flexible – A good model is one that is flexible – allowing a number of different 
decision problems to be represented by a model structure 
3.4.11 – Transparency – A good model and model process is one that is transparent in terms 
of how it has been developed 
3.4.12 Integrity - A good model is one that has been developed with integrity by the modeller 
i.e. built objectively and not with bias towards a particular outcome 
3.4.13 Robust - A good model is one that has followed a rigorous process of development 
3.4.14 Confidence in – A good model is one that the modeller has confidence in, in terms of 
its development and result 
3.4.15 Credible- A good model is one that is credible in terms of how it has been built and 
what information has been used to develop it 
3.4.16 Good modeller – A good model is one that has been developed by a ‘good’ modeller 
3.4.17 Difficult to know – The informant(s) struggles to define what a good model is 
3.4.18 - 'Ideal model [process]' – Informants’ discussion of what they would define as being 
an ideal model or an ideal modelling process 
3.5 Poor model - What the informant defines as a poor model [process] 
3.5.1 Wrong mode/inappropriate structure - A model is poor due to an incorrect model type 
or structure being used 
3.5.2 Inappropriate assumptions - A model is poor due to it having been based on unrealistic 
or inaccurate assumptions 
3.5.3 No input - A poor model is one that has had no or little input from a wider modelling 
team/other experts 
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3.5.4 Lacks transparency - A poor model is one that is not transparent in terms of the methods 
that have been used to develop it  
3.5.5 Inconsistency - Relating a poor model outcome to one that does not address the original 
decision problem 
3.5.6 Missing stage – A poor model is one where essential stages of the modelling process 
have been missed  
3.5.6.1 Lack of model checking activities – A model is of poor quality because it has not undergone 
enough model checking activities 
3.5.7 Technical errors – The standard of a model is poor due to technical errors, in reference 
to the way that the model has been programmed into software  
3.5.8 Lack of modelling expertise – The person building the model does not have the 
appropriate expertise, leading to a poor model (outcome) 
3.5.9 Data inputs - The model is of a poor standard because of the data that has been used to 
develop and/or parameterize it  
3.5.10 Lack of generalisability – A poor model is one that’s design means that its results are 
not generalizable  
3.5.11 Lack of credibility – A poor model is one that lacks credibility due to either the 
methods or inputs that have been used to develop it 
3.5.12 Lack of flexibility – A poor model is one that cannot be used outside the context of the 
decision problem that it was originally designed to address 
3.5.13 Biased – A poor model is one that is biased due to the way in which it has been 
developed 
3.6 Problems- Reference to any problems or issues that the informant(s) may have 
encountered in the model building process  
3.6.1. Practical issues - Where informants have cited practical issues that have occurred 
whilst building a model 
3.6.2 Miscommunication – Discussion of problems that have arisen in model development due 
to miscommunication between the parties involved 
3.7 Improvements -Informants reflect on any improvements that they feel could be made to 
their own modelling process 
3.8 Timeframe –Discussion of the timeframes that the informants follow when building a 
model 
3.9 Client involvement – Discussion and reflection on the nature of client involvement in the 
model building process 
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3.10 Patient involvement – Discussion and reflection on the nature of patient involvement in 
the model building process 
3.11 Model reviewing – Reflection on the process an informant has used or is using to review 
other models 
 
4. Clinician involvement – Reference to developing a model in conjunction with clinical 
experts 
4.1 Pathway plotting - Reference to the process of planning and developing the model 
pathways with clinicians 
4.2 Data values – Reference to use of clinician opinion in identifying and obtaining data 
values to be used in a model 
4.3 Checking – Reference to the clinicians’ involvement in checking aspects of the model 
4.4 Model focus – Reference to the clinicians’ involvement in decided what the model should 
look at and question, what should be included in the model 
4.5 Number – Reference to the number of clinicians that are involved in model development  
4.6. Relationship – Reference to the nature of the professional relationship that the informants 
have with the clinicians who they are working with 
4.7 Nature - Reference to the nature of a clinician’s involvement on a project 
4.7.1 Recruitment – Discussion on how clinicians are recruited to modelling projects 
4.7.2 Meetings – Reference to how the meetings between modellers and clinicians might take 
place 
4.7.3 Engagement – Discussion on the ability of clinicians to engage in a model’s 
development process 
4.7.3.1 Understanding – Reference to the fact that clinicians are able/not able to engage in a 
model development process because of their understanding/lack of understanding of health 
economic modelling  
4.7.3.2 Personality – Reference to the fact that clinicians may engage more/not engage in 
model development due to their personal preferences and attitude towards collaboration and 
modelling 
4.7.3.3 Vested interest – Reference to the fact that a clinician having a ‘vested interest’ in a 
particular model result may have an effect on how engaged they are in the model 
development process 
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4.7.3.4 Methods of engagement – Informants’ comments on methods that they use or can be 
used to engage clinicians in model development  
4.8 Modelling team – Reference to the team who are involved in the model development 
process (outside of the modeller (informant) and the clinicians) 
4.9 Agreement – Referring to agreement between modeller and clinician on certain aspects of 
the modelling process 
4.10 Disagreement - Reference to issues or disagreements between the modeller (informant) 
and clinicians or between the clinicians themselves  
 
5. Modelling guidance - Reference to types of modelling guidance and the informants’ 
use or opinion of it, or guidance given by the informant  
5.1 Type of guidance – The informant's reference to the type of modelling guidance that is 
generally available (or that they are aware of as being available) 
5.2 Use of guidance – In reference to the informant’s use of modelling guidance 
5.3 Attitude towards guidance – In reference to the informant’s attitude towards particular 
modelling guidance or the concept of modelling guidance in general 
5.3.1 One size- fits-all - Attitude of the informants towards the possibility of developing or 
having a ‘one-size-fits-all’ guidance  
5.4 Informant’s guidance - Guidance given by the informant as to how a model should be 
developed (reference to the particular actions that a modeller should carry out i.e. their ‘top 
tips’) 
 
6. Future research - Suggestions from the informants concerning which aspects of the 
modelling process should be investigated further for the purpose of developing modelling 
guidance. 
6.1 Area of focus – Discussion of which aspects of model development particularly require 
further investigation and potentially the development of guidance 
6.2 As a whole – Discussion of what the developed guidance should focus on as a whole 
6.3 Format – Discussion on how the developed guidance should be organised and formatted 
6.4 Case studies – Specific suggestions related to the subject of case studies for phase two  
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Appendix 16: Excerpt from matrices 
comparing responses of interview 
informants – phase one 
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Appendix 17: Consent form for phase one 
of the research   









1. I confirm that I have read and understood the information sheet for the research entitled 
‘best practice in decision-analytic model building study’. I confirm that I have had the 
opportunity to consider the information provided, ask any questions and have those 
questions answered. 
 
2. I understand that my participation in the study is entirely voluntary and that I am free to 
withdraw from the study at any time without giving any reason or explanation. I 
understand that any personal information collected within this project will be 
anonymised and will remain strictly confidential. 
 
3. I agree to participate in the above study and consent to the interview being audio 
recorded. I understand that the data may be looked at by the Research Team at the 
University of Birmingham and anonymised quotes from this interview may be included 





I hereby consent to participate in this research project and confirm that I understand and agree 




Signature of Participant: ……………………….    Date: ……………. 
 





Should you have any further queries or concerns please contact: 
 
Sam Husbands 
Health Economics Unit 
Public Health Building 






Participant Identification Code: …………….. 
Name of Researcher: Samantha Husbands 
 
To take part in the study you must agree to the following: 
 
Please Initial Boxes and 
Sign Below to Consent 
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Appendix 18: Informant information sheet 
- phase two 
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Best Practice in Decision-analytic Model-Building  Case Study - Information 
Sheet 
Information for the participant 
We would like to invite you to participate in our research study. This information sheet has been 
designed to help you to decide whether you would like to take part. It will explain the purpose of the 
research, what will be required of you as a participant, and how the data gathered from you will be 
managed. Please take a couple of minutes to read through the information below and ask any 
questions about the research that you may have.  
Information about the research  
This research study is being carried out and funded by the University of Birmingham. The overall 
objective of this research is to develop best practice guidance for building the structure of a decision-
analytic model, in conjunction with the opinion and work of expert modellers and clinicians.  
This study has been approved by the Science, Technology, Engineering and Mathematics Ethical 
Review Committee at the University of Birmingham.   
Why have I been invited to take part? 
You have been invited to take part in this research due to your involvement in the model development 
process at this modelling centre and due to your clinical or modelling expertise. This research will be 
in the format of a case study which will observe the development of a model from beginning to end 
with the intention of reporting on best practice guidance that can be used by those involved in the 
development of decision-analytic models nationally. It is anticipated that developing guidance that can 
be used to improve modelling processes will lead to better quality models generally which can be used 
to inform important funding and policy-making decisions. The guidance will also be designed to help 
those that are new to the modelling process, making it useful for training purposes. The case studies 
will involve the researcher (Samantha Husbands) being present to observe modelling meetings and 
being included in email and telephone correspondence between the modelling and clinical team. 
Samantha will also be present to conduct interviews with any clinical or modelling experts who are 
willing to discuss their thoughts and opinions on the observed modelling process. Samantha’s 
involvement in the modelling process will be entirely non-participatory and so is not expected to 
disrupt the flow of work within the centre. 
Do I have to take part? 
No, you are under no obligation to participate. Your involvement is completely voluntary, but would 
be very beneficial to this research. 
What will happen if I take part? 
Should you agree to take part you will be asked for written consent to be involved in the research 
and for your involvement to be audio-recorded (i.e. discussion in modelling meetings). You may also 
be asked to take part in a short interview on the modelling process however, you are under no 
obligation to agree to this.  
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Can I withdraw from the research? 
Yes, at any time. You are not obliged to provide a reason for your decision to withdraw. Upon 
withdrawal, we will ask you whether you give permission for us to continue to use your data. If you do 
not give permission we will automatically remove it from the study and destroy it. If you decide to 
withdraw we ask that this request is given within one week of your involvement in the research to 
avoid the data being analysed and used to inform future observation and interviews. 
How will the data from my involvement in the case study be used?  
It will be used to inform the content and format of the best practice modelling guidance which will be 
the final outcome of this research. The aim of the case study is to observe and discuss what constitutes 
best practice in the modelling process, where guidance is needed in model building and what the final 
guidance should include. The interviews will be used to follow-up on what Samantha has observed in 
the meetings, email correspondence and the model development process generally. They will focus on 
the opinions of modellers and clinicians on the current process of model development in relation to 
best practice, and what should be documented in the final guidance. 
The findings of this research will form an integral part of a PhD thesis, with key results being presented 
through seminars, academic journals and conferences.  
Is the research confidential? 
Yes, the research is confidential. Any data you give will be anonymised and assigned a unique identity 
code to enable us to store your data safely and keep your personal information and digital recordings 
separate. All personal and interview information will be kept on a secured computer network which 
only the lead researcher (Samantha) will have access to. Data will be stored at the University of 
Birmingham for 10 years. Any writing or publications relevant to this research will not include any 
information that can identify you.  
Where can I get more information about the study? 
If you require any further information about the research please contact Samantha Husbands on  
  
What if I have a complaint about the research? 
If you want to raise any concerns about the research please contact Professor Joanna Coast at 
j.coast@bham.ac.uk.  
What now? 
Please take your time to decide whether you would like to take part in this study and ensure that you 
ask any other questions that you may have.  
If you would like to take part in the research please sign the consent form.  
Thank you. 
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Appendix 19: Interview guide for phase 
two  
  






    REPEAT PURPOSE OF THE RESEARCH 
    INTRODUCE TAPE RECORDER 
 
                    CONFIDENTIALITY AND ANONYMITY                                                  CONSENT FORM 














Can you tell me about your role in the development of the current 
model? 
 What does it involve? 
 At what stages are you involved? 
 Who else do you work with on a model? 
 What is their involvement? 
 
Can you talk me through the development process so far of the model 
that you are working on? 
 
How do you feel that the model’s development is going? 
 Is there anything that you feel has gone particularly well? 
 Is there anything that you feel has not gone as well? 
What is your opinion of the structure of the model that has been developed so far? 
 What do you think is good about it? 
 What do you think is not as good?  
 Where do you think the greatest uncertainty lies within the model? 
 
How do you feel that the communication is going between everyone involved in the   
process (between the modellers and clinicians)? 
 Can you tell me more about how this communication is managed? 
 Do you think that there is any way in which this communication could be improved? 
 
What are your thoughts on the model development process that is used? 
 What are its strengths? 
 What are its weaknesses? 




Have you worked on many models? 
 Here? Elsewhere? 
 Has your role always been the same on every model (even if elsewhere)? 






When you’ve been involved in the development of other models, was there anything 
different about the process used? 
 Was it better or not as good as the current process? 
 In terms of communication? 
 
Are you given any guidance on how to conduct your role in the modelling process? 
Which aspects of your role do you find particularly difficult? 
 
Do you think that there is anything that can be done to make your role in the 
modelling process easier? 





[QUESTIONS FOR MODELLERS] I am gauging from the interviews and the previous research that guidance on ‘X’ area of the modelling process might be important, what do you think? 
 What do you think the content of this guidance should be? 




Ask any additional questions which have been generated 
through observation or which are relevant to the particular stage 




Is there anything else you would like to add which could contribute to this research? 
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Appendix 20: Informant interview 
information sheet – phase two  
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Best Practice in Decision-analytic Model-Building Case Study – Interview 
Information Sheet 
Additional information 
You have already been given an information sheet which outlines the purpose and nature of the case 
study that you have agreed to be involved in. Another copy of this is attached for your information. 
This information sheet has been designed to provide additional information on the interview 
element to help you to decide whether you would like to take part. It will outline the purpose of the 
interview, what is required of you as a participant and how the data gathered from you will be 
managed. Please take a couple of moments to read through the information below and ask any 
questions about the interview that you may have.  
 
What is the purpose of the interview? 
The interview element has been designed to allow the researcher (Samantha Husbands) to follow-up 
and ask questions on the model building practice that she has observed during the case study. The 
aim of this is to decide through discussion with modellers and clinicians involved in the modelling 
process, what constitutes best practice in a model’s development.  
 
Why have I been invited to take part? 
Having already agreed to take part in the observation element of this case study we are now asking 
you to take part in a face-to-face, semi-structured interview which will allow Samantha to learn in 
more detail about the modelling process, your thoughts and opinions on best practice, and the 
modelling guidance that will be produced as the outcome of this study.  
 
Do I have to take part? 
No, you are under no obligation to participate. Your involvement is completely voluntary, but would 
be very beneficial to this research.  
What will happen if I take part? 
If you agree to take part the interview will last up to one hour. During this time you will be asked to 
discuss your opinion on the current model that you are working on and how the methods used relate 
to what you consider to be best practice in model development. You will also be asked for your 
opinion on what the final guidance produced through this research should focus on and include. Your 
thoughts and opinions will inform what is reported as best practice in the model building guidance 
that will be developed through this research.  
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Can I withdraw from the research? 
Yes, at any time. You are not obliged to provide a reason for your decision to withdraw. Upon 
withdrawal, we will ask you whether you give permission for us to continue to use your data. If you 
do not give permission we will automatically remove it from the study and destroy it. If you decide to 
withdraw we ask that this request is given within one week of the interview’s completion to avoid 
the data being analysed and used to inform future observation and interviews. 
 
How will the data from my interview be used?  
It will be used to inform the content and format of the best practice modelling guidance which will be 
the final outcome of this research. The data gathered from the observations and the interviews will 
be used in conjunction to allow Samantha to understand what should be considered and 
documented as best practice in model building.  
The findings of this research will form an integral part of a PhD thesis, with key results being 
presented through seminars, academic journals and conferences.  
 
Is the research confidential? 
Yes, the research is confidential. Any data you give will be anonymised and assigned a unique identity 
code to enable us to store your data safely and keep your personal information and digital recordings 
separate. All personal and interview information will be kept on a secured computer network which 
only the lead researcher will have access to. Data will be stored at the University of Birmingham for 
10 years. Any writing or publications relevant to this research will not include any information that 
can identify you.  
 
Where can I get more information about the study? 
If you require any further information about the research please contact Samantha Husbands on 
  
 
What if I have a complaint about the research? 




Please take your time to decide whether you would like to take part in this study and ensure that you 
ask any other questions that you may have.  
 
If you would like to take part in the research please sign the consent form.  
 
Thank you. 
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Appendix 21: Consent form for phase two 
of the research (consent for interview) 
 









1. I confirm that I have read and understood the interview information sheet for the 
research entitled ‘best practice in decision-analytic model building study’. I confirm that 
I have had the opportunity to consider the information provided, ask any questions and 
have those questions answered. 
 
2. I understand that my participation in the interview is entirely voluntary and that I am 
free to withdraw from the interview at any time without giving any reason or 
explanation. I understand that any personal information collected within this project will 
be anonymised and will remain strictly confidential. 
 
3. I agree to participate in the above interview and consent to it being audio recorded. I 
understand that the data may be looked at by the Research Team at the University of 






I hereby consent to participate in this research project and confirm that I understand and agree 




Signature of Participant: ……………………….    Date: ……………. 
 





Should you have any further queries or concerns please contact: 
 
Sam Husbands 
Health Economics Unit 
Public Health Building 






Additional Consent for Interview  
 
Participant Identification Code: …………….. 
Name of Researcher: Samantha Husbands 
 
To take part in the study you must agree to the following: 
 
Please Initial Boxes and 
Sign Below to Consent 
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Appendix 22: Thematic framework for 
Case Study A 
 
1.1 Background 
1.1.1 Objective of the model 
1.1.2 Modelling team 
 
1.2  Structural development 
1.2.1 Patient population 
1.2.2 Learning about condition 
1.2.3 Pathway plotting 
1.2.3.1 Beginning the pathway 
1.2.3.2 Where patients go and why 
1.2.3.3 Decisions on how to model pathways 
1.2.3.4 Outcome of pathways  
1.2.3.5 Making structural assumptions 
1.2.3.5.1 Process for making assumptions 
1.2.3.5.2 Assumptions made 
1.2.3.6 Determining model boundaries  
1.2.3.6.1 Time horizon 
1.2.3.6.2 Excluding patients 
1.2.3.7 Basis of a structure 
1.2.3.7.1 NICE guidelines 
1.2.3.7.2 Use of clinical literature 
1.2.3.7.3 Use of clinical effectiveness data  
1.2.3.8 Comparator 
1.2.3.8.1 Allowing for misdiagnosis 
1.2.3.9 Location of treatment pathway (generalisability) 
1.2.4 Communication in structural development 
1.2.4.1 Clarification of health economic terms 
1.2.4.2 Miscommunication/misunderstanding 
1.2.5 Clinical collaborators  




1.2.7 Implementation in software 
 
1.3  Data: populating the model  
1.3.1 Clinical data 
1.3.1.1 Probability data 
1.3.1.2 Clinical-effectiveness data  
1.3.2 Economic data 
1.3.2.1 Cost data 
1.3.2.2 Utility data 
1.3.3 Clinician involvement 
1.3.4 Problems with data 
1.4  Results 
1.4.1  Results 
1.4.1.1 Questioning results 
1.4.1.2 Questioning assumptions 
1.4.1.3 Miscommunication over results 
1.4.1.4 Presentation of results  
 
1.5  Model checking 
1.5.1 Model checking 
1.5.1.1 Secondary analysis 
1.5.1.2 Internal validation 
1.5.1.2.1.1 Sensitivity analysis   
1.5.1.3 External validation 
1.5.1.4 Structural validation 
1.5.1.5 Clinician involvement 
 
1.6  Clinician involvement 
1.6.1 Number of clinicians  
1.6.2 Meetings with clinicians 
1.6.3 Clinician understanding of health economics and modelling 
1.6.4 Guidance for clinicians 
 
    
338 
 
1.7  Informant reflections 
1.7.1 Reflections on model structure 
1.7.2 Reflections on roles in model development 
1.7.3 Reflections on communication 
1.7.4 Issues and problems within model development 
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Appendix 23: Thematic framework for 
Case Study B 
 
1.1 Background 
1.1.1 Objective of the model 
1.1.2 Modelling team 
1.1.3 Clinician training 
 
1.2  Structural development 
1.2.1 Patient population 
1.2.2 Learning about condition 
1.2.3 Pathway plotting 
1.2.3.1 Beginning the pathway 
1.2.3.2 Where patients go and why 
1.2.3.3 Decisions on how to model pathways 
1.2.3.4 Outcome of pathways  
1.2.3.5 Making structural assumptions 
1.2.3.5.1 Process for making assumptions 
1.2.3.5.2 Assumptions made 
1.2.3.6 Determining model boundaries  
1.2.3.6.1 Time horizon 
1.2.3.6.2 Excluding patients 
1.2.3.7 Basis of a structure 
1.2.3.7.1 NICE guidelines 
1.2.3.7.2 Use of clinical literature 
1.2.3.7.3 Use of clinical effectiveness data  
1.2.3.8 Comparator 
1.2.3.8.1 Allowing for misdiagnosis 
1.2.3.9 Location of treatment pathway (generalisability) 
1.2.4 Communication in structural development 
1.2.4.1 Clarification of health economic terms 
1.2.4.2 Miscommunication/misunderstanding 
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1.2.5 Clinical collaborators  
1.2.6 Iterative 
1.2.7 Implementation in software 
 
1.3  Data: populating the model  
1.3.1 Clinical data 
1.3.1.1 Probability data 
1.3.1.2 Clinical-effectiveness data  
1.3.2 Economic data 
1.3.2.1 Cost data 
1.3.2.2 Utility data 
1.3.3 Clinician involvement 
1.3.4 Problems with data 
 
1.4  Results 
1.4.1 Results 
1.4.1.1 Questioning results 
1.4.1.2 Questioning assumptions 
1.4.1.3 Miscommunication over results 
1.4.1.4 Presentation of results  
 
1.5  Model checking 
1.5.1 Model checking 
1.5.1.1 Secondary analysis 
1.5.1.2 Internal validation 
1.5.1.2.1.1 Sensitivity analysis   
1.5.1.3 External validation 
1.5.1.4 Structural validation 
1.5.1.5 Clinician involvement 
 
1.6  Clinician involvement 
1.6.1 Number of clinicians  
1.6.2 Meetings with clinicians 
1.6.3 Clinician understanding of health economics and modelling 
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1.6.4 Guidance for clinicians 
 
1.7  Informant reflections 
1.7.1 Reflections on model structure 
1.7.2 Reflections on roles in model development 
1.7.3 Reflections on communication 
1.7.4 Issues and problems within model development 
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